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ABSTRACT

A BIOETHICS TOOL FOR THE IMPLEMENTATION OF
GLOBAL PRINCIPLES BY THE PHARMACEUTICAL INDUSTRY

By
Daniel J. Hurst
December 2017

Dissertation supervised by Henk ten Have, MD, PhD
Due to scandals of scientific misconduct, a climate of mistrust of science exists amongst
the general public. This becomes of concern when we acknowledge that it is difficult for science
and technology to flourish without broad societal trust. The pharmaceutical industry has often
felt the brunt of such mistrust and has suffered many reputational setbacks over the past several
years. Such reputational decline has a strong moral dimension, as it stems from issues such as the
questionable conduct of clinical trials, pricing schemas, and access to medicines for low- or
middle-income countries. The end product of such issues is the public not viewing
pharmaceutical and biotechnology companies favorably. Since pharmaceutical and
biotechnology companies are intrinsically tied to health and human flourishing, an ethical
framework to aid in resolving both the ethical issues facing the industry and the resulting
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reputation it yields on both the industry as a whole and individual companies, could certainly be
valuable.
The central supposition of this dissertation is that additional work needs to be done in the
area of pharmaceutical ethics and corporate social responsibility. Currently, no specifically
global bioethics tool exists to implement ethics principles into the business practices of
pharmaceutical and biotechnology companies, which constitutes a glaring gap in the
implementation of ethics principles. This dissertation thus aims to do the following: (i) clarify
the ethical grounding of pharmaceutical corporate social responsibility, and (ii) develop a global
bioethics tool that can be utilized by the pharmaceutical industry as a manner to aid in
implementing global ethics principles. The global bioethics tool seeks to implement a global
ethical framework on the basis of performance indicators and best practices, with a long-term
goal of helping society regain its trust in the pharmaceutical industry. While there are numerous
bioethical guidelines available, it is argued that the UNESCO Universal Declaration on Bioethics
and Human Rights, as a global ethics document with the backing of the global community, can
be utilized to create such a tool by which to measure the ethical practices of pharmaceutical and
biotechnology companies.
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Chapter 1: Introduction
Due to scandals of scientific misconduct, a climate of mistrust of science exists amongst
the general public. This becomes of concern when we acknowledge that it is difficult for science
and technology to flourish without broad societal trust. The pharmaceutical industry has often
felt the brunt of such mistrust and has suffered many reputational setbacks over the past several
years. Such reputational decline has a strong moral dimension, as it stems from issues such as the
questionable conduct of clinical trials, pricing schemas, and access to medicines for low- or
middle-income countries (LMICs). The end product of such issues is the public not viewing
pharmaceutical and biotechnology companies favorably. Since pharmaceutical and
biotechnology companies are intrinsically tied to health and human flourishing, an ethical
framework to aid in resolving both the ethical issues facing the industry and the resulting
reputation it yields on both the industry as a whole and individual companies, could certainly be
valuable.
The central supposition of this dissertation is that additional work needs to be done in the
area of pharmaceutical ethics and corporate social responsibility. Currently, no specifically
global bioethics tool exists to implement ethics principles into the business practices of
pharmaceutical and biotechnology companies, which constitutes a glaring gap in the
implementation of ethics principles. This dissertation thus aims to do the following: (i) clarify
the ethical grounding of pharmaceutical corporate social responsibility, and (ii) develop a global
bioethics tool that can be utilized by the pharmaceutical industry as a manner to aid in
implementing global ethics principles. The global bioethics tool implements a global ethical
framework on the basis of performance indicators and best practices, and the tool has a number
of goals: 1) helping society regain its trust in the pharmaceutical industry through transparency
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about bioethical concerns, 2) increase the bioethics agenda of the industry and, in turn, increase
the trust and reputation of the industry, and 3) create a platform of defining and sharing industry
best practices, generating global industry standards, and providing a forum for fellow
stakeholders to dialogue. While there are numerous bioethical guidelines available, it will be
argued that the UNESCO Universal Declaration on Bioethics and Human Rights, as a global
ethics document with the backing of the global community, can be utilized to create such a tool
by which to measure the ethical practices of pharmaceutical and biotechnology companies.
The request for and importance of responsible business practices are increasing, and
recent high-profile scandals have led to decreased societal trust of pharmaceutical companies and
resulted in poor reputation for the industry. This has spurred a number of private consultancy
companies, non-governmental organizations (NGOs), and others to measure and benchmark the
performance of the pharmaceutical industry. This initiative will provide more than that. The
industry will develop a needed common voice and have the opportunity to collaborate and learn
from each other. Furthermore, a great strength of such a tool is that it would come from inside
the industry rather than being imposed on it by external forces. When the industry takes the lead
rather than external parties it will send a strong signal to onlookers that particular firms are
serious about ethical conduct and self-regulation.
Currently there is no tool for the measurement of bioethics implementation. Other such
tools have been implemented for business and human rights,1 as well as social responsibility and
sustainability. Though there are overlaps between issues of human rights, social responsibility,
and sustainability and what the proposed global bioethics tool aims to accomplish, this tool will
be unique for being the first in the area of bioethics for pharmaceutical and biotechnology
companies.

2

Chapter two discusses the relationship between global bioethics and human rights in
order to provide the necessary foundation for discussing the UNESCO Universal Declaration on
Bioethics and Human Rights, as well as the context in which the global bioethics tool operates.
The gradual evolution of global bioethics will be first discussed. This will be followed by the
status of the human rights discourse and the current relationship between global bioethics and
human rights. The symbiotic relationship between global bioethics and human rights will be
considered in detail.
The first section of chapter two examines the gradual evolution of global bioethics from
the fields of medical ethics and bioethics. The history of medical ethics growing out of the
atrocities committed during World War II has been well documented.2 After the Allied victory,
the Nuremberg Trials convened, which, in part, resulted in the Nuremberg Code.3 The
Nuremberg Code is centered on the research relationship between physician/researcher and
patient/subject.4 Since that time, medical ethics, and bioethics specifically, has been charged
with, at times, placing the loci of focus too strongly on individual matters while neglecting the
social context of medicine.5 While focused on the individual rights and welfare of the research
participant from the beginning, bioethics and a wave of personal autonomy became more distinct
in the 1970s during debates over life-sustaining treatments, making headway into medical clinics
and hospital units.6
It was in 1970 that the term bioethics was coined, marking a significant shift from the
discipline of medical ethics that paved the way.7 Yet, from its creation, the usage of the word had
different meanings. One stream of thought, originating with Andre Hellegers at Georgetown
University, saw bioethics as primarily an extension of medical ethics focused on medical issues
and medical technology, with still a very individualized approach.8 Yet the alternate stream,
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though not as popular, attempted to incorporate social and global perspectives into the
discipline.9 This was largely due to the work of Van Rensselaer Potter who envisioned bioethics
as a bridge between science and the humanities.10 Indeed it was Potter who, heavily influenced
by the work of Aldo Leopold, would later coin the term “global bioethics” because of his
discontent with the lack of a social perspective incorporated into bioethics.11 From the beginning
of bioethics there were major differences and even clashes between the Potter and the
Hellegers/Georgetown understandings of bioethics. Though the Hellegers/Georgetown approach
came to be the more widely accepted, Hellegers also proposed a global approach to bioethics,
bringing his vision much closer to Potter’s evolving view.12
Some scholars such as physician-philosopher Tristram Engelhardt have passionately
argued that there is no such thing as a global or universal ethic due to the competing philosophies
present in the world. Engelhardt has written that the Universal Declaration on Bioethics and
Human Rights is marked by a “general vacuity of its principles, as well as a failure to take
seriously the moral difference characterizing the contemporary age.”13 Hence, no consensus on a
variety of topics is achievable.14 The most notable document within the field of global bioethics
written in the past few years is arguably the UNESCO Universal Declaration on Bioethics and
Human Rights. Critics have faulted the UNESCO declaration for excluding mainstream
bioethicists, an absence of peer review, and failing to acknowledge socioeconomic and other
factors, which have impeded its implementation.15 Others have argued that there is no unified
global field of bioethics,16 and still others maintain that the UNESCO declaration merely
reformulates existing principles of bioethics, does not lend much new, and could actually be
harmful to the impoverished of the world.17 These many critiques are serious, and the objections
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will be thoughtfully considered and a response that argues it is possible to create a global ethical
framework for bioethics will be provided.
In the second section of chapter two, the evolution of human rights is examined. The
literary corpus of human rights declarations advanced in the aftermath of World War II.
However, these documents have a much richer history. The rationales of 17th century philosopher
John Locke can be seen in them, as it was Locke who laid a foundational theory of human
rights.18 The Lockean heritage can also be seen in the U.S. Declaration of Independence (1776)
and the French Declaration of the Rights of Man and of the Citizen (1789), which were the first
direct political statements to express the equality, universality, and naturalness of human rights.19
At the formation of the United Nations over 150 years later, the framework of human rights
ideologies expounded in the U.S. and French declarations would prove invaluable.20
The claim that all human beings have a “right” to something (such as access to medicine, food,
safety) can be both a moral/ethical claim based upon the intrinsic dignity of humans, and it can
be a legal claim that is based on specific codified, enforceable law. Oftentimes the language of
rights is used in conjunction with the moral/ethical dimension and does not necessarily align with
an existing law. Yet, inscribing rights into law can be a difficult maneuver, for there is
considerable debate about the content of human rights.21 While the UN and other prominent
organizations and states have been essential to advocating and furthering the idea of human
rights, criticisms still arise. Jeremy Bentham is renowned for calling human rights “execrable
trash” and simply “rhetorical nonsense, —nonsense upon stilts.”22 A key concept in human rights
is human dignity, which is often taken to be the foundation from which human rights emerge.
However, amongst modern critics, a large number of ethicists and bioethicists have labeled
human dignity a useless concept.23 Further, dignity has been labeled “vacuous,”24 and some have
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labeled appeals to dignity as a “conversation stopper.”25 The Canadian Supreme Court recently
issued a ruling summarizing their disappointment at the role of human dignity in constitutional
law, stating, “[It] has also proven to be an additional burden on equality claimants, rather than
the philosophical enhancement it was intended to be” (R. v. Kapp, SCC 41 (2008), 2 S.C.R. 483,
paragraph 22).26 This is important for the human rights discourse because the secular iteration of
human rights is generally grounded in the concept of dignity, as witnessed in the UN Universal
Declaration of Human Rights27. Hence, a close examination of the critiques of human rights will
be provided in this analysis.
While we must not gloss over the criticism, human rights treaties have proven valuable in
disseminating the human rights discourse of the latter 20th century. Governments have joined
international human rights treaties for different reasons, including with the goal of following the
rules, as a way to set an example for other countries, or as a means of reassuring their own
citizens of their seriousness in this matter. Some governments have been more ready to ratify
treaties if their neighbors have done similarly.28 Nonetheless, other countries commit to human
rights treaties and violate their agreements at will. In early 2016 Amnesty International released
a list of the ten worst attacks on human rights across the world in 2015.29 Of the ten countries
that Amnesty International listed as perpetrating the violations, all are UN member states, four
were original signatories to the UN Universal Declaration of Human Rights in 1948, and four are
current members of the UN Human Rights Council.30 Hence, a state’s approval of certain
declarations does not imply implementation or enforcement. Making human rights salient
involves not only merely raising the issues to an international audience, but persistent
campaigning, monitoring, and reporting to force governments to recognize shortcomings and
acknowledge the validity of human rights agreements.31 This section will also need to explore

6

some preliminary ideas of how to implement human rights, as the goal of the proposed global
bioethics tool is to actually implement the principles in the pharmaceutical and biotechnology
sector.
The preceding two subsections of chapter 2 examined global bioethics and human rights
separately. This final section seeks to show their relation. Bioethics has not often been thought of
in a human rights context and, conversely, human rights has only rarely taken great concern for
bioethical issues.32 Global bioethics and human rights stand in a symbiotic relationship. Whereas
human rights law and cosmopolitan ideals inspired the development of a global bioethics
discourse, the converse is similarly true; global bioethics contributes to human rights.33
However, we should not get the impression that global bioethics can simply be reduced to the
application of universal human rights norms to moral issues, for this would be a false view.34
The human rights discourse is attractive for global bioethics for a variety of reasons. A
number of thinkers, such as George Annas, have argued that medicine must develop a global
language and global strategy in order to help persons all over the world.35 Individual nationstates are inadequate to address global health issues, and culturally or religiously specific
principles are insufficient for addressing the growing issues in global bioethics. What is needed
is a universal language and moral framework that is founded on universally shared, transcultural
beliefs, which the human rights framework fulfills.36
Generally, human rights are invoked in three bioethics contexts: 1) the protection of
humans from being harmed by medicine, 2) the discussion about humans as subjects to medical
experiments, and 3) regarding the rights of patients relative to their healthcare services and
providers.37 The discipline of bioethics can learn from human rights due to the nature of human
rights being grounded in the community and in nature itself. In this way, human rights cannot be
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separated from economic and social rights, which is something bioethicists will need to explore
internationally and interculturally.38 Further, Lisa Forman and Stephanie Nixon have delineated
at least three ways that bioethics and human rights complement each other, including how global
bioethics can advance human rights and, conversely, how human rights can advance global
bioethics. 39 These points are essential in order to understand rightly how the fields of global
bioethics and human rights interplay and are can be utilized in ethics guidelines such as the
UNESCO Universal Declaration on Bioethics and Human Rights.
Chapter three examines corporate social responsibility and the pharmaceutical and
biotechnology industry. For the proposed global bioethics tool, corporate social responsibility is
an integral component. Corporate Social Responsibility (CSR) is an increasingly important issue
to stockholders and the general public. This section will first introduce the concept of social
responsibility and will then turn to an examination of CSR applied to the pharmaceutical and
biotechnology industry.
A key concept in global bioethics is the notion of social responsibility and health, which
significantly broadens the agenda of bioethics so that the social and basic issues related to the
provision of healthcare for populations all over the globe are taken into account.40 This section
examines the concept of social responsibility in global health and bioethics. Social responsibility
and health combine two basic ideas: 1) several actors aside from states and governments are
responsible for health, and 2) global problems reflect common challenges and, therefore, should
be addressed through common action.41 This concept has made it into prominent ethics
documents such as the UNESCO Universal Declaration on Bioethics and Human Rights
(UDBHR).42
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The history of social responsibility is rather recent, with a majority of the formal writings
only being traced back to around the 1950s.43 Today, the concept focuses on the responsibility of
the broader society, specifically private companies, toward not only property and profits but also
to those who are affected by or involved in the activity of a company. In a broad sense, the term
is meant to denote a change or enlargement of perspective in the strategies and aims of,
specifically, firms, and calls on them not only to meet their legal duties but also to commit to
improve the welfare of society.44 In bioethics, the notion of social responsibility transcends the
doctor-patient relationship and delves into issues of health economics, public policy, and social
determinants of health.45 Social responsibility in the bioethics context aims to redress the balance
of the field towards a more global, collective approach that brings solidarity to the fore.46
Assuming that society is partly responsible for the health of its members does not settle the
question of how society should fulfill this responsibility. It has been argued that greater attention
should be paid to strategies of promoting health in ways other than simply access to healthcare,
such as environmental and public health and health research.47 Indeed, these strategies are
closely aligned with the field of global bioethics.48
Social responsibility cannot be adequately comprehended without an understanding of
both solidarity and cooperation.49 Émile Durkheim was one of the first social theorists to devote
significant attention to the notion of solidarity, and he noted that societies are only constructed
through social cohesion.50 At a basic level, solidarity involves two aspects: caring for the defense
and promotion of the conditions of social life for which members of a group are collectively
responsible, and caring particularly for the needs and interests of the weaker members of the
group.51 Durkheim, Comte, and other thinkers will be interacted with on this topic. Cooperation
is in many respects a similar concept to solidarity. In the UNESCO UDBHR, the two concepts
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are combined into a single principle, not to argue that they are synonymous, but rather to
highlight their closeness and complementarity.52 John Stuart Mill was an early advocate of
cooperation in the nineteenth century to solve social troubles. Reacting against the inequality and
exploitation of labor he witnessed in his day, Mill proposed that such ills could be overcome
through cooperative processes involving free associations between workers and other workers
and between workers and capitalists.53 Mill was onto the idea that human rights cannot be fully
realized without cooperation, and that in order to see true change, joint action and cooperation is
required.54
The second section of chapter 3 introduces the specific study of CSR and how it relates to
the pharmaceutical and biotechnology industry. CSR has been defined by the UN, at its broadest,
to signify the overall contribution of business to sustainable development.55 There is not
unanimous support for CSR. Since its early beginnings there have been notable critics. This
section will first present a number of general criticisms leveled against CSR, initially focusing
largely on the debate between Milton Friedman and those who hold to an opposite viewpoint,
such as Edward Freeman and Peter Drucker. Friedman’s repudiation of CSR was broadcast
widely in a popular-level New York Times Magazine article in 1970, entitled, “The Social
Responsibility of Business Is to Increase Its Profits.”56 This view was countered by thinkers such
as Peter Drucker57 and Edward Freeman.58 The positions of both sides will need to be critically
considered. Though there are many critics of CSR, the fastest growing cause for shareholders is
sustainability.59
In regards to pharmaceutical and biotechnology companies, some commentators have
made the case that the industry cannot merely be concerned for their own profit margins to the
neglect of the very people who depend on their medications. That is, the business decisions of
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pharmaceutical companies directly impact human health, which makes corporate social
responsibility particularly important.60 Prominent NGOs and international groups such as
UNESCO, Oxfam, Save the Children, and Voluntary Service Overseas, have challenged the
pharmaceutical industry to adopt a broader scope of responsibility and improve its efforts to
tackle the health crisis affecting LMICs.61 In particular, the pharmaceutical industry has recently
been accused of exceedingly high prices. In an August 2015 poll completed by the Kaiser Family
Foundation, one of the premier healthcare public policy think tanks in the US, it was found that
most Americans feel that drug costs are unreasonable (72%) and that drug companies put profits
before people (74%).62 Further, in a 2012 Harris poll, only 12% of persons in the US believed
that drug companies were generally honest and ethical.63 These polls were taken prior to a
succession of high-profile pricing scandals that rocked the industry, including the September
2015 price hike of Daraprim by Turing Pharmaceuticals,64 the Valeant Pharmaceuticals
controversy over price inflation at the same time,65 and the August 2016 revelation that the price
of EpiPen® produced by Mylan has increased 400% from 2007 to 2015,66 and that Mylan falsely
classified the drug in order to overcharge Medicaid for its reimbursement, resulting in a halfbillion dollar fine by the US Department of Justice.67 The importance of personal accounts, a
tactic used for years by human rights and humanitarian NGO’s,68 was significant in the EpiPen®
case, raising the visibility of the situation and causing public outcry.69
These scandals produce negative impacts on pharmaceutical reputation. A recent study
estimates that it is the intangible assets of a company, including reputation, that currently
represent as much as 40-60% of a company’s market capitalization, leading to the conclusion
that a company’s reputation is among its most valuable assets.70 Yet, reputation is at the very
heart of a business. The reputation problem facing the pharmaceutical industry is currently too
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sizeable for any one company to address alone. The industry must work together to rebuild
trust.71 Hence, the proposed dissertation seeks to build a tool by which the industry can
collaborate and dialogue on issues of bioethics, including the sharing of best practices, and
making their implementation of bioethics principles available to the general public and
stakeholders in a transparent manner.
For the global bioethics tool to become a reality, we must answer the question of whether
this is something that is truly needed. Is there sufficient demand for the type of information that
the tool would provide to convince pharmaceutical and biotechnology companies to participate?
Would the disclosure of the bioethical performance of a pharmaceutical or biotechnology firm
influence an individual’s decision on what products to use, how to invest, where to work, or how
they perceive a specific company?72 There may be numerous reasons why a pharmaceutical or
biotechnology company would engage in CSR. Businesses have viewed CSR as a way to
improve their reputation and legitimacy, brand image, gain a competitive advantage, reduce
business risks and costs, and enhance shareholder value.73 There is some empirical data
regarding the impact of corporate social responsibility on a company’s bottom line. Research
suggests there is a positive relationship between a company’s corporate social responsibility
actions and consumer attitude about the company and its products.74 However, when it comes to
CSR and a firm’s bottom line, the data is mixed. Between 1972 and 2002, over 100 studies that
empirically examined this relationship were published.75 To much dismay, the empirical studies
have never been in agreement. Some studies found a positive correlation.76 Others determined a
negative association.77 Still, others found no correlation at all.78 Hence, there must be other
reasons rather than financial for a company to participate in CSR. For the pharmaceutical and
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biotechnology industry, reputational gains and restoring trust is a hugely beneficial effect of
CSR.
Nonetheless, there is precedent for harnessing market forces to recognize and promote
acts of social responsibility through a system of accreditation, certification, or rating. Surveys
show that consumers are likely to avoid products that are linked to socially irresponsible and
untrustworthy companies and will go so far as pay a premium to patronize ethical companies.79
This will need to be further examined, as well as the current mechanisms of implementing CSR,
such as the UN Global Compact,80 UN Guiding Principles on Business and Human Rights,81
Dow Jones Sustainability Group Index,82 amongst others.
Chapter four examines the bioethics guidelines that have been produced since the end of
World War II and the role of governance in bioethics. The purpose of such an undertaking is to
analyze the evolution of bioethics guidelines, note where there are areas of convergence and
divergence between documents, and to introduce the UNESCO Universal Declaration on
Bioethics and Human Rights as well situated to be the foundation of the global bioethics tool.
While no guideline is perfect, and changes occur within medicine, technology, and society to
prompt changes to guidelines, the UDBHR, based upon a moral human rights framework and
broad enough to cover many social dimensions of bioethics, is very well suited for this task.
Section 4.1 examines the ethics guidelines produced from 1947 to the present. Since
World War II, a number of prominent bioethics guidelines have been produced, almost
exclusively by a Western commission, leading to the conclusion by some that modern bioethics
predominantly reflects the traditions of Western moral philosophy and political and social
theory.83 Some of these guidelines address a narrow aspect of bioethics, some have a degree of
governmental authority, some are issued by non-governmental organizations, and others are
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advisory.84 The Nuremberg Code, as stated above, was a product of the aftermath of World War
II and has been a staple of research ethics since its inception. However, it has exerted more
rhetorical invocation rather than actual practice. This may be due to it’s blanket prohibition of
any research that is not voluntary or for its lack of interpretive or enforcement mechanism.85
While it was in many ways the beginning of medical ethics guidelines, many followed. The
World Medical Association (WMA) appalled by the atrocities of WWII, issued a code of
medical ethics in 1948 that was known as the Declaration of Geneva. This code proved very
ambiguous and difficult to interpret.86 The WMA adopted its more prominent Declaration of
Helsinki originally in June 1964.87 It has since undergone seven revisions, tripling its original
size, with the most recent version being approved in 2013.88 While the document is very
prominent in the field of research ethics, it has been criticized for a number of reasons, including
being contradictory, poorly phrased, and making unjustified and unethical recommendations.89
The National Commission for the Protection of Human Subjects of Biomedical and Behavioral
Research (1974-78) produced a report that proved very significant for the direction of healthcare
ethics.90 They selected seven principles that should underlie biomedical human research. These
seven would be reduced to three in the Belmont Report (1978): respect for persons, beneficence,
and justice.91
The Council for International Organizations of Medical Sciences (CIOMS), in
collaboration with the World Health Organization (WHO) first issued guidelines on human
experimentation and medical ethics in 1982. The current 2002 version of their guidelines is now
the third installment of CIOMS guidelines for biomedical research, superseding the 1993 and
1982 guidelines. The present version consists of 21 guidelines with commentaries.92
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Good Clinical Practice is an international quality standard that is provided by the
International Conference on Harmonization (ICH), an international body that defines standards.93
Governments can use these standards by transposing them into regulations for clinical trials
involving human subjects, such as what the US Food and Drug Administration (FDA) has now
done.94 These standards for clinical trials are oftentimes referred to as ICH-GCP. ICH-GCP has
been criticized by some commentators for lacking the breadth, depth, and moral authority of the
Declaration of Helsinki.95
Indeed the past two decades have witnessed an upsurge of interest in international
declarations on bioethics and, specifically, global bioethics and the governance of bioethics.96
The 1997 Council of Europe Convention for the Protection of Human Rights and Dignity of the
Human Being with regard to the Application of Biology and Medicine is a notable example.97 As
this document preceded the Universal Declaration on Bioethics and Human Rights, it is lauded
as “the first international treaty in this field.”98 In this section, in order to make a concise and
well-analyzed argument for the utilization of the Universal Declaration on Bioethics and Human
Rights as the grounding for the global bioethics tool, these aforementioned bioethics guidelines
will need to be systematically analyzed, their strengths and weaknesses analyzed, and
conclusions drawn as to why they are less suited for the task of a global bioethics tool than the
UNESCO Universal Declaration on Bioethics and Human Rights.
Section 4.2 analyses the UNESCO Universal Declaration on Bioethics and Human
Rights. In order to solve global problems, global solutions and the commitment of the global
community are necessary.99 In 2001, the UNESCO Director-General was asked to look into the
possibility of developing a universal bioethics instrument. On the basis of the International
Bioethics Committee’s subsequent report, the 2003 General Conference declared the setting of
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universal bioethical standards to be “imperative and desirable.” An extensive drafting and
consultation period then ensued, involving member states and other stakeholders.100 Because of
the need to incorporate international and universal perspectives, the declaration is by necessity
the result of compromise. Indeed, it is this compromise and internationality that provides
strength to the declaration and its normative ethical standards. The declaration represents the
views of the UNESCO Member States and not just scientists and ethics experts.101
The Universal Declaration on Bioethics and Human Rights is well positioned to be the
framework upon which the global bioethics tool is built for at least the following reasons: 1) it is
the first and only bioethics declaration to gain the approval of international governments (all
UNESCO Member States), with the input of bioethics experts, rather than solely a group of
individuals with bioethics or scientific expertise, 2) it efforts to incorporate major principles in
bioethics, such as those included in the Declaration of Helsinki and ICH-GCP, 3) the Declaration
also stretches beyond individual orientations to bioethics to a global perspective, focusing on
issues such as the environment, respect for cultural diversity, capacity building, and future
generations, and 4) the Declaration is very useful for countries that lack an infrastructure in
bioethics. The need for worldwide standard-setting in bioethics has been strongly expressed by
low- or middle-income countries (LMICs) who want to share the benefits of the developments of
science and technology and not only be the providers of data and resources.102
Section 4.3 begins by elaborating on what is meant by “governance” and especially its
role in global bioethics. Understanding the role of governance in bioethics requires the historical
consideration of how bioethics became institutionalized into the specific forms of committees,
regulatory bodies, and commissions.103 Governance has developed alongside globalization and is
no longer sufficient to be applied merely within states. Cooperation towards the oversight and
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implementation of global bioethics principles cannot be considered the work of a particular state,
but must be the doing of a coalition of partners, which may necessarily involve those who are
regularly affected by bioethics, such as the pharmaceutical industry. There are many problems
for global bioethics governance both at the international state level (between governments) and
at the level of commerce (between companies) that will need to be discussed.104 The need for
greater cooperation at the state level and the level of commerce will be explained in this section.
Further, different models for implementing governance upon companies externally (i.e. not from
directly within the individual firm) will be presented and analyzed for the current proposed
global bioethics tool.
The Commission on Global Governance has defined governance as follows:
Governance is the sum of the many ways individuals and institutions, public and private,
manage their common affairs. It is a continuing process through which conflicting or
diverse interests may be accommodated and co- operative action may be taken. It
includes formal institutions and regimes empowered to enforce compliance, as well as
informal arrangements that people and institutions either have agreed to or perceive to be
in their interest.105
While governance is often thought of in terms of states and governments, it is also applicable to
companies, foundations, and institutions. In the realm of bioethics, declarations and, specifically
the applications of the principles, at local levels such as companies and research universities, as
well as at national levels, is the idea of governance.106 For global bioethics, if there are global
ethical frameworks, how can they be applied at a global level in order to address problems on a
global scale?107 Some have proposed a system of accreditation, certification, or rating to validate
how pharmaceutical companies are doing in regards to certain indicators.108 This section will
also examine systems of accreditation, certification, and rating.
In the literature and in practice there are differing models of accreditation, certification,
and rating for companies in regards to implementation of ethical principles. Accreditation
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systems date back around a century to when the Joint Commission was established. Certification
systems are more recent and achieved popularity largely in response to activists who viewed the
logging industry and population growth as threats to forests and the environment. Rating systems
date back to around the turn of the twentieth century and have been notably used by the Access
to Medicine Foundation in their biennial publication.109 These different models will need to be
considered for the proposed global bioethics tool. While some sort of rating system is certainly
promising for the proposed global bioethics tool, a system of certification or accreditation is
outside the bounds of the project at this time. That is, this tool is not currently designed to be a
statement that participating companies have eliminated harmful bioethics practices and are
certified as being upstanding bioethics citizens. Rather, the proposed tool is a measure of how
well companies are doing in regards to applying and implementing certain principles. While it is
envisioned that stakeholders and the general public will be able to compare how Company X is
doing in comparison to Company Y, a system of certification or accreditation would be asking
too much of the global bioethics tool at this stage. A model that is more promising at this stage is
rating. While there have been shown to be many positive benefits of a rating system, such as
stimulating companies towards competition within the industry and thus greater social
responsibility,110 rating does not inspire collaboration between competitors. The proposed project
is based around the idea of generating best practices for the industry and spurring greater
transparency rather than rating companies.
Chapter five presents the global bioethics tool, including methodology and the
development of indicators. The proposed global bioethics tool involves four main steps: First, a
preliminary phase, consisting primarily of desk research, is conducted to develop indicators,
research the viability of the project, and determine the interest level of UNESCO. Second, an
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exploratory phase seeks to gather interest from 4-5 top pharmaceutical and biotechnology
companies so that a partnership can be formed. The exploratory phase also involves reaching out
to the UN Global Compact to discover if there are partnership opportunities with them. The third
phase commences once there is a commitment from 4-5 companies. This phase is also the
longest and consists of refining the indicators, interviewing the companies, generating best
practices, producing a functioning self-reporting website, and other activities in order to make
the global bioethics tool eventually reach the point of sustainability. Finally, the fourth phase
forms a non-profit foundation to house the global bioethics tool. To make the foundation
financially sustainable, member organizations would pay into the foundation with a dues
structure based upon the annual revenue of the organization. Such a system has been set up
before, as similar dues structures are used by Business for Social Responsibility111 and other
industries have also set up similar foundations, such as IPIECA, the global oil and gas industry
association for environmental and social issues.112
Section 5.1 begins by presenting the rationale and methodology behind the creation of the
proposed global bioethics tool. In order to justify that the proposed global bioethics tool is
needed, we must provide evidence that there is sufficient demand for this type of evaluation from
stakeholders in order to convince pharmaceutical and biotechnology companies to participate. In
other words, is there a strong business case for firms in the pharmaceutical industry to divulge
aspects of bioethics implementation and assist the industry in developing best practices? Jennifer
Miller has described the case for accreditation, certification, or rating within the pharmaceutical
industry based upon consumer interest.113 Similarly, this rationale is significant for the proposed
global bioethics tool. We must remember that prescription sales are not the only products that
pharmaceutical companies are concerned about. Many companies offer a vast array of over-the-
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counter (OTC) medicines or home products. For instance, Bayer is known for their aspirin and
Johnson & Johnson is known for numerous OTC medicines as well as medical supply products
like Band-Aid. Hence, even persons who do not regularly take prescription medication are likely
to use at least some of the non-prescription products from a pharmaceutical company. The
benefits of a voluntary, transparent global bioethics tool reach beyond restoring reputation and
positive public image for the pharmaceutical industry. Such a tool would aid the industry in
better understanding and defining what good ethical practices look like, motivate companies to
incorporate better ethical processes into their operations, and send a clear message to multiple
stakeholders that they are serious about implementing bioethics into their business. Hence, this
subsection begins by detailing the justification for the tool.
Following this, the methodology of creating the global bioethics tool from its inception to
the present is explained. In January 2016 the bioethics division of Novo Nordisk awarded a 6month grant to Duquesne University to work on developing a global bioethics tool for use by the
pharmaceutical and biotechnology industry and to see if such a tool is viable for the industry.
The Principal Investigators (PIs) on the study were Lise Holst, MD, PhD, Director of Global
Bioethics Management at Novo Nordisk and Henk ten Have, MD, PhD, Director of the Center
for Healthcare Ethics at Duquesne University. As chief researcher on this project, the author was
deeply invested in the project from its origin. This section will describe the process that took
place in beginning the project and the different phases, including trying to collaborate with
multiple stakeholders, comprising major pharmaceutical and biotechnology companies and
UNESCO. In July 2016 the grant was extended for an additional 6-month period as an
“exploratory study” to investigate the feasibility of engaging primarily pharmaceutical and
biotechnology companies in setting up this initiative. A number of major, top-20, pharmaceutical
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and biotechnology companies were contacted to ascertain their interest in collaborating on this
project. The entire methodology describing the process of how the project unfolded will be
presented in detail in this subsection.
A primary goal of the global bioethics tool is to create a platform through which
companies can discuss and develop industry best practices. To achieve this, a process of
determining best practices and benchmarking will need to occur. Benchmarking is the systematic
search for best practices that leads to superior performance.114 The concept of benchmarking
draws from the Japanese industrial practice dantotsu, referring to a method for finding the best
practice that consistently yields the best results in that industry.115 From its inception,
benchmarking has been utilized to identify aspects of an organization’s activity that could be
more efficient/effective by comparison with the performance of other relevant organizations. The
data regarding the other relevant organizations and their key processes are used to identify and
implement changes.116 There are four types of benchmarking: internal, competitive, functional,
and generic. Each type has its specified outcomes and benefits depending on what the
organization wants to achieve, and each will be discussed.117
Benchmarking is perceived by many as a strategic tool to increase productivity, enhance
learning, assess performance, and continuously improve upon an operation.118 While there is no
single accepted method for making benchmark analyses, a frequently used model is proposed by
Robert Camp, a pioneer in the field of benchmarking. Camp divides benchmarking into two main
parts: practices and measures.119 He delineates a twelve-step process on benchmarking that is
split into five phases. The process starts with deciding what to benchmark and whom to involve,
following up with planning and conducting investigations to collect data, determining
performance gaps and projecting future performance levels, and communicating findings. The
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final steps are focused on revising and improving performance goals, developing an action plan,
and finally implementing action plans, monitoring results, refining benchmarks when necessary,
attaining leadership position, and fully integrating the practices into the processes.120This model
of benchmarking will be examined along with others, including the proposed set-up of
Spendolini,121 Watson,122 Zairi,123 and Letts.124 A possible set-up for how to determine best
practices and how best to utilize benchmarking for the proposed global bioethics tool will be
presented.
Section 5.2 presents the development of indicators. Performance measurement is a
fundamental principle of good management. The measurement of performance is significant
because it identifies performance gaps between current and desired performance and provides
indication of progress towards closing the gaps. The use of key performance indicators may
identify precisely where to take action to improve performance. Key performance indicators
represent a set of measures focusing on those aspects of organizational performance that are the
most critical for the current and future success of the organization.125
A key performance indicator can be defined as an item of information collected at regular
intervals in order to track or measure the performance of a particular system.126 Qualitative and
quantitative key performance indicators are used as a means of measuring and monitoring the
progress towards particular goals and objectives.127 In the UNESCO Universal Declaration on
Bioethics and Human Rights, the core of the declaration is found in fifteen principles (Articles 317).128 Indicators, in the form of questions, are developed based upon each of these principles so
that one can qualitatively assess how a particular company is doing in implementing the
international standards. In developing these indicators, the UNESCO UDBHR was first
compared to the other prominent bioethics guidelines, such as those presented in 4.1. As an
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example of this process, Article 15 of the UDBHR concerns benefit sharing and states the
following:
Chapter 6 Benefits resulting from any scientific research and its applications should be
shared with society as a whole and within the international community, in
particular with developing countries. In giving effect to this principle, benefits
may take any of the following forms: (a) special and sustainable assistance to,
and acknowledgement of, the persons and groups that have taken part in the
research; (b) access to quality health care; (c) provision of new diagnostic and
therapeutic modalities or products stemming from research; (d) support for
health services; (e) access to scientific and technological knowledge; (f)
capacity-building facilities for research purposes; (g) other forms of benefit
consistent with the principles set out in this Declaration.
2. Benefits should not constitute improper inducements to participate in
research.129
As the Declaration of Helsinki also discusses sharing of benefits in Articles 22 and 34, the two
documents were compared for similarities and to see the general requirements of benefit sharing
in each document. Additionally, prominent, current literature on each of the principles was
examined and will continue to be investigated during this process to better understand how each
principle could be implemented by the pharmaceutical and biotechnology industry. For the
principle of benefit sharing, the following three indicators have been developed based upon the
principle of benefit sharing:
Chapter 6 How does the company ensure that the benefits resulting from its scientific
research are shared with society as a whole?
2) When conducting clinical trials, does the company ensure that in advance
of the trial, provisions are made for post-trial access for all participants who
still need an intervention identified as beneficial in the trial (DoH, Article 34,
2013)
3) How does the company ensure against improper inducements to participate
in research?
Therefore, other prominent bioethics guidelines were consulted while forming these indicators,
as well as the two Pis on this study, one of which is an expert in corporate social responsibility
and pharmaceutical bioethics, and the other an authority in global bioethics. Moreover, the
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importance of substantial stakeholder engagement to further refine these indicators cannot be
overstated. Nonetheless, the developed indicators provide a good starting ground for the global
bioethics tool.
The process for developing these indicators will be discussed in greater detail, and the
indicators will be presented. To arrive at the indicators, the principles of the UNESCO
declaration were closely examined. The principles of the UNESCO declaration were also
examined alongside corresponding principles found within other prominent ethics guidelines,
such as those presented in chapter four. The commentary on each of the UNESCO declaration
principles found in both The UNESCO Universal Declaration on Bioethics and Human Rights:
Background, Principles and Application and the Handbook of Global Bioethics were both were
initially consulted, as they are primary source material from those who helped craft the
document. Additionally, experts both in the field of global bioethics and in the pharmaceutical
industry were consulted. The result is a list of indicators for each of the core fifteen principles.
Admittedly, the indicators that have been developed constitute a beta version of the global
bioethics tool. In order to further verify the quality of the indicators, further consultation with
global bioethics experts and industry stakeholders will need to take place, as well as applying the
indicators to actual companies.
Chapter six develops the reporting framework for the global bioethics tool and applies the
indicators that were presented in the previous chapter to major pharmaceutical and/or
biotechnology companies. As implementation is an ongoing process, it is envisioned that the
indicators discussed in the previous chapter will need revising on an ongoing basis in
consultation with various stakeholders. Nonetheless, this first step of application is necessary in
order to establish a baseline of where certain companies are in implementing the principles of the
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Universal Declaration on Bioethics and Human Rights. In order to accomplish this, publicly
accessible information has been utilized. Additionally, persons from each company are to be
contacted for further information if needed.
Section 6.1 presents the reporting framework for the global bioethics tool. In regards to
reporting, the global bioethics tool is envisioned as a set of questions with a self-reporting
framework for companies. One problem with reporting frameworks in general is that they can
become cumbersome. Every reporting framework that a company joins will require a separate
report, which could result in numerous reports being filed annually with much manpower
utilized.130 The overabundance of reporting in the human rights realm by state actors has been
shown to spread a government’s available resources thinly rather than investing in high-quality
reporting.131 Global Reporting Initiative, an international independent standards organization that
helps businesses and governments understand and communicate their impacts on issues such as
climate change, human rights, and corruption, estimates that the cost for a company to report
issues of sustainability can vary from as little as €2,000 to over €100,000.132 For small and
medium-sized businesses, such reporting may be especially onerous.133 Hence, in order for an
implementation mechanism such as the global bioethics tool to be maximally effective, a selfreporting framework that seeks to minimize the burden placed upon companies seems optimal.
The reporting frameworks of several organizations in the industry will be examined for
their strengths and weaknesses in order to make a recommendation for this project. The reporting
framework of the UN Global Compact is known as the “communication on progress” (COP).
Signatories are required to submit an annual report on how they are implementing the ten
principles of the UNGC in their practices.134 Additionally, a collaboration between The Danish
Institute for Human Rights, the Confederation of Danish Industry, the Ministry of Economic and
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Business Affairs, and the Danish Investment Fund for Developing Countries has created a Global
Compact Self Assessment Tool that is designed to help a company evaluate how they are doing
in integrating and implementing the UNGC in their company. The tool contains indicators that
are set up in the form of indicators so that companies can see how well they are doing in
implementing the ten principles.135 An entity named “Shift” in 2015 launched a UN Guiding
Principles Reporting Framework that seeks to help companies self-report on their activities
implementing the UN Guiding Principles on Business and Human Rights. The Reporting
Framework takes the form of a questionnaire (31 questions) for companies to answer as they
strive to meet their human rights responsibilities.136 These reporting tools and others will be
examined in order to make a recommendation for how to proceed with reporting for the global
bioethics tool.
Section 6.2 seeks to apply the global bioethics tool, with the list of indicators developed
in section 5.2 and the reporting framework developed in section 6.1, to at least two
pharmaceutical and/or biotechnology companies—one of which is a major Western company
and the second a firm based in a LMIC. The purpose of choosing a company both from a highincome country (HIC) and a LMIC is to demonstrate that the global bioethics tool is a useful
instrument for any pharmaceutical or biotechnology company that is involved in research and
development, not only large Western entities. In the exploratory phase of the study (JulyDecember 2016), conducted in conjunction with Novo Nordisk, companies were initially
screened for whether they were signatories to the UN Global Compact, if they were included in
the 2014 Access to Medicine Index, Dow Jones Sustainability Indices, and whether they were a
member of Business for Social Responsibility. If a company was found in multiple of these then
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they were viewed as having interests in the area of CSR. Hence, this formed the initial criterion
for contacting companies.
This section is largely hypothetical as it applies the indicators and benchmarks to
different companies. In order to accomplish this, publicly accessible information is utilized.
Public information found on the company’s websites, available in academic literature, and
reported through alternative mechanisms such as the UN Global Compact COP will be scoured.
Additionally, representatives from each company are to be contacted for further information on
an as needed basis. While this section is hypothetical, the purpose of applying the tool in this
section is to demonstrate its viability. Hence, the global bioethics tool is not merely a curious
academic exercise, but it is a practical way to more fully implement bioethical principles into the
business practices of the pharmaceutical and biotechnology industry. Applying the tool to
specific companies will also showcase areas where the tool is in need of refinement. However,
refinement will best come through engagement with multiple stakeholders and having intimate
knowledge of the workings and practices of specific companies, which is difficult to accomplish
by an outsider.
Chapter seven is the concluding chapter, reviewing the dissertation and the need for a
global bioethics tool in order to address issues within the pharmaceutical and biotechnology
industry. While a model global bioethics tool was developed with specific indicators and
benchmarks, the global bioethics tool is not a complete endeavor. To be most effective at
achieving the aspired goals, the tool must continually be tested and altered if needed. This will
happen in consultation with multiple stakeholders. The process of attempting to implement the
UDBHR principles and gain pharmaceutical industry support around the tool is examined in this
chapter, and the reasons for not implementing the tool in industry will be studied. Further options
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for seeing the tool adopted by the pharmaceutical and biotechnology industry, such as alternate
ways of promotion or seeking support from others in the industry, will be assessed.
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Chapter 2: Global Bioethics and Human Rights
Chapter two discusses the relationship between global bioethics and human rights in order to
provide the necessary foundation for discussing the UNESCO Universal Declaration on
Bioethics and Human Rights, as well as the context in which the global bioethics tool operates.
The gradual evolution of global bioethics will be first discussed. This will be followed by the
status of the human rights discourse and the current relationship between global bioethics and
human rights. The symbiotic relationship between global bioethics and human rights will be
considered in detail.
2.1) Global Bioethics
This section examines the gradual evolution of global bioethics from the fields of medical
ethics and bioethics. The history of medical ethics growing out of the atrocities committed
during World War II has been well documented.1 In the aftermath of World War II the Allied
powers established the Nuremberg tribunals (1946-47), which brought forth charges and
convictions for many of those involved in the Nazi experiments and Jewish Holocaust.2 Sixteen
physicians were found guilty, and seven of those were hanged for their crimes.3 Included in the
Nuremberg judgment was the Nuremberg Code, ten statements of ethical rules to govern
research, designed to protect the rights and welfare of those who participate in human research.
The Nuremberg tribunals would assist in the revival of human rights and established the legal
precedent that heads of state, governmental officials, and military members could be punished
for crimes committed against humanity.4
The Nuremberg Code is centered on the research relationship between
physician/researcher and patient/subject.5 The Nuremberg Code required that research with
human participants utilize voluntary informed consent, aim at positive results for society that
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cannot be obtained another way, be designed on the results of animal experimentation, be set up
in a way that avoids unnecessary physical and mental suffering and injuries, have risks/benefits
adequately assessed, be conducted by qualified personnel in a proper facility, and, participants
must be free to terminate their participation in the experiment at any point. Lastly, medical
personnel are obligated to suspend and perhaps even terminate the experiment at any point when
they observe that continuation would be unsafe.6 These ten guidelines would prove influential in
forming a foundation for the new discipline of medical ethics, and we cannot separate the root of
modern bioethics from the atrocities committed during this period. It is important to note the
initial response of the American judges to the horror of the Nazi doctors and the concentration
camps was to articulate, in the first principle of the Nuremberg Code, the doctrine of informed
consent. This is one of the key foundations of bioethics, and it was born at Nuremberg in 1947.7
By the end of World War II, the Allied nations recognized the need for a new
international body to oversee world affairs and replace the largely ineffective League of Nations.
A new intergovernmental organization, the United Nations (UN), was born in 1945.8 To a large
extent, the UN was formed as an attempt to reaffirm faith in the dignity and worth of all
mankind, as well as the fundamental human rights that all persons globally share.9 In spite of
several countries initially opposing inserting human rights into the charter of the UN, eventually
the constituents agreed and devoted a few lines of the document to reaffirming faith in
fundamental human rights and in the dignity and worth of the human person. In hopes of curbing
the scale of human atrocities witnessed in World War II from happening again, the UN retains a
Security Council that is charged with maintaining international peace and security. Further, the
UN charter provided for an International Court of Justice to be established at The Hague in the
Netherlands as the primary judicial branch of the UN.10
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In 1948 the UN adopted the Universal Declaration of Human Rights (UDHR) without
dissent and with eight nations abstaining.11 The UDHR was clearly impacted by the Nuremberg
tribunals and the condemnation of physicians and scientists for horrific crimes committed against
humanity. The UDHR opens with a statement recognizing “the inherent dignity of all members
of the human family.”12 While the UDHR is not legally binding on countries, it does carry
significant moral authority.13 Though it is erected on the footings of its eighteenth century
predecessors, the UDHR was the first explicit human rights declaration of the contemporary
system of international human rights law.14 The UDHR proclaimed the equal rights and inherent
dignity of all humanity by articulating a broad range of rights to be protected in pursuance of
core human rights values.15
However, the UDHR did more than simply reaffirm the eighteenth century notions of
equality and certain freedoms. The UDHR expressly prohibited slavery and called for a variety
of other universal rights, including the right to marry, to right to education, the right to work with
equality of pay, and many others.16 The issue of universality—that there are rights that apply to
all persons in all stages of life and in all contexts—is one of the topics understood by many to be
a common feature in both bioethics and human rights.17 This universality found within the
modern discourse on human rights has been drawn largely from the paradigm shifting nature of
both the US and French declarations. Therefore, it can be said that the UDHR presented a global
framework that transcends culture, ethnicity, and religion.
What is more, the UDHR made specific, original contributions to efforts to achieve
global health equality. It declared that the right to health was universal in scope and recognized
that governments are responsible for the health of their people. Thus, the UDHR effectively
recognizes every person’s right to a standard of living adequate for health and wellbeing. With
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the intergovernmental backing of the UN, this empowers rights-holders.18 An essential shift was
occurring in which the language of the universal right to health transferred from appeals to
charity to demands upon nation-states based in legally binding duties and justice. This approach
is advantageous because humanitarianism is redefined from the language of compassion to a
language of rights and dignity. This redefinition grounds humanitarianism in the moral-legal
framework of international human rights law. In this regard, people are viewed as citizens of the
world with the same claims and rights as everyone else. Thus, human rights make people equal
and give them more power.19 The effects of this would see governmental policy-makers viewing
health as an area implicating legal and moral duties.20
Though many applaud the work of the UDHR and similar documents, some critics have
taken issue with them, finding them inconsistent and overblown. They argue that a human rights
framework cannot be imposed on healthcare. Thus, in their view, the principles of human rights
work best as limitations on governments because they specify actions that they may not
undertake.21 While these criticisms should not be taken lightly, a human rights framework has
been seen to work well when imposed on healthcare, for it empowers people and promotes
equality and justice.
Unlike the focus of modern bioethics or the human rights discourse, the focus of medical
ethics is relatively narrow, concerning itself chiefly with the relationship between
doctor/researcher and patient/subject. This is predominantly seen in the Nuremberg Code, which
was in many ways a template for how medical ethics developed in the years leading up to the
birth of bioethics. While the focus of medical ethics was narrow, the link between bioethics and
human rights is historically strong, as is seen in the relationship between the Nuremberg Code
and the UDHR.22
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Before the modern elaboration of bioethics, in the time period between Nuremberg and
the early 1970s, there came the development of what is typically referred to as medical ethics. In
the decades following WWII, medical ethics took a turn as medical science and medical
technology advanced and became increasingly technical. Traditional duties of the physician were
challenged, as it was no longer clear-cut what constituted benefit and harm. Medicine grew very
technical and very expensive in Western nations. New intellectual resources were summoned to
analyze and critique the novel questions: What is benefit? What is harm? How should expensive
resources be distributed? What does justice mean in a healthcare context? Professionals that were
hardly proficient in medicine—chiefly, theologians and philosophers—were called upon to enter
into these discussions.23 Theologians, with an extensive tradition of reflecting on life, suffering,
and death, were already more accustomed to engaging in moral theory than many philosophers,
steeped in the deontological and teleological theory of the day.24 The works on healthcare ethics
penned by Catholic moralists during the early twentieth century provided a discussion of
fundamental moral principles that were underpinned by natural law, divine revelation, and
magisterial instruction. The Catholic moral theologians also provided casuistic analysis of
specific topics they saw as paramount to their day: abortion, contraception, et. Al. As the age of
bioethics opened in the latter part of the twentieth century, such prominent Catholic moralists as
Richard McCormick, a Jesuit priest, and Charles Curran would criticize these methods for their
interpretations of both natural law and the magisterium. Therefore, by the time medical ethics
was being formed, Catholic moral theology was in a state of disorder due to internal
disagreements over its methods.25
McCormick was the main Catholic moralist to preside over this period of medical ethics.
While faithful to the natural law heritage of the Church, he was also open to revision when
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necessary. Thus, he entered the bioethical dialogue rather seamlessly as he held that moral
judgments based on reason could be understood by all rational persons, irrespective of religious
orientation. Perhaps his greatest contribution to bioethical theory came when he took up the
discussion of double effect and both refined and expanded its principles. McCormick’s legacy is
that of helping to liberate Catholic moral theology from a rigid application of natural law that
would form a method for moral analysis.26
Protestant ethics at the time focused considerably on personal morality and biblical
obedience. Two chief Protestants presided over the formation of healthcare ethics: Joseph
Fletcher and Paul Ramsey. Fletcher, an avowed act-utilitarian, deeply stressed situationism. His
theory, essentially, posited that apart from the intention of an agent, which must be love, the
rightness or wrongness of a moral action was only determined by the situation.27 Thus, Fletcher
easily championed the goodness of every advance in medicine, for he only found criticism when
harm might outweigh the benefits for society collectively. Ramsey, starkly contrasting Fletcher,
provided a deontological ethic to the conversation of healthcare ethics. Rigorous biblical
principles support Ramsey’s analysis of moral issues in medicine. Further, Ramsey promoted the
work of casuistry because he saw the imperative for healthcare ethics to deal competently with
concrete issues.28
For philosophers, in the years leading up to the birth of medical ethics, the chief theories
of normative ethics were grouped into teleological and deontological categories. Utilitarianism,
the central example of teleology, was presented as compelling for moral philosophy, yet suffered
from many weaknesses. Similarly, deontological approaches would also be dismissed as relying
too heavily on intuition. Moreover, logical positivism was highly favored in America as a
method of analysis to be applied to disciplines outside philosophy. To be sure, no overarching
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theory dominated the philosophical field. Thus, those philosophers who decided to cross into the
bioethical realm were unlikely to bring an orthodoxy or collective methodology to the
discussion.29
It was in 1970 that the term bioethics was coined, marking a significant shift from the
discipline of medical ethics that paved the way.30 The word “bioethics” has a somewhat
contentious birth. Both Van Rensselaer Potter at the University of Wisconsin and Andre
Hellegers at Georgetown University would begin using the word nearly simultaneously, leading
some to argue for a bilocated birth of the term.31 The stream of thought originating with
Hellegers saw bioethics as primarily an extension of medical ethics focused on medical issues
and medical technology, with still a very individualized approach.32 Yet, Potter’s alternate
stream, though not as popular, attempted to incorporate social and global perspectives into the
discipline.33 Potter, a research oncologist, envisioned bioethics as a bridge.34 It was a bridge
between the present and the future, science and values, nature and culture, and man and nature.35
It was Potter who, heavily influenced by the works of C. H. Waddington, a Scottish
geneticist, Pierre Teilhard de Chardin, the French Jesuit philosopher and geologist, and Aldo
Leopold, the American environmentalist, would later coin the term “global bioethics” because of
his discontent with the lack of a social perspective incorporated into bioethics.36 Potter stated at
the time of coining the term “bioethics” that it was Waddington who influenced him more than
any other individual. Waddington was concerned with the need to develop ethical theory in the
light of biological knowledge and was, in Potter’s estimation, “essentially a bioethicist before the
word was invented.”37 It was Teilhard who anticipated what today is termed “globalization.” One
of his main beliefs was that humanity would develop into a global community. Teilhard devoted
his life to reflection on the place of human beings in the universe and the grand scheme of
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evolution. These ideas resonated with Potter as he recognized that Teilhard, like himself, was
absorbed in the problem of human progress and the survival of humankind.38 Further, the works
of Aldo Leopold intrigued Potter due to Leopold’s environmental and conservationist efforts.
Leopold also acknowledged that human survival depended on the maintenance of a healthy
ecosystem and the regulating of human fertility. Potter saw these ideas as monumental for
Leopold’s thinking, yet also noted that Leopold’s views on items such as the overconsumption of
renewable and nonrenewable resources by an increasing human population were simply
neglected and overshadowed by those who felt his love for nature was a more comfortable aspect
of his philosophy on which to latch. These ideas were immensely important for Potter and
greatly aided in informing and shaping his views on global bioethics.39
However, these views were at odds with other streams within bioethics. From the
beginning of bioethics there were major differences and even clashes between the Potter and the
Hellegers/Georgetown understandings of bioethics. Potter saw the field of bioethics addressing
the pressing questions of the day: war, population growth, poverty, politics, and environmental
concerns. He saw these concerns as of utmost priority for the survival of mankind.40 Potter
would term this “the science of survival”.41 The search for wisdom, according to Potter, should
be promoted in terms of the survival and improvement of humankind.42 However, the
contemporary orientation of bioethics is oriented mainly around medical issues and technologies,
which places it at odds with Potter’s initial conception. Though the Hellegers/Georgetown
approach came to be the more widely accepted, Hellegers also, surprisingly, proposed a global
approach to bioethics, bringing his vision much closer to Potter’s evolving view.43
Not at all satisfied with the restricted medical application of bioethics, in 1975 Potter
stated that the word bioethics had become fashionable and not in line with what he had intended.
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Potter saw the Georgetown interpretation of bioethics as simply medical ethics under a new
name and as restricted to individual survival with little consequence for societies and
populations. Further, Potter thought the direction of bioethics was emphasizing individual
autonomy over the common good, was too specialized, and merely doing applied ethics rather
than creating anything significantly new. Yet, perhaps his chief complaint was that the
Georgetown definition of bioethics provided no global perspective for LMICs and displayed no
interest in environmental or social concerns.44
Bioethics had been proposed by Potter to combine human values with ecological facts.
Many forgot this.45 Disappointed with the Georgetown interpretation of a narrow concept of
bioethics taking priority over his broader conception, Potter would craft the term “global
bioethics” in 1988 to broaden the scope of bioethics to address the concerns he saw as
prominent. For Potter, the word “global” suggests that the approach should be unified,
comprehensive, and worldwide in scope.46 Global bioethics, in Potter’s view, would truly be
worldwide in that it would go beyond international bioethics. Global bioethics is not merely a
matter of simply crossing borders, but it concerns the entire planet as a unified whole. Hence, it
is worldwide. Potter’s second meaning of global referred to bioethics as more encompassing and
comprehensive, combining traditional biomedical ethics with concerns for the environment and
ecosystem.47 This new approach would also emphasize the problems that Potter saw as urgent
concerns for the survival and progress of mankind.
Potter’s contention that bioethics is too insular rather than expansive is a common
critique today. Since Nuremberg, medical ethics, and bioethics specifically, has been charged
with, at times, placing the loci of focus too strongly on individual matters while neglecting the
social context of medicine.48 While focused on the individual rights and welfare of the research
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participant from the beginning, bioethics and a wave of personal autonomy became more distinct
in the 1970s during debates over life-sustaining treatments, making headway into medical clinics
and hospital units.49 Recently, however, particularly since the turn of the millennium, bioethical
discourse has evolved to a degree and has been concerned with and characterized by a global
perspective on issues and has been more closely linked with international human rights law.50
Yet, for this to continue and truly see bioethics transformed into a global perspective, the field
must expand into various directions. While modern-day bioethics has incorporated other fields
into its perspective, such as human rights, others are lagging. A clear environmental ethic and
deep social concern continues to be noticeably absent. Bioethics is nowadays primarily focused
on the problems of HICs and how they affect individual persons. The plight of LMICs and
general populations is most often grossly neglected. The Western view of bioethics also often
assumes that it can merely be exported to other contexts around the world as a universal, onesize-fits-all framework.51
For much of the late twentieth century and early twenty-first century, following Potter’s
formulation of global bioethics, his idea were not influential and his publications not recognized
by those in the influential bioethics community.52 However, due to globalization, this is no
longer true. Since the late 1970s, the global political economy and rules of trade have been
transformed by neoliberal ideology and practices. The policies enacted under this ideology have
supported the rise of globalization and global trade.53 Though there is no standard, agreed upon
definition for globalization, it has been described as encompassing transnational economics and
politics and the transmission of knowledge.54 Others have thought of globalization as the world
getting “flat” in a sense due to the interconnectedness of peoples that makes geography and
distance not seem quite real.55 Human beings are interconnected now in a complex system of
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interdependency with changes and developments on one side of the world affecting the other.
Marshall McLuhan termed this phenomenon “the global village.”56 Raúl Urzúa has proposed a
multifaceted definition of globalization that is characterized by the acceptance of a set of
economic rules for the entire world designed to maximize profits and productivity by
universalizing markets and production, technological innovation and organizational change
centered on flexibility and adaptability, the reduction of the welfare state, and the dissemination
of common cultural values.57 The field of economics and finance, with the integration of national
economies into international or global ones, through trade, foreign direct investment, and capital
flows is a key feature of globalization.58 Nonetheless, while there is no agreement about how to
define globalization, some common themes emerge from the definitions. It is agreed that
advances in communications and technology have created greater interconnectedness with
persons all over the globe. Further, globalization can be said to include at least the following five
key dimensions: 1) economical, 2) political, 3) environmental, 4) cultural, and 5) ideological.59
The process of bioethics becoming a global enterprise has many causes, some of which
are due to the changing context of globalization. There are at least four reasons why bioethics
has become global. First, globalization has influenced how we perceive the world. Traveling and
interacting with new cultures and ways of life has brought about the encounter of different
worldviews and ethical reasoning. Ideas, philosophies, and worldviews do not stop at
geopolitical boundaries, as the world is a global community. Second, globalization has changed
decision-making in ethical and non-ethical matters by highlighting the interconnectedness of our
world. A third reason deals with international cooperation. The existence of very contagious,
communicable diseases that may cause pandemics, such as Ebola and the Zika virus, or issues
such as clinical research in LMICs, warrants thoughtful dialogue and cooperation in problem
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solving at an international level between nations. Fourth, bioethics has also become a global
enterprise due to inequalities in health care. Unequal treatment in the access to health care
addresses issues of social justice, and it is this social nature that is a defining characteristic of a
global approach to bioethics.60
In addition to the above four reasons why bioethics has become a global enterprise, Henk
ten Have has distinguished four stages in which this gradual process of globalization has taken
place. The first stage of the globalization of bioethics witnessed a broader scope introduced into
the agenda of bioethics. In this stage, the individual autonomy narrative is increasingly criticized
as being too narrow and reductionist, without regard for the common good. Many bioethicists
have criticized such a minimalist approach to bioethics. Daniel Callahan has been foremost
among them since the early days of the field.61 It was thanks in large part to the efforts of
Norman Daniels for providing comprehensive commentaries on social responsibility for health,
thereby broadening the traditional scope of bioethics. Daniels claims that society has an
obligation to protect the opportunities of its members, an argument which he forms by examining
theories of justice.62 This has been a key development for the field of bioethics that has long been
steeped in individual clinical medicine and medical technology, yet has struggled to address the
social and institutional context of medical decisions. Hence, bioethics should become more
global in the sense of more encompassing, which is gradually being seen.63
The second stage in this development has been the confrontation of bioethics with a new
set of problems associated with globalization. As aforementioned, deadly communicable
diseases, starting with the HIV/AIDS pandemic in the 1980s, made bioethics aware of its limited
ethical framework and insufficiency to address problems of global magnitude. The emergence of
the HIV/AIDS pandemic brought to the surface the significance of social determinants of health,
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such as poverty and education. These global issues required global solutions, and thus
necessitated the bioethics debate to broaden if it was going to be useful in addressing these
pressing matters. Ten Have has noted that other issues in the 1990s, such as organ trafficking, the
brain drain of doctors and clinicians from LMICs to HICs, and the trade and conduct of
international corporations also began to crop up on the bioethical agenda. This reiterates Potter’s
vision of a global bioethics no longer solely focused on narrow individual concerns.64
The third stage of transforming bioethics into a global effort has been the abundant rise of
international activities and collaborations. Since 1985 the Council of Europe has had a standing
bioethics committee.65 During the 1990s, prominent international organizations established
bioethics programs, such as UNESCO in 1993.66 The WHO also established a Global Health
Ethics Unit and held its first biennial international summit in 1996.67 Local and/or national
centers and organizations of bioethics began springing up in the 1990s. The 1994 UNESCO
Directory lists the names of 498 such centers outside the United States, and in 1995 the second
edition of the Encyclopedia of Bioethics was published containing articles of bioethics from a
variety of nations and cultures.68 Ten Have credits the Human Genome Project as a major
impetus for international cooperation in bioethics, as 5% of its annual budget was allocated to the
research of ethical, legal, and social issues of human genomics.69
The final stage of transforming bioethics into a global endeavor has been the process of
elaborating universal frameworks. For bioethics to address the problems generated by
globalization sufficiently, proceeding as it has done in other cultures will not suffice. Bioethics
will have to increasingly become more multicultural and incorporate a broader scope into its
perspective. This does not necessarily equate to being in agreement with every particular
culture’s practices. Rather, respect for different cultures and being sensitive to other values,
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while at the same time applying a global approach, is essential to protect individuals, minorities,
and vulnerable populations.70 Therefore, to deal with the challenges of multiculturalism and
expand its scope, bioethics also needs to expand to a broader ethical framework. The 1997
European Convention on Human Rights and Biomedicine was an important step to seeing this
goal actualized. In 2005 UNESCO went further by adopting the Universal Declaration on
Bioethics and Human Rights.71
Global bioethics as a field has matured since Potter’s introduction of the term in 1988.
Both characteristics of global bioethics espoused by Potter are not likely to be disputed: bioethics
has become both worldwide and comprehensive. Controversial to some, however, is the notion
of global bioethics in general and, in particular, the question of whether global bioethics should
advance a transcultural framework of ethical values and principles. Universal ethical theories
that aim to transcend cultural differences are looked upon with suspicion.72 Skeptics generally
assume that “cultural relativism” is also present in the moral domain, and disagreement seems to
be the norm in moral matters. Samuel Huntington has written that this clash between the major
cultures and religions is unavoidable, due to cultural relativism.73 Hence, it is questionable to
some whether the entire enterprise of global bioethics is even possible.
Some scholars, such as physician-philosopher Tristram Engelhardt, have passionately
argued that there is no such thing as a global or universal ethic due to the competing philosophies
present in the world. Engelhardt has fervently contended that contemporary moral reflection is
marked by prominent disagreement. This is seen in the way that moral philosophers support
different moral theories. Further, Engelhardt acknowledges there are certain persistent concerns
in bioethics, such as the morality of abortion and euthanasia, which have been troubling
humanity for millennia without great consensus. He views this as confirmation of the lack of a
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global bioethics. What is more, Engelhardt maintains that it is impossible through secular
reasoning to resolve competing moralities and diverging views on bioethics.74 In particular,
Engelhardt has written that the Universal Declaration on Bioethics and Human Rights is marked
by a “general vacuity of its principles, as well as a failure to take seriously the moral difference
characterizing the contemporary age.”75 Hence, no consensus on a variety of topics is
achievable.76 Engelhardt perceives numerous flaws in the UDBHR. First is the vacuity of its
principles and lack of serious thinking on moral differences, as quoted above. Engelhardt sees
this as a move to deny the challenge that moral diversity presents to governance and political
stability. As an example, Engelhardt cites Article 10 of the UDBHR that states the equality and
dignity of every human being should be respected. His qualm is that the Article is silent on the
status of human embryos, the morality of abortion, and what justice and equality demand.77
Engelhardt’s intention here may be to protect embryos, fetuses, and the unborn. While
this may be a worthy goal for Engelhardt, it misses the nature of the UDBHR. As an
intergovernmental document, with some 190 countries with various cultures and mores adopting
it, the principles of the UDBHR had to be, in some sense, general. If the UDBHR had made
pronouncements on the moral status of embryos or the practice of abortion then it would have
made it abundantly difficult to have any country adopt it. While the text of the UDBHR does not
address embryos and fetuses, the 2009 commentary published on the process of how the
UDBHR was prepared and giving more insight into each of the principles, does. The
commentary recognizes that new technologies used at the beginning of life, as well frozen
embryos, have brought a new set of ethical problems that may increase inequity, inequality, and
injustice.78 What is more, other international ethics guidelines, such as the very prominent
Declaration of Helsinki, likewise does not mention fetus, embryo, or abortion anywhere in its
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text. This is simply the nature of international documents. There must be compromise, enough
generality, and appeal to a common denominator in order to achieve consensus among
collaborators.
Second, Engelhardt criticizes the portrayal of cultural diversity in the UDBHR: “Though
the Declaration acknowledges cultural diversity, it fails to appreciate the depth of moral
diversity, for this would bring the very possibility of the Declaration into question.”79 To back
this claim, Engelhardt cites Article 12 of the UDBHR: “Respect for Cultural Diversity and
Pluralism.” Engelhardt’s critique is that Article 12 announces a vaguely articulated view of
human equality without much footing to back it up. He combines this critique with a misgiving
about Article 13 on solidarity, stating that the nature and scope of solidarity claims are left
undefined. Engelhardt concludes that the claims are “either platitudinous, ambiguous, or
ungrounded.”80 However, it is unclear what Engelhardt would like to see in Articles 12 and 13’s
stead or how he would like to see them elaborated. The nature of an ethics declaration like the
UDBHR is that it states the most general claim of which there can be consensus to adopt it. Each
of these articles have been subsequently further articulated in both the 2009 commentary on the
UDBHR81 and in a subsequent 2014 publication entitled Handbook of Global Bioethics,82 each
of which was edited by the former director of the UNESCO Division of Ethics of Science and
Technology at the time of the UDBHR’s creation and adoption.
Cheryl Cox Macpherson has faulted the UNESCO UDBHR for excluding mainstream
bioethicists, an absence of peer review, and failing to acknowledge socioeconomic and other
factors, which have impeded its implementation.83 To answer the charge of excluding
mainstream bioethicists, the vast majority of mainstream bioethicists hail from Western, HICs.
However UNESCO, as an UN organization, must attempt to be representative of all nation-states
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and regions of the world, not only the West. The activities of UNESCO must try to incorporate
all perspectives that are relevant to all Member States. To develop the UDBHR, different bodies
of experts were consulted, including the International Bioethics Committee (IBC) of UNESCO,
the Intergovernmental Bioethics Committee of UNESCO (IGBC), and the meetings of
governmental experts. The IBC is composed of 36 experts from different disciplines, including
genetics, medicine, law, philosophy, and history.84 The 2004-2005 committee was composed of
19 members from LMICs and 17 from HICs, with the late Edmund Pellegrino of Georgetown
University, a very prominent bioethicist, representing the USA.85 Hence, the committee was very
diverse and simply because there was a lack of “mainstream” bioethicists, however that is
defined, does not lead to the conclusion that there was an inherent flaw in methodology. Many of
these persons involved in the crafting of the UDBHR are bioethics experts in their respective
countries or regions, and being unknown to a Western audience does not lead to the conclusion
that they are incompetent in the field of bioethics.
Further, Macpherson finds fault with a supposed lack of peer review for the UDBHR.
Peer review is the evaluation of scientific, academic, or professional work by others working in
the same field.86 Yet, numerous expert groups had access to the drafts of the declaration and
were able to comment. Macpherson seems to fault UNESCO for not eliciting public comments
on the final draft. Yet, this would not technically be a peer review process, for peer review is an
evaluative system amongst expert peers in the field. It is unclear whether establishing “channels
for public comment,” as Macpherson would have liked to see, would have made any positive
contribution upon the UDBHR.87
Others have argued that there is no unified global field of bioethics. Researchers in one
study looked at the web-linking patterns of bioethics institutions, the citation patterns of
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bioethics papers, and the buying patterns of bioethics books in order to determine if there was
indeed a unifying global bioethics. The result was that they found that bioethicists do not link to
each other’s websites as much as expected, do not cite each other as much as expected, and do
not converge on the same books as much as expected if bioethics were truly a global, unified
field.88 Yet, these results are now a decade old and they are not wholly surprising. Global
bioethics is a growing field and has received greater attention since the adoption of the UDBHR,
though in many ways is still a niche field. Still, others maintain that the UNESCO declaration
merely reformulates existing principles of bioethics, does not lend much new, and could actually
be harmful to the impoverished of the world.89 It is true that many of the principles found within
the UDBHR can be found in other ethics guidelines. However, a key feature of the UDBHR, as
will be further expounded upon in 4.2, is that it was approved by governments rather than an
organization. This marks new territory for bioethics and signals a truly global acceptance.
Further, the charge that the UDBHR could be harmful to the impoverished of the world is only
conjecture. Richard Ashcroft has written, “If the declaration is cited at all in litigation or
policymaking, it will probably be as evidence that standards weaker than those in some existing
international guidelines (such as the Helsinki Declaration) are legally and internationally
acceptable.” And if this happens, Ashcroft speculates, the vulnerable could fare much worse than
before.90 Ashcroft is purely speculating on this point and there is no case law or precedence to
suggest this is actually plausible. Indeed, the request to develop a common framework of ethical
principles, which would become the UDBHR, was explicitly made by developing countries that
were fearful that with the rapid evolution and globalization of medical science and research they
would insufficiently benefit from the advances and suffer too many harms as a result. A major
concern of these countries was that international medical research and healthcare endeavors
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would proceed along double standards so that persons in LMICs would receive substandard care
and be involved in research trials deprived of the ethical protections that exist in HICs. This call
from LMICs to craft a global normative framework demonstrates that global bioethics principles
are not necessarily imposed upon the developing world by a small handful of powerful, rich
nations.91 Further, it will become clear in section 4.1 when various bioethics guidelines are
examined that the Declaration of Helsinki is not greatly more specific than the UDBHR.
These many critiques of both global bioethics and the UDBHR are serious and responses
to them have been offered while maintaining the argument that it is possible to create a global
ethical framework for bioethics. However, we should be under no illusion that the field of global
bioethics or the UDBHR is flawless. Yet, to deal with global issues in public health, healthcare,
research, and advancing technologies, a robust, complex global bioethics that takes into account
diverse perspectives will be required. This is due to the nature of the problems facing bioethics
today. The problems facing the globe today are complex, transnational, and affect persons of
many cultures and perspectives. Importantly, global bioethics is not a static field that is simply
now finished. Rather, it is dynamic and must be continually changing in order to address the
intricate, ever-changing issues of the day.92
Looking forward, the majority of LMICs in the world today have a limited bioethics
infrastructure. They lack expertise, educational programs, bioethics committees, and legal
frameworks to protect patients and human research participants. Yet, because of globalization,
many of the similar ethical questions that have emerged in HICs where bioethics is firmly
entrenched into medicine are now being seen in these LMICs with limited capacity. A great
benefit of the UDBHR is that it has been developed in collaboration with these LMICs. Work
still needs to be done in order to ensure that the principles of global bioethics are actually
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enacted on the ground in these countries. However, great strides have already been made, which
is very encouraging.
2.2) Human Rights
This chapter now turns its attention to the development of human rights and the human
rights discourse. It is difficult to discuss human rights without also discussing human dignity, as
the two are often closely linked in the literature and human dignity is generally understood to be
the bedrock of human rights. This section will proceed as follows: first, a history of the human
rights discourse will be examined. Second, the relationship of human dignity to human rights
will be assessed. Criticism of both the human rights discourse and human dignity will be
evaluated. Third, the current state of human rights in the world and the problems associated with
implementation will be presented. Finally, the increasing recourse to human dignity within
bioethics will be explained.
The question, “What are human rights?” is generally taken as a request for an exhaustive
catalogue of valid rights. This section will not so much focus on a list of individual rights as
trying to understand the history of human rights and what a “human right” means. The Office of
the UN High Commissioner for Human Rights (OHCHR) has defined human rights as follows:
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Human rights are rights inherent to all human beings, whatever our nationality, place of
residence, sex, national or ethnic origin, colour, religion, language, or any other status.
We are all equally entitled to our human rights without discrimination. These rights are
all interrelated, interdependent and indivisible.
Universal human rights are often expressed and guaranteed by law, in the forms of
treaties, customary international law, general principles and other sources of international
law. International human rights law lays down obligations of Governments to act in
certain ways or to refrain from certain acts, in order to promote and protect human rights
and fundamental freedoms of individuals or groups.1
This definition of human rights will be the working definition of this analysis. It is important to
note how society has come to a place of accepting and generally respecting human rights, which
comprises much of the rest of this section.
Historically, human rights can trace its roots to the time of the High Middle Ages—
around the eleventh through thirteenth centuries. However, the contemporary usage of the term
can be found in the seventeenth century with the influential work of John Locke. At the time,
Europe was recovering from the ravages of the Thirty Years War and decades of religious
conflicts. Locke laid the foundation for a theory of human rights that would remain significant to
this day.2 Newly established democracies would also find the human rights discourse important
for their politics and foundations. The US Declaration of Independence, adopted by the Second
Continental Congress in 1776, was one of the first governmental documents that argued for
universal human rights. The Declaration would prove to be a lasting proclamation of human
rights. Asserting that “all men are created equal, that they are endowed by their Creator with
certain unalienable Rights, that among these are Life, Liberty and the pursuit of Happiness,” the
Declaration would be paradigm shifting and affect the contours of human history.3 Through the
drafting of the Declaration of Independence, the framers created something radically novel:
governments that are justified by their guarantee of universal rights.4
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At the root of the Declaration of Independence’s “unalienable Rights” is a respect for the
worth and equality of every human life, which is known as a universalistic approach to human
rights. Though this principle did not work itself out in practice as much in theory, with persistent
attitudes of racism and sexism exceedingly prevalent in the government at the time of its
passage, the principle of equality is nonetheless present. In a true universalistic approach human
rights is seen to be both transcultural and transnational. It transcends ethnicity, geo-political
boundaries, religion, encompasses the breadth of the human race, and is rooted in humanity’s
inherent dignity. This sketching of mankind’s basic rights would have dramatic implications for
later human rights discourse, which would service the development of global bioethics. Indeed,
several key values have been identified as a basis required for global bioethics. These include
such notions as respect for all human life, acknowledgment and defense of human rights, equity,
freedom, and democracy.5 These concepts are not original to the global health discourse, but
rather are altogether present, to one degree or another, in the 1776 US Declaration of
Independence. Thus, the connection between the robust emergence of conversation on human
rights in the late eighteenth century to the modern-day development of global bioethics can begin
to be seen.
The French Declaration of the Rights of Man and of the Citizen, a fundamental document
of the French Revolution, would be fashioned just over a decade after the similar American
manuscript, being passed by France’s National Constituent Assembly in August 1789. Thomas
Jefferson, the key framer of the US Declaration of Independence, would also prove instrumental
in this rendition of human rights, which, notably, at the time, were referred to as natural rights.
Jefferson was a regular consultant to General Lafayette, the French aristocrat and military officer
who also fought in the American Revolution and introduced the original version of the French
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Declaration. In the French Declaration, it was unabashedly declared that all men, not merely
French, were born and remain free and equal in rights. Thus, quite similar to its American
predecessor, the French Declaration proclaimed universal human rights and fundamental
freedoms.6
John Locke in his Two Treatises of Government defended the claim that people have
rights, such as the right to life, liberty, and property. These rights have a foundation independent
of the laws of any particular society. In Locke’s formulation, governments exist by the consent
of the people in order to protect the rights of the people and promote the public/common good.7
Locke was writing in a seventeenth century British context and his thoughts can be seen in the
US and French Declarations. Locke’s ideas continue to be influential for modern political
thought and were re-confirmed at the 1993 Vienna World Conference on Human Rights, which
proclaimed that it is the duty of states to promote and protect all human rights and fundamental
freedoms, regardless of their political, economic and cultural systems.8
Before both the Americans and French declared the basic rights of mankind, the foremost
champions of universal rights resided on the margins of powerful kingdoms in Western
European countries such as Germany, the Netherlands, and Switzerland.9 As a consequence of
these two declarations, the use of rights language would increase dramatically after 1789 and
human rights would be pushed to an international audience. Its philosophies would be spread
across the Western world, and its principles would soon prove to be a hallmark of many modern
societies.10 At the formation of the UN over 150 years later, the framework of human rights
ideologies expounded in the US and French declarations would prove invaluable. The imperative
of framing human rights in public policy would become commonplace and be seen as a state’s
fundamental obligation to its citizens, just as it was viewed in the embryonic US and French
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democracies. Global bioethics would likewise recognize the need for policy-making as a tool to
ensure that human rights are being secured and justice is not scorned. An integrated framework
of moral-legal international human rights law would prove 57ubsidized57n57 for both the UN
and global bioethics.
It is important to note that the claim that all human beings have a “right” to something
(such as access to medicine, food, safety, housing) can be both a moral/ethical claim based upon
the intrinsic dignity of humans, and it can be a legal claim that is based on specific codified,
enforceable law. Oftentimes the language of rights is used in conjunction with the moral/ethical
dimension and does not necessarily align with an existing law. While ethical precepts are
oftentimes seen as primarily governing individual conduct, human rights are principally the
rights that individual persons have against their government. They are negative rights in that they
require governments to respect human rights by refraining from certain actions. Yet they are also
positive rights in that they place a duty upon governments to provide for certain things, such as
healthcare and education.11 Nonetheless, inscribing rights into law can be a difficult maneuver,
for there is considerable debate about the content of human rights.12 Although there is debate
about what may constitute a human right and the extent of rights, the basic notion of human
rights has not changed since its foundations.
The human rights discourse has certainly at times been invoked hastily and abused. Some
have used it as a trump card, seeing it overrule all other considerations. While the human rights
discourse should not be used in such a flippant and reckless manner, human rights are
independent of merit and are essential to an individual simply by nature of being human.13 As
has been iterated, the modern discourse of human rights has been greatly furthered by the UN,
which has prescribed that human rights are “universal legal guarantees protecting individuals and
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groups against actions and omissions that interfere with fundamental freedoms, entitlements and
human dignity.”14 The UN has also stated that duty bearers, most prominently states but also
businesses, are legally bound to respect, protect, and fulfill human rights. This means that the
state must refrain from interfering with a person’s enjoyment of human rights, it must prevent
others from infringing upon that enjoyment, and it must take positive measures to ensure the
realization of human rights.15
This section will now transition to an assessment of the relationship of human dignity to
human rights. The UN has declared that the foundation of any human rights should be human
dignity. This is most prominently seen in Article 1 of the UDHR: “All beings are born free and
equal in dignity and rights. They are endowed with reason and conscience and should act
towards one another in a spirit of brotherhood.”16 Hence, the UDHR expresses rights as an
existential entitlement—persons are entitled to them on the basis of their identity as human
beings.17 This is echoed in other documents, such as the International Covenant on Civil and
Political Rights, which states that the rights detailed within “derive from the inherent dignity of
the human person.”18 Nonetheless, while there is large international consensus about the nature
of human rights, and even the content of rights, this is not to dismiss that there is also criticism of
the human rights discourse and the concept of human dignity, which will both be discussed in
this section.
The concept of human dignity has been the subject of many centuries of philosophical
discussion. Plato and Aristotle concluded that the essence of every human individual is not just
pure matter, but a spiritual principle, which they termed the soul. They argued that, due to the
spiritual capabilities of human beings, they are essentially spiritual beings and, based upon this
premise, that humankind is fundamentally unique among living beings. Nonetheless, the modern
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iteration of human dignity was not yet clearly extant in ancient Greek philosophy, as is
exemplified by their justification of slavery. However, it has been noted that the thoughtful
reflections on the spiritual dimension of human beings that is present in ancient Greek thought
provided an invaluable basis for the later developments of Stoic and Christian philosophy and
theology.19
Stoicism insisted particularly on rationality as the principal element of human dignity.
Further, it was Roman Stoic philosophers who seem to have been the first to use the term dignity
(dignitas) to indicate the intrinsic and universal worthiness of human beings. Further, the JudeoChristian tradition founded universal dignity as a consequence of being made in the “image of
God” (Gen. 1:26-27). During the Renaissance period and the rise of humanism, the Italian
philosopher Pico della Mirandola insisted on the intrinsic moral worth of humankind based upon
Greek philosophy and biblical sources. Additionally, Mirandola believed that human dignity
consists in the freedom of choice that characterizes humankind in comparison to other living
beings because the different possibilities open to the human person include the highest one. Near
the end of the eighteenth century, Immanuel Kant would develop one of the most influential
accounts of human dignity in the history of philosophical thought on the subject. For Kant,
intrinsic human dignity is grounded on the capacity for practical rationality, especially the
capacity for autonomous self-legislation under the categorical imperative. Hence, autonomy is
the ground of human dignity for Kant.20
While the concept of human dignity has particularly developed within the Western world,
the concept is not alien to other contexts. Human dignity is not purely a Western construct, for
Islamic scholar Abdul Aziz Said has argued that “[i]n Islam as in other religious traditions,
human rights are concerned with the dignity of the individual.”21 Within Islam there is an
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emphasis on the special place of human beings on earth. According to the Qur’an, Allah gave to
humankind the best form (95:4), breathed into them their spirit (15:29; 38:72), gave intellect and
freedom to humanity (16:78; 23:78), bestowed dignity on the progeny of Adam (17:70), placed
humanity even above his angels (2:31), and made them his representative on earth (2:30; 33:72).
Hence, it is commonly understood that the Qur’an assigns dignity to all human beings.22
Muslims are regularly and compellingly instructed to treat their fellow humankind with respect
and dignity. The bases for these injunctions are not human rights but rather divine commands.23
Further, Roberto Andorno has noted that according to Chinese scholars there is a correlate of
human dignity in the teachings of Confucianism. The important Confucian philosopher Xunzi
(third century BC) believed that, though humanity is not innately good, all humans are born with
the capacity to become good, and this is what makes each individual special.24
Human dignity has also been enshrined in international human rights law, the most well
known being the UDHR. The relationship between human dignity and human rights in
international law concerns providing equal respect for every human being while also attempting
to apply concrete norms that are needed to flesh out that principle in social life. In international
law there is near universal consensus that human dignity is the foundation of human rights. That
is, equal rights for persons derive from human dignity simply by virtue of being human. Hence,
at present, the entire international human rights system is founded on the supposition that people
do really have inherent dignity, which has been questioned by many thinkers and will be
discussed later in this section.25 Further, the validity of human dignity and human rights is not
conditional upon their explicit recognition and/or acceptance by states. Consequently, it can be
stated that the idea of human dignity points to a requirement of justice toward every individual.
John Rawls picked up on this and stated that this requirement presupposes that “each person
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possesses an inviolability founded on justice that even the welfare of society as a whole cannot
override”.26
Certainly there have been thinkers who have refuted the human rights discourse and the
concept of human dignity. Jeremy Bentham is renowned for calling human rights “execrable
trash” and simply “rhetorical nonsense, —nonsense upon stilts”.27 At the time of his writing,
Bentham was criticizing the 1789 French Declaration and also had some strong words for
extravagant tenets found in the 1776 US Declaration. While he denounces human rights,
surprisingly Bentham offers no constructive alternative theory of rights, such as one grounded in
utilitarianism.28 Bentham is not alone in his criticism of human rights or human dignity. Among
modern critics, a large number of ethicists and bioethicists have labeled human dignity a useless
concept.29 Further, dignity has been labeled “vacuous”,30 and some have labeled appeals to
dignity as a “conversation stopper”.31 The Canadian Supreme Court recently issued a ruling
summarizing their disappointment at the role of human dignity in constitutional law, stating, “[It]
has also proven to be an additional burden on equality claimants, rather than the philosophical
enhancement it was intended to be” (R. v. Kapp, SCC 41 (2008), 2 S.C.R. 483, paragraph 22).32
This is important for the human rights discourse because the secular iteration of human
rights is generally grounded in the concept of dignity, though this is also somewhat contentious
as others view it as grounded more in the common humanity and universal interests of
humankind.33 The view that rights are founded in human dignity is central to the UDHR in which
the first line of the preamble reads, “Whereas recognition of the inherent dignity and of the equal
and inalienable rights of all members of the human family is the foundation of freedom, justice
and peace in the world” and a few lines later, “Whereas the peoples of the United Nations have
in the Charter reaffirmed their faith in fundamental human rights, in the dignity and worth of the
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human person and in the equal rights of men and women.” This is further supported in Article 1
of the Declaration.34
However, even if dignity is accepted to be the foundation of human rights, it is not clear
from where that dignity derives. That is, if the ground of human rights is human dignity, what is
the ground of human dignity? From a Judeo-Christian theological perspective, dignity is found in
simply being a member of the human race, as humans are endowed with dignity by their Creator
and formed in the imago Dei (Genesis 1:26-27). Yechiel Barilan views human dignity as
originating in the Hebrew Bible, and then being developed by Stoicism and Christianity.35 Yet,
from an atheological position, such a derivative is uncertain. Commentators will similarly argue
that dignity is inherent to humankind, yet no further discussion of its origin is to be found. Too
often the impression is given that dignity is an irreducible value, that we have burrowed deep
below the rights that are recognized in the familiar human rights charters and that once we
burrow down to human dignity it is not necessary to dig any deeper. Kantian thought states that
the dignity of persons is based in metaphysical significance of our possession of moral capacity,
the ability to act on principle even when every empirical impulse or inclination, every sentiment,
and every element of self-interest pressures us to the contrary.36 Hence, the very foundation of
human dignity is not agreed upon universally. Nevertheless, though the grounding of dignity is
disputed, most do not deny that humans possess dignity.
Additional criticism of human dignity comes from those who closely associate it with
biblical and classical origins. However, there is nothing in the core of human dignity, from a
secular perspective and how it has been used by organizations such as the UN, that allies it with
specific ideologies or religions. Concepts of dignity can be found in antiquity, the monotheistic
religions, and in secular enlightenment writings. Though it is found in varied contexts, dignity
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still comes under attack as being too closely associated with conservative and religious ethics.37
Hence, human rights and human dignity are not without their share of criticism.
While we must not gloss over the criticism, human rights treaties have proven valuable in
disseminating the human rights discourse of the latter twentieth century. Governments have
joined international human rights treaties for different reasons, including with the goal of
following the rules, as a way to set an example for other countries, or as a means of reassuring
their own citizens of their seriousness in this matter. Some governments have been more ready to
ratify treaties if their neighbors have done similarly.38 Nonetheless, other countries commit to
human rights treaties and violate their agreements at will. In early 2016 Amnesty International
released a list of the ten worst attacks on human rights across the world in 2015.39 Of the ten
countries that Amnesty International listed as perpetrating the violations, all are UN member
states, four were original signatories to the UN Universal Declaration of Human Rights in 1948,
and four are current members of the UN Human Rights Council.40 Hence, again and again in the
past century it has been demonstrated that human rights, in and of themselves, do not offer
absolute protections for individuals against state and non-state actors. Examples of this include
not only medical research in Germany and Japan during WWII, but also the Tuskegee Syphilis
Study (1932-72) in the US, the Guatemalan Syphilis Study conducted by US researchers (194648), and the harassment of activists and stifling of religious freedom in China. Indeed, it has been
demonstrated that states that have become signatories to numerous human rights treaties and
declarations have at times been the greatest abusers of human rights. The mere adoption of
certain principles is no assurance of implementation.
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The problem of implementation is also apparent in the annual publication of US
Department of State, entitled Country Report on Human Rights Practices. The preface to the
2015 edition, written by Secretary of State John Kerry, begins with a bleak assessment:
The 2015 edition of the Country Reports on Human Rights Practices points to a global
governance crisis. In every part of the world, we see an accelerating trend by both state
and non-state actors to close the space for civil society, to stifle media and Internet
freedom, to marginalize opposition voices, and in the most extreme cases, to kill people
or drive them from their homes.41
Indeed, state actors and non-state actors, such as ISIS, Boko-Haram, and the Taliban, alike,
commit human rights atrocities. States that are signatories to international human rights treaties
continue to commit human rights abuses. Hence, this leads to at least two conclusions: 1)
adoption of a human rights instrument is no assurance of implementation, and 2) there is still
much work to be done to ensure the implementation of human rights. Making human rights
salient involves not only merely raising the issues to an international audience, but persistent
campaigning, monitoring, and reporting to compel governments to recognize shortcomings and
acknowledge the validity of human rights agreements.42
Implementation is not an easily achievable solution. The Office of the United Nations
High Commissioner for Human Rights (OHCHR) has stated that the route from developing
normative standards to operationalizing those standards largely depends on the availability of
appropriate tools for policy formulation and evaluation within countries. OHCHR has also
prescribed that both quantitative and qualitative indicators are an essential tool to seeing this
accomplished. OHCHR has defined indicators as,
[A] human rights indicator is specific information on the state or condition of an object,
event, activity or outcome that can be related to human rights norms and standards; that
addresses and respects human rights principles and concerns; and that can be used to
assess and monitor the promotion and implementation of human rights.43
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However, indicators are not utilized in a systematic manner, which constitutes a gap in human
rights implementation. The use of appropriate indicators is a key way to help countries assess
their progress in ensuring the enjoyment of human rights by their people.44
As an intergovernmental organization, the UN generally takes a top-down approach to
human rights (i.e. passing formal treaties and declarations at the international level, creating
institutions, etc.). Fuyuki Kurasawa has argued that the top-down approach needs to be reversed
by examining how groups and individuals caught in the struggle against abuses construct and
enact human rights. Kurasawa does not make the case that normative endeavors, such as crafting
universal ethical principles, or juridical constructs that seek to legally entrench human rights are
wrong. These initiatives are necessary, he states. However, what these initiatives miss, in
Kurasawa’s estimation, is the substantive core of what constitutes global justice. For Kurasawa,
the crucial question is less the specification of norms and rules and rather the interpretation of
how global justice is enacted by persons and groups on the ground. It is the arduous process of
making and doing global justice by individuals that Kurasawa sees as vital to actually
implementing human rights.45
While organizations and individuals may differ on what is most needed to see human
rights implemented on the ground so that humankind can enjoy these inalienable rights, there is
no question that additional work needs to be done to ensure this enjoyment. The idea of creating
indicators, briefly presented above, will play a major role in this dissertation, as it is the
backbone of the global bioethics tool that will be presented in chapter five and then applied in
chapter six. Before this section concludes it is also important to understand the increasing
recourse to human dignity within bioethics.
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Andorno has distinguished three stages of increasing recourse to human dignity in
bioethics. The first stage initiated just after the end of the WWII and focused on issues relating to
medical research on human subjects, particularly the requirement of free, uncoerced informed
consent of participants. This culminated in the Nuremberg Code, as has been presented earlier.
While the Nuremberg Code does not explicitly refer to human dignity, it is evident that it is
inspired on this notion. According to Andorno, “The nonnegotiable nature of the code principles
puts in evidence that the idea of an unconditional human worthiness was in the mind of the
judges that formulated them.” Seven decades after the Nuremberg Code was drafted then it
remains the bedrock of research ethics and the connection of how human dignity relates to
bioethics. Andorno sees the second stage in the recourse to human dignity in the field of
bioethics as starting near the end of the 1970s. This stage stretched beyond the domain of
medical research and began to cover medical practices and techniques at both the beginning and
end of life, such as assisted reproductive technologies, embryonic research, futility, and
questions regarding physician assisted suicide and euthanasia. This wider, multifaceted function
of human dignity is visible in at least two global, intergovernmental declarations adopted since
the end of the 1990s: the Universal Declaration on the Human Genome and Human Rights and
the Universal Declaration of Bioethics and Human Rights. The latter is perhaps the finest
example of the significant and multifaceted role that human dignity plays in bioethics. Finally,
the third stage began near the end of the 1990s and marked much more of a dramatic shift.
Human dignity began to be appealed to in order to articulate concerns about biotechnological
developments that may impact humanity as a whole. Not only is the dignity of existing
individuals at stake in this third stage, but also the value attached to the integrity of the human
species.46
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The emerging global instruments relating to bioethics utilize the concept of human
dignity as an overarching principle with the integration of the new commonly adopted standards
into a human rights framework. These instruments present themselves as an extension of
international human rights law into the specific field of bioethics. Several reasons seem to
explain this strategy. First, because biomedical activities are directly related to the most basic
human rights such as the right to life and to physical integrity, as was argued in the Nuremberg
Code, having recourse to the large swath of human rights norms to ensure their protection is
sensible and can be an invaluable tool for promoting human flourishing and the common good in
the field of biomedicine. Second, because international human rights law is based on the
supposition that basic rights transcend culture and state borders, the human rights framework can
aid in facilitating the formulation of global standards. Third, human dignity is a rather abstract
principle that alone is unable to provide concrete responses to many challenges raised by
biomedical advances. This is why human dignity normally operates through other much more
concrete ideas, such as informed consent, which are usually expressed using the terminology of
“rights.”47 This relationship between human rights and bioethics is very essential for the work of
global bioethics and will be furthered examined in 2.3.
2.3) Symbiotic Relationship
The preceding two subsections examined global bioethics and human rights, largely
separately. This section seeks to show their relationship. First, a general relationship between
global bioethics and human rights will be examined. Second, the symbiotic relationship between
global bioethics and human rights will be presented.
Bioethics has not often been thought of in a human rights context and, conversely, human
rights has only rarely taken great concern for bioethical issues.48 However, the boundaries
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between human rights and global bioethics are not static, but they are permeable, and the major
health issues around the globe are more effectively tackled by harmonizing the disciplines.49
Further, global bioethics and human rights stand in a symbiotic relationship. Whereas human
rights law and cosmopolitan ideals inspired the development of a global bioethics discourse, the
converse is similarly true; global bioethics contributes to human rights.50 However, we should
not get the impression that global bioethics can simply be reduced to the application of universal
human rights norms to moral issues, for this would be a false view.51 Rather, human rights form
the point of departure and context for global bioethics. Human rights may also function as a
constraint and final authority upon bioethical principles.52 Indeed, when the two field of human
rights and global bioethics are taken together rather than separately then they stand to contribute
more and offer greater weight than either alone.53
The history of the relationship between bioethics and human rights is quite old, as has
already been established earlier in this chapter. The American judges at Nuremberg were
comfortable crossing borders between American medical ethics (known today as bioethics) and
international human rights law.54 The Nuremberg Code explicitly links medical ethics and
human rights with one another. Since that time, human rights based approaches to bioethics have
proliferated. When the formal discipline of bioethics was established in the 1970s, it did not take
long for literature on bioethics and human rights to also be published.55 This field continues to
expand and develop, as witnessed in the recent linking of feminist bioethics to both human rights
and global ethics.56
While the 1947 Nuremberg Code links health and medical ethics to human rights, so does
the UDHR. Article 25 of the UDHR specifically connects human rights to health:
(1) Everyone has the right to a standard of living adequate for the health and well-being
of himself and of his family, including food, clothing, housing and medical care and
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necessary social services, and the right to security in the event of unemployment,
sickness, disability, widowhood, old age or other lack of livelihood in circumstances
beyond his control.
(2) Motherhood and childhood are entitled to special care and assistance. All children,
whether born in or out of wedlock, shall enjoy the same social protection.57
The centrality of human rights in bioethics, and more specifically the UDHR, is acknowledged
internationally.58 In a 2003 report of the International Bioethics Committee of UNESCO, the
authors state that, “modern bioethics is indisputably founded on the pedestal of the values
enshrined in the Universal Declaration of Human Rights.” What is more, UNESCO’s 2005
Universal Declaration on Bioethics and Human Rights explicitly adopts the UDHR as its basis.
Additionally, the Council of Europe’s 1997 Convention on Human Rights and Biomedicine is
another good example of the central role that human rights is beginning to play in the biomedical
field. The Preamble refers to the UDHR and notes that the protection and realization of human
rights in biomedicine is highly valuable.59 Although this is a regional rather than a global
instrument, its potential impact on a global scale should not be overlooked as it is the only
intergovernmental legally binding instrument that comprehensively addresses the linkage
between human rights and biomedicine.60
The health provisions in the UDHR were echoed in the International Covenant on
Economic, Social, and Cultural Rights (ICESCR), adopted by the UN General Assembly in late
1966. This treaty highlights several individual rights, including: right to work, right to fair
wages, right to education, and “the right of everyone to the enjoyment of the highest attainable
standard of physical and mental health.”61 Article 12 of the ICESCR guarantees the right to
health to all individuals and communities.
As described in section 2.1, the notion of global bioethics is not so much a matter of
geography as it is about dealing with phenomena with a global dimension. The issues of today,
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due to the globalization of the world, transcend geopolitical boundaries and cultures and are not
dependent upon the particularities of a specific society. These issues also make us search for
moral views that are said to be shared globally. Because of this, modern bioethics is increasingly
connected with international law and, in particular, human rights law. This is due to a similar
global vision that is shared between global bioethics and human rights.62 Indeed, it has been
recognized that international human rights law and the ideals of cosmopolitanism inspired the
development of global bioethics.63 By utilizing human rights language, global bioethics expands
the circle of moral concern by including a sense of commonality for all humanity and implying
that human beings have responsibilities to one another, not only their fellow nation-state citizens,
simply by virtue of this common humanity.64
One challenge for medicine and health from the latter part of the twentieth century
forward is the globalization being experienced. George Annas has argued that medicine and
health must develop a global language and global strategy that can be used to improve the health
of the world’s citizens, particularly those in LMICs.65 This has been echoed by others such as
Elizabeth Fenton and John Arras who have stated that what is needed is a universal language and
moral framework that is founded on universally shared, transcultural beliefs. They have held that
the human rights framework fulfills this need.66 The human rights discourse is attractive for
global bioethics for a variety of reasons, as will be described in this section.
Individual nation-states are inadequate to address global health issues, and culturally or
religiously specific principles are insufficient for addressing the growing issues in global
bioethics. Further, bioethics in itself is unable to achieve the universal language and moral
framework that is needed. Western-dominated medical ethics has been too closely focused on the
individual and has yet to live up to its global aspirations as Potter envisioned. Yet, coupled with
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human rights, bioethics attains much more force. Annas has noted that bioethics is not only
necessary to make basic human rights a reality, for example by prohibiting physician
involvement in torture, but also can advance medicine in a symbiotic manner.67 In biology,
symbiosis is the relationship between two different kinds of living things that live together and
depend on each other.68 For health and human rights, this symbiotic relationship is quite unique:
health worsens when human rights are ignored, and human rights abuses impact health.69
Generally, human rights are invoked in three bioethics contexts: 1) the protection of
humans from being harmed by medicine, 2) the discussion about humans as subjects to medical
experiments, and 3) regarding the rights of patients relative to their healthcare services and
providers.70 The language of human rights can be used by individuals and non-governmental
organizations (NGOs) to inspire one another towards their goals and in their activities. Several
physician groups have been leaders in promoting human rights, such as International Physicians
for the Prevention of Nuclear War, Physcians for Human Rights, and Médecins du Monde.71 The
influential and perhaps best-known humanitarian physician’s group, Médecins sans Frontières
(Doctors without Borders) has officially stated that a defining principle of their organization is
the determination to speak in public when faced with mass violations of human rights.72
However, this is brought into question by recent narratives on the organization.73 Nonetheless,
physicians and healthcare workers interested in promoting human rights have numerous
professional organizations they can support.
It has already been discussed above how health is recognized as a fundamental human
right in human rights law and obligates states toward the protection and promotion of health for
those persons under its governance. This symbiotic relationship between human rights and health
has been described by Jonathan Mann, former director of the WHO’s AIDS program, as a
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relationship of natural allies. That is, the human rights discourse is considered by many to be a
formidable tool in advancing health standards in the world.
While the aforementioned has largely focused on the relationship between human rights
and global health, we can now reflect on how global bioethics advances human rights. It is
argued that these two fields when taken together are often able to offer more than either
separately. First, global bioethics is able to reinforce the normative claims of international human
rights law. Though there are many aspects of human rights law that are legally binding and have
been codified into international treaties and state law, other aspects are less developed and more
controversial, making them much more difficult to enforce on an international stage. Such
instances highlight the place for ethical arguments to bolster the normative claims of the human
rights discourse and stimulate their reception and acceptance into law. As an example,
international human rights law is only weakly applicable to corporate actors. The UN has sought
to alter this in very recent years with the passage of the UN Guiding Principles on Business and
Human Rights and the UN Global Compact, though these are not binding upon states or
individual corporations.
Despite this, and as this dissertation in part shows, there is a growing call for greater
corporate social responsibilities regarding human rights in many areas, including the area of
health. In 2008 the UN Special Rapporteur on the Right to Health issued a report entitled Human
Rights Responsibilities for Pharmaceutical Companies in Relation to Access to Medicine.74 Once
again, this is an example of non-binding or soft law—actions companies should undertake but
are not legally bound to. Lisa Forman and Stephanie Nixon rightly recognize that while these
frameworks couch their responsibilities in the language of rights, they are perhaps more
appropriately classified as ethical duties rather than legal. Nonetheless, the guidelines offer the
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pharmaceutical industry greater precision in regards to their ethical actions, as well as indication
of how to measure the ethical actions of the industry. This has the combined effort of
strengthening both human rights and bioethical frameworks in this area, as well contributing to a
positive view of corporate social responsibility in the public eye, which may aid in recognizing
the legal enforceability of certain duties in the future.75
Second, global bioethics can also broaden the advocacy framework of human rights. A
critical global bioethics seeks to understand dilemmas as having their roots in institutional
arrangements, power struggles, and political, social, and economic contexts. Access to power
and how power is used is often very near the core of global health disparities. It is clear that
global bioethics cannot understand global problems in health without also looking at the multifaceted causes of these dilemmas. By adding these complementary forms of argumentation to a
rights-oriented human dignity argument, the result can be one of strengthening advocacy calls for
action.76
A third and final way in which global bioethics can advance human rights is in the debate
between individual human rights versus public health. These two are often pitted as one against
the other, with either individual rights being sacrificed for the sake of the community, or the
welfare of the greater community potentially suffering for the sake of maintaining individual
human rights.77 By its nature, the primary objective of public health is the promotion of
population benefit, which has a very utilitarian outlook.78 Forman and Nixon have recognized
that while rights are individual entitlements, they also have strong communal elements.79 For
instance, an individual right to health, prescribed in several international documents, cannot be
readily realized for the masses without a collective governmental system to ensure this right. The
recurrent concern within healthcare systems is how much precedence individual rights may have
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over the welfare of the common good, and vice-versa. This was witnessed very publically in the
Ebola crisis of 2015 in which a US nurse returned to New Jersey after serving in West Africa and
was forced into quarantine.80 The tension between liberty and public health has been attempted
to be solved by a number of different public health theories: libertarian, collectivist, liberal, and
paternalistic models have all been suggested by some.81
The UK Nuffield Council has proposed a revised liberal model termed the “stewardship
model” that attempts at easing the tension between individual human rights and the welfare of
the public.82 In such a model, nation-states have responsibilities towards their citizens that stretch
beyond a Lockean natural rights view. The government is regarded as a steward both to
individuals, taking into account different needs arising from age, gender, ethnic background or
socio-economic status, and to the population as whole. In this stewardship model, the state is
obligated to seek to provide conditions that allow people to be healthy, especially in relation to
reducing health inequalities. This envisages a more active role of the state than that presented in
a typical liberal schema. The government should enact public health policies that promote the
health and welfare of its citizens. The government should impose transparent and democratic
decision-making so as to safeguard the balancing of individual liberty with public health.83
As such, the stewardship model can be highly differentiated from a paternalistic model.
Paternalism has a greater likelihood to impose coercive measures on a population to achieve a
desired goal, which greatly infringes upon individual liberty and autonomy. Rather, stewardship
is sensitive to this tension and seeks the least intrusive manner of achieving a specific policy
goal. Further, due to greater levels of transparency and democratic process in the stewardship
schema, policies must be adequately justified so that they can achieve consensus. Within a
stewardship model, public health policies should be compatible with the views of the public, and
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the public should have the opportunity to scrutinize the suitability of proposed polices.84 The
Nuffield Council makes use of ethical arguments throughout their proposal for public health
principles. Articulating these principles as ethical norms may have the effect of strengthening
their acceptance and application by those who are likely to view human rights as imposing
objectionable impediments to public health practice.85 Hence, this is yet another way in which
global bioethics may act to advance public health.
Just as global bioethics advances human rights, the converse is also true, for this is the
nature of a symbiotic relationship. Human rights advance global bioethics in at least six ways.
First, human rights recognize the duty of states and governments to citizens, yet many HIC
governments are reducing expenditures on health due to soaring costs. This reasoning has also
been thrust upon LMICs and the result is a refocusing on states’ obligations to realize a legal
right to health for its citizens. Global bioethics analyses of public policy for health in HICs and
LMICs can be informed by human rights doctrine that views health as a chief responsibility of
governments.86 This perspective is poignantly articulated in the Universal Declaration on
Bioethics and Human Rights, as well as reflected in global health policy outcomes such as the
2011 Rio Political Declaration on the Social Determinants of Health87 and the UN Political
Declaration on the Prevention and Control of Non-Communicable Diseases.88
Second, the social determinants of health are becoming incredibly more prominent in
global bioethics and discussions of social responsibility. Human rights contribute to recognizing
the protection of rights as itself a determinant of health. One major objective of global bioethics
is the identification, analysis, and advancement of ideas about how to improve global health. Yet,
as Forman and Nixon have noted, this recognition that the protection of human rights is itself an
important determinant of health is largely absent from the discourse on determinants.89
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Third, a human rights framework is useful for global bioethics because it facilitates the
formulation of universal standards due to the fact that international human rights law is based
upon the assumption that some basic rights transcend social and cultural diversity. Because
bioethics regularly deals with an array of socio-cultural diversity and philosophical and religious
pluralism, the usefulness of the universality of the human rights framework is key.90 Moreover,
large numbers of international instruments have been adopted to ensure the respect for individual
persons in diverse contexts since the passage of the UDHR. It seems only fitting to make use of
this rich normative and institutional system in order to protect persons from harm in the field of
biomedicine.91 Hence, the human rights framework may provide a more useful approach for
analyzing and responding to health challenges than any other framework at the disposal of
medicine and bioethics.92
It has already been stated that individual nation-states are inadequate to address global
health issues, and culturally or religiously specific principles are insufficient for addressing the
growing issues in global bioethics. What is needed, it is argued, is a lingua franca, a universal
language and moral framework that is founded on universally shared, transcultural beliefs. It is
argued that the human rights framework fulfills such a call.93 The human rights framework
transcends culture, nationality, and religion and presents transcultural normative judgments in a
diverse world. Several common characteristics are shared by human rights and bioethics. The
modern human rights discourse grew out of the atrocities of World War II, as did medical ethics
with the Nuremberg Code, which has been described as the grandmother of modern bioethics.94
While human rights and bioethics have similar origins they also have similar goals: humans
should never again be used as a means to an end. The ideals of equality and human dignity that
transcend cultures—an idea that is permeated in the human rights discourse—is very attractive
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for global bioethics. Further, if it is accepted that the human rights discourse is an appropriate
context within which global bioethics principles can be developed, the advantage to this is that
the human rights principles are generally accepted across the globe and adopted by the
international community. Human rights can also provide a sort of check or restraint on bioethics
by signaling that ethics principles must align with accepted human rights.95
A fourth way in which human rights advances global bioethics is through the concept of
human dignity. The concept of human dignity is the cornerstone of both human rights and global
bioethical norms. The human rights discourse has a long history of utilizing the concept of
dignity, yet, by itself, the concept is unable to provide responses to most challenges of bioethics
and biomedical advances. The abstract principle of human dignity forms the foundation on which
concrete concepts of global bioethics (such as informed consent, non-discrimination, personal
integrity) can be built. These concrete concepts are usually formulated using the terminology of
“rights”.96
Fifthly, Henk ten Have has contended that the international human rights discourse adds
to the normative force of bioethical discourse. Human rights are seen as non-negotiable and
unable to be compromised because of their root in human dignity. Hence, the weight of human
rights is that it presents a framework of principles and norms that are to be upheld and protected
without regard for the consequences because of the gravity of what is at stake. Ten Have points
out that at times medical research has attempted to apply double standards in its practices, such
as a lower standard in a developing country than in a developed one. However, the human rights
discourse is aptly able to respond to such practices and counter that ethical principles are
universal, not context-specific, and the ends do not justify the means (i.e. gathering health
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research data for the improvement of a population does not justify doing so in an ethically
dubious manner that may include the exploitation of persons).97
Lastly, the human rights discourse is attractive to global bioethics due to its very practical
nature. Bioethicists today can be found in all levels of hospital administration and government
service, as clinical ethicists, on IRBs and ethics committees, drafting policy for hospitals and
federally for the NIH. Human rights can be helpful in matters of public policy due to its practical
element that emphasizes the rights people are endowed with simply by being human. Hence,
when preparing policy on research guidelines or national healthcare services, the normative and
practical edges of human rights provide a universal language for bioethicists to utilize.98
The claims above are indicative of the strong relationship between global bioethics and
human rights. However, not everyone is enthusiastic about this relationship. Elizabeth Fenton
and John Arras have voiced their concern that advocates of a human rights foundation for
bioethics are making unreasonable and unsustainable demands on the language and conceptual
framework of human rights. Their argument is chiefly that human rights ought to be an important
part of our thinking on many bioethical issues, though they ought not exhaust the thinking.99
Hence, they are not critiquing the relationship between human rights and bioethics but rather
those ethicists who would frame all discussions in the human rights discourse. This seems
sensible, for a general endorsement of the human rights discourse does not provide unfettered
warrant to shove all moral, political, medical, and legal controversies into the human rights
linguistic and methodological framework.100 Rather, we would do well to use the human rights
framework only when prudent, or else we run the risk of making nearly all issues human rights
topics and diminish what human rights actually mean.

78

The fields of human rights and global bioethics both have much they can learn from one
another. By embracing collaborative efforts then the fields are able to perceptively contribute to
one another, create stronger arguments, and have greater influence than either could separately.
These points are essential in order to understand rightly how the fields of global bioethics and
human rights interplay and are can be utilized in ethics guidelines such as the UNESCO
Universal Declaration on Bioethics and Human Rights. As the field of human rights is much
more mature than global bioethics, stretching back several centuries, it is able to offer wellestablished notions of state responsibilities towards health and human flourishing, as well legal
frameworks for action, as is evidenced in the UDHR.101 These ideas are very well developed and
engrained in social and political thought. Further, global bioethics offers firm ethical arguments
and frameworks for action. These arguments and normative frameworks are needed to address
the global health dilemmas of our day. The Universal Declaration on Bioethics and Human
Rights prominently brought the two fields together in 2005, which will be further examined in
4.2.
However, further investigation and research into the applications of this intersection
should be undertaken for further strengthening. Those within the fields of public health, global
bioethics, and human rights are able to gain analytic tools by embracing the largely untapped
potential in such collaboration. Further investigation and research may include the intersection of
global bioethics and human rights in relation to the restriction of rights in the service of global
health interests, responses to new and emerging epidemics and pandemics, and the ethico-legal
basis for formulating the obligations of state and non-state actors towards global health.102
In summary, this chapter began with an examination of global bioethics. The birth of
global bioethics was seen, growing out of medical ethics and bioethics. Van Rensselaer Potter
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was tremendously pioneering and influential during this period, coining both the terms
“bioethics” and “global bioethics” and attempting to set the agenda for the new fields. Following
this, an exploration of human rights was seen. The chapter concluded by analyzing the symbiotic
relationship between global bioethics and human rights and how each field is able to contribute
to the other.
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Chapter 3: Corporate Social Responsibility and the Pharmaceutical and Biotechnology
Industry1
For the proposed global bioethics tool that is presented in this dissertation, corporate
social responsibility is an integral component. Corporate Social Responsibility (CSR) is an
increasingly important issue to stakeholders and the general public. This chapter will first
introduce the concept of social responsibility and its relation to global health and bioethics and
will then, in the second section, turn to an examination of CSR applied to the pharmaceutical and
biotechnology industry.
3.1) Social Responsibility in Global Health and Bioethics
A key concept in global bioethics and global health is the notion of social responsibility
and health, which significantly broadens the agenda of bioethics so that the social and basic
issues related to the provision of healthcare for populations all over the globe are taken into
account.2 This section examines the concept of social responsibility and how it functions within
global health and bioethics.
Social responsibility and health combine two basic ideas: 1) several actors aside from
states and governments are responsible for health, and 2) global problems reflect common
challenges and, therefore, should be addressed through common action.3 The notion of social
responsibility, as a term, is relatively new, with a majority of the formal writings only being
traced back to around the 1950s.4 The term appeared in the context of the ethics of private
companies as a manner of defining the moral duties of companies in society that stretch beyond
the limits of legal obligations.5 While the term may be novel, the concept itself is relatively old,
with forms of the idea found in the thirteenth century writings of Thomas Aquinas.6 Indeed, the
world’s major religions over the centuries have encouraged extending the notion of responsibility
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to others beyond the confines of family to communities and even further.7 Today, the concept
focuses on the responsibility of the broader society, specifically private companies, toward not
only property and profits but also to those who are affected by or involved in the activity of a
company, which will be explicitly seen how it is applied to the pharmaceutical and
biotechnology industry in 3.2. In a broad sense, the term is meant to denote a change or
enlargement of perspective in the strategies and aims of, specifically, companies, and calls on
them not only to meet their legal duties but also to pledge to improve and advance the welfare of
society.8 This idea has evolved within bioethics and is increasingly recognized. The current
section examines the role and concept of social responsibility in bioethics, specifically how a
shift from bioethics as committed to an individualistic framework that does not place a high
value on the social context to the notion of social responsibility has occurred.
The modern concept of social responsibility and health can be said to address the socioeconomic determinants of health.9 Evidence cited in the World Health Organization’s (WHO)
2008 Final Report of the Commission on the Social Determinants of Health demonstrates that the
health of both individual and communities is intrinsically tied to social factors.10 According to
the WHO, the social determinants of health—a term that emerged from epidemiology—are the
conditions in which people are born, grow, live, work, and age. All of these circumstances are
shaped by the ways money, power, and resources are distributed at local, national, and global
levels.11 Similarly, economic determinants, including income and job status, affect health, as
higher income and advanced social status have been linked to better health. The WHO reports
that as the income gap between the rich and poor increases, so do the differences in health.12 The
principle of social responsibility and health states that innovations in science and technology
should address these determinants through access to healthcare and essential medicines, access to
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nutrition and potable water, reduction of poverty, and the elimination of the marginalization of
certain persons or classes of persons.13 Because the greatest share of health problems is
attributable to the social conditions in which people live and work, tackling major health
determinants, through social responsibility, is an important step to improve levels of health.14
Social responsibility may be thought of as part of what has been traditionally known as
moral or ethical obligations. Such obligations are not legally enforceable by governmental
authorities (i.e. they are non-binding). Nonetheless, though such moral obligations are not
necessarily legally enforceable does not necessarily render them less important than enforceable
regulations. This merely indicates there is no legal precedent or compelling force to fulfill
them.15 As noted above, the notion of social responsibility and health combine the following two
basic ideas: 1) Many actors, not just governments, have a responsibility towards health. 2)
Global problems reflect common challenges, and thus, should be addressed by common action.
Both of these ideas will be explored in turn. The idea that the governments of states are not
solely responsible for the health of persons expresses that individuals, as well as private and
public organizations such as healthcare sectors, educational services, and private companies,
have a personal responsibility towards health as members of the global society.16 Within global
bioethics, the UNESCO Universal Declaration on Bioethics and Human Rights (UDBHR)
expressly iterates this perspective in Article 14 of the document, entitled “Social responsibility
and health,” which will be further examined in 3.2 and applied to the pharmaceutical and
biotechnology industry.
The second basic idea of social responsibility is that global problems reflect common
challenges and should be addressed by common action, which presupposes the principles of
solidarity and cooperation, which are explored later in this section as a necessary foundation of
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social responsibility. Because the protection and promotion of global health involves the
cooperation and unity of multiple stakeholders, including private corporations, new frameworks
of action may be necessary in order to enhance this type of cooperation at the global level.
Further, this accepts that health is a common good and common action should be taken to try to
achieve it. While governments should guarantee some adequate level of access to healthcare,
healthcare is only one element of health. Other determinants will include environmental
concerns, access to potable water and nutrition, and shelter. These common goods should also be
protected and, if required, common action taken toward this end.17
It is important to note that the notion of social responsibility and health should not detract
from responsibility for health on a personal level. Illness, generally, is not something that simply
happens to a person. Persons have a greater likelihood of remaining healthy if they take care of
themselves and adopt healthier lifestyles. Concern for the personal or individual’s role in
maintaining health is ancient and can be found in the writings of the Greek physician writing in
the second century.18 Yet, while we cannot discredit that individuals play a large role in their
own health, we also must not overlook the social and environmental dimensions of health, which
is what the concept of social responsibility for health places before us.19
The notion of social responsibility and health cannot be interpreted as an isolated idea. In
particular, social responsibility must be viewed in light of the concepts of solidarity and
cooperation, as they form foundations for a proper understanding of social responsibility.20
Solidarity is not a new concept. The usage of the term solidarité increased during the French
Revolution and found entrance into Napoleon’s Code Civil in 1804, where it was increasingly
extended into the political realm. However, it was the work of August Comte that increased the
visibility of solidarity in contexts that were not immediately religious or political. For Comte,
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solidarity was a remedy for the increasing individualization and atomization of society, which he
viewed as detrimental to social concerns and the wellbeing of the collective. This approach
resonates with social contract theorists, such as Thomas Hobbes, John Locke, and Jean-Jacques
Rousseau. While these three prominent philosophers differ greatly in their approach of the nature
of humanity, a commonality is that they justify the need for governmental authority. Because of
their belief that it is impossible for individuals to live safe and fulfilled lives outside of organized
social systems, people are implicitly assumed to have agreed to waive their natural freedom to do
what they want and to submit themselves to the rule of an authority, which provides them civil
freedom in return.21
Émile Durkheim was one of the first social theorists to devote significant attention to the
notion of solidarity.22 Durkheim noted that societies are only constructed through social
cohesion.23 Durkheim defined solidarity as a consensus among the individuals of a group, and he
demarcated two types of solidarity: mechanical and organic. Mechanical solidarity is the social,
physical, and cultural integration of persons in society who have common values, which thus
provides motive for persons to unite toward the objective of maintaining equality and
perpetuating the group. Organic solidarity is much more established in modern society, which
has become increasingly differentiated and interdependent because of the relatively greater
division of labor, which requires greater interrelation and cooperation between individuals.24
Today, organic solidarity predominates, at least in most developed countries, since its pillars are
based on social reference points that are determined from norms established through rights.
Durkheim stressed that organic solidarity may be developed through mutual interdependence and
reliance upon others, with emphasis placed on the individual. Solidarity has been cited by some
commentators as essential to addressing common global threats, such as pandemics and
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environmental concerns. However, the concept of solidarity may be most useful to global health
as a critique to charity-based approaches, which is key for social responsibility.25
Hence, the notion of solidarity has been around since ancient times and refers to the
social bonds between groups of people that prevent the breakdown of a particular society.
Embedded in this concept is the belief that people are connected to one another due to possessing
a common goal and identity.26 According to this group conception of solidarity, generally in
most groups there will be some tendency to prefer or to be benevolent towards other members of
the group.27 Massimo Reichlin notes that the idea of solidarity involves, on the one hand, the
disposition to care for the defense and promotion of the conditions of social life for which the
members of the group are collectively responsible and, on the other hand, the disposition to take
particular care of the needs and interests of the weaker members of the group.28 Indeed the
expression of solidarity is presented through mutual actions that occur among people who are
within the same environment, in a kind of “social corporatism” in which those persons involved
have an interdependent relationship. These interpretations may derive from Aristotle, who placed
the foundations of solidarity in a position that is incompatible with individualism.29
It has been recognized that if solidarity can be harnessed towards meeting goals such as
the promotion of health and social development then it can be a powerful motivating force. Yet,
we must think further on why global solidarity is necessary. Two arguments are presented here
for the necessity of solidarity. The first is that in addressing global problems such as access to
medicine, access to potable water, lack of education, and poverty, more is needed than simple aid
and generosity of affluent donors. While the driving motivation behind such aid is goodwill and
helping humanity, the recipients are often viewed as helpless victims. Solidarity introduces a
mindset that is not synonymous with charity, compassion, fraternity, or philanthropy. While they
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convey similar but not identical ideas, there are conceptual clarifications that must be offered to
distinguish these terms.30 The central differing quality is that solidarity signifies that a
relationship amongst equals exists. In such a symmetrical relationship then it necessarily means
the inclusion of cooperation toward a common goal.31
Secondly, global solidarity may be considered a necessity due to the shared, common
experience of humanity. If health is considered a common good for all humanity, the health of
the world’s citizens is a shared concern. While individuals acting alone may be near powerless in
the face of ominous global problems, as a unified whole, populations can make a lasting
difference. Hence, it has been realized that solidarity is a critical motivating factor for collective
action towards a common goal. It is at this point that we can note that solidarity is crucial for the
moral discourse of global bioethics because it demonstrates that humans are primarily social
beings.32 Social science has provided evidence that humans flourish best when in community.33
This idea dates back to at least Aristotelian thought and is essential in order to address the global
health concerns of today.34 Kofi Annan, in his final speech to an American audience as
Secretary-General of the United Nations, seemed to have hinted at this idea when he stated that
global solidarity is both necessary and possible. Annan proposed that without solidarity, no
society can be truly stable, and prosperity cannot truly be secured.35
Cooperation is in many respects a similar concept to solidarity. However, it is worth
noting how these concepts differ and each form a foundation for social responsibility. An
understanding of the significance of cooperation presupposes that there are benefits or mutual
advantages in interactions between states, institutions, organizations, groups, or individuals.36
John Stuart Mill was an early advocate of cooperation in the nineteenth century to solve social
troubles. Reacting against the inequality and exploitation of labor he witnessed in his day, Mill
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proposed that such ills could be overcome through cooperative processes involving free
associations between workers and other workers and between workers and capitalists.37 Mill was
onto the idea that human rights cannot be fully realized without cooperation, and that in order to
see true change, joint action and cooperation is required.38
While the need for global cooperation is not generally contested, seeing it come to reality
is often fraught with political difficulties and can be fragile. This can be explained, at least in
part, because two views of cooperation are often in play: cooperation as instrumental and
cooperation as an end in itself. Cooperation that is instrumental is based off self-interest, can be
short-lived, and goes against the perspective of global bioethics. Humanity, in the perspective of
global bioethics and in the concept of social responsibility, cooperates with one another because
of their shared interests and experiences, which is cooperation as an end in itself. The moral
impetus behind such cooperation is the global concern for humankind and the problems it
faces.39
Bioethics has not always had a bent towards social responsibility. Bioethics has been
charged with focusing too strongly on the individual to the neglect of the social setting and
cultural milieu in which medicine exists, as was presented in Chapter 2.1.40 Since clinical
medicine is dedicated to the treatment of the individual, bioethics tended to stake its claim on
this part of the moral terrain to the inattention of others.41 This lack of consideration for the
social setting continues to be visible in the wider landscape of mainstream bioethics that
generally leans toward a focus on the individual perspective.42 Albert Jonsen, writing in 2001,
was so candid as to say that bioethics lacks a clear and substantial social theory and that as a
discipline, bioethics has, in general, failed to integrate social responsibility into its discourse.43
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The critique of Jonsen and others is that mainstream bioethics may give a head nod to the social
context and to theories of justice, yet these considerations are only background questions.
However, the call for bioethics to embrace an ethic that goes beyond an individual
orientation has been around for decades on the peripheries, overshadowed by the dominance of
individualism.44 In a 1988 interview, Daniel Callahan was quick to combine medicine and
society by noting that societal values, principles, and virtues help to fashion the medical
community.45 Indeed, while bioethics has a history of being staunchly engrained in
individualism, exceptions have occurred, even from its inception, such as with the work of the
bioethics pioneer Van Rensselaer Potter that was previously presented in chapter two. Another
notable example is the 1975 Asilomar Conference. Scientists convened to discuss safety
concerns of new recombinant DNA and its implications on broader society. Further, in 1988 the
Human Genome Project became the first major scientific undertaking to dedicate significant
portions of its budget to associated ethical and social issues. The Human Genome Organization
(HUGO) was created to foster this international conversation.46
As time has progressed, the scientific community has steadily understood that social
responsibilities for health are a fundamental concern for the ethics of professional public health
practices. The WHO was among the first to promote social responsibility for health in their
“Fourth International Conference on Health Promotion: New Players for a New Era—Leading
Health Promotion into the 21st Century.” Held in 1997, the conference recommended that both
the public (e.g. governments) and private sector (e.g. corporations) should promote health
through enacting policies that avoid causing harm to individuals, protect the environment, restrict
the production and trade of harmful goods, safeguard the citizen in the marketplace and
workplace, and include equity-focused health impact assessments as an integral part of policy
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development. This conference was followed in 2000 by the Fifth Global Conference on Health
Promotion in which it became clear that social responsibility means different things to different
people. Hence, the need for defining what is meant by social responsibility became apparent.
Universal consensus on this has still yet to be achieved, as many definitions of social
responsibility are in use today.47
Though social responsibility has typically not been at the forefront of bioethics, attempts
have been made to develop theoretical models that would include the views of social
responsibility for health and wellbeing. The discussions on access to healthcare in the 1980s
through today have brought social and political philosophy into bioethics.48 Further, Johanna
Ahola-Lanunonen points out that several authors have called for a “bioethics of population
health” that would address the difficulties of global and domestic health inequalities, as well as
matters of social justice. Such commentators believe that bioethics has a duty to abandon its
fixation with the clinical dilemmas of high-tech questions and should further integrate questions
of social structure, socioeconomic position, and cultural background more fully into moral
analyses.49
A major impetus for broadening the scope of bioethics to include a social perspective has
primarily come from bioethicists interacting with epidemiological research on social
determinants of health and health inequalities.50 Norman Daniels, a political philosopher and
bioethicist, has provided comprehensive commentaries on the concept of social responsibility for
health.51 Daniels claims that society has a duty to protect the opportunities of its members, an
argument that he forms by examining multiple theories of justice. He reasons that health holds a
special moral importance over other things because maintaining it makes a significant
contribution to protecting the range of opportunities open to individuals. Hence, because of its
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importance, there is a social obligation to protect the health of the population.52 Informing his
view of health are also the social determinants. Daniels finds that many of these social
determinants of health are unequally distributed among ethnicity, gender, and class.53 It should
be noted that there is an abundance of empirical evidence to support the significance of social
determinants of health.54 It may be likely that public health measures based principally on the
idea of individual responsibility place the most demanding burden on the most vulnerable groups
in the population, as those in more privileged positions are better equipped to pay for the
treatments needed. To counter such questionable reasoning, a greater emphasis on social
responsibility for health is needed that would seek to counteract the original inequalities.55
It has also been realized that the move of bioethics from an individual-oriented
perspective to one that has begun to consider the broader social and global context is the
consequence of increased globalization across the spheres of political and social life. Bioethics
has witnessed rise of global health as a conceptual framework of analysis, due in large part to
new and resurgent health threats that cross geo-political borders quickly, such as the Ebola and
Zika viruses. This, in turn, has heightened both the recognition of numerous worldwide factors
affecting health and of shared global vulnerability.56 Because of this globalization and the
perceived need for moving towards social responsibility in bioethics, Johanna Ahola-Launonen
has stated that the recognition of social matters for bioethics is important in order for the social
determinants to no longer be of secondary concern and to truly embrace the multidisciplinary and
interdisciplinary nature of bioethics. Hence, it can be seen that social responsibility has evolved
into more of a prominent position in bioethics, though it has not yet achieved the fully integrated
position that many are calling for.57
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The concept of social responsibility in global health and bioethics plays a major role in
the UNESCO UDBHR. This social dimension of bioethics is novel to the UDBHR and was
added to subsequent drafts of the document out of a necessity to go beyond the limits of pure
medical ethics with the aim of placing bioethics within the context of the political and social
world.58 Article 14 of the UDBHR expressly iterates this perspective in Article 14 of the
document, entitled “Social responsibility and health.” The inclusion of Article 14 moves the
document beyond the realm of medical ethics and reiterates the need to place bioethics and
scientific advances within a larger context of reflection that is open to the corporate, political,
and social world.59 Article 14 reads:
1. The promotion of health and social development for their people is a central purpose of
governments that all sectors of society share.
2. Taking into account that the enjoyment of the highest attainable standard of health is
one of the fundamental rights of every human being without distinction of race, religion,
political belief, economic or social condition, progress in science and technology should
advance:
(a) access to quality health care and essential medicines, especially for the health
of women and children, because health is essential to life itself and must be
considered to be a social and human good;
(b) access to adequate nutrition and water;
I improvement of living conditions and the environment;
(d) elimination of the marginalization and the exclusion of persons on the basis of
any grounds;
(e) reduction of poverty and illiteracy.60
Article 14 offers a forceful summary both of the social determinants that require addressing and
of the “sharing” of responsibility that is essential to perform the task. A list of the main foci of
this commitment is clearly bulleted in the second point. However, it is in the wording of the first
point that the conceptual link between social responsibility and health is unmistakably stated.
The statement implies two things: 1) no actual promotion of health for people is possible without
making development of the whole society a pivotal issue, and 2) “all sectors” of society are
called upon to share this responsibility that is unquestionably and in the first place a
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responsibility of governments, but can in no way be considered a responsibility of governments
alone, lest the goal of promoting health be missed.61 Governments are the first to be addressed by
a call for social responsibility in health, as it has been generally agreed that governments have
some measure of responsibility towards the promotion of health.62 Governments have at their
disposal both the means to promote health (through legislation) and the resources to fund such
endeavors (through taxation).63 However, while the responsibility towards health may be a
responsibility primarily held by governments, it is not solely a responsibility of governments.
The innovation here for healthcare is that the protection and promotion of health is
regarded as a shared responsibility. As the policies and practices of multinational companies
have the ability of affecting millions of people, the normative argument embedded here is that
companies have an obligation to prevent or remediate the negative affects of business for the
benefit of the health of others.64 Article 14 also does not make it possible to regard the
geographical boundaries of a society as the limit of obligations. If this were so, governments
would merely need to discharge these obligations for their citizens and companies would only be
encouraged to look after their shareholders, clients, and employees. The vision behind Article 14,
and the concept of social responsibility more generally, is that health can no longer be isolated to
pockets of interests and responsibilities dispensed by states. Global trade, international research,
and pandemics, for example, clearly involve social relationships that reach well beyond
geographic boundaries.65
Social Responsibility is also a focal point of UNESCO’s International Bioethics
Committee (IBC), which in 2010 issued a report On Social Responsibility and Health. The report
emphasizes the need for new perspectives that go beyond medical ethics and bioethics, and the
IBC contends that scientific progress must be located within a context that is open to the social
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world.66 Hence, there is a robust call for a broader, more integrated notion of social responsibility
from certain corners of bioethics, especially within international and global bioethics, which is
becoming progressively visible in the literature.67
Today, social responsibility is oftentimes synonymous with corporate social
responsibility, which is, very simply defined, how social responsibility applies to corporate
entities. This is largely the subject of 3.2 and, specifically, how CSR applies within the
pharmaceutical and biotechnology industry and to the issue of pharmaceutical pricing, which is a
perennial problem for the industry.
3.2) CSR and the Pharmaceutical and Biotechnology Industry
After an introduction to the concept of social responsibility in the previous section, this
chapter now turns its attention to the specific study of CSR and how it has developed within and
applies to the pharmaceutical industry. A key area that has come under fire in recent years in the
pharmaceutical and biotechnology industry is the area of pricing. Pharmaceutical pricing is a
tremendously important CSR issue and, due to its pervasiveness in the media today, will
comprise large portions of this section to try to elucidate how CSR can speak into this issue.
Companies that are integrally tied to human health and flourishing, such as the pharmaceutical
industry, may be especially addressed by calls for social responsibility in global health. CSR
rests upon the premise that most modern companies likely create “bads” as well as goods, and
accordingly should conduct activities that deliver social or environmental benefits to offset any
adverse consequences of their business. Pharmaceutical companies seem to be special cases
because their business decisions directly impact human health and flourishing, making CSR
efforts particularly important for them. Further, the UNESCO Universal Declaration on
Bioethics and Human Rights can ably address issues of CSR and pricing within the
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pharmaceutical and biotechnology industry. Hence, the UDBHR will be invoked in this manner
in this section. First, this section will offer an explanation of what CSR is, its origins, and its
criticism. Second, CSR will be applied to the pharmaceutical and biotechnology, with the use of
the UDBHR, on the persistent issue of drug pricing. Finally, methods for implementing greater
CSR within the industry will be examined.
Section 3.1 presented the term “social responsibility” and briefly introduced the
expression “corporate social responsibility” or CSR. CSR is a relatively new concept that focuses
on a company’s responsibility toward property and profits as well as those who are affected by or
involved in the activity of a company. CSR has been defined by the UN, at its broadest, to
signify the overall contribution of business to sustainable development.68 However, a universal
consensus on the definition of CSR has not been achieved, as many definitions are in use today.69
Yet, most view it as more than corporate philanthropy. While companies are bound to legal
duties, CSR calls upon companies to meet additional duties that stem from a commitment to
improve the welfare of societies, which are more ethical than legal duties. This idea widens the
scope of responsibility for corporations from merely stockholders and investors to include also
stakeholders—any person or group that can affect or be affected by the achievement of an
organization’s objectives.70
The concept, practices, and manners of implementing CSR are disputed and rejected by
many commentators.71 The principle is rejected by many on the claim that health is solely the
responsibility of governments. Companies that see their sole obligation as to improve the state of
their shareholders and fulfill legal obligations see no moral necessity to contribute to the
common good of society. This is the argument chiefly advocated by the Nobel economist Milton
Friedman. Friedman, a well-respected academic of the time, contended that, “few trends could so
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thoroughly undermine the very foundations of our free society as the acceptance by corporate
officials of a social responsibility other than to make as much money for their stockholders as
possible.”72 This stance would be broadcast widely in a popular-level New York Times Magazine
article in 1970, entitled, “The Social Responsibility of Business Is to Increase Its Profits,” which
was more easily accessible to masses of people than an academic textbook.73 For Friedman, a
free-market economy meant that the shareholder assumed primacy. Friedman’s position, which
is argued persuasively, stands as a quintessential statement of conservative political economists’
rejection of CSR.74 Yet, one outstanding problem with this narrow view of social responsibility
is that it fails to appreciate that corporate decisions often have powerful and far-reaching social
impacts. Such firms are social agents, whether they realize it or not.75
While there were many writers on CSR in this era, Edward Freeman and Peter Drucker
stand out for their contrasting positions to Friedman. Freeman, along with colleague William
Evan, in 1988 published their influential article, “A Stakeholder Theory of the Modern
Corporation.”76 This was the beginning of the new stakeholder approach in management that
looks not only at the legitimate profit-making ventures of a firm, but also at the many individuals
and organizations that are targeted by and/or involved in the activity of a corporation.77
Similarly, Drucker advocated for the view that successful companies focus on responsibility
rather than power, as well as their reputation in society rather than merely piling up short-term
results.78 Drucker furthered the idea that profitability and responsibility are not mutually
exclusive for a company; they are compatible. While this was not a novel point, Drucker insisted
that businesses ought to convert their social responsibilities into business opportunities.79 He
emphasized, “But the proper ‘social responsibility’ of business is to tame the dragon, that is to
turn a social problem into economic opportunity and economic benefit, into productive capacity,

102

into human competence, into well-paid jobs, and into wealth.”80 Hence, Drucker believed that
social problems could be opportunities for business growth. This vein of reasoning has continued
in CSR, as many are now advocating for it as smart business. What is more, Drucker advocated
that, “Leaders in every single institution and in every single sector…have two responsibilities.
They are responsible and accountable for the performance of their institutions, and that requires
them and their institutions to be concentrated, focused, limited. They are responsible also,
however, for the community as a whole”.81 Therefore, Drucker did not see the role of the modern
corporation as merely concerned for profits, but rather for profits and people. The modern-day
concept of CSR embodies these values.
Certainly not everyone is in agreement with figures like Freeman and Drucker. The
notion of CSR may be criticized as simply being opportunistic and as a manner for companies to
garner good public relations, not a moral strategy.82 This seems to be backed by certain empirical
evidence that pharmaceutical companies engaged in CSR do so with motives of reputational
benefit, employee satisfaction, higher rankings in sustainability indices, entrance into new
markets, long-term economic returns, and improved population health.83 While these motives
may not in and of themselves be entirely wrong, it is troubling that any mention of doing so as a
moral obligation is noticeably absent. Nonetheless, it might be difficult to make a strong
argument that companies must perform social goods out of pure altruism. After all, companies
still do need to be concerned with business and profits to stay afloat. John Stuart Mill wrote,
“[U]tilitarian moralists have gone beyond almost all others in affirming that the motive has
nothing to do with the morality of the action, though much with the worth of the agent. He who
saves a fellow-creature from drowning does what is morally right, whether his motive be duty or
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the hope of being paid for his trouble.”84 Consequently, while there may be merit to some of the
criticism regarding motivations, this is not enough to dismiss the principle of CSR altogether.
In an article that appeared in The Wall Street Journal in mid-2010, Aneel Karnani,
Professor at the University of Michigan, avowed that the notion of CSR is an illusion and
potentially dangerous. Karnani’s warning is that a focus on social responsibility will either delay
or discourage more effective measures to enhance social welfare in those cases where profits and
the public good are at odds. Further, as society looks to companies to address these problems, the
real solutions may be ignored.85 Hence, Karnani views social responsibility as merely a
temporary fix to address societal concerns. His solution in order to strike a balance between
profits and public good is mainly consigned to the government to provide regulation. Karnani,
however, does not address the moral dimension of the argument. As this analysis has argued, the
decisions of corporations affect myriad peoples. There are vast numbers of stakeholders that are
affected by a company’s actions. And because of this, it is argued that a responsible company
will seek to both mitigate negative impacts and increase positive effects.
Some argue that if CSR exists and should be exercised by companies then it is best to be
handled in a voluntary manner and based upon self-regulation rather than external compulsion.
However, voluntariness is not always a very strong motive for change.86 One benefit of some
sort of external mechanism is the accountability that such a structure brings, as well as the
transparency it offers to stakeholders. Additionally, others critique CSR from an economic
viewpoint, arguing that social responsibility does not aid companies financially in ways that
some advocates propose. The business case for CSR and trying to empirically determine what
impact it has on the bottom line has tried to be determined for over four decades. Between 1972
and 2002, over 100 studies that empirically examined this relationship were published.87 To
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much dismay, the empirical studies have never been in agreement. Some studies found a positive
correlation.88 Others determined a negative association.89 Still, others found no correlation at
all.90 Nonetheless, the case for social responsibility in business stretches beyond merely looking
at whether or not it is best for the company’s bottom line and to the idea that businesses have a
moral obligation to look out not only for their profits but also for stakeholders (those affected by
the practices of the business) and the environment.
While over 100 studies have examined the link between CSR and financial performance,
and the results have been inconclusive, some have taken this to suggest that there is no a priori
reason for businesses to adopt CSR into their practices. Yet, there are growing calls from society
for businesses to adopt a wider range of social and environmental responsibilities. Oftentimes
those in the pro-CSR camp attempt to offer a business case for CSR, endeavoring to justify CSR
on economic grounds. Surely some kind of business case for CSR is necessary in order to call
attention to it and achieve “buy-in” from the business sector, yet the majority of these arguments
create too strong a bifurcation between ethical and economic justifications for CSR. This
assessment is perpetuated by the view that businesses must meet both social responsibilities and
business responsibilities. Yet, we must question whether such a split is actually necessary. The
dominant view, espoused by Friedman and others, that businesses must pursue that which is
good and valuable and worth pursuing (i.e. profits) is inherently ethically laden. Hence, it can be
argued that there is no true separation between ethics and economics. Such a separation between
economics and ethics is perpetuated when one attempts to justify positive social behavior in
economic terms rather than as a value worth pursuing in and of itself—as an integral element of
a healthy capitalist business system.91
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However, the economic argument for CSR remains highly controversial. Deborah Doane
charges that CSR as a concept simplifies some complex economic arguments and fails to
acknowledge that trade-offs must be made between the financial health of the company and
ethical outcomes. Doane levels several arguments against CSR, though two will be presented
here. She states two common myths associated with CSR: 1) It is a myth that there will be a
competitive race to the top over ethics amongst businesses, and, 2) It is a myth that in a
globalized economy, countries will compete to have the best ethical practices. Doane’s critique is
that businesses simply hide their irresponsible acts and seek to promote their more ethical ones.92
Hence, there is no real ethical company, only those who do a better job at cloaking their
troubling practices. While transparency is an issue with companies, steps are being taken to
address it, especially within the pharmaceutical industry with activities such as the Good Pharma
Scorecard project developed by Bioethics International.93 Doane’s critique that there will be a
competitive race to the top has not been the experience of the Access to Medicine Index (ATMI).
ATMI is a biennial publication that was first published in 2008 and is now well recognized in the
pharmaceutical sector for their efforts at social responsibility. This is evidenced by a recent
independent, third party evaluation that found that ATMI has made commendable contributions
towards advancing the engagement of the industry with the issue of access to medicine.
According to the study, ATMI has become a well-regarded authority on access to medicine and
has succeeded in building consensus between stakeholders for the industry.94 The driving idea
behind ATMI is that companies will compete, in a sense, for a coveted high ranking on the
index. It has been shown that competition can be a catalyst for price reductions, and it is argued
that by ranking pharmaceutical companies and publishing the results publicly then competition in
regards to access to medicine can be sparked.95 A recent empirical study that analyzed the
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available data on pharmaceutical companies’ CSR efforts also studied the role of ATMI and the
Dow Jones Sustainability Index (DJSI) in promoting global health. The researchers concluded
that there is a need for more attention to be garnered in order for the indexes to meet their
potential.96
Doane’s highly skeptical view of business that purports that companies merely promote
good behavior and hide their bad ones simply does not seem to hold up under scrutiny.
Organizations today are more controlled by their stakeholders and companies are forced, in a
sense, to display greater amounts of transparency in their conduct since stakeholders can freely
disseminate information about a firm’s behavior. Further, the advent of new forms of technology
has also had the effect of increasing transparency now that anybody can readily report on the
activities of a company.97
Criticism of social responsibility also appears from firms who are established in the field
of global health. Pharmaceutical and biotechnology companies are under increasing societal
pressure to act responsibly in a globalized world. As a healthcare industry, many have insisted
that drug companies cannot merely be concerned for their own profit margins to the neglect of
the very people who depend on their medications. An August 2015 poll showed that 74% of the
American people believe that drug companies routinely prioritize profits before patients.98 Many
commentators have argued for the responsibility of pharmaceutical companies to address the
challenges posed by health crises affecting low- or middle-income countries (LMICs), for, they
suggest, a socially responsible company has a moral obligation not only towards shareholders but
also to stakeholders.99 Further, the business decisions of pharmaceutical companies directly
impact human health, which makes corporate social responsibility particularly important.100
Klaus Leisinger, a critical thinker in this area, has suggested that CSR in the pharmaceutical
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industry, as in other sectors, encompasses responsibilities with differing degrees of obligation.
Leisinger distinguishes between three classes of what is required of business by society, what is
expected of business by society, and what is desired of business by society. He argues that
companies should do more than the minima moralia, especially in view of global social
problems. However, noting that such companies have historically been slow to address issues of
ethics and access demonstrates, at least implicitly, they have not fully embraced the idea of
social responsibility.101
While many pharmaceutical companies now have dedicated CSR departments, the
industry has not embraced the concept as quickly as some have hoped. The pharmaceutical
sector has typically been unwilling to address issues of access to essential medicines through a
systematic approach to differential pricing for LMICs. Rather, providing access for costly
medicines in LMICs has typically been done through a company’s corporate philanthropy unit.
Yet, CSR is about more than mere philanthropy, as it challenges companies to rethink their
attitudes towards markets in LMICs in order to evaluate and improve the impact their business
has on human development and flourishing.102 Hence, by not addressing such issues then the
industry has indirectly criticized, or at least not embraced, the concept of social responsibility.
The obligation for pharmaceutical companies to make social responsibility a priority is due to the
nature of their business. Simply, the business decisions of pharmaceutical companies directly
impact human health and flourishing.103
Small or lesser-established pharmaceutical or biotechnology companies may also be more
hesitant to deal with ethical issues such as social responsibility. Some have argued that they only
need to begin worrying about ethics when their products come to market. However, research
verifies that companies miss important opportunities when they assume they only need to
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address ethical issue after developing a product. A solid foundation in ethics from the beginning
will allow companies to better understand the larger ethical minefields. Further, some companies
have also attempted to argue that they are fine as long as they follow FDA guidelines and stay
within the law. However, the expectations of society are evolving so that mere legal compliance
is not viewed as a sign of necessarily ethical behavior.104 The pharmaceutical industry has been
charged by the media and academia alike with not spending enough resources for the
development of new vaccines and drugs to treat issues such as tropical diseases and the ailments
of those in LMICs.105 This lack of interest on the part of the pharmaceutical industry could be
explained by the high cost of biomedical research and the small or negative profit margins a
company could expect.106 Ethics bodies such as the International Bioethics Committee of
UNESCO have emphasized that the pharmaceutical industry is particularly addressed by social
responsibility.107 Though some have argued that pharmaceutical companies have no special
responsibility towards global health, this argument is increasingly seen as implausible for those
whose activities clearly have a direct impact on health and human flourishing.
As this section transitions to seeking to understand more thoroughly how CSR is applied
to the pharmaceutical and biotechnology industry, it must first be acknowledged that the industry
suffers from a CSR and reputation crisis. A major source of this crisis is the numerous pricing
scandals that have rocked the industry. In an August 2015 poll completed by the Kaiser Family
Foundation, one of the premier healthcare public policy think tanks in the US, it was found that
most Americans feel that drug costs are unreasonable (72%) and that drug companies put profits
before people (74%).108 In September 2016 the survey was repeated and found that 77% of
Americans felt drug costs were unreasonable.109 These statistics are not entirely surprising, for an
enduring quandary for the pharmaceutical industry has been its aggressive pricing policies. Yet,
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one important issue that is not taken into account in this poll is the enormous research and
development costs borne by pharmaceutical and biotechnology companies. It is worth
considering whether or not the poll would have achieved similar results if the researchers also
mentioned these enormous costs and the average 12 years of research and development to
produce a new drug.
Nevertheless, there are two paradigm recent examples of the public believing drug costs
are unreasonable. The first is the case of Turing Pharmaceuticals and the aftermath that followed
in the media and by influential politicians, such as Hillary Clinton, who has called for plans
control the “price gouging”.110 It was revealed in September 2015 that Turing Pharmaceuticals
had acquired a 62-year-old drug, Daraprim. In and of itself, this would be unremarkable, but
Turing and their CEO Martin Shkreli also announced that they would be raising the price of the
anti-protozoal drug from $13.50 to $750 per tablet—a 5,000% increase that may be prohibitively
expensive for many.111 Unsurprisingly, this drew national scorn towards the company and the
industry in general, as Turing was seen as taking advantage of HIV/AIDS patients who rely on
the drug.112 Similarly, in late August 2016 the American drug company Mylan reached national
headlines for the prices of their product EpiPen, which has increased in price 400% since
2009.113 Similar to the Turing debacle, Mylan drew the attention of U.S. Members of Congress
and the scorn of politicians.
These two fresh examples of skyrocketing prices are reminiscent of the late 1990s and
early 2000s when the pharmaceutical industry came under fire for not making HIV/AIDS
treatments widely available to Sub-Sahara Africa. In 1987, azidothymidine (AZT) became the
first anti-HIV drug to be approved by the FDA. Additional antiretroviral drugs soon followed,
and by 1997 the number of AIDS deaths had declined significantly in the US. However, by the
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end of 2003, fewer than 7% of people in LMICs in need of antiretroviral treatment had access to
these medicines, largely due to price. In late 1997, the South African government, under the
leadership of Nelson Mandela, took legislative measures to reduce the pharmaceutical prices.114
The new law included two provisions aimed at bringing down pharmaceutical prices. The first
provision sought to take advantage of a gray market by allowing the import of drugs from
countries where they may be available for less. The second provision would let the South African
government grant licenses to local manufacturers to make their own generic versions. The
pharmaceutical companies objected strongly, fearing the erosion of their patent protections.115
By the end of the controversy, pharmaceutical companies were painted in a very negative light,
and South Africa promised to adhere to its obligations under the Agreement on Trade-Related
Aspects of Intellectual Property Rights (TRIPS).116 Since then, the industry has made broad
accommodations on pricing and access to HIV/AIDS drugs.117 Yet, from these examples, it is
clear that the area of pricing is one that is commonplace and regularly publicized.
To be certain, innovation in the pharmaceutical sector is expensive, and risk must be
rewarded. A recent study by the Tufts Center for the Study of Drug Development estimates that
developing a new prescription drug that gains marketing approval can cost $2.6 billion USD and
take longer than a decade. This figure takes into account the costs of unsuccessful research and
lost investment opportunity.118 To be sure, these significant costs are a major argument against
regulating drug prices, for it is held that putting a cap on drug prices will drive down innovation.
Indeed, some commentators have argued that patients definitively will not receive new lifesaving medications if prices are capped.119 Such a strong statement is not easily defensible.
Though some novel drugs may be worth paying high prices for, drug prices in the US often have
more to do with what the market will bear than anything else.120 Hence, one reason for the lack
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of more reasonable pricing structures for pharmaceuticals may be the result of an American free
market run amok. The claim is often made that high prices and profits are nothing short of being
exceedingly unwarranted and unethical. The argument is often delivered in terms alleging that
pharmaceutical companies could (and ought) easily deliver less expensive products while
maintaining a superior quality and not sacrificing research and development. Yet, the task of
assessing what constitutes an unethical price or excessive profit proves quite difficult.121 To be
sure, businesses are entitled to a reasonable profit as a reward to investors, itself, and as stability
for long-term sustainability. Basic tenets of business dictate that companies, such as those in the
pharmaceutical or biotechnology industry, are private corporations that are responsible to
shareholders for making profits, and they must produce profits to stay afloat. However, the real
problem of research and development is the industry-wide practice of viewing innovation solely
from a manufacturing perspective rather than from the perspectives of patients and other
stakeholders. Pharmaceutical companies must continue research and development in ways that
optimize the medical and economic benefits to shareholders, but they also need to listen to
stakeholders and innovate in ways that address real stakeholder needs as opposed to solely
industry needs.122
The issue of pricing and profit attains much greater significance when the item in
question is not a luxury good, such as a BMW or the latest smartphone, or even a non-essential
drug such as Viagra, but an indispensable one, such as life-saving or life-prolonging medicine.123
Hence, normative claims are at stake here. Should free market forces determine the price of
essential goods such as pharmaceuticals, or should their pricing be regulated? Is it, in fact,
morally wrong for a company to charge high prices if the market can bear it and the consumer
can pay it? What are the ethical implications of excessive profit at the expense of human
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suffering? A key question that warrants thought is whether or not other viewpoints should be
considered. Should companies in the health sector take the needs of the sick into account in light
of their considerable stake in these issues?124 These are questions that only begin to touch the tip
of the proverbial iceberg and hope to be examined, to differing degrees, within this analysis.
Though many recognize the high pharmaceutical prices in the US, not all agree that
pharmaceutical companies are to blame. Rafi Mohammed, a pricing strategy consultant, has
written that pharmaceutical companies are, in fact, not to blame, for they have merely executed
well on the rules set by the US government as well as the dictum of “make the most money” set
by their shareholders. Mohammed rather sees the onus on the American people for not taking
responsibility for deciding how drug prices are set.125 While there is truth that Congress has not
proved keen on enacting regulatory guidelines for pharmaceutical pricing, we also must not gloss
over the moral agency of individual actors in the industry and companies. It does not follow that
simply because regulatory guidance is lacking that pharmaceutical and biotechnology companies
are ethically justified by charging whatever prices the market can bear.
For pharmaceutical and biotechnology companies, caring about their pricing structures
and how the public views them should be high on their priority list. Corporate reputation is the
sum total of perceptions of a company. These perceptions are largely based on what the company
does or neglects to do (Chong 2012). Further, failure to respond to issues, such as access to
medicines can quickly lead to reputational harm.126 Pharmaceutical companies have seen their
reputation in the public image eroded over recent decades. The Reputation Institute, a leading
consulting and advisory firm on reputation, has noted that the pharmaceutical industry reputation
score is 67.6, which is an “average” score. Anything from 70-79 is considered “strong,” and an
excellent is a score of 80 or above. However, they also note that the industry reputation is very
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polarized, with roughly one-third of respondents viewing the industry as having an excellent
reputation, and another third perceiving it as weak or poor.127 This is not only an American
problem, but it is a global phenomenon. The reputational decline coincides with a 2013
PatientView survey of mainly European patients in which only 30% of those surveyed rated
pharmaceutical companies as good, a 7 percentage point decline from the previous year. Among
the reasons cited for the downward shift in opinion included: offering drugs with only short-term
health benefits, not doing enough to discover chemical entities suitable for neglected patient
groups, a perceived lack of transparency of pharmaceutical companies, and drug prices that, in
some cases, are still unaffordable to many patients or their payers.128
While the pharmaceutical sector struggles to regain a positive public image, it must be
stressed that a company’s reputation is vital. A recent study estimates that it is the intangible
assets of a company, including reputation, that currently represent as much as 40-60% of a
company’s market capitalization, leading to the conclusion that a company’s reputation is among
its most valuable assets.129 Pharmaceutical and biotechnology research needs the cooperation and
participation of large segments of society, and citizens need confidence that researchers are
working for the benefit of the population. When the public reads of issues of scientific
misconduct or what they perceive to be “greed” and working adversely for the population’s
benefit, societal trust in research is undermined. Greed is simply a bad way of doing business,
especially when it makes people oblivious to the suffering of others. Indeed, such behavior is at
odds with civic virtue. A society or business that seeks to press for maximum advantage and
exploit their neighbors in order to make windfall profits is not praiseworthy.130 Indeed, science
and technology cannot flourish without societal trust, which is one of the reasons global
bioethics is expanding.131
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Generally, public confidence in business is low, and the public’s scrutiny of business is
high.132 This may be even more so for the pharmaceutical industry that has been tied to dubious
marketing practices, excessive policies, and the flaunting of regulations and law. Corporate
reputation depends on the past experience that persons have had with a company and the extent
or nature of their communication with it through the media and conversation. For companies in
the pharmaceutical and biotechnology sector, how stakeholders view companies is influenced
largely by the lay professional media (print, TV, radio, online) and the internet (blogs and social
media).133 Hence, the pharmaceutical industry reputation appears to be an amalgam of perception
by its different stakeholders, including investors and patients, as well as the reality of its policies,
practices, systems, and performance.134 Yet, reputation is at the very heart of a business,
especially one that is so closely aligned with personal welfare of the public, such as the
pharmaceutical industry. The reputation problem facing the pharmaceutical industry is currently
too sizeable for any one company to address alone. The industry must work together to rebuild
trust.135 This restoration will not be an easy task. Some research indicates that it takes an average
of 3.5 years for a company to restore a declining reputation.136 For an industry like the
pharmaceutics business, the timeline may be greatly protracted. Transparency, as has already
been advocated, will need to be high on the priority list in order to accomplish this. This will be
explored in further in the subsequent subsection in which manners of restoration are explored in
detail.
Up to this point it has been shown that pharmaceutical and biotechnology companies
suffer from a CSR and reputation crisis that is largely a result of pricing troubles. Many
commentators have made the case that the industry cannot merely be concerned for their own
profit margins to the neglect of the very people who depend on their medications. That is, the
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business decisions of pharmaceutical companies directly impact human health, which makes
CSR particularly important.137 Prominent NGOs and international groups such as UNESCO,
Oxfam, Save the Children, and Voluntary Service Overseas, have challenged the pharmaceutical
industry to adopt a broader scope of responsibility and improve its efforts to tackle the health
crisis affecting LMICs.138
Global bioethics, and a tool such as the UNESCO Universal Declaration on Bioethics and
Human Rights is a powerful instrument to involve multiple stakeholders in shared concerns and
approaches. The availability of a global ethical framework that takes into consideration
viewpoints from all UNESCO member states presents an excellent opportunity to rebuild trust
and a positive reputation for pharmaceutical and biotechnology companies. Particularly, private
companies need to rebuild the trust of society because of issues of accessibility of healthcare and
affordability of medical treatment. There is generally no qualm from society that the
pharmaceutical industry be concerned for profits, for they are not charities.139 There is concern
that they also have regard for social issues. Transparency will be a first step, but to increase
reputation and regain societal trust, more will be required.
As presented in section 3.1, Article 14 of the UNESCO UDBHR directly addresses social
responsibility. Responsibility in Article 14 does not refer to the personal responsibility of
individuals, but rather to the responsibility of an individual as a member of society. Such a view
entails that many actors are responsible for promoting health, not only governments.140 It is
similarly the responsibility of private enterprises such as pharmaceutical and biotechnology
companies. Indeed, every industry activity implies social responsibility. Businesses must manage
working conditions, interface with how they affect the environment, set pricing for drugs that
either make the drug accessible or not, and so forth. The globalization of the healthcare industry
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has made these responsibilities more evident.141 The policies and practices enacted by
multinational corporations have the potential to affect millions of people, and the normative
argument that companies have the onus of preventing or remediating negative effects of their
activities for health places emphasis on the notion of corporate social responsibility.142 Hence,
the notion of social responsibility does not let companies operate under the belief that their
decisions do not have impacts on countless individuals. Rather, social responsibility stresses that
all sectors—public and private—are to view the protection and promotion of health as a shared
societal responsibility.
Pharmaceutical and biotechnology companies have utilized programs of CSR for a
variety of causes.143 However, these companies have been critiqued by some for only attempting
to repair compromised public beliefs about their perceived unethical commercial endeavors.144
That is, if a major pharmaceutical company were to offer free vaccines for the children of a
specific developing country, and to do so as the pivotal message of an advertising strategy, then
an unavoidable conclusion might be that in many circumstances, the protection and promotion of
health are merely the means a company uses to obtain something else (approval, loyalty, trust,
readiness to buy) much more than a goal as such. While there may be merit to some of the
criticism regarding motivations, this is not enough to dismiss the principle of CSR. Even the
most instrumental application of the practices stemming from the principle of social
responsibility is not a justification to reject the principle for, quite the reverse, it underlines its
importance and the potential extensiveness of its effects.145 Hence, whether a company performs
responsible acts to enhance their prestige or out of undiluted altruism, this matters little as long
as the responsible decision is made and the act realized.146
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As a healthcare industry, many have insisted that drug companies cannot merely be
concerned for their own profit margins to the neglect of the very people who depend on their
medications. That is, the business decisions of pharmaceutical companies directly impact human
health, which makes corporate social responsibility particularly important.147 UNESCO, agreeing
with the assessments made by the non-governmental organizations (NGOs) Oxfam, Save the
Children, and Voluntary Service Overseas, challenges the pharmaceutical industry to adopt a
broader scope of responsibility and improve its efforts to tackle the health crisis affecting
LMICs.148 A socially responsible company, so the reasoning goes, ought to have policies in place
on access to treatment for LMICs which include the following five priorities: 1) pricing, 2)
patent, 3) joint public private initiatives, 4) research and development, and 5) the appropriate use
of drugs.149
An obligation for CSR rests upon certain claims about businesses having moral
responsibilities. It is argued that all businesses are shaped by and depend upon social values,
such as honesty, integrity, fidelity, and fairness. Values play a pivotal role in creating a climate
within and among companies for conducting business, and without these values in place,
corruption, theft, fraud, and various other ethical problems would make it impossible to do
business. Hence, businesses recognize the importance of ethical conduct. Many people would
accept the premise that moral values play an important role within business, but they might argue
that they do not play a role in the interaction between businesses and the larger society in which
they operate. However, David Resnik have argued that businesses have societal responsibilities
because they exist within societies where people care about the environment, public safety,
public health, and other goods. Resnik contends there are at least two reasons why businesses
have social responsibilities: 1) Businesses that ignore their social responsibilities may face the
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public’s wrath. For example, a company that recklessly pollutes a river will have to face the
backlash for it. Therefore, social responsibility makes good business sense. 2) Corporations are
like moral agents in that they make decisions that have important effects on human beings. If
corporations are like moral agents, then they have some of the same duties that apply to other
moral agents. In particular, corporations have obligations to avoid causing harm and to promote
social welfare and justice.150
Applied to the pharmaceutical industry, Resnik asserts that large, global pharmaceutical
companies have social responsibilities to LMICs based upon the principles of beneficence and
justice. Regarding beneficence, pharmaceutical companies should seek to promote the greatest
balance of benefits and harms for society. Concerning justice, pharmaceutical companies should
distribute benefits and burdens equitably. One way that pharmaceutical companies, Resnik
claims, may exercise these responsibilities to LMICs is by investing in research and development
related to diseases that affect LMICs, offering discounted drug prices, and initiating drug
giveaways.151
However, Resnik’s analysis is certainly not without its critics. Norman Daniels has taken
issue with Resnik’s formulations, and he posits that social moral responsibilities do not derive
from what society cares about, as Resnik believes, but rather they are the result of a kind of
social contract that establishes them. Further, Daniels takes issue with Resnik’s claim that
businesses have social responsibilities because they are like moral agents. However, Daniels’
principal assertion is the skepticism he expresses regarding a reliance upon appeals to moral
social responsibilities as a solution to the problem of affordable drugs. To make his case, Daniels
points to the fact that developing countries have regularly ignored intellectual property rights and
taken drug production into their own hands because global pharmaceutical companies have
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rarely exercised their social responsibilities. Daniels concludes that the solution to affordable
drugs for developing countries lies in domestic and international regulatory action to regularize
the contributions of pharmaceutical companies towards meeting the needs of those developing
countries.152 While regulation may be an appropriate action, Daniels does not elaborate at all on
how such action would be accomplished.
In a 2004 article in the prominent newsmagazine The Economist, the author raises many
doubts about CSR. Subscribing to a classic view that the proper role of businesses is to only
show concern for the profits of shareholders, the article emphasizes, “From an ethical point of
view, the problem with conscientious (as opposed to fake) CSR is obvious: it is philanthropy at
other people’s expense.” While the author acknowledges that CSR may be good for profits, it is
also much too quick to label CSR as unethical.153 Rather than engaging in a serious conversation
about the merits and snags of CSR, the author ends up sounding dismissive. We must be
cognizant that business practices not only affect investors and employees but also persons in
numerous sectors of society. Nevertheless, this classic reasoning about businesses only showing
regard for their direct shareholders is commonplace, and it is a view that Freeman, Drucker, and
others, such as the UNESCO UDBHR, have sought to counter.
Thus far in this analysis the CSR and reputation problems experienced by the
pharmaceutical and biotechnology sector have been analyzed. It has been argued that much of
the woes of the industry stem from the public viewing these companies as simply concerned with
profits and not people. This is a major issue for pharmaceutical and biotechnology companies,
and if companies are to engage CSR seriously, implementation mechanisms must be thoughtfully
considered. In the below, the possibility of using price differentiation for pharmaceuticals will be
analyzed and then the use of social pressure as a way to instill change will be assessed.
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One manner of combating prohibitive prices would be to reach agreements with the
pharmaceutical industry on a voluntary price differentiation between HICs and LMICs, allowing
the latter to pay only production costs and not the hefty research and development costs.154 Price
differentiation (also called differential pricing, equity pricing, or preferential pricing) is a
promising approach for access to expensive medications in LMICs. In such a schema, HICs
would pay more for drugs, while LMICs would only pay production costs and not the cost of
research and development. Hence, prices are set in such a way that reflects a country’s ability to
pay, as measured by level of income.155 To put an example in real terms, the Danish company
Novo Nordisk, for instance, sells their products for 20% of the price they charge developed
countries in the least-developed countries of the world. The principle behind this is to keep the
value of the drug. If they were purely to give it away, they claim, it makes the drug valueless,
and it also would not respect the hard work of the employees of Novo Nordisk who developed
these products.156 Differential pricing allows pharmaceutical companies to signal that their
pricing policies are socially responsible and consistent with their obligations to society and not
merely geared towards maximizing their profit.157
It may be surprising to learn that there is considerable variation in the retail price of a
drug, not only among countries, but even within a country. Factors such as import tariffs, taxes,
and various mark-ups depending if the drug is sold retail or wholesale also contribute to these
differences. Organizations such as the WHO have called for differential pricing to become
standard operating procedure for pharmaceutical and biotechnology companies.158 The aim of
such a program is quite clear: to enable LMICs to access essential drugs that would normally be
at too high a price point for their population to access. Further, one of the factors that the Access
to Medicine Index scores is the area of “Pricing, manufacturing, and distribution”. More
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companies are now using a tiered pricing structure, yet the overall effect on affordability of drugs
remains unclear. Hence, transparent data about just how affordable a company’s products are in a
LMIC is needed.159
However, it is not surprising that the pharmaceutical industry has historically been, in
general, opposed to such widespread appeals, for it would remove the pricing of drugs from the
free market. As recently as 2002, the US pharmaceutical industry trade association, known as
PhRMA, robustly defended free-market economics for pharmaceuticals. Yet, one need not even
be a vehement critic of capitalism to doubt the assertion that every marketable good has a price,
and the price is set by a free-market economic system.160 However, pharmaceutical business
models are gradually changing to incorporate aspects of social responsibility that include
affordable pricing. This is not a short-term outcome but is a long-term schema. Nonetheless,
some businesses are realizing that the public and shareholders no longer see improving access to
essential medicines for LMICs as simple philanthropy but rather as another sustainable way to do
profitable business.161
Many pharmaceutical companies have adopted price differentiation policies, and the
2014 Access to Medicine Index notes that, compared to 2012, more companies have committed
to or newly engage in equitable pricing, tailoring their prices to different population segments.
However, the Index also brings words of admonishment to the pharmaceutical industry for
lacking universal pricing guidelines for their sales agents. The majority of companies, as the
Index notes, have yet to set clear, universal pricing guidelines for their sales agents in countries,
and most do not monitor mark-ups. Further, even where guidelines are in place, no company
trains its agents on their implementation, and no company has guidelines that universally apply
to third-party distributors, wholesalers and retailers.162 Hence, as can be seen, price
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differentiation is an area in need of additional work. For companies to take the moral duty of
social responsibility and health sincerely they must address these concerns.
Critics of these proposals will surely form an argument based upon economics. While this
is primarily an ethics analysis, the economics of this situation are hard to evade. To emphasize,
the concern for CSR presented in this analysis does not imply that pharmaceutical companies
should simply becomes charities that distribute their products at a loss or for meager profits.
Long-term stability of the pharmaceutical industry does depend heavily upon substantial profits.
Yet, this paper has argued that the industry as a whole must seek to more appropriately balance
their concern for profit with an equal consideration of the importance of social responsibility and
justice.
Indeed it must be noted that there may be negative side effects of interfering in the
pricing structures of pharmaceuticals. The classic critique is that a decrease in profits will
inevitably lead to a decrease in research and development spending, which will, in turn, decrease
innovation. George Scangos, CEO of American biotechnology company Biogen, has flatly stated
that interfering in drug prices will slow the development of pharmaceuticals and biotechnology
products.163 Further, shareholders will not go for such a course of action. Admittedly, it is
difficult to define what a reasonable level of profitability would be for a drug. However, one has
only to look at the pricing scandals discussed in the introductory sections of this analysis to note
that there are issues that need addressing systematically. Klaus Leisinger has been prominent in
the area of pharmaceutical social responsibility by balancing it with realistic forethought about
pricing and intellectual property rights. While not getting into specific economic
recommendations, he does argue that private enterprises, such as pharmaceutical firms, have
neither the societal mandate nor the capabilities to provide healthcare to the sick throughout the
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world. Nevertheless, private enterprises do have some responsibilities to society if they are to be
good corporate citizens.164 Those with expertise in pharmacoeconomics and finance will need to
determine the financial viability of enhanced CSR, for this is largely outside the scope of this
ethics analysis.
For a global solution of pharmaceutical social responsibility in regards to pricing to
become reality, an emphasis on social pressure may be the most beneficial means of achieving
the desired end. Social pressure on companies to change their practices has certainly worked
before. John Ruggie, professor at the Harvard Kennedy School and chief drafter of the UN
Guiding Principles on Business and Human Rights, has noted that businesses require not only a
legal license to operate but also a social license. Nike is a case example of this when they came
under harsh social pressure in the 1990s due to low wages and abusive working conditions in
their overseas production facilities. After initially denying their responsibility, Nike accepted its
obligation to their offshore workers and eventually became a founding member of the UN Global
Compact.165 Social pressure has also been effective on the pharmaceutical industry itself. Oxfam
and Médecins Sans Frontières (MSF) joined forces at the turn of the millennium to cut drug
prices for LMICs.166 MSF has witnessed particular success in its campaign, which has involved
monitoring the patent barriers, prices, and availability of antiretroviral medication, as well as
pushing for the adoption of policies that promote access to affordable drugs. Due to their
pressure and generic competition, the price of antiretroviral drugs has dropped by more than 99%
over the last decade.167 These experiences could be repeated for a more systematic reduction of
pricing in both HICs and LMICs. A compelling campaign for responsible pricing by a similar
NGO may prove persuasive to raise societal awareness and sway companies into concrete action.
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A less likely example of social pressure might take the form of a pharmaceutical or
biotechnology company taking the lead on CSR to be a pioneer in their sector. Such a company
might have a particularly high commitment to the principles found in research ethics guidelines
or they simply may desire the positive public relations that they would reap. Media interest
would assuredly be piqued if a pharmaceutical company decided to routinely campaign for and
enact internal policies on responsible pricing. Regardless of the motive, the company would have
a high degree of transparency and display how they are attempting to be socially responsible, and
they would endeavor to hold similar companies accountable. Such a scenario coming from
within the industry would be a unique contribution to the field of social responsibility, as most
reporting mechanisms come from external sources. Indeed, highlighting this method is the chief
purpose of this dissertation. A pharmaceutical or biotechnology firm could take the UNESCO
UDBHR as a starting document and create measurable indicators and benchmarks from it to
ascertain both qualitatively and quantitatively how they are doing in fulfilling the principles. This
will be much further examined in chapters five and six.
CSR on a large scale has been promoted by the UN in the Global Compact, an initiative
launched in 2000 to encourage companies towards doing business in a responsible manner and
taking actions to advance broader societal goals that brings together over 12,000 signatories in
170 countries. Through its ten principles on human rights, labor, the environment, and anticorruption, the Global Compact aims at committing companies to a non-binding agreement with
the objective of corporate sustainability and taking actions that advance societal goals. The
Global Compact is a unique initiative for the breadth and volume of companies who have
become signatories to it. Through encouraging its partnering companies to operate responsibly
and take actions that support society, the Global Compact works to ensure that business activity
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adds value not only to the bottom-line, but also to people, communities, and the planet. In fact,
creating measureable benchmarks to ascertain how a particular firm is doing in regards to
fulfilling the principles of a global document is not so far-fetched, as such a project has already
been undertaken on the Global Compact.168 Signatories to the Global Compact must submit an
annual Communication on Progress to disclose how they are attempting to implant the ten
principles into their practices. Indeed, in the area of global health, many pharmaceutical
companies now have designated units for incorporating corporate social responsibility, such as
the UN Global Compact principles, into their business policies and practices.169
We must remember that the Global Compact is voluntary, non-binding, and is primarily
driven through peer or social pressure, social norms, and potential benefits to the company
through positive public relations.170 While the majority of the foremost pharmaceutical and
biotechnology companies have committed to Global Compact and its ten principles, there are
certainly differing levels of compliance. Additionally, the Global Compact was not specifically
designed for the pharmaceutical or biotechnology sector; it is much too broad. Therefore, while
Global Compact has proven effective at getting companies to sign on to broad corporate
sustainability principles, a more specific compact for those companies involved in the healthcare
sector, and the social pressure for companies to join it, might be an appropriate step towards
responsible pricing. Creating such a platform based upon the UDBHR from within the industry
with a way to measure and self-assess how different firms are doing in fulfilling the principles
may be a good step for the industry. While this is no guarantee of reaping reputational benefits as
a result, it does seem that such a step would be looked upon favorably by outsiders.
Social or peer pressure can also come from external sources, such as the Access to
Medicine Index, Dow Jones Sustainability Index, or Bioethics International. An underlying
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notion of these indexes is that sustainability and social responsibility practices constitute a
potential component for long-term value creation from which shareholders will benefit.171
Further, such external bodies aim to publish publicly accessible reports on how pharmaceutical
companies are doing in specific areas. For example, the Access to Medicine Index, published
every two years, ranks pharmaceutical companies’ efforts to improve access to medicine in
developing countries. The Index is built upon an interesting supposition: simply ‘naming and
shaming’ companies in the pharmaceutical industry does not encourage change. Instead, good
practice needs to be recognized within the pharmaceutical industry that shows which companies
do the most to improve access to medicine and how. The biennial reports of ATMI seem to
indicate that pharmaceutical companies do change their practices when under this type of
scrutiny. Similarly, DJSI, launched in 1999, was the first global sustainability benchmark. DJSI
tracks the stock performance of the world’s leading companies in terms of economic,
environmental, and social criteria. According to DJSI, the data they provide serve as benchmarks
for investors who integrate sustainability considerations into their portfolios, as well as providing
an effective engagement platform for companies who want to adopt sustainable best practices.172
Hence, social or peer pressure may include such external bodies taking a more robust role in
helping to change the pricing policies of pharmaceutical and biotechnology companies.
This analysis has examined the notion of social responsibility and health and has kept the
issue at the forefront for pharmaceutical and biotechnology companies as a way to repair
society’s trust and restore a positive reputation. Reputation is key for a company, and what may
matter more than anything is the specific acts of a company. Ian Read, CEO of Pfizer, has
remarked, “Making reputation and respect all the more important to us is knowing that we gain it
in drops, but lose it in gallons”.173 Read, and surely others in the industry, understands that their
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reputation is at stake by what they do. Hence, for the pharmaceutical and biotechnology sector to
regain societal trust and restore a positive reputation, steps need to be taken. Though there are
many areas in which the industry can improve upon in order to act responsibly and take seriously
a call to social responsibility and health, this section will focus on issues of transparency and the
need for companies to be very vocal about what the company is doing to act responsibly.
Transparency has been focused on at various points in this analysis because of its
importance. Transparency is a vital ingredient for building merited trust in the pharmaceutical
sector and their work. The public must feel that they can trust a company and how they price
their products. As complaints grow about astronomical drug prices, pharmaceutical and
biotechnology companies are coming under pressure to disclose the research and development
costs and profits of those drugs, as well as the rationale for charging what they do.
Pharmaceutical cost transparency bills were introduced in at least six state legislatures in 2015,
aimed at making drug companies justify their prices, which the industry often attributes to high
research and development costs.174 Such legislation, if enacted, may prove successful at forcing
the hand of pharmaceutical companies to reveal such data about pricing. Yet, this is not likely to
help the reputation of the pharmaceutical sector, for what would be more desirable would be
pharmaceutical and biotechnology companies freely offering this information rather than doing
so involuntarily.
In practical terms, transparency may also involve more information about what a
company is doing in regards to CSR. Most major pharmaceutical and biotechnology companies
have some form of CSR department. Yet, to demonstrate that CSR is more than an exercise in
merely public relations, companies will need a clear, comprehensive policy on the subject, which
include measurable targets that are implemented and reported on by a board.175 Many companies
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have signed onto a document such as the UN Global Compact and include a report on their
progress to implement the ten principles, which is a matter of public record and readily
accessible on the Compact’s website. However, many of these reports are not highly detailed and
lack depth and clarity of what a company is practically doing to implement human rights and
social responsibility into their company ethos.
Business transparency will also include data transparency. For years, drug companies
have been accused by the public of reckless disregard for patient safety.176 The antidepressant
Paxil (paroxetine) was introduced by GlaxoSmithKline (GSK) in 1992 and soon became a
blockbuster drug for the company. Yet, it was found in the years since that GSK had performed
outcome switching in the clinical trials for Paxil, a procedure in which the questions that a
scientific study was initially set up to answer are swapped part way through for a different lot.
Very little data showed that Paxil was any better than the placebo, yet it was marketed as a
breakthrough in depression medication. In 2012 the company was fined $3 billion USD by
American authorities for misrepresenting data on a variety of drugs, one of which was Paxil.177
Such misrepresentation of data is commonplace.178 While some attempts have been made for
greater sharing of data, the industry as a whole has not embraced data sharing with open arms. In
2013, drug company AbbVie filed a lawsuit (which has subsequently been dropped) to halt the
European Medicines Agency from releasing clinical trial data for its chemotherapy and
immunosuppressant drug Humira (adalimumab). The pharmaceutical industry argues that
proprietary business information needs to be protected; yet withholding safety data that could
affect clinical decision-making is inexcusable. The sustained lack of data transparency gives
volumes of credence to critics and the public that drug companies have lost their ethical
compass.179
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A second area for pharmaceutical and biotechnology companies to focus on in order to
restore their reputation is to be very vocal about the good they are trying to do. History is littered
with examples of companies that addressed social issues and, in turn, received reputational
benefits. The case of Nike, already presented above, is an example of this.180 The pharmaceutical
industry needs to effectively communicate how it has reformed unethical practices so that the
public is assured that past underhanded practices will not be repeated.181 Further, if a company
finds an ethical remedy to a problem that works, these best practices should be shared so that
other players in the industry can be involved as well. Being more vocal about altruistic activities,
such as philanthropic drug or vaccine access programs, benefit sharing, the embrace of
environmentally friendly technologies, or other forms of assistance may go far in countering the
public’s image of the greedy pharmaceutical company.182
International solidarity and cooperation may also be a necessary component of attaining
the vision of social responsibility. The challenge of a global social responsibility for health may
entail a willingness to improve the sharing of resources, standards of education, and policies
oriented to ameliorating the negative social determinants of health. Stefano Semplici has written
that this may entail attempting to reverse the brain drain of skilled health and research
professionals from LMICs to high-income countries.183 While a difficult undertaking, the
populations of LMICs are served well by highly skilled professionals, so it would be prudent for
governments to seek to retain these specialists. Such retention may not be cheap, but it would be
prudent and in the best interest of the people. While none of these recommended courses of
action are foolproof systems to ensuring social responsibility in global health, further research
into enacting these via policy or other means may be sound guidance. Surely the majority of this
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is not novel, but some of these courses of action may need to be enhanced to see social
responsibility for global health to come to fruition.
For pharmaceutical and biotechnology firms that are regularly involved in research and
development, a manner that should be considered, as mentioned above, is using the UNESCO
UDBHR as a standard-setting tool in research ethics. The UDBHR, as a global ethics document
with the adoption of some 190 UNESCO Member States, is well positioned to aid the
pharmaceutical industry in ethics. Again, such an initiative would have the most force if it were
begun from inside the industry rather than from an external agency. Further, as a global
document operating at the global level, the UDBHR attempts to take into account the
perspectives of Western and non-Western states, HICs and LMICs, alike. Surely this is no
guarantee that the industry’s or a specific firm’s reputation would increase as the result of such a
platform. However, this does seem like a sensible way to attempt a resolution.
In conclusion, this chapter has presented corporate social responsibility in the
pharmaceutical and biotechnology industry. Section 3.1 discussed the topic of social
responsibility in global health and bioethics. It was argued that the notion of social responsibility
and health combine the following two basic ideas: 1) Many actors, not just governments, have a
responsibility towards health. 2) Global problems reflect common challenges, and thus, should
be addressed by common action. Further, the principles of solidarity and cooperation were
examined as crucial for social responsibility and health. Finally, the role of social responsibility
in the UNESCO UDBHR was examined in 3.1. In section 3.2, corporate social responsibility
specifically applied to the pharmaceutical and biotechnology industry was analyzed. This section
began by noting several major pharmaceutical pricing scandals and the resulting impact this has
had upon the reputation of the industry. The major positions on CSR were examined, and several
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critiques of CSR were offered. The section concluded by offering the possibility of using price
differentiation for pharmaceuticals and the use of social pressure upon companies as manners of
instilling change.
Social pressure is a very promising idea to combat high pharmaceutical prices and to
embed CSR further within the pharmaceutical and biotechnology industry. Social pressure has
worked before, such as the case of Nike presented above. However, while external social
pressure is certainly of value, having this type of pressure come from within the industry itself
would be ideal. For pressure to come from within the industry rather than externally may be
superior because it would send a strong message to the public and stakeholders that the industry
has heard their cries for change, understands its problems, and has sought to remedy its issues.
The global bioethics tool, presented further in this dissertation in chapters 5 and 6, aims to
achieve such a goal by creating a collaboration of pharmaceutical and biotechnology companies
that wish make a change within the industry and position themselves as leaders of
pharmaceutical and biotechnology CSR. As the UNESCO UDBHR includes a principle on social
responsibility, and as it was approved the governments of the world, it is well positioned to be
the ethics document from which to build consensus on bioethical CSR issues for the
pharmaceutical and biotechnology industry.
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Chapter 4: Analysis of Current Bioethics Guidelines and Governance
Chapter four examines the bioethics guidelines that have been produced since the end of
World War II and the role of governance in bioethics. The purpose of such an undertaking is to
analyze the evolution of bioethics guidelines, note where there are areas of convergence and
divergence between documents, and to introduce the UNESCO Universal Declaration on
Bioethics and Human Rights as well situated to be the foundation of the global bioethics tool.
While no guideline is perfect, and changes occur within medicine, technology, and society to
prompt changes to guidelines, the UDBHR, based upon a moral human rights framework and
broad enough to cover many social dimensions of bioethics, is appropriate for the task of
creating a global bioethics tool to unite pharmaceutical and biotechnology companies around
ethical principles. Section 1 attempts to move chronologically through the major ethics
guidelines of the twentieth and early twenty-first century. Section 4.2 then introduces the
UDBHR in detail and makes an argument for why it is used as the foundation of the proposed
global bioethics tool. Finally, section 4.3 examines the role of governance in bioethics,
examining the various forms of accreditation, certification, and rating.
4.1) Ethics Guidelines: 1947—Present
Since World War II, a number of prominent bioethics guidelines have been produced,
almost exclusively by a Western commission, leading to the conclusion by some that modern
bioethics predominantly reflects the traditions of Western moral philosophy and political and
social theory.1 Many guidelines for the ethical conduct of research with human have been
produced as the result of misconduct and scandal.2 Some of these guidelines address a narrow
aspect of bioethics, some have a degree of governmental authority, some are issued by nongovernmental organizations, and others are advisory.3 Much regulatory guidance tends also to
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have a specific purpose, such as the International Conference on Harmonisation, which has the
purpose of generating shared policies across HICs for the “registration of pharmaceuticals for
human use.”4 The following table depicts the selected guidelines that will be discussed within
section 4.1. These guidelines have been selected as they represent monumental landmarks in the
field of research ethics.
Guideline

Issuing Body

Nuremberg Code
Declaration of Geneva

Nuremberg Military Tribunal
decision in United States v.
Brandt et. Al
World Medical Association

Declaration of Helsinki

World Medical Association

Belmont Report

National Commission for the
Protection of Human Subjects
of Biomedical and Behavioral
Research
US Department of Health and
Human Services (DHHS) and
16 other US federal agencies
Council for International
Organizations of Medical
Sciences

45 CFR 46 (Common Rule)
International Ethical
Guidelines for Biomedical
Research Involving Human
Subjects
Good Clinical Practice
Resolution 196/96: Rules on
Research Involving Human
Subjects— Convention for the
Protection of Human Rights
and Dignity of the Human
Being with regard to the
Application of Biology and
Medicine: Convention on
Human Rights and
Biomedicine (Oviedo
Convention)

International Conference on
Harmonisation
Council of Europe
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Year Issued, Revised, and/or
Amended
1947
1948; revised: 1968, 1983,
1994, 2005, 2006
1964; revised: 1975, 1983,
1989, 1996, 2000, 2008, 2013;
notes of clarification: 2002
and 2004
1978/79

DHHS guidelines: 1981
Common Rule: 1991
1982; revised: 1993, 2002,
2016
1996
1997

In this section, in order to make a concise and well-analyzed argument for the utilization of the
UNESCO Universal Declaration on Bioethics and Human Rights as the grounding for the global
bioethics tool, these aforementioned bioethics guidelines will need to be systematically analyzed,
their strengths and weaknesses analyzed, and conclusions drawn as to why they are less suited
for the task of a global bioethics tool than the UNESCO Universal Declaration on Bioethics and
Human Rights.
The Nuremberg Code, as has already been presented earlier, was a product of the
aftermath of World War II and the Nuremberg Military Tribunal decision in United States v.
Brandt et. Al. The Nuremberg Code has been a staple of research ethics since its inception.
However, it has often exerted more rhetorical invocation, owing in part to its historical
significance, rather than actual practice. This may be due to it’s blanket prohibition of any
research that is not voluntary or for its lack of interpretive or enforcement mechanism.5 To be
sure, the Nuremberg Code was a reaction against the grave violations committed against
humankind in the name of “science”, yet to insist “the voluntary consent of the human subject is
absolutely essential” seems too far.6 This would prohibit much pediatric research, research on
dementia patients, and would totally exclude any sort of proxy consent. Nonetheless, the
Nuremberg Code was a very fine guideline for its day and age, though it may have overly reacted
due to the atrocities of WWII. While the Nuremberg Code was in many ways the beginning of
medical ethics guidelines, many would follow.
The World Medical Association (WMA), also in response to the crimes committed by the
physicians and scientists during WWII, issued a code of medical ethics in September 1948 that
was known as the Declaration of Geneva. It was envisioned as a modern update to the
Hippocratic Oath and intended to be sworn by physicians upon admission to the medical
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profession.7 The Declaration of Geneva is still in use today and has been revised five times, in
1968, 1983, 1994, 2005, and 2006.8 From its genesis, the Declaration of Geneva code proved
very ambiguous and difficult to interpret.9 The extent to which the declaration is disseminated
and utilized as an oath by physicians entering into the medical profession varies greatly by
country, and its total usage by new doctors entering the profession is not adequately known. In
many regions of the world, the declaration is not recognized as a contemporary successor to the
Hippocratic Oath.10
The more prominent and well-respected ethics guideline produced by the WMA is the
Declaration of Helsinki (DoH). Originally adopted in June 1964, it has since undergone seven
revisions, tripling its original size, with the most recent version being approved in 2013.11 The
DoH is very prominent in the field of research ethics, arguably the most widely known and
influential in the field. Indeed, perhaps the largest strength of the DoH is its current standing as
the most well known guideline on medical research ethics. The DoH has enjoyed international
status placing it over and above national legal and policy issues in certain cases. Other notable
strengths of the declaration include the importance it places on balancing risk and benefit,
attempting to define the moral status of clinical research, and its considerations of justice for
patients, subjects, and entire populations.12
While there are certainly numerous strengths to the DoH, a number of weaknesses exist
and reasons for why it is less suitable than the UNESCO UDBHR to be used as the foundational
guideline for the global bioethics tool. Richard Ashcroft has noted that every version of the DoH
has contained contradictions, vague formulations, and controversial elements.13 Physicianbioethicist Ezekiel Emanuel takes the criticism of the 2013 DoH even further by charging that
there are at least nine distinct problems with the current version: 1) it has an incoherent structure,
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2) it confuses medical care and research, 3) it addresses the wrong audience, 4) it makes
extraneous ethical provisions, 5) it includes contradictions, 6) it contains unnecessary repetitions,
7) it uses multiple and poor phrasings, 8) it includes excessive details, 9) and it makes
unjustified, unethical recommendations.14 Emanuel also takes issue with the frequency with
which the DoH is revised, approximately every six years, as he sees this as fostering sloppiness
in the drafting process and undermining the legitimacy and goals of the declaration. Such glaring
revisions include putting forward certain ethical requirements such as the use of placebos and
post-trial access—and then later revising and minimizing their reach, which seems to be an
admission that the original claims were erroneous.15
Furthermore, certain human rights groups have accused the DoH of diluting universal
ethical standards of care by permitting placebos to be used on research subjects in LMICs rather
than the best-proven treatment, which is a tremendous cost savings to the trial sponsor. Critics
accuse that such dilution is tantamount to a double standard, purely based on economics,
convenience, and efficiency. Nonetheless, Aurora Plomer has defended the use of the DoH above
the UDBHR on two questionable grounds: 1) the uncertain status of the UNESCO UDBHR as a
source of international law; and 2) professional codes of practice, particularly the DoH, play an
essential role in ensuring that fundamental human rights are respected.16 In response to Plomer, it
is uncertain as to why she questions the status of the UDBHR as a source of international law.
First, the UDBHR does not itself anywhere claim to be binding law. Further, it has been adopted
by all UNESCO Member States and each state is then free to create from it their own national
laws. In the UN system, declarations act like recommendations but are named as such due to
their importance. Declarations are adopted during the General Conference of a specialized UN
agency, such as UNESCO, and governments who adopt them agree (at least in principle) to
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implement them in their own countries. While they are part of the body of what is known as “soft
law” (body of laws that is intended over the long run to produce binding rules), they contribute to
the expansion of positive law and provide the public with a tool to drive their governments to
act.17
Yet, Plomer writes, “The UDBHR does not as yet have the status and authority of a
legally binding document in international law.”18 This is a true statement and neither UNESCO
nor anyone else to my knowledge has made such an argument. Further, while a true statement,
the very same could be said of the DoH—that it does not yet have the status nor the authority of
legally binding international law. Countries may enshrine the DoH into its legal codex, but the
document itself, and perhaps more specifically the WMA, have no power to produce
international law. Hence, this is not a valid argument. Contrary to Plomer’s criticism, UNESCO
has been successful in creating several national bioethics committees in a number of countries,
promulgating core bioethics curriculum in universities around the globe, and helping to enact
ethically relevant legislation in various Member States.19 To date, ethics committees have been
put in place and continue to be supported by UNESCO in 17 countries, and several other
countries from various regions of the world have approached UNESCO to create similar
institutions.20
Plomer’s second contention for why the UDBHR should not supersede the position of the
DoH is that professional codes of practice, particularly the DoH in her view, play an essential
role in ensuring that fundamental human rights are respected. There is no argument here. From
the very origins of bioethics guidelines, beginning with the Nuremberg Code, human rights has
been intertwined with bioethics. Indeed, the chief purpose of the Nuremberg Code was to protect
the fundamental human rights of patients and research participants. Hence, the argument that
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professional codes of conduct play an important role in ensuring the respect of fundamental
human rights does not place the DoH on any greater footing than the UDBHR, because the
UDBHR similarly plays an essential role in ensuring that fundamental human rights are
respected. Therefore, under close scrutiny, the arguments Plomer uses for why the DoH should
not be abandoned in favor of the UDBHR do not seem to hold up.
Future versions of the DoH need to offer justification for why previous editions are being
revised. Further, the DoH should establish universal, minimum standards without which research
is unethical and cannot be conducted. National laws, regulations, and other guidelines should
decide on the specification and application of these broad principles, not the DoH itself. Hence,
the universal document could then be tailored to local circumstances by specification in the laws
of individual countries. Emanuel has stated correctly that in order for the DoH to be a truly
authoritative document then it must aspire to “tentative immortality”. That is, while revisions of
the text may be necessary as biomedical research changes, the document should be meticulously
crafted with the objective of enduring for decades rather than merely six-year intervals.21
Perhaps the most compelling reason for why the DoH is less suited for the task of
creating a global bioethics tool is due to the nature of its creation. The DoH was created by a
small handful of people and then has been imposed upon states without their adequate input. In
the 2000 version of the DoH it places itself above national legislation and legal norms, which
suggests that where legal norms conflict with anything with the DoH, the DoH should take
precedence. Article 9 of the 2000 DoH reads, in part, “No national ethical, legal or regulatory
requirement should be allowed to reduce or eliminate any of the protections for human subjects
set forth in this Declaration.”22 Such a statement leaves no room for national legislation to
question the prescriptions of the DoH and places the DoH on a paramount moral standing
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equivalent to such enduring documents as the Universal Declaration of Human Rights. The
problem with such a claim is twofold. First, the DoH is not as enduring as it might believe, as is
evidenced by its numerous revisions and clarifications, some of which backtrack on earlier
pronouncements. Second, the DoH was not adopted by national governments, as UN declarations
are, but rather by the World Medical Association’s General Assembly with a very limited
membership. In fact, at the time of this writing, only 111 countries were constituent members of
the WMA, representing just over half of the world’s nations, which leaves out considerable
opinions and viewpoints. Indeed, the drafting of the DoH has generally been done by an even
smaller group of physicians, usually three or four. Such small numbers raise a number of
questions about the drafting process and whether viewpoints from various cultural contexts are
adequately respected and taken into account.23 Having such small numbers of persons involved
in creating such a significant document is also troubling because it may lend itself to pushing
particular viewpoints and stifling others. Yet, ethics must rise above individual or group interests
to advocate for and present what is universally true and binding upon humankind.24 Henk ten
Have has suggested that UNESCO be present in consultative and deliberative processes for the
revisions of the DoH.25 Such an idea is good, as a large international organization such as
UNESCO would greatly aid the drafting process of the DoH and add valuable perspectives.
However, it is difficult to foresee such a proposal coming to light and the WMA inviting
UNESCO into that process.
Therefore, though there are numerous strengths of the DoH and it has been widely used
by the international biomedical research community, problems continue to plague it. Section 4.2
will present in greater detail the UNESCO Universal Declaration on Bioethics and Human
Rights and provide further justification for why it is more suitable than the Declaration of
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Helsinki to serve as the foundational document for the proposed global bioethics tool that seeks
to unite pharmaceutical and biotechnology companies.
The National Commission for the Protection of Human Subjects of Biomedical and
Behavioral Research (1974-78) produced a report that proved very significant for the direction of
healthcare ethics,26 largely as a response to the scandal of the Tuskegee Syphilis Study.27 The
National Commission selected seven principles that should underlie biomedical human research.
These seven would be reduced to three in the Belmont Report: respect for persons, beneficence,
and justice.28 The Belmont Report was issued in its final form in late September 1978 and then
published into the Federal Register on April 18, 1979. While the Belmont Report is not very
extensive, it articulates a basic core framework of ethical precepts and has become greatly
influential for guiding the direction of research ethics in the US. In the area of academic
bioethics, the Belmont Report has also proved very significant. Much of the influence of the
Belmont Report is attributed to being the first official biomedical ethics account to identify three
fundamental principles.29 Soon after its release, Tom Beauchamp and James Childress published
their seminal tome in 1979: Principles of Biomedical Ethics. Within it they promoted the
principles of autonomy (respect for persons), beneficence, non-maleficence, and justice, very
similar to the principles laid out within the Belmont Report, and their method would become
known as principlism. Beauchamp and Childress’ four principles, inspired in large part by the
Belmont Report, would largely shape the agenda of normative bioethics for the decades
afterward.30
While continuing to be widely prominent, the principlism view is not without its due
criticism. Principlism has been critiqued for a number of reasons, including that it gives
insufficient attention to the practical context one is analyzing and the lived experiences of the
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people in that situation. Rather, principlism merely attempts to fit all ethical questions into its
four-principle mold. A second criticism is that the approach is overly Western. While no one
seriously argues the fact that bioethics has grown out of a Western milieu, leaving it there
without expanding and taking into consideration differing viewpoints and experiences would be
insular and not helpful in the long run. Critical reflections upon the Western sociocultural
context within which bioethics developed is a rare phenomenon. Hence, the four pillars of
principlism have at times led to the position that these pillars are unquestionable, and any
sociocultural perspective that deviates from these tenets is presumed to be erroneous.31
While the Belmont Report (and the principlism approach) has formed the groundwork for
much of the national legislation on medical research ethics in the US, such as the Common Rule
(45 CFR 46),32 it is also very limited in its scope and does not address the breadth of biomedical
topics of today. Though the Belmont Report has been highly influential within a US context,
outside the US, though it is still widely known, its reach and authority on national bodies is not
as well accepted. Indeed, the Belmont Report was primarily meant for a US audience, as is
recognized by its team of American-only drafters and its lack of an international perspective.
Therefore, while the Belmont Report is fundamental for biomedical research ethics, it is judged
not to be well suited to act as the foundational document for the proposed global bioethics tool.
In the US, Title 45, Part 46 of the Code of Federal Regulations (generally stylized as 45
CFR 46) concerns the protection of human participants in research. These regulations are put in
place by the Office for Human Research Protection of the Department of Health and Human
Services. The legally binding regulations found in 45 CFR 46 are based in large part on the
Belmont Report and other work completed by the US National Commission. The Department of
Health and Human Services revised and expanded these regulations in the late 1970s and early
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1980s in order to offer basic protections to human subjects involved in both biomedical and
behavioral research.33 45 CFR 46 is divided into four subparts: Subpart A is typically referred to
as the “Common Rule” and contains the uniform set of guidelines in US federal policy for the
protection of human research participants. Subpart B provides additional protections for pregnant
women, in vitro fertilization, and fetuses. Subpart C contains additional protections for prisoners.
Subpart D contains additional protections for children. Subpart A, or the Common Rule,
primarily includes requirements for assuring compliance by research institutions, requirements
for researchers’ obtaining and documenting informed consent, and requirements for Institutional
Review Board membership, function, operations, review of research, use of federal funds, and
record keeping.
The governance process of 45 CFR 46 to ensure the compliance process for human subject
protection is quite simple. The Department of Health and Human Services requires that any
institution that is engaged in non-exempt human research must submit a written letter of
compliance to the Office for Human Research Protection. Through the assurance of compliance,
an institution commits to the Department of Health and Human Services that it is and will
comply with the requirements set forth in 45 CFR 46.34
The US 45 CFR 46, while fine as a national code, is inadequate for a global or universal
guideline. First, 45 CFR 46 is binding legislation in the US that is not specifically designed for
an international audience. It was designed to function within the US as binding protections for
human research subjects rather, and has proved effective in that task, yet its international
exposure is limited. Second, and most importantly, if 45 CFR 46 were used as the foundational
document for the global bioethics tool then it would be exceedingly difficult to have any
pharmaceutical and/or biotechnology company that is based outside the United States participate.
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The global bioethics tool would be viewed upon as an act of Western ethical imperialism if 45
CFR 46 were recommended as the foundational guideline. Hence, this makes it not useful for the
proposed global bioethics tool.
The Council for International Organizations of Medical Sciences (CIOMS) was formally
constituted by both the World Health Organization (WHO) and the United Nations Educational,
Scientific, and Cultural Organization (UNESCO) in 1949, and continues to remain under the
sponsorship of these two UN organizations.35 CIOMS first issued guidelines on human
experimentation and medical ethics in 1982. The fourth and current version was released in
December 2016 and is now the fourth installment of CIOMS guidelines, superseding the 2002,
1993 and 1982 guidelines. The present version consists of 25 guidelines with commentaries on
each of the guidelines that aid in explaining it.36 The membership of CIOMS consists of 44
member organizations, representing, according to the organization itself, many of the biomedical
disciplines.
CIOMS has sought to unite itself intimately to the DoH. In the 2002 version it explicitly
states the nature of their relationship:
CIOMS set out, in cooperation with WHO, to prepare guidelines to indicate how the
ethical principles that should guide the conduct of biomedical research involving human
subjects, as set forth in the Declaration of Helsinki, could be effectively applied,
particularly in developing countries, given their socioeconomic circumstances, laws and
regulations, and executive and administrative arrangements.37
Hence, CIOMS envisions their guidelines as complementing the DoH by elaborating how the
very general, succinct principles in the DoH can be applied, with particular regard given to
LMICs. Indeed, the 2002 revision of the CIOMS guidelines was prompted in part by new issues
and questions that have arisen in regards to multinational research. The revision attempted to
respond to these pressing questions of science. Strong support for the revision was elicited by the
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WHO and the Joint UN Programme on HIV/AIDS (UNAIDS) and also included support and
expertise from both HICs and LMICs. The 2002 revision took nearly four years to complete and
consensus was reported as difficult to achieve.38 For the 2016 revision, preparations began as
early as 2009, with the Executive Committee of CIOMS seeing it as valuable to craft a new
version that would coincide with the 2008 version of the DoH and respond to several
developments in the field of biomedical research. In 2011 the Executive Committee elected to
establish a group to revise the CIOMS guidelines. This group consisted of ten members, one
chair (president of CIOMS), four advisers (from WHO, UNESCO, COHRED and WMA) and
one scientific secretary. While CIOMS has stated that the composition of the group ensured that
different cultural perspectives were present, there is reason to question such an assertion and if
research saturation could truly be achieved due to the small group of consultants.39 This revision
process resulted in the release of the new CIOMS guidelines in December 2016.
Though CIOMS was established in the very infancy stages of bioethics, its membership,
as of late 2016, is still very limited, including 44 international, national, and associate member
organizations, which, CIOMS asserts, represent many of the biomedical disciplines, national
academies of sciences, and medical research councils.40 Twelve countries are National Members,
and of these, nine are HICs and 3 LMICs.41 Though CIOMS has thoughtfully considered how to
apply many of the principles of the DoH, it is questionable whether or not it is truly a global
guideline and has sincerely attempted to consider the sociocultural viewpoints of large varieties
of persons and groups. With only three National Members being from LMICs, it is worrisome
that the views of the developing world may not be completely represented in the guidelines.
Hence, while the CIOMS guidelines have done much good work in further specifying the DoH,
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its practicality to be used as the foundation for the proposed global bioethics tool is problematic
due to its small membership and seemingly limited consultative process.
Good Clinical Practice is an international quality standard for designing, conducting,
recording, and reporting trials that involve human participants. Good Clinical Practice is
provided by the International Conference on Harmonisation (ICH), an international body that
defines standards.42 ICH states, “Compliance with this standard provides public assurance that
the rights, safety, and well- being of trial subjects are protected, consistent with the principles
that have their origin in the Declaration of Helsinki, and that the clinical trial data are credible.”43
Governments can use these standards by transposing them into regulations for clinical trials
involving human subjects, such as what the US Food and Drug Administration (FDA) has now
done.44 The objective of the Good Clinical Practice (GCP) guidelines is “to provide a unified
standard for the European Union (EU), Japan, and the United States to facilitate the mutual
acceptance of clinical data by the regulatory authorities in these jurisdictions.”45 These standards
for clinical trials are oftentimes referred to as ICH-GCP.
The stated purpose of ICH, the body that created GCP, is to create common rules across
developed countries for the registration of pharmaceuticals for human use. The mission of the
ICH is stated as:
ICH’s mission is to make recommendations towards achieving greater
153ubsidized153n153 in the interpretation and application of technical guidelines and
requirements for pharmaceutical product registration, thereby reducing or obviating
duplication of testing carried out during the research and development of new human
medicines.46
Hence, the aim of ICH is more along the lines of increasing the efficiency of pharmaceutical
drug approval rather than the protection of those persons participating in research, as is
demonstrated in its deferring to the Declaration of Helsinki in these matters.47 Indeed, there are
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essentially thirteen principles of the ICH-GCP and the first principle states that clinical trials
should adhere to the DoH.48 The remainder of the document can essentially be divided into two
parts. The first part, including from Guideline 3 to Guideline 5, sets out the detailed duties and
responsibilities of ethics committees/IRBs, investigators, and research sponsors that are relevant
to human subject protection. The second part, from Guideline 6 through Guideline 8, provides
guidance on the documentation of the clinical trial process and the pertinent information that
must be documented at each stage of the clinical trial.49
The US Food and Drug Administration (FDA) recognizes the GCP guidelines for its
international clinical trials. In 2008 the FDA amended its regulations on acceptance of foreign
clinical studies not conducted under an investigational new drug application. The amendment
replaces the requirement that these studies be conducted in accordance with ethical principles
stated in the Declaration of Helsinki (specifically the 1989 version), with a requirement that the
studies be conducted in accordance with GCP.50 It was widely believed that the FDA made this
decision due to less stringent guidelines of the GCP. The ICH-GCP guidelines do not address
certain ethical requirements that are stipulated in the DoH, such as the use of placebos versus
standard therapy, post-trial access to treatment and other benefits for participants (benefit
sharing) the public disclosure of trial design, the publication of trial results, and the disclosure of
conflicts of interest by researchers.51 The FDA, feeling that the WMA overstepped its mandate
with revisions of the DoH that increasingly required more and more from researchers and
sponsors opted to simply abandon the DoH.52
Hence, ICH-GCP has been criticized by some commentators for lacking the breadth,
depth, and moral authority of the Declaration of Helsinki.53 Further, Sharon Kaur and Choony
Yeow Choy raise an astute observation, stating that at the heart of the ICH, which heavily
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impacts the GCP, is two main activities: first, ensuring that wherever drug development and
manufacturing takes place, drugs are developed, tested, registered, and monitored in a fashion
that ensures both quality and safety; and second, making the development of new drugs more
efficient and less expensive. Hence, with this in mind, Kaur and Choy conclude that it is no
surprise that the ICH-GCP guideline is to a large extent made up of administrative duties.54 As
such, the ICH guidelines are insufficient to be used as the guiding document from which to build
the global bioethics tool, as a chief purpose in creating the tool is enhancing the ethical conduct
of pharmaceutical and biotechnology companies in how they conduct clinical trials and in their
dealings in LMICs. The ICH-GCP is largely concerned with the administrative duties of IRBs
and defers to the DoH for much other human research protection.
By this point it is evident that there have been numerous bioethics guidance documents
created. The past two decades have witnessed an upsurge of interest in international declarations
on bioethics and, specifically, global bioethics and the governance of bioethics.55 The 1997
Council of Europe “Convention for the Protection of Human Rights and Dignity of the Human
Being with regard to the Application of Biology and Medicine: Convention on Human Rights
and Biomedicine”, often simply termed the Oviedo Convention in reference to the location of the
convention in Oviedo, Spain, is a notable example.56 As this document preceded the Universal
Declaration on Bioethics and Human Rights by nearly a decade, it is sometimes lauded as “the
first international treaty in this field,” yet it is limited only to Europe.57 The Council of Europe,
founded in 1949, is an intergovernmental organization that is mandated with fostering political,
legal, and cultural cooperation between its 47 member states. The Council of Europe has the
ability of passing legally binding treaties for its members on a wide variety of topics at the
international level.58 The Council of Europe has passed a number of relevant treaties for
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bioethics, such as Treaty No. 168 on the “Prohibition of Cloning Human Beings,”59 Treaty No.
203 on “Genetic Testing for Health Purposes,”60 Treaty No. 216 “Against Trafficking in Human
Organs,”61
The Oviedo Convention contains 38 articles that seek to affirm that progress in biology,
medicine, and technology should be used for the benefit of present and future generations, stress
the need for international cooperation, recognize the importance of promoting a public debate on
the questions posed by the application of biology and medicine, and resolve to take the necessary
measures to safeguard human dignity and the fundamental rights and freedoms of individual
persons with regard to the application of biology and medicine.62 At the time of its ratification,
the Oviedo Convention was praised by Roberto Andorno as “the best current example of how to
promote the protection of human rights in the biomedical field at a transnational level.”63
Andorno, even after the adoption of the UDBHR by UNESCO Member States and having been a
member of the International Bioethics Committee from 1998-2005 has written that though the
Oviedo Convention is a regional rather than a global instrument, “its potential impact on a global
scale should not be overlooked as it is the only intergovernmental legally binding instrument that
comprehensively addresses the linkage between human rights and biomedicine.”64 A great
strength of the Oviedo Convention, as Andorno points out, is that it is legally binding upon
fellow Council of Europe states. Further, human dignity acts as the bedrock of the guidelines,
with the primacy of the individual person seen as paramount.65
Additionally, the Oviedo Convention, much like the UDBHR which would follow eight
years later, takes a comprehensive approach to bioethics. In 1997 when ratified, up to that point
other international instruments in bioethics had attempted to unite human rights and bioethics,
yet they focused on narrow aspects. For instance, UNESCO’s Declaration on the Human
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Genome and Human Rights (1997) concentrated exclusively on genetics. Yet, the Oviedo
Convention aimed at covering the whole domain of bioethics, linking it with human rights, and
creating a truly unique document.66 The linking of bioethics to human rights was not novel to
Oviedo, as it was done in the Nuremberg Code. However, the scale of it, how explicit it is, and
the fact that Oviedo is a binding document is novel. Several reasons justify why the Oviedo
Convention, and later the UDBHR, appeal so strongly to human rights. First, there is an obvious
link between health issues and fundamental human rights. Second, the claim of human rights is
universalistic, which greatly facilitates the creation of transcultural, transnational standards.
Third, key concepts in the biomedical field are already formulated using the language of rights
(informed consent, right to health, access to health care and medicines, etc.). Fourth, there is a
lack of any conceptual and institutional instrument other than the human rights framework to
produce an international framework of norms relating to biomedicine, as the human rights
framework is able to function as a lingua franca.67
We should not get the image that the Oviedo Convention is without flaws, though.
Despite its binding nature, the European Court of Human Rights cannot enforce the Oviedo
Convention, whose only task in this matter is to state opinions regarding the interpretation of its
norms (Article 29), without mention to any specific pending court case. Further, there are no
sanctions provided should a member state violate the norms of the Convention. Additionally, the
Oviedo Convention has also been critiqued for its silence on the topic of abortion and having
very little to say about the permissibility of certain reproductive techniques, euthanasia, and endof-life decisions. The obvious conclusion that is drawn from this is that the drafters considered
these topics too controversial to approach comprehensively out of fear of not gaining consensus
and the Convention not being ratified. However, if this is in fact the reason for the omission of
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contentious topics, one commentator has noted that the Convention then cannot be considered a
wide-ranging basic document on biomedical ethics.68 Further, numerous other bioethics
guidelines have omitted these provocative issues as well, so similar critiques could be made
about them.
Yet, such a judgment may be hasty, for the Oviedo Convention is wide-ranging on the
basic elements of biomedical ethics that can could be agreed upon at an international level, and it
leaves open the possibility for national legislatures to craft more stringent policy if they choose
to do so. An example of this would be the legal position of abortion in Poland. Poland, a Member
State of the Council of Europe, has much tougher abortion laws than the rest of Europe,
permitting abortion only in cases of severe and irreversible damage to the fetus, a serious threat
to the mother’s health, or if the pregnancy is the result of rape or incest.69 The only two European
states with more strict abortion laws are Malta and Vatican City, the latter not being a Member
State of the Council of Europe. Hence, Poland has adopted the Oviedo Convention like other
Member States and because the Convention does not cover abortion, the national legislature has
upheld and continually enforced its more stringent regulation, which they are free to do. They
have even at various points attempted to completely outlaw abortion, but these attempts have
failed. However, if this had been attempted within the Oviedo Convention itself then the vast
majority of Council of Europe Member States, who do not hold the viewpoint of Poland on this
issue, would never have been in harmony.
In summary, despite its criticism, the Oviedo Convention has many pronounced strengths
and was very pioneering for its time. While it is a binding document, it is also, strictly speaking,
a regional document, as having only been ratified by the 47 European Council Member States.
While this is a great feat for Europe, this will not be suitable for a global audience. One
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weakness of the Oviedo Convention versus the UDHBR is that the UDBHR was crafted with
global input—HICs and LMICs—rather than solely regional input. If the Oviedo Convention
were used as the foundational document for the proposed global bioethics tool then there would
be numerous states that would feel as though they were merely being subjected to a Europeanimposed imperialism. Hence, the strength of the UDBHR over the Oviedo Convention is that the
UDBHR was developed with global participation and achieved global, rather than regional,
consensus.
As this section has now examined eight bioethics documents that have been produced
from 1947 forward, before moving forward to section 4.2 where the UNESCO UDBHR will be
examined then some concluding remarks are offered. Ezekiel Emanuel, David Wendler, and
Christine Grady have charged that existing biomedical ethics guidance is neither comprehensive
nor systematic. In their view, current guidelines lack justifications for their claims, leading to the
conclusion that their principles are either thought to be prima facie, self evident, or beyond
debate. They state that there is a great need for a broader, systematic, and comprehensive
framework that includes both an ethical justification for ethics principles and includes how to
apply and fulfill each principle in practical terms.70 Indeed, bioethics declarations generally are
not very lengthy, and their principles are typically not justified very well within the text.
Additional commentaries have, however, been produced on certain documents, which are
helpful. Further, one goal of the proposed global bioethics tool is to include how to apply the
principles to the pharmaceutical and biotechnology industry. With the use of sharing best
practices then this has the possibility of being very helpful for the industry and enhance their
bioethical performance.
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Therefore, in conclusion, section 4.1 presented eight of the most prominent bioethics
guidelines that have been created since the end of World War II. It was seen that there are many
notable strengths to these guidelines, yet none of them are suitable to be the foundation of the
proposed global bioethics tool. The weaknesses of each guideline were examined, with particular
attention given to the WMA Declaration of Helsinki, as it arguably the most well-known and
utilized bioethics guideline today. While immensely popular, the revision and drafting process of
the DoH was called into question for not adequately taking into account the viewpoints of
sufficient numbers of people. In the following section, the UNESCO Universal Declaration on
Bioethics and Human Rights is examined. Reasons for why the UDBHR is more suitable than
other guidelines to act as the foundation document for the proposed global bioethics tool will be
assessed.
4.2) UNESCO Universal Declaration on Bioethics and Human Rights
In order to solve global problems, global solutions and the commitment of the global
community are necessary.71 Further, not only are there global health problems, but education,
insights, and fresh solutions to these problems flow in all directions.72 Ergo, the need for global
solutions will need to be collective and collaborative, and these solutions will affect countless
persons. For bioethics, the proposition to develop a universal declaration to work at solving some
of these global problems was suggested in 1999 by science ministers at the World Conference on
Science in Budapest, Hungary. The ministers of science, concerned by the rapid progression of
science and technology and the importance of sharing knowledge with LMICs, decided that it
was necessary begin dialoging on the subject.73 In 2001, the UNESCO Director-General was
asked to look into the possibility of developing a universal bioethics instrument. On the basis of
the International Bioethics Committee’s subsequent report, the 2003 General Conference
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declared the setting of universal bioethical standards to be “imperative and desirable.” An
extensive drafting and consultation period then ensued, involving member states and other
stakeholders.74 Because of the need to incorporate international and universal perspectives, the
UDBHR is by necessity the result of compromise. Indeed, it is this compromise and
internationality that provides strength to the declaration and its normative ethical standards. The
declaration represents the viewpoints of the governments of UNESCO Member States rather than
scientists and biomedical ethics experts.75
UNESCO was well suited for the task of crafting universal, normative bioethics
guidelines. First, from its founding, UNESCO has emphasized its role as a moral conscience.
This was expressed by the first Director-General, Julian Huxley, when he stated that science and
values must be married in order to contribute to peace and human flourishing. UNESCO acting
as a moral conscience is also reflected in it creating an International Bioethics Committee in
1992 because of the need to have these sensitive and important biomedical conversations at the
global level. Second, UNESCO has the unique position, as an intergovernmental organization,
not merely to explain or clarify bioethics principles but to seek their application in state policies.
While the organization certainly has its flaws, no other global entity combines the standardsetting work and practical implementation activities in the field of bioethics at the same level of
UNESCO, which makes it unique. Third, UNESCO has acted as a bridging agency, not only
between science and values, as was envisioned by Potter, but between countries as well. Moral
perspectives from all Member States are brought together into one organization and each are
given fair treatment. Those who might critique bioethics guidelines as the result of Western
imperialism have no such argument for the work of UNESCO. LMICs and even some HICs,
such as Saudi Arabia, are reported to very sensitive to such accusation of Western imperialism,
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and this is exemplified in their scrutiny of proposals from Western nations. Lastly, UNESCO has
a crucial ideological role that has aided it in making global pronouncements. As ten Have has
recognized, “UNESCO is driven by certain values that are utterly relevant for global
bioethics.”76 Particularly, UNESCO places an emphasis on the common heritage of
humankind—the idea that certain elements/resources are part of humanity’s shared inheritance
and should be protected for future generations. This directs attention both to human flourishing
and the common good of humankind. Seeing the common heritage of humankind enacted,
though, can only be accomplished through pragmatic acts of global solidarity, cooperation, and
authentic respect for diversity.77
In mid-2016 the author received a grant from the bioethics division of Novo Nordisk to
work on the creation of a voluntary industry-based and industry-originated global bioethics tool.
During the fall of 2016 the author had numerous conversations with representatives from major
pharmaceutical and biotechnology companies to attempt at generating support for creating a
global bioethics tool to be used by the pharmaceutical and biotechnology industry that is based
upon the UNESCO Universal Declaration on Bioethics and Human Rights. One question the
author received on at least two occasions was the rationale for the using the UDBHR rather than
the better-known DoH. The UDBHR is better positioned than any other biomedical ethics
framework, including the DoH, to be the framework upon which the global bioethics tool is built
for at least the following four reasons: 1) it is the first and only bioethics declaration to gain the
approval of international governments (all UNESCO Member States), with the input of bioethics
experts, rather than solely a group of individuals with bioethics or scientific expertise, 2) it
efforts to incorporate major principles in bioethics, such as those included in the Declaration of
Helsinki and ICH-GCP, 3) the Declaration reaches beyond individual orientations to bioethics to
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a global perspective, focusing on issues such as the environment, respect for cultural diversity,
capacity building, and future generations, and 4) the Declaration is very useful for countries that
lack an infrastructure in bioethics. The need for worldwide standard-setting in bioethics has been
strongly expressed by LMICs who want to share the benefits of the developments of science and
technology and not only be the providers of data and resources for the world.78 Each of these
four reasons will be explicated below.
First, the UDBHR is very unique among research ethics guidelines as it is the first and
only bioethics declaration to gain the approval of all international governments with the input of
international experts in bioethics. The UDBHR was unanimously adopted on October 19, 2005 at
the 33rd General Conference of UNESCO by all Member States.79 As an international
organization, UNESCO is charged with taking into account all perspectives that are relevant to
all Member States so that one nation or context is not improperly favored over another and to
ensure that the cultural diversity of the world is respected. The UDBHR was primarily drafted by
UNESCO’s International Bioethics Committee (IBC)—the only ethics committee with a truly
global scope, composed of 36 experts in different disciplines: genetics, medicine, law,
philosophy, ethics, history, and social sciences.80
The UDBHR was not crafted by a small group of persons. Rather, UNESCO Member
States had considerable input. In January 2004, nearly two years before its formal adoption, a
written consultation with Member States was launched; 191 Member States,81 Associate Member
States and Permanent Observer Missions received a simple, concise questionnaire inviting
responses concerning (1) aims and scope, (2) the structure, and (3) the content of the declaration.
While only 67 official replies were received, representing only approximately one-third of
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Member States, the replies were helpful in determining the scope of the declaration and what
would be included within it.82
Second, the UDBHR efforts to incorporate the major principles in bioethics into one
universal document. Having the declaration consist of general principles that could be the object
of a large, worldwide consensus and which could be applied to new scientific advances in the
future was thought to be advantageous and the best route to pursue.83 In one sense, the UDBHR
presents a related network of principles. The UDBHR principles themselves are associated with
other principles that have been adopted in the UN system and principles that have been used for
many decades in the international governance of medical research. Because of this historical and
pragmatic background, many UDBHR principles are not new, but are in fact practical
“translations” for their use in global bioethics governance. Therefore, it can be said that the
UDBHR focuses, to a large extent, on basic principles of bioethics that are intended to withstand
the test of time, and that it has incorporated many principles from other existing bioethics
guidelines, making it truly a universal document in its scope.84 While this is true, the UDBHR
still has incorporated more innovative principles into its guidelines as well, such as the
requirement of benefit sharing, the connections of bioethics with the larger environment, and
giving consideration to future generations.
Third, the UDBHR reaches beyond individual orientations to bioethics to a global
perspective, focusing on issues such as the environment (Article 17), respect for cultural
diversity (Article 12), capacity building (Article 24), and future generations (Article 18). Saying
that these are global, universal issues that affect the entire planet and every nation on it is not
hyperbole. The universality of the UDBHR is not merely a matter of crossing borders or
continents; it concerns the plant as a whole and, hence, embraces the vision of Potter in the early
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days of bioethics.85 Justice Michael Kirby, chair of the UDBHR drafting committee, addressed
this very point by stating that the UDBHR “lifts the eyes of bioethicists from the patient’s
bedside and the hospital ward to a new insistence on the relevance to the bioethics discipline for
society, the community, humanity, all living beings and the biosphere”.86
Henk ten Have and Bert Gordijn have argued that the establishment of a global bioethical
framework such as the UNESCO UDBHR signifies the genesis of a “global moral community”.
This is recognized in global bioethics principles such as protecting future generations, as cited
above, but also through the principle of benefit sharing (Article 15) that seeks to counteract the
injustices of biopiracy.87 This brings into the forefront conversation on the common heritage of
humankind—that the earth is not the sole possession of one people group or generation, but is
inherited with each passing generation and entrusted to the current generation for safekeeping.
This is also quintessential Potter, who viewed ethics as a tool to extend the idea of human
community broader to include the soil, water, plants, and vertebrate and invertebrate life forms.88
Fourth, the UDBHR is very useful for countries that lack an infrastructure in bioethics.
UNESCO has had ethics standard-setting activities for several decades now. Considering that
many Member States have only a limited infrastructure in bioethics, such as LMICs, they lack
expertise, educational and training programs, research committees, legal frameworks, and public
debate.89 The common principles and shared values that are focused on in the UDBHR create the
space for the global standards of the UDBHR to be used by both HICs and LMICs. This attempts
to address a large gap that was present in bioethics.90 This highlights the usefulness of not only
UNESCO as a universal, standard-setting organization, but also of the UDBHR.
To attempt to further answer the question of why the UNESCO UDBHR should be the
guideline of choice for the global bioethics tool rather than the more prominent DoH is the task
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of the remainder of this section. As has been stated elsewhere, the UDBHR is the first
international effort for a global approach to bioethics, involving governmental and nongovernmental actors, and eventually being unanimously adopted by all UNESCO Member
States. This was quite the feat, considering the countless religious and sociocultural backgrounds
that were represented. However, this demonstrated that UNESCO had the ability to locate
common ground between nations in order to set a minimum universally accepted standard for
bioethics.91
While human rights and bioethics have had an intertwined relationship since the
development of the Nuremberg Code, the UDBHR is the first international instrument to
comprehensively integrate international human rights law into biomedicine. Richard Magnus has
pointed out that, “By broadening the scope of the respect principle from personal autonomy to
human dignity, the UDBHR overcomes a shortcoming of previous bioethics documents, which
seemed to accord respect only to autonomous persons.”92 Magnus’ argument is that the UDBHR
includes protections for those who are not yet (future persons and generations) as well as those
who are no longer morally autonomous, such as infants, those with mental disorders, and those
suffering with dementia. Future persons are to be respected and protected as well, for human
dignity requires that new technologies and procedures, like germ-line interventions, do not result
in a compromise of the integrity of humankind. Further, integrating the human rights framework
into bioethics is a meaningful task because these most fundamental rights and freedoms are
desirable to all persons, irrespective of characteristics such as ethnicity and gender, as well as
intellectual and physical abilities. Hence, the UDBHR recognizes and affirms that science and
technology cannot be advanced without thoughtful reflection on the impact of humanity’s actions
on both the environment and the rest of humankind. Due to the fact that the UDBHR encourages
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such consideration and recognizes the need to give due regard to other human beings that we
share this common planet with, the UDBHR can truly be considered a universal bioethics
guideline. Hence, the UDBHR, unlike much bioethical discourse that focuses heavily on the
individual person, places great emphasis on both the larger society and even the global
community.93
Further, one significant contribution of the UDBHR is that it provides guidance for
transnational health research (Article 21), stating that research should go before ethical review of
the host state and the state in which the sponsor is located, transnational health research should
be responsive to the needs of the host country, terms for benefit sharing should be reached when
negotiating a research agreement, and, very specifically, states should take appropriate measures
to combat bioterrorism and illicit traffic in organs, tissues, samples, genetic resources, and
genetic-related materials. Therefore, UNESCO has tried to implement strategies to ensure that
science is not unjustifiably impeded and research participants in all corners of the globe are duly
protected. There are hints of the principle of global justice in this Article and throughout the
UDBHR.94
Finally, the UDBHR has sought to focus on basic principles that are intended to
withstand the test of time. Many principles have been derived from other existing guidelines and
some are unique to the UDBHR. By focusing on common principles and values that are shared
by humankind, the UDBHR was able to establish global normative standards that were
acceptable and could be used by both HICs and LMICs. The comprehensive approach of
integrating human dignity and human rights into bioethics was a first in the field for the
UDBHR.95
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The UDBHR is not a perfect bioethics document, just as a UNESCO is not a perfect
organization, if there is even such a thing. Further work needs to be done in elaborating the
principles articulated in the UDBHR and, specifically, how they are and have been applied in
real-world scenarios, such as in governments, research universities, and even individual
companies. This will take further dialog between countries, industries, and individual companies,
as well as a greater depth of understanding the religious and sociocultural divisions of the world.
Indeed, it would be useful for UNESCO to publish detailed accounts of exactly how a
developing world country, with little capacity in research ethics, has sought to implement the
UDBHR. Such a work would not only be fascinating from a policy and governance standpoint, it
would conceivably be of great value and benefit to other LMICs in similar situations who are
looking to implement the UDBHR.
Further empirical research on the ground, dealing with the lived experiences of actual
people, will need to be conducted to find out what works and what does not. The compilation
and publication of best practices would be very helpful for countries, organizations, universities,
and companies trying to implement the UDBHR into its operations. The IBC has done some of
this work, elaborating on certain principles through the use of reports on the principles of consent
(Article 6), respect for human vulnerability and personal integrity (Article 8), and social
responsibility and health (Article 14).96 Further the 2009 commentary on the UDBHR also
discusses the work of application in some detail.97 Yet, such work needs to increase in order for
the application of the UDBHR to continue growing. Indeed, a great strength of the proposed
global bioethics tool is its use of best practices as a way to encourage companies to adopt similar
practices.
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To conclude this section, we must recognize that certainly UNESCO’s resources are not
inexhaustible and must be prudently utilized. However, in order for the UDBHR to achieve
greater acclaim and wider recognition in the world, these may need to be priorities. Further, as
has been asserted above, one task of UNESCO is to be a standard-setting organization for
bioethics. In order to fulfill this agenda in a more comprehensive manner, UNESCO must also
look to the application of standards and not merely to the setting of them. Such work will
undoubtedly be opposed by some, as there will be varying opinions on the application of
principles. This is why extensive dialogue between relevant stakeholders is immensely
important. Yet, the application of principles and even sharing best practices between countries,
industries, and individual companies seems to be the next step in the process of ensuring that
essential principles of bioethics and human rights are being adhered to. The following section
provides analysis of the topic of bioethics governance and different models of accreditation,
certification, and rating that have been created in order to send a signal to the public about the
activities of a company.
4.3) Bioethics Governance and the Differing Models of Accreditation, Certification, and Rating
The previous two sections described the various biomedical ethics guidelines that have
been developed in the aftermath of WWII onwards and argued for the role of the UNESCO
UDBHR as being most well suited for the task of creating a global bioethics tool from which to
unite pharmaceutical and biotechnology companies. This section begins by elaborating on what
is meant by “governance” and elaborates its role in global bioethics. This section then moves into
the differing models of accreditation, certification, and rating, and makes some recommendations
for their use in the global bioethics tool.
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To determine the principles of bioethics, enshrined in different guidelines and
declarations as presented in the previous two sections, is one thing. Yet, the application of
principles is different, and this is the work of governance. Broadly, governance can be defined as
the actions and means that are adopted by a society to promote cooperative action and deliver
collective solutions toward a desired, common goal.98 Global governance is this type of
cooperative action between actors, primarily states, on a global scale. Within a specific country
or locale, bioethical problems are addressed with the common mechanisms of government. Henk
ten Have has recognized that these common mechanisms, such as legislation and political
decision-making, do not always work in such a globalized world. Indeed, this is one of a number
of challenges that globalization has created. On a global scale, no authority exists that is
responsible for the application of principles, and the global nature of the problems that are
encountered today make national approaches insufficient. Practices that are rejected in one
country on ethical grounds, sometimes with the backing of legislation (such as the case of
abortion in Poland presented in 4.1), are permitted in another country. This highlights the grave
challenge, if not impossibility, of simply applying an ethical position within one country at a
global level to all countries. For global health, states have recognized that they are not effective
in regulating health, which has highlighted the need for a governance system that encompasses
both state and non-state actors.99 This is the problem of governance.100
Indeed, governance has developed alongside globalization and is no longer sufficient to
be applied merely within states. By the mid-nineteenth century, globalization in the form of
increased trade and travel between states precipitated the need for governments to initiate
dialogue on health threats that were considered to be of international significance, such as the
plague, yellow fever, and cholera. This would evolve to collective action between states on other
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issues such as pollution, humanitarian law during wartime, and labor agreements.101 Hence, the
need for cooperation on global health matters is apparent.
Similarly, cooperation towards the oversight and implementation of global bioethics
principles cannot be considered the work of a particular state, but must be the activity of a
coalition of partners, which may necessarily involve those who are regularly affected by
bioethics, such as the pharmaceutical industry. There are many problems for global bioethics
governance both at the international state level (between governments) and at the level of
commerce (between companies) that will need to be discussed.102 The need for greater
cooperation at the state level and the level of commerce will be explained in this section. For
pharmaceutical and biotechnology companies, the problem of globalization and the issue of
governance are particularly salient. These companies are bound legally to the rules in which they
operate, yet these can differ significantly from one country to another. A HIC may have strict
legislation in place to protect research subjects from harm, yet a LMIC may not have similar
protections in place. This emphasizes the problem caused by the globalization of multinational
corporations, the relevance of governance, and the need for a mechanism such as the global
bioethics tool that will be presented in the subsequent chapters.
Understanding the role of governance in bioethics requires the historical consideration of
how bioethics became institutionalized into the specific forms of committees, regulatory bodies,
and commissions.103 First introduced by the World Bank and later receiving academic dignity in
James Rosenau and Ernst-Otto Czempiel’s influential essay collection on Governance without
Government in 1992, the concept of governance has become a highly utilized term in both
political and scientific debate.104 The concept of global governance became more widespread
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after its use in the 1995 report of the Commission on Global Governance, which met to report on
the future of the UN and has defined governance as follows:105
Governance is the sum of the many ways individuals and institutions, public and private,
manage their common affairs. It is a continuing process through which conflicting or
diverse interests may be accommodated and co- operative action may be taken. It
includes formal institutions and regimes empowered to enforce compliance, as well as
informal arrangements that people and institutions either have agreed to or perceive to be
in their interest.106
Hence, governance was thought of by the Commission as an output of the international system
that is aimed at addressing issues that have the potential to affect everyone, irrespective of
national borders.107 While governance is often thought of in terms of states and governments, it
is also applicable to companies, foundations, and institutions. In the realm of bioethics,
declarations and, specifically the applications of the principles, at local levels such as companies
and research universities, as well as at national levels, is the idea of governance.108 It is this type
of governance that is most applicable for the proposed global bioethics tool that is presented in
chapter five.
There are at least two notable challenges for global governance. First, the question is
often posed of how the globalized world can be successfully governed. Two premises are
embedded in this question. First, globalization has entailed that some processes, services, and
challenges are not met by either local institutions (public or private) or by traditional policymaking means. The distinction between domestic and international, that was once more marked,
has become more obsolete in a sense. A second premise is that a government-like, hierarchical
management style to solve the world’s problems is simply not possible in the absence of a world
government.109 Hence, some have criticized the notion of global governance as being overly
utopian and claiming it can only work in the presence of a unified world government.
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Nevertheless, cooperation between states and global solidarity towards a common goal is not a
utopian ideal, but is an attainable goal.
Ten Have has pointed out that such pressing issues of our day, such as ever-present
pandemics, migration spurred by conflicts, and climate change, cannot be adequately addressed
by states and interstate cooperation alone. He has identified at least five facets of global
governance: 1) a focus on global problems, 2) necessity of collective action, 3) a variety of
actors, including not only state governments but intergovernmental organizations and NGOs, 4)
various levels of activity, and 5) diverging objectives.110 Health has been an objective of global
governance for many years, as evidenced by the UN’s Millennium Development Goals,
established in 2000, three of which are specific to health and others indirectly involve health as a
stepping stone to the fulfillment of another goal and to a better standard of living.111 Surely
individual governments bear the brunt of responsibility for the health of their citizens, as was
argued in chapter three. However, in the absence of a global government, global health problems
must be addressed, managed, and coordinated in a different manner, making global cooperation
and solidarity a necessity.112
John Ruggie, the chief architect of the UN Guiding Principles on Business and Human
Rights, has contended that, “The root cause of the business and human rights predicament today
lies in the governance gaps created by globalization—between the scope and impact of economic
forces and actors, and the capacity of societies to manage their adverse consequences. These
governance gaps provide the permissive environment for wrongful acts by companies of all
kinds without adequate sanctioning or reparation. How to narrow and ultimately bridge the gaps
in relation to human rights is our fundamental challenge.”113 Thomas Weiss and Ramesh Thakur
have attempted to define what these governance gaps actually are, and each will be briefly
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explained: knowledge gaps, normative gaps, policy gaps, institutional gaps, and compliance
gaps.114 First, a gap in knowledge signals that little or no consensus exists about the nature,
origins, seriousness, and magnitude of a problem. Second, a gap in norms is present due, in large
part, to the enormously difficult task of achieving a consensus on universally accepted norms.
Third, policy gaps showcase that there is disagreement on the formulation of norms, who should
be involved in the formulation, and how to implement policies. Fourth, institutional gaps often
limit governance due to lack financial resources and adequate authority. Fifth, compliance gaps
indicate that the monitoring and enforcement that is needed to ensure compliance to an agreed
upon norm or standard is deficient. Indeed, the challenge of filling global governance gaps is
exhibited by the tremendous difficulty in ensuring compliance.115
Governance gaps in global health become even more evident when applied to real-life
scenarios. The first cases of the recent Ebola virus epidemic were reported in the West African
nation of Guinea in December 2013. The disease would later spread to neighboring Sierra Leone
and Liberia. In hindsight, the WHO has recounted that in Guinea, the origin of the outbreak, it
took nearly three months for health officials and their international partners to identify the
causative agent as the Ebola virus. However, by that time, the virus was firmly entrenched in
society, and its spread was primed to explode.116 After more than six months into the Ebola
outbreak there was no strong sense of who was leading the international response, how funds
were being collected and distributed, which organizations were providing medical equipment and
personnel, and when any of these efforts would make a noteworthy difference in slowing the
epidemic in West Africa.117
What contributed to this protracted length of time to target the specific disease and to
coordinate a response? West African countries had never before experienced an Ebola outbreak,
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and they were poorly prepared for this unfamiliar and unexpected disease at every level,
including early detection of the first cases to orchestrating an appropriate response. Healthcare
providers and clinicians in these countries had never managed Ebola cases, and laboratories in
the countries had never diagnosed a patient specimen.118 This could be considered a gap in
knowledge. However, gaps in knowledge were not the only contributory factor. The WHO has
reported that certain high-risk behaviors among those in the countries were also heavily present
during the epidemic. Adherence to ancestral funeral and burial rites were singled out as
175ubsidi large explosions of new Ebola cases. Data available in August 2014, as reported by
Guinea’s Ministry of Health, indicated that 60% of cases in that country could be linked to
traditional burial and funeral practices. This is comparable to an estimate in November 2014 by
WHO staff stationed in Sierra Leone who estimated that 80% of cases in that country were
linked to these practices. In Liberia and Sierra Leone, some mourners have been known to bathe
in or anoint others with rinse water from the washing of corpses and to sleep in close proximity
to an infectious corpse for several nights. Several experts have noted that when technical
interventions to treat diseases cross purposes with entrenched cultural practices, such as what
was seen in West Africa, culture always wins.119 This is evident of a knowledge gap, but it also
goes beyond that. Knowledge is often not the decisive problem. In the Ebola outbreak,
eventually the virus had been identified, diagnostic tests were available, and the mechanisms of
contagion and prophylactic measures were known. However, knowledge can be ignored, and this
was observed in West Africa.120 Hence, this may more closely be described as a gap in
compliance on the part of many people in the affected West African states.
“Good” global governance as defined by Weiss and Thakur implies not that an
organization, such as the UN, holds exclusive policy jurisdiction, but rather an optimal
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partnership between the state, intergovernmental, and non-governmental actors are cooperating
at national, regional, and global levels.121 This seems to imply not only greater cooperation than
what is present currently, as illustrated in the scenario of the recent Ebola epidemic of West
Africa, but also that governance is not exclusively directed towards states, as it is often defined.
For global health governance, the WHO remains at the center, but it increasingly shares
responsibility and agenda-setting activities with other organizations. The current system is highly
fragmented, involving the contributions and activities of many actors, such as multinational,
national, and private organizations with missions and responsibilities that intersect at various
points, a diverse set of fundraising and fund distribution, and an assortment of monitoring and
evaluation standards.122
Global health governance has been critiqued for many reasons, including, first, for its
fragmented nature, as discussed above. Second, it has also been criticized for a lack of
participation and/or cooperation by certain actors, which also contributes to the fragmented
nature of global health governance. Till Bärnighausen, David E. Bloom, and Salal Humair of the
Harvard School of Public Health have stated that this problem, in part, arises because certain key
global health institutions are established and funded by individual donors or private firms who
are not obligated to invite any particular group of people to participate in their decision-making.
Affluent donors have the ability to skew public health and medical programs towards the issues
of greatest concern to them, though not necessarily of the most urgent need.123 Third, a lack of
transparency is yet another reason for criticism leveled against the current form of global health
governance. Lack of transparency extends to matters of decision-making, political moves, and
how finances are expended. Connected to this is a fourth reason for criticism: lack of
accountability. There is a need for institutions and individuals to account for their decision-
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making and hold responsibility for the consequences of their decisions. Transparency is a first
and necessary step, but in and of itself it is insufficient for comprehensive accountability. Fifth, a
final reason that global health governance is often criticized has already been alluded to:
effectiveness and efficiency. The effectiveness and efficiency of global health governance is
often called into question especially in times of pandemic or epidemic when coordination of
healthcare and resources is necessary, yet, as has been seen in both the Ebola and more recent
Zika response, is not always a reality. The consequences of poor coordination and multiple, and
include duplication of efforts, breakdowns in communication, lost opportunities to learn from
one another, and inadequate patient care.124
A number of methods and proposals have been offered for how to improve upon global
health governance.125 Spicer et al have proposed that mechanisms focused on partnership and
collaboration between entities, as well as coordination between them, could aid participation in
global health and the transparency of these entities.126 Sridhar has stated that the principal
responsibility for global health lies with the WHO. Nonetheless, there are various other actors,
primarily private donors, such as the Bill and Melinda Gates Foundation, who pour enormous
sums of money into global health. While this funding is positive, an unintended consequence is
the great competition for that money amongst organizations, leading some to question whether
the actual needs of developing countries are being met or is the agenda of the donor being
accomplished. Hence, some sort of monitoring mechanism could benefit this process.127 In this
dissertation, the global bioethics tool is offered as a mechanism to aid global health governance
in regards to ethical issues surrounding pharmaceutical and biotechnology companies.
Just as global health governance in the realm of the WHO and other non-profit entities
whose chief aim is to improve human health and enhance the conditions through which human
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beings flourish is oftentimes in a state of disarray due to competing interests, lack of
coordination, and inadequate amounts of transparency with the public and even with similar
organizations, the same is true of for-profit corporations who have a similar aim of eradicating
disease and improving human health. For-profit pharmaceutical and biotechnology companies
are, by their very nature, involved in global health. Their governance mechanisms include the
laws in their particular country or region, such as the FDA in the US and legislation passed by
the EU or Council of Europe in Europe. Yet, companies within this industry rarely communicate
with one another. As has been seen in previous chapters, the concept of corporate social
responsibility is increasing within the pharmaceutical and biotechnology industry, and individual
companies have responded to the public’s outcry on matters of CSR. Yet, these efforts are
largely done company-by-company apart from the coordination of the industry. In the field of
pharmaceutical bioethics more generally, very little cooperation between companies exists. Yet,
as this dissertation demonstrates, cooperation between for-profit companies on global bioethics is
not only hypothetically possible, it is achievable.
Bioethics plays an important role in global health governance because governance is not
merely a technical or managerial approach based on facts and scientific expertise. Rather,
governance also involves the values, norms, and ideas of persons and collective societies, which
is a particular strength of bioethics. The field of bioethics has a wealth of reflective resources at
its disposal that can make intellectual contributions to the clarification of normative perspectives
that guide policies and institutions in specific directions. Today, bioethics is increasingly
becoming a mechanism of governance itself.128 Not only are individual nation-states utilizing
bioethics in their crafting of public policy, such as the notable 1974 National Commission for the
Protection of Human Subjects of Biomedical and Behavioral Research that produced the
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Belmont Report, but such bioethics governance is happening on a global scale as well. The
methodology of bioethics governance is typically similar, whether done at the local or global
level. First is the creation of an ethics committee, and second is the development of an ethical
framework.129
Ten Have has recognized that nowadays governance is often accomplished through
bioethics. This approach is based on four functions of global bioethics: regulation, oversight,
deliberation, and interaction. Regulation in regards to bioethics is the process of developing
normative instruments to be used by countries and organizations. These were examined in 4.1
and 4.2. Oversight refers to the ethics committees that have proliferated in countries to provide
assurance that regulations are being fulfilled. Deliberation is an important step in order for
making bioethics be representative of large swaths of people. Developments in science,
technology, and medicine must be publicly discussed and debated. Finally, the function of
interaction refers to the values and ethics that must be engaged with in global bioethics.130
For global bioethics, if there are global ethical frameworks, how can they be applied at a
global level in order to address problems on a global scale?131 This is a question that the
proposed global bioethics tool seeks to answer. Using ten Have’s four functions of global
bioethics above, the instrument of regulation for the global bioethics tool is the UDBHR. The
mechanism of oversight is the self-reporting and transparency embedded in the global bioethics
tool. The process of deliberation would take place between pharmaceutical and biotechnology
companies on a number of bioethics topics in trying to discern best practices and how best to
apply the principles of the UDBHR within the industry.
For the functions of regulation and oversight, some have proposed a system of
accreditation, certification, or rating to validate how pharmaceutical companies are doing in
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regards to certain indicators. Companies, and even entire industries, have participated in systems
of accreditation or certification due to public distrust. When the voices of public distrust become
louder and directed at a single industry, then there is an increased risk of government regulation.
For example, a national, independent accrediting body, the Association for the Accreditation of
Human Research Protection Programs, originated in large part to assist institutional review
boards do the work of self-regulating in order to keep government regulators at bay.132
In the literature and in practice there are differing models of accreditation, certification,
and rating for companies in regards to implementation of ethical principles. Accreditation
systems date back around a century. During the early 20th century accreditation agencies were
established in both education and healthcare. For education, accreditation was used to establish a
common basis from which to admit students to different institutions.133 In healthcare, the
precursor to the Joint Commission would propose establishing a system of hospital
standardization circa 1910.134 In 1917-1918 the American College of Surgeons developed a onepage Minimum Standards for Hospitals.135 Today, scores of accreditation agencies exist covering
industries such as education and healthcare to agencies that monitor and assess greenhouse gas
emissions and nutraceuticals. Accreditation systems can serve as indicators of a product’s or
company’s environmental impact, as well as, in the case of nutraceuticals, whether the product
actually contains what it specifies to and is made with certain stringent standards.
Such a system is also possible for the pharmaceutical and biotechnology industry, as has
been demonstrated recently by Jennifer Miller and her colleagues at Bioethics International.136
Bioethics International has created a rating index called the “Good Pharma Scorecard” that
ranks the twenty largest pharmaceutical companies and every new FDA approved drug on
clinical trial transparency and legal compliance. Key criteria such as design of clinical trials, how
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clinical trials are conducted, clinical trial transparency and data sharing, medical marketing
concerns, accessibility of medicine and vaccines are examined in order to come up with a
ranking list for the different companies.
Voluntary codes of conduct have also sprung up to try to regulate and govern aspects of
business. A lack of effective legal responses from national governments and other international,
regional, and multilateral institutions to restrain the conduct of multinational corporations that is
considered socially undesirable has given rise to them being challenged by NGOs in the
international economic and sociopolitical arena. These NGOs have been quite effective in
pressuring multinational corporations to be accountable for their business activities and the
negative side effects of their business practices in such areas as environmental protection, fair
treatment of workers, human rights abuses, and bribery and corruption. The recognition of
increasingly hostile sociopolitical environments on the part of individual multinational
corporations and industry groups has prompted these organizations to take action in the form of
voluntary codes of conduct that would pledge certain standards of conduct and outline corporate
and industry responses to societal concerns. It has been recognized that the primary focus of
these codes of conduct is twofold: 1) assuage public concerns and build further trust/repair
reputation in multinational corporations; and 2) take actions that would improve their current
state of affairs without unduly restricting the company in the conduct of their business or
imposing burdensome regulatory oversight and heavy financial liabilities upon them.137 It is
worth noting that voluntary codes of conduct differ from CSR principles. In direct contrast to
conventional codes developed by individual companies or an industry, CSR-related codes of
conduct call on companies and entire industries to voluntarily assume the costs associated with
the industry’s negative externalities.138
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Voluntary certification systems are a rather recent invention and achieved popularity in
the late 1980s largely in response to activists who viewed the logging industry and population
growth as threats to forests and the environment. Activist groups and NGOs created incentives
for the logging industry to address societal concerns by participating in the SmartWood
Rainforest Alliance certification program.139 The Rainforest Alliance was a multi-stakeholder
group with independent, third-party certification, which assures consumers that the wood
products they purchase come from well-managed forest.140
Rating systems date back to around the turn of the twentieth century and have been
notably used by the Access to Medicine Foundation in their biennial publication.141 One of the
first was produced by John Moody in 1909, who saw the need for such a tool after the stock
market crashed in 1907. Moody’s company published a book, known as Moody’s Manual, that
offered investors an analysis of security values. Moody’s Manual analyzed the railroads and their
outstanding securities and offered concise conclusions about their relative investment quality.
Moody expressed his conclusions using letter rating symbols and with this endeavor he became
the first to rate public market securities.142 Today, rating systems are prolific—available in
numerous industries to aid stakeholders in comparing companies and identifying industry best
practices. Such systems do not require industry support, as many are based on information that is
publicly available via other publications and reports.143 In the pharmaceutical sector, the Access
to Medicine Index (ATMI), published by the Access to Medicine Foundation, rates the top 20
research-based pharmaceutical and biotechnology companies on how they make medicines,
vaccines, and diagnostics more accessible in LMICs. Along with a numerical ranking system,
ATMI also includes examples of what each company is doing well, incorporating best practices,
and areas in which they could improve.
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The benefits of an accreditation, certification, or rating system for the pharmaceutical
industry, according to Miller, are at least fourfold: 1) it would allow stakeholders better
understand and define what it looks like for pharmaceutical companies not to act well and,
contrasting, 2) it would help them also to understand and define what it looks like for the
industry to act well; 3) it would motivate companies to move from bad practices to good
practices, and 4) it would identify and communicate when the good has been implemented in
ways that are trustworthy. Further, Miller includes steps for how such a system would be created.
First, the concerns of stakeholders or the perceived problem areas are identified and prioritized
for addressing initially. Second, standards or benchmarks are set to address the concerns. Third,
measurement instruments are developed in order to evaluate the degree to which individual firms
have or have not implemented these standards. Follow-up to ensure how particular firms are
doing would consist of a self-assessment questionnaire, completed by the company, on how it
senses its own performance in relation to the specified standards. This process might entail
companies submitting certain types of evidence demonstrating how it attempts to comply with
the standards throughout their organization. The second follow-up step in Miller’s proposed
process would involved the certification body dispatching a team to interview a selection of the
company’s employees who are responsible for implementing the standard in order to determine
the veracity of the company’s implementation claims. Finally, companies that receive a
satisfactory score are accredited or certified and would be free to use a seal or label attesting to
that for a defined period.144
These different models each have their own merits and need to be considered for the
proposed global bioethics tool. While some sort of rating system is certainly promising for the
proposed global bioethics tool, a system of certification or accreditation is outside the bounds of
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the project at this time. As it currently stands, the global bioethics tool is not designed to be a
statement or verification that participating companies have eliminated harmful bioethics
practices and are certified as being upstanding bioethics citizens, which is what accreditation and
certification mechanisms, such as the proposal by Miller, in large part, attempt to do. Rather, the
proposed tool enhances the transparency of the industry and is a measure of how well companies
are doing in regards to applying and implementing certain principles. While it is envisioned that
stakeholders and the general public will be able to compare how and what Company X is doing
in comparison to Company Y, a system of certification or accreditation would be asking too
much of the global bioethics tool at this germinal stage.
A model that is more promising at this very infantile stage of the proposed global
bioethics tool is rating, which is very similar to the process of the ATMI. While there have been
shown to be many positive benefits of a rating system, such as stimulating companies towards
competition within the industry and thus greater social responsibility,145 rating does not typically
inspire collaboration between competing companies, as the very nature of a rating system is to
perform your best so as to be better than others. Yet, the proposed global bioethics tool is based
around the idea of generating best practices for the industry and spurring greater transparency
rather than rating companies. The global bioethics tool seeks to form a collaborative partnership
between firms in the pharmaceutical and biotechnology industry. Hence, even a rating system is
not overly promising for the global bioethics tool at this stage. Rather, as will become apparent
in the subsequent chapters, the proposed global bioethics tool seeks to be an industry-initiated
bioethics governance tool, which would be novel for the pharmaceutical and biotechnology
industry.
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In conclusion, this chapter began by first exploring eight bioethics declarations and
guidelines that have been created over the past seven decades. The Nuremberg Code, Declaration
of Geneva, Declaration of Helsinki, Belmont Report, 45 CFR 46 (US Common Rule), CIOMS
guidelines, Good Clinical Practice, and a resolution from the Council of Europe (Oviedo
Convention) were all examined. It became evident during this process that while there are
undoubtedly many merits to all these biomedical ethics guidelines, they are not well suited for
the task of creating a global bioethics tool that could be used to unite pharmaceutical and
biotechnology companies.
Section 4.2 then presented the UNESCO Universal Declaration on Bioethics and Human
Rights in detail and provided justification for why UNESCO is a suitable organization to aid in
this task and why the UDBHR is appropriate for the foundation of the proposed global bioethics
tool. It was seen that the UDBHR is the first and only bioethics declaration to gain the approval
of international governments, it efforts to incorporate major principles in bioethics, it reaches
beyond individual orientations to bioethics to a global perspective, and it is useful for countries
that lack an infrastructure in bioethics. As a universal document, grounded in human rights and
having been adopted by the global community, the UDBHR is currently the premier bioethics
guideline for this project.
Finally, section 4.3 discussed the issue of bioethics governance and the differing models
of accreditation, certification, and rating that have been created. An analysis of each was
completed. This is useful in order to explore how these might apply to the proposed global
bioethics tool. The proposal of Jennifer Miller for how a pharmaceutical accreditation or
certification program might look was also reviewed. It was determined that at this stage in the
global bioethics tool, such a mechanism would not be advised.
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Now that the groundwork for the proposed global bioethics tool has been laid, chapter
five presents the methodology for the creation of the tool and the development of indicators.
Chapter five also introduces the benchmarking process and how the tool is envisioned working in
practice. Chapter six then applies the tool to specific pharmaceutical and biotechnology
companies. Chapter seven is then a concluding chapter that discusses further research that needs
to be completed and offers next steps on developing the global bioethics tool.
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Chapter 5: Global Bioethics Tool: Methodology and the Development of Indicators
The proposed global bioethics tool involves four main steps: First, a preliminary phase,
consisting primarily of desk research, is conducted to develop indicators, research the viability of
the project, and determine the interest level of UNESCO. Second, an exploratory phase seeks to
gather interest from 4-5 top pharmaceutical and biotechnology companies so that a partnership
can be formed. The exploratory phase also involves reaching out to the UN Global Compact to
discover if there are partnership opportunities with them. The third phase commences once there
is a commitment from 4-5 companies. This phase is also the longest and consists of refining the
indicators, interviewing the companies, generating best practices, producing a functioning selfreporting website, and other activities in order to make the global bioethics tool eventually reach
the point of sustainability. Finally, the fourth phase forms a non-profit foundation to house the
global bioethics tool. To make the foundation financially sustainable, member organizations
would pay into the foundation with a dues structure based upon the annual revenue of the
organization. Such a system has been set up before, as similar dues structures are used by
Business for Social Responsibility1 and other industries have also set up similar foundations,
such as IPIECA, the global oil and gas industry association for environmental and social issues.2
Section 5.1 begins by presenting the rationale behind the creation of the proposed global
bioethics tool. This then transitions into an analysis of determining best practices and
benchmarking. Section 5.2 then presents the indicators that have been developed for the
principles of the Universal Declaration on Bioethics and Human Rights. Each of the principles
within the UDBHR has been translated into specific questions, termed indicators, so that
individual pharmaceutical and biotechnology companies can ascertain qualitatively how they are
doing in implementing the principles.
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5.1) Rationale, Methodology, and Benchmarking
In order to justify that the proposed global bioethics tool is needed, we must provide
evidence that there is sufficient demand for this type of evaluation from stakeholders in order to
convince pharmaceutical and biotechnology companies to participate. In other words, is there a
strong business case for firms in the pharmaceutical to divulge aspects of bioethics and human
rights implementation and assist the industry in developing best practices? Jennifer Miller has
described the case for accreditation, certification, or rating within the pharmaceutical industry
based upon consumer interest, which was discussed in the previous chapter.3 Similarly, this
rationale is significant for the proposed global bioethics tool. We must remember that
prescription sales, vaccines, and immunizations are not the only products produced by
pharmaceutical companies. Many firms offer a vast array of over-the-counter (OTC) medicines
or home health products. For instance, Bayer is known for their aspirin and their “One A Day®”
line of vitamins, and Johnson & Johnson is known for numerous OTC medicines like Tylenol®
as well as medical supply products like Band-Aid®. Hence, even persons who do not regularly
take prescription medication are likely to use at least some of the non-prescription products from
a pharmaceutical company.
The benefits of a voluntary, industry-initiated, transparent global bioethics tool reach
beyond restoring reputation and positive public image for the pharmaceutical industry. Such a
tool would aid the industry in better understanding and defining what good ethical practices look
like in practical terms, motivate companies to incorporate better ethical processes into their
operations, and send a clear message to their multiple stakeholders that they are serious about
implementing bioethics into their business. Miller has written that the concerns of stakeholders
around the business practices of the pharmaceutical industry fall into four interrelated categories:

194

(a) the design and management of clinical trials, (b) the dissemination of trial results, (c)
corporate marketing strategies, and (d) the accessibility of medicines.4 Recent headlines that
have painted the industry in a bad light have primarily revolved around the accessibility of
medicines and, more specifically, the pricing of these medicines. This was detailed in chapter
three and will not be reiterated here. Yet, as Miller recognizes, the pricing of products may be a
primary category of concern, but it is not the sole category.
Many concerns persist around the design and management of clinical trials and the
dissemination of results. In particular, industry sponsorship of trials and the conflict of interest it
poses is great. In a 2005 study that analyzed 397 psychiatric clinical trials, the authors concluded
that industry sponsorship of a clinical trial was associated with a greater likelihood of reporting a
drug to be superior than a placebo.5 That industry-funded trials are more likely to produce a
positive result than independently funded trials has been reported both in scientific, peerreviewed literature and in more popular media.6 Critics have charged that pharmaceutical and
biotechnology companies regularly suppress unfavorable study findings and/or disseminate them
in ways that are misleading and have a likelihood of biasing the body of evidence about drug
efficacy and safety.7 Further, industry critics argue that companies substitute alternate endpoints
for genuine clinical endpoints to make a novel drug in the clinical trial process look more
successful. Critics also believe that pharmaceutical and biotechnology companies cherry-pick
research participants who make drugs appear more effective than they actually will be if released
in their intended markets. The obtaining of genuine informed consent in clinical trials from
participants in LMICs is another area of worry that has been persistent for decades.8 Hence,
problems surrounding the design and management of clinical trials seem ubiquitous.
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What is more, as Miller has noted, corporate marketing strategies have also been a
category of attention. Only two countries in the world allow pharmaceutical direct-to-consumer
advertising of prescription drugs: New Zealand and the US.9 In the US, this type of advertising is
under fire. At the November 2015 Interim Meeting of the American Medical Association,
physicians adopted new policy to ban pharmaceutical advertising.10 Researchers have linked
direct-to-consumer advertising with unnecessary increased utilization of prescriptions,
diminished time evaluating a patient by a physician, and misinformation.11 The promotion of offlabel drugs and the utilization of financial incentives, grants, lavish gifts, and large honorariums
for consulting or speaking for physicians and researchers has also been criticized.12 The four
categories of concern that Miller has highlighted aid in showcasing the rationale for the proposed
global bioethics tool. The public’s perception of the pharmaceutical and biotechnology industry
is not flattering, and the proposed tool may be part of the solution.
The global bioethics tool began taking shape in the summer of 2015 when Dr. Henk ten
Have contacted the bioethics division at Novo Nordisk to ascertain if there might be an
opportunity for this author to gain experience in corporate bioethics. This was warmly welcomed
by Novo Nordisk and resulted in a meeting in November 2015 at Duquesne University between
the author, Dr. ten Have, and Dr. Lise Holst of Novo Nordisk to discuss a project proposal for
the global bioethics tool. In January 2016 the bioethics division of Novo Nordisk awarded a 6month grant to Duquesne University to work on developing a global bioethics tool for use by the
pharmaceutical and biotechnology industry and to see if such a tool is viable for the industry.
The Principal Investigators (Pis) on the study were Lise Holst, MD, PhD, Director of Global
Bioethics Management at Novo Nordisk and Henk ten Have, MD, PhD, Director of the Center
for Healthcare Ethics at Duquesne University and former Director of the Division of Ethics of
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Science and Technology at UNESCO (2003-2010). As chief researcher on this project, the
author was deeply invested in this project from its origin. The following will describe the process
that took place in beginning the project and the different phases, including trying to collaborate
with multiple stakeholders, comprising major pharmaceutical and biotechnology companies and
UNESCO.
After the November 2015 meeting between Holst, ten Have, and myself, a grant to begin
work on the project was drafted and submitted by Duquesne University to Novo Nordisk. The
grant was approved, and the initial preliminary phase of the project commenced in January 2016.
The first step involved identifying possible indicators for assessing the implementation of the
UDBHR principles. These indicators will be discussed in much greater detail in 5.2. The second
step of the preliminary phase examined existing reporting methods for the implementation of
human rights principles and CSR. In the third step, the development of a “Global Compact for
Bioethics,” patterned off the UN Global Compact, was explored. Such a tool would ideally be
connected to a UN organization, and since UNESCO was the body in charge of the UDBHR,
they were contacted regarding their interest in being connected to this project. In May 2016, the
author and the two Pis traveled to UNESCO headquarters in Paris, France in order to meet with
Dafna Feinholz, PhD, Chief of Section – Bioethics and Ethics of Science. Feinholz expressed
pronounced interest in the global bioethics tool and creating some level of partnership between
the bioethics division of UNESCO and the formation of this tool. Lastly, benchmarking and
examining best practices comprised the fourth step of the preliminary phase, which will be
explained later in this section.
In July 2016 the grant was extended for an additional 6-month period as an “exploratory
study” to investigate the feasibility of engaging primarily pharmaceutical and biotechnology

197

companies in setting up this initiative. A number of major, top-20, pharmaceutical and
biotechnology companies were contacted to ascertain their interest in collaborating on this
project. The entire methodology describing the process of how the project unfolded will be
presented in detail in this subsection.
A primary goal of the global bioethics tool is to create a platform through which
companies can discuss and develop industry best practices. To achieve this, a process of
determining best practices through benchmarking will need to occur. The concept of
benchmarking began in the late 1970s by the Xerox Corporation as a way to position itself more
competitively in the market. Definitions of benchmarking vary considerably, but key themes
include measurement, comparison, identification of best practices, implementation, and
improvement. Numerous definitions are available in the literature, with one article citing at least
49 unique definitions for benchmarking.13
Essentially, benchmarking is the process of identifying the highest standards of
excellence for products, services, or processes, and then making the improvements necessary to
achieve those standards, which are commonly termed “best practices”. 14 Another way to
describe benchmarking is simply as the systematic search for best practices that leads to superior
performance.15 Hence, no matter how benchmarking is defined, it is always best-practiceoriented. In the late 19th century, the management science work done by Frederick Taylor
encouraged work processes to be compared through the scientific method. Taylor believed there
was a single “best way” for work to be performed, which could be discovered via scientific
study, and should then be applied as the standard for performance.16
The concept of benchmarking also draws from the Japanese industrial practice dantotsu,
referring to a method for finding the best practice that consistently yields the best results in that
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industry.17 From its inception, benchmarking has been utilized to identify aspects of an
organization’s activity that could be more efficient/effective by comparison with the
performance of other relevant organizations. The data regarding the other relevant organizations
and their key processes are used to identify and implement changes.18
The benefits of benchmarking are substantial. First, benchmarking is able to enhance
transparency. There is a push from society for companies to be more transparent about their
processes. The UN Guiding Principles on Business and Human Rights desire for companies to
both know and show that they are respecting human rights. This type of thinking can be applied
to all issues of bioethics; companies should know what they are doing and should show it.
Hence, the hope of benchmarking and the global bioethics tool is to be an effort that drives
transparency in regards to a company’s actions on human rights and bioethics, which is certainly
very relevant for the investors, employees, local communities, customers, and other stakeholders
of a company, not to mention government regulators and the general public.19 Companies,
through the use of benchmarking are able to know and show their actions and achievements,
which allows stakeholders to evaluate the company. This opens the door to multi-stakeholder
contribution to open dialogue, and this transparency has the ability to benefit not only
stakeholders and the general public, but also the company itself. Benchmarking and the
transparency that may go along with it is a signal to stakeholders that the company has nothing to
hide and truly does attempt to operate in a responsible manner.
Second, accountability is increased with benchmarking. With benchmarking it is much
easier for stakeholders and for others inside the industry to hold the company accountable for its
actions. The hope with the global bioethics tool is that benchmarking would spur companies to
greater ethical responsibility. Third, benchmarking allows companies to more readily compare
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their actions to one another. For the individual company, benchmarking allows for internal
comparison, as the company is able to gauge progress over a specific time period, such as from
year to year. Benchmarking can also allow for competition between companies, which has been
witnessed by the Access to Medicine Index.20
The history of modern-day benchmarking is not very old. Robert C. Camp, a logistical
engineer for Xerox, would head up the now-famous study on benchmarking at Xerox and would
also coin the term in late 1980.21 Benchmarking was perceived to be a strategic tool to increase
productivity, enhance learning, assess performance, and continuously improve upon an
operation.22 While there is no single accepted method for making benchmark analyses, a
frequently used model is proposed by Camp. Camp divides benchmarking into two main parts:
practices and measures.23 He delineates a twelve-step process on benchmarking that is split into
five phases. The process starts with deciding what to benchmark and whom to involve, following
up with planning and conducting investigations to collect data, determining performance gaps
and projecting future performance levels, and communicating findings. The final steps are
focused on revising and improving performance goals, developing an action plan, and finally
implementing action plans, monitoring results, refining benchmarks when necessary, attaining
leadership position, and fully integrating the practices into the processes.24 This is depicted as a
chart below:
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Phase 1:
Planning

Phase 2:
Analysis

Phase 3:
Integration

Phase 4:
Action

Phase 5:
Maturity

1) Identify what
to benchmark

4) Determine
current
performance gap

6) Communicate
findings and gain
acceptance

8) Develop action
plans

11) Attain
leadership
position

2) Identify
comparative
companies

5) Project future
performance
levels

7) Establish
functional goals

9) Implement
specific actions
and monitor
progress

12) Fully
integrate
practices into
processes

3) Determine
data collection
method and
collect data

10) Recalibrate
benchmarks

To demonstrate how this can be applicable for pharmaceutical and biotechnology
companies, as a succinct example to show how benchmarking might be applied, let us use a case
study for illustrative purposes:
Company X is a major pharmaceutical company who has vast experience working with
clinical trial participants from various cultures. Lately, though, they have become
concerned that their normal processes of consent have not been adequate to convey the
information about the proposed study to a particular people group in South America on
whom they would like to perform a research trial for a neglected tropical disease (NTD)
Company X has decided to use a new strategy for consent amongst this people group in
South America, which will consist of having one of their researchers live in the
community for up to 6 months in order to learn more about their customs. Though this is
time consuming and will delay the start of their clinical trial, they see value in measuring
whether the group fully understands the clinical trial. Company X wants to know if their
new strategy for consent in this group (who are very communal and their culture is much
different than the trial’s sponsoring country) has the following outcomes: 1) whether it
actually helps to convey the information they need to the persons in an understandable
way, and 2) whether it is efficient in terms of time and resources compared to what they
have been doing in the past and what other companies are doing.
So, to use Camp’s model of benchmarking to assess Company X’s new mode of consent in
comparison to the mode used by other companies in a very succinct, elementary manner might
look something like the following:
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Step 1: Identify what to benchmark—The new consent process/strategy among a
people group in South America on whom Company X wants to begin a trial for a NTD.
Outcomes to measure include 1) whether the new consent strategy actually helps to convey the
information they need to the persons in an understandable way, and 2) whether it is an efficient
use of resources compared to what they have been doing in the past and what other companies
are doing. Camp recommends for the company to prepare a project description describing the
rationale for wanting to benchmark a specific process.25
Step 2: Identify comparative companies—There are surely other companies who have
performed trials on people groups that are more communally oriented. Company X needs to
identify these companies. One tremendous benefit of the global bioethics tool is that many
pharmaceutical and biotechnology companies would be gathered together around a common goal
of increasing bioethical performance and, thus, it would be simpler for Company X to identify
companies to whom they can compare their processes.
Step 3: Determine data collection method and collect data—Company X will need to
devise a method for determining whether the persons they are seeking consent from truly
understand what they are potentially agreeing to. Further, Company X also wants to measure the
resources utilized for this new strategy of consent, so they will need to keep track of this. They
will also need their comparative companies to be transparent about their strategies and results.
Step 4: Determine current performance gap—This step moves into the analysis phase
and Company X would then determine how their new strategy for consent measures up to their
comparative companies. There very well may be a performance gap where another company has
received better results on something they are doing or their resource utilization is lower. This is
termed the performance gap.
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Step 5: Project future performance levels—Once the current performance gaps have
been defined in the previous step, the future performance levels need to be projected. Camp
defines this as the difference between expected future performance and the best in the industry.26
Continuing with our example, Company X will need to evaluate if the gap between where they
currently are and where they want to be is widening or closing.
Step 6: Communicate findings and gain acceptance—Once the performance gap has
been discovered and Company X has projected future performance levels, it is time to
communicate those findings. For the global bioethics tool, this is envisioned as a multistakeholder process. That is, Company X will communicate their findings on their new informed
consent process and how it compares to other companies. The opportunities that have been
identified by the benchmarking process will also have to be communicated internally within
Company X, and it will need to be accepted that change needs to occur in order to better their
informed consent process.
Step 7: Establish functional goals—To establish functional goals, Camp recommends
stating important benchmark findings into statements of operating principles.27 For company X,
let us postulate that another company was shown to receive greater levels of understanding
among their research population and they spent less time doing so. Hence, for Company X,
functional goals might be twofold: 1) Obtain greater level of understanding of the proposed
clinical trial by the research population, while 2) reducing the time it takes to obtain consent and
thereby reducing personnel costs.
Step 8: Develop action plans—Step 8 begins the action phase of the benchmarking
process. Now that the company knows that there is a gap in performance between where they are
and where other competitors in the industry stand, in this step Company X will begin to plan and
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plot how they are going to work towards their functional goals. Not only must Company X
develop plans for how they will reach their functional goals, but they also must plan how they
will attain the support of their organization for the implementation of their new goals.28
Step 9: Implement specific actions plans and monitor progress—Implementation
depends largely on understanding the new practices and the differences that are being made in
the processes. The roles and responsibilities of individuals must also be understood. Monitoring
progress includes standard approaches of monitoring that all business undertake with their
processes of evaluation: comparing progress against predefined milestones, determining causes
for variance, taking corrective action where variance is significant, and reviewing results with
stakeholders and management.29 Periodic review of progress would then be based on the new
functional goals.30 Hence, for our example, Company X will now implement the action plans
they developed in the previous step.
Step 10: Recalibrate benchmarks—Benchmarks and best practices are rarely, if ever,
static. They are more often fluid and because of the fluidity, recalibration needs to occur in order
to stay current with evolving conditions and be able to maintain superior performance.
Benchmarking recalibration will not just happen. Rather, it must be deliberate and planned.31
For the global bioethics tool, recalibrating benchmarks will be a continuous process in which
pharmaceutical and biotechnology companies are transparent with others in the industry and with
the public about what they are doing in regards to implementing bioethics and human rights. The
process for recalibration, according to Camp, is simply a matter of re-implementing steps 1-10 of
the benchmarking process.
Step 11: Attain leadership position—Step 11 moves into the maturity phase of
benchmarking. The benchmarking process will need to be continually evaluated and given
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attention by company management and by partners of the global bioethics tool. Camp notes that
once a company attains leadership position in a specific area over competitors, the company
must continually refine and improve, lest they lose their leadership.32
Step 12: Fully integrate practices into processes—The final step in the process is to
fully integrate the new practices into processes. At this step, all levels of the company should
have buy-in on the new practices and procedures. For Company X, not only are researchers and
field scientists now fully trained on their new process of consent, but managers have integrated it
into their operational policies, data analysts and those who write up the consent documents and
IRB proposals are intimately aware of the changes.
There are two broad types of benchmarking: internal and external. Within these broad
categories there can be numerous sub-types. Camp delineates four types of benchmarking:
internal, competitive, functional, and generic. Each type has its specified outcomes and benefits
depending on what the organization wants to achieve, and each will be discussed.33 Internal
benchmarking is the most straightforward of the four types, and it should be viewed as a starting
point for businesses. In internal benchmarking, as well as the other types, the same process is
undertaken as described in the above graphic, yet the target of the benchmark differs. For
internal benchmarking, one is looking at processes within the company and comparing them to
other similar processes. Indeed, a prerequisite for effective benchmarking is a focus on the work
process, which is why internal benchmarking is oftentimes a more straightforward and
streamlined process.34 In the second type of benchmarking—competitive benchmarking—one is
looking to compare a process within their company to a leading competitor in their industry.
Camp notes that at some stage, the gaps between the competitor company and one’s own
company must be known in order to assess the strengths and weaknesses of the company.35 This
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is a very similar process to what is hoped to be achieved with the global bioethics tool in order to
discover best practices.
Functional benchmarking is a third type of benchmarking, and is the process of
comparing a business function to that of a functional leader, which is often not in the same
industry. As the pharmaceutical and biotechnology industry is such a specialized industry, and as
the global bioethics tool is concentrated on the area of biomedicine and clinical research, this
type of benchmarking may not prove as beneficial. Finally, a fourth type of benchmarking is
known as generic process benchmarking. In this type of benchmarking, a key business process
that the company wants to benchmark is identified, such as product shipping. Once the process to
be benchmarked is identified, benchmarking is pursued to find the best practices in product
shipping, wherever they may be. This type of benchmarking also typically occurs across various
industries and, one again, this usefulness of this type of benchmarking for the global bioethics
tool seems limited.36
Camp’s model of benchmarking is not the only model. Others have been proposed by
Spendolini,37 Watson,38 Zairi,39 and Iacobucci.40 Michael Spendolini attempts to simplify the
benchmarking process by benchmarking the benchmarking processes that were in use in leading
companies of the early 1990s, such as Xerox, AT&T, and DuPont. From this analysis he offers a
five-stage process for benchmarking: Step 1) Determine what to benchmark; Step 2) Form a
benchmarking team; Step 3) Identify benchmarking partners; Step 4) Collect and analyze
benchmarking information; Step 5) Take action.
Gregory Watson reportedly surveyed nearly 70 models of benchmarking for his research
on the subject.41 He utilizes a four-phase approach, with numerous steps comprising each phase.
The four phases are: 1) planning the benchmark project, 2) collecting the necessary data, 3)
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analyzing the data for performance gaps and enablers, and 4) improving by adapting process
enablers. Watson goes into a fair amount of depth in describing the steps that accompany each
phase.42 Nonetheless, Camp’s model still appears to be more in-depth. This is not to say that
there are not aspects of benchmarking to be learned from Watson, for his process is not markedly
different than others, it is merely to suggest that Camp’s model may prove more useful in the
beginning stages of the global bioethics tool. What is more, the global bioethics tool seeks to
attract major pharmaceutical and biotechnology companies to participate. These companies
surely have their own wealth of experience in benchmarking, which should be harvested and
gleaned.
Mohamed Zairi outlines a 16-step process for implementing benchmarking. Steps 1-7
comprise the effectiveness stage, and steps 8-16 comprise the competitiveness stage. Zairi’s steps
will be briefly detailed here: 1) Understand internal processes; 2) Evaluate current processes, 3)
Identify process limitations/opportunities for improvement; 4) Improve processes; 5) Measure
and evaluate; 6) Set internal standards; 7) Control and manage processes; 8) Select process
suitable for benchmarking; 9) Identify suitable partners; 10) Agree on measurement strategy;
11) Compare standards; 12) Understand why difference in performance; 13) Change relevant
practices for improving performance; 14) Compare standards; 15) Repeat experience with
same/new partners on regular basis; 16) Apply benchmarking to all processes.43 A strength of
Zairi’s work is that it documents the European view and application of benchmarking, rather
than the American viewpoint where benchmarking originated.44 Yet, Zairi does not provide the
detailed commentary on each of the steps in his process as Camp does. Hence, his model might
prove difficult for a novice to follow and implement.
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Dawn Iacobucci and Christie Nordhielm have proposed that benchmarking begin by
starting from the customer’s point of view. They write,
To begin the process, list each step of your customers’ buying experience, from the initial
recognition of need to the final follow-up after the purchase. Next, determine which
factors most influence customers’ perception of value at each step. Finally, identify
companies that excel at each factor—no matter what industry they’re in. By breaking
down the value delivery system into detailed, customer-focused steps, this process helps
managers identify relevant companies to study.45
This approach is novel and has potential for positive outcomes, yet it would need to be
significantly tailored for the use of benchmarking human rights and ethics activities, as the
global bioethics tool seeks to do.
At this point at least six different processes of benchmarking have been briefly analyzed
and it seems that the process of benchmarking and determining best practices as proposed by
Camp is most suited for the proposed global bioethics tool. This is not to say that his model may
not need additional tweaking for the purposes of the global bioethics tool, but at this juncture it
seems well suited for this task.
Benchmarking is far from being free of criticism, and it is most often criticized on three
fronts: information, implementation, and theory. In regards to information-oriented criticism,
Andrew Campbell has asserted that businesses spend considerable effort in benchmarking while
attempting to gather data describing advantages, often covertly, and they may fail to focus on
their own unique situation. This may make the company prone to distraction and misdirection.
Campbell also argues that benchmarking is always a retrospective process, as you are looking to
what your competitors have done in the past, which may not yield considerable advantage in
fast-moving markets.46 This is a fair criticism that companies must keep in mind when deciding
to start a benchmarking process. What is more, Metin Kozak and Kevin Nield claim that the
information required to implement benchmarking properly inherently reduces heterogeneity
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within industries and escalates the risks of uncompetitive homogeneity if product differentiation
declines.47 Surely this is a risk, yet this risk within the pharmaceutical and biotechnology
industry does not seem plausible, for their industry thrives on innovation of products and
competition. Benchmarking human rights and ethical issues would not seemingly reduce
heterogeneity of products in terms of pharmaceuticals.
In regards to implementation-oriented criticism, Gregory Watson, whom we have
discussed above, in his 1993 book cited two major difficulties that he perceived in implementing
a rigorous benchmarking study: 1) deciding what process for the company to focus the
benchmarking resources on, and 2) agreeing on what organizations to solicit as partners in order
to compare processes.48
There are many theory-oriented critiques of benchmarking.49 Robert Pederson has
questioned the ability of benchmarking to provide anything aside from marginal improvements
in processes.50 Yet, the experiences of Xerox and others like it would show otherwise. Michael
Hammer and James Champy argued that benchmarking has the potential to produce a restrictive
framework for innovation by only focusing on those business processes that are already
occurring within one’s industry. They further argued that benchmarking sets a ceiling on
ambition by seeking to be only equal to the best and not surpassing it.51 However, in Camp’s
benchmarking model he is very keen to discuss not only trying to equal the best in the industry,
but to attain the leadership position by continuing to improve. Further, in regards to theoryoriented critiques, as early as 1979, Julie Wolfram Cox and colleagues lamented the absence of a
sufficiently developed theory that would explain the differences between effective and
ineffective efforts of implementing benchmarking.52 K.W. Wöber has also stated that
benchmarking lacked a rigorous foundation in management science and added that a generally
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accepted methodology for selecting suitable benchmarking partners was only addressed in the
year 2000.53 Indeed, this is a fair criticism, as the majority of the literature on benchmarking is
overwhelmingly more pragmatic than deeply theoretical. The literature is largely process-driven
and oriented around case studies of benchmarking success stories.
Benchmarking companies on areas of human rights and/or ethics is a fairly novel project,
but it has been done before. Currently, the Corporate Human Rights Benchmark (CHRB), a
collaboration between Aviva Investors, Business & Human Rights Resource Centre, Calvert
Investments, Institute for Human Rights and Business, VBDO, and Vigeo Eiris, is attempting to
do just that. The CHRB touts itself as the “first-ever ranking of the world’s largest publicly listed
companies on their human rights performance.”54 It aims to rank the top 100 companies across
the agricultural, apparel, and extractives sectors on their human rights related policies,
procedures, processes, practices, and responses in order to try to incentivize companies to greater
performance.
The CHRB is based on publicly available information, such as from the company’s
website or other public documents, for example CSR reports or newspaper articles. This
approach differs from the methodology of the proposed global bioethics tool, as the global
bioethics tool expects for companies to self-disclose this information and share it with others as a
mechanism for learning and spurring one another to best practices. Nonetheless, the CHRB is
grounded primarily in the UN Guiding Principles on Business and Human Rights.
The CHRB has created indicators to score companies on human rights. For each indicator
a company can score zero, one, or two points based upon the sufficiency of the company’s
response for the indicator. A complete methodology has been released by the CHRB that
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demonstrates companies can indeed be benchmarked on their approach to human rights. The
pilot CHRB benchmark was released in mid-March 2017.
As this section concludes, it is important to bear in mind that benchmarking will not be
an easy, quick process, for it will take substantial time and commitment from all participating
companies. Further, companies will have to guard against becoming complacent once easily
attainable goals have been accomplished. In the late 1990s, the toy manufacturer Mattel
announced that it was implementing a new global code of conduct, including such items as legal
and ethical business practices, for all its production facilities and manufacturers. In the initial
phases of the new code of conduct, processes for improving upon its business practices were
swift and effective, and the code was seen as successful. However, as time went by, it became
apparent that all of the easily attainable goals had been achieved and that further progress would
be incremental and accommodated in normal business operations. Mattel eventually decided to
discard public disclosure of its code compliance activities.55 The lesson to be learned from the
Mattel case study is that at the beginning of the life of the global bioethics tool, there will,
presumably, be some easily achievable goals that will not take much effort. Yet, the work of
improving the implementation of human rights and bioethics does not stop once the simple items
are complete. This highlights the need for companies that are involved in the global bioethics
tool to continually push one another on towards advancing human rights and bioethics within
their own companies and not to grow complacent.
5.2) Development of Indicators
Performance measurement is a fundamental principle of good management. The
measurement of performance is significant because it identifies performance gaps between
current and desired performance and provides indication of progress towards closing the gaps.
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The use of key performance indicators may identify precisely where to take action to improve
performance. Key performance indicators represent a set of measures focusing on those aspects
of organizational performance that are the most critical for the current and future success of the
organization.56
A key performance indicator can be defined as an item of information collected at regular
intervals in order to track or measure the performance of a particular system.57 Qualitative and
quantitative key performance indicators are used as a means of measuring and monitoring the
progress towards particular goals and objectives.58 In the UNESCO Universal Declaration on
Bioethics and Human Rights, the core of the declaration is found in fifteen principles (Articles 317).59 Indicators, in the form of questions, are developed based upon each of these principles so
that one can qualitatively assess how a particular company is doing in implementing the
international standards. In developing these indicators, the UNESCO UDBHR was first
compared to the other prominent bioethics guidelines, such as those presented in 4.1. As an
example of this process, Article 15 of the UDBHR concerns benefit sharing and states the
following:
Benefits resulting from any scientific research and its applications should be shared with
society as a whole and within the international community, in particular with developing
countries. In giving effect to this principle, benefits may take any of the following forms:
(a) special and sustainable assistance to, and acknowledgement of, the persons and
groups that have taken part in the research; (b) access to quality health care; (c) provision
of new diagnostic and therapeutic modalities or products stemming from research; (d)
support for health services; (e) access to scientific and technological knowledge; (f)
capacity-building facilities for research purposes; (g) other forms of benefit consistent
with the principles set out in this Declaration.
2. Benefits should not constitute improper inducements to participate in research.60
As the Declaration of Helsinki also discusses sharing of benefits in Articles 22 and 34, the two
documents were compared for similarities and to see the general requirements of benefit sharing
in each document. Additionally, prominent, current literature on each of the principles was
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examined and will continue to be investigated during this process to better understand how each
principle could be implemented by the pharmaceutical and biotechnology industry. For the
principle of benefit sharing, the following three indicators have been developed based upon the
principle of benefit sharing:
1) How does the company ensure that the benefits resulting from its scientific research
are shared with society as a whole?
2) When conducting clinical trials, does the company ensure that in advance of the trial,
provisions are made for post-trial access for all participants who still need an intervention
identified as beneficial in the trial (DoH, Article 34, 2013)
3) How does the company ensure against improper inducements to participate in
research?
Therefore, other prominent bioethics guidelines were consulted while forming these indicators,
as well as the two PIs on this study, one of which is an expert in corporate social responsibility,
pharmaceutical bioethics, and animal welfare, and the other an authority in global bioethics.
Moreover, the author is under no illusion of the importance of substantial stakeholder
engagement to further refine these indicators, which cannot be overstated. Nonetheless, as the
first expedition into such a global bioethics tool to instrumentalize the UNESCO UDBHR for the
pharmaceutical and biotechnology industry, the developed indicators provide a good starting
ground for the global bioethics tool. In the explanatory memorandum of April 2005 the IBC
stated that, “Principles always require further interpretation since the norms implicit in principles
have to be translated into concrete laws, policies, guidelines and practices.”61 This is exactly
what the global bioethics tool has sought to do for the pharmaceutical and biotechnology
industry.
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The following tables showcase the indicators that have been developed for each of the
principles (Articles 3-17) of the UNESCO UDBHR. Following each of the tables is an
explanation of how the indicators were arrived at and further steps that might be taken.
Article 3 – Human dignity and human rights
UNESCO
UDBHR

Indicators:

1. Human dignity, human rights and fundamental freedoms are to be
fully respected.
2. The interests and welfare of the individual should have priority over
the sole interest of science or society.
General:
• How does the company avoid infringing on the human rights of
others? (cf UN Guiding Principles on Business and Human Rights
(UNGPBHR) Principle 11)
• How does the company ensure the welfare of its employees by
providing safe and suitable working conditions?
• How does the company implement standards of working hours for its
employees, such as those put forth by the International Labour
Organization?
• How does the company ensure fair living wages in relation to the
context of their employees such as to meet the basic needs of
employees and dependents?
• How does the company ensure the elimination of all forms of forced
or compulsory labor in its employees and suppliers? (cf UN Global
Compact (UNGC) Principle 4)
• How does the company ensure the effective abolition of child labor of
its employees and its suppliers? (UNGC Principle 5)
• How does the company ensure that a system is in place so that
employees may voice concerns regarding aspects of human dignity and
human rights? (UNGPBHR Principle 18)
• Does the company have in place a human rights due diligence process
to identify, prevent, mitigate and account for how they address their
impacts on human rights? (UNGPBHR Principle 15b)
Human Research:
• How does the company promote and safeguard the health, wellbeing,
and rights of human research participants?
• Does the company place the goal of generating new knowledge in
clinical trials above the rights and interests of the individual research
participant?
• How is the priority of patients’ safety respected during a trial, and
after market marketing of a new product?
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Safety:
• How do investigators ensure the research is acceptable within the
community it takes place? How does a company ensure it complies
with good scientific principles that would lead to best science and
greatest benefit?
• How is it ensured that participants during a trial obtain new
information that might affect their decision to continue in the trial?
Article 3 is standard fare for the protection of human dignity and human rights in the
context of medical research on human participants. In international law, human dignity is a
foundational principle connoting equal respect for every human being, and human rights are the
concrete, tangible norms that are needed to flesh out the principle of human dignity in social
life.62 To become functional for the pharmaceutical and biotechnology industry, human dignity
and human rights must take on tangible form. That is, concrete actions need to be specified.63
Notably, the principle makes use of the familiar Kantian formula that persons should not be
treated as a means only, but rather always as an end in themselves.64 Hence, persons should not
be instrumentalized, and the interests and welfare of the individual should have priority over the
interest of science and society. From this, certain specifications for companies, specifically the
pharmaceutical and biotechnology industry, can begin to be formulated. Specifications may
include the following: 1) certain requirements on the welfare and safety of the employees and
research trial participant, 2) fairness in regards to hours (ILO), wages, and leave, 3) nondiscrimination policies, and 4) fair treatment of employees. To create the indicators for this
Article, the principles of both the UN Global Compact and UN Guiding Principles of Business
and Human Rights were examined to see what could be learned and borrowed from them. As the
UNESCO Declaration is very unique in its explicit connection of bioethics to human rights, other
bioethics guidelines were not as useful for this Article. This Article, as well as Article 4, contains
the most indicators of any. To make this tool functional and easy to use, succinct and minimal
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indicators have attempted to be created. This dissertation presents merely an initial version of
this tool that has undergone a simple peer-review process. To make the tool even better and more
usable, more stakeholders will need to be involved in this process.
Article 4 – Benefit and harm
UNESCO
UDBHR

Indicators:

In applying and advancing scientific knowledge, medical practice and
associated technologies, direct and indirect benefits to patients,
research participants and other affected individuals should be
maximized and any possible harm to such individuals should be
minimized.
General:
• How is any possible harm minimized?
• How is direct and indirect benefit maximized?
• How does a company ensure that investigators and staff are trained
and scientifically qualified
• How is the cont. evaluation of a marketed product through research of
safety, efficacy, accessibility and quality ensured?
• If a clinical trial participant is harmed, how is harm assessed and who
determines/assesses if compensation is appropriate?
Review:
• Are qualified research ethics committees (institutional review
board/ethical review board) present and reviewing research protocols to
ensure benefit is maximized and harm minimized?
• Who and how is it decided if the non-clinical and clinical knowledge
is adequate to support a clinical trial?
Conflicts of Interest:
• How are conflicts of interest amongst research ethics committee
members and affiliated researchers stated and mitigated?
Risk Monitoring:
• How is harm/benefit ratio determined by the company?
• What is the procedure for stopping a research study if the risks of
proceeding are shown to outweigh the potential benefits? (WMA
Declaration of Helsinki Article 20, 2008)
• How does the company respond to a situation in which a research
participant has an apparent research-related harm occur?

Article 4 states a very basic principle of human research: benefits should be maximized
and risks/harms should be minimized. There are several methods currently in use to discern how
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benefits can best be balanced against harms, and this will not need to be specified by the
company. Methods for evaluating the ratios of harm and benefit are usually qualitative,
probabilistic value judgments made by patients, health professionals, investigators, or
policymakers, such as the “QALYs” method (quality adjusted life years).65 The proposed
indicators do not currently go into this level of detail, yet this is an area of further consideration
in the future.
This Article, similar to Article 3, dates back to the Nuremberg Code. The indicators were
initially created very broad, simply inquiring about how harms are minimized and benefit
maximized, generally. The indicators then move into questions about ethics review of a proposed
study. The express purpose of such a committee as an institutional review board (IRB) is to
ensure the rights and welfare of humans participating in research.66 Conflicts of interest must
also be managed accordingly, which is typically the role of the IRB. A simple working definition
states that a conflict of interest is a situation in which financial and/or other personal
considerations have the potential to compromise or bias professional judgment and objectivity. A
person need not have to act on a conflict in order for there to be one present; there merely has to
be the potential for one. Not only may a conflict of interest lead to injury or serious harm to
study participants, but also, on a larger scale, a conflict of interest has the ability to damage an
entire research enterprise by reducing the trust and confidence that people may have in
research.67
Risk monitoring is the next category of indicators in Article 4. These questions, similar to
the other indicators, would require companies to qualitatively provide answers. To streamline
this process, these indicators may be able to be combined with others, but this would need to be
accomplished with other stakeholders in order to further dialogue. Finally, the category of animal
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research is often overlooked in biomedical ethics, which mainly focuses on humans rather than
non-human animals. However, for pharmaceutical and biotechnology companies, the use of
animals in scientific research is imperative. Animal research has played a vital role in many
scientific and medical advances of the past and continues to aid our understanding of various
diseases and how drugs work. Yet, the use of animals in scientific research has been hotly
debated.68 Pharmaceutical and biotechnology companies often contract the brunt of criticism
from lobbying and special interest groups, such as PETA (People for the Ethical Treatment of
Animals).69 Because we must recognize that the ethical treatment of animals is important to
many stakeholders, four indicators were created to help the company analyze how they utilize
animals in their research.
Article 5 – Autonomy and individual responsibility
UNESCO
UDBHR
Indicators:

The autonomy of persons to make decisions, while taking responsibility
for those decisions and respecting the autonomy of others, is to be
respected. For persons who are not capable of exercising autonomy,
special measures are to be taken to protect their rights and interests.
Research Participants:
• How does the company ensure the autonomy (freedom, liberty, selfdetermination) of human research participants?
• How is the right to withdraw at any time without repercussions for the
participant ensured?
Employees:
• How does the company uphold the freedom of association and the
effective recognition of the right to collective bargaining? (UNGC
Principle 3)

The right of personal autonomy is greatly important in medical research and while there
are limits to the right to exercise one’s autonomy, these limits are restricted, typically enshrined
in law, and usually deal with protecting the autonomy of other persons.70 Therefore, the
importance of the right to personal autonomy is why it also imperative that research participants
are allowed to continue to exercise that right within the confines of a clinical study, which
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includes the right to withdraw from the study at any time and for any reason without fear of
retribution or reprisal.
While autonomy is certainly greatly important, it is not the sole paradigm for bioethics or
even the chief paradigm, as some have attempted to make it out to be. The inadequacy of
autonomy as the singular normative paradigm for bioethics is visible when one considers the
profound vulnerability of patients or research participants in the clinical and/or research setting.
Patients seeking care surely desire information and the opportunity to give consent to treatment.
Similarly, many clinical trial research participants desire information about a potential therapy
for their disease or ailment. Yet, first and foremost, they are asking for help.71 The right of
autonomy and individual responsibility is also important for employees of pharmaceutical and
biotechnology companies, as the UNGC and International Labour Organization (ILO) recognize
the freedoms to associate and to bargain collectively as fundamental rights 72
Article 6 – Consent
UNESCO
UDBHR

1. Any preventive, diagnostic and therapeutic medical intervention is
only to be carried out with the prior, free and informed consent of the
person concerned, based on adequate information. The consent should,
where appropriate, be express and may be withdrawn by the person
concerned at any time and for any reason without disadvantage or
prejudice. 2. Scientific research should only be carried out with the
prior, free, express and informed consent of the person concerned. The
information should be adequate, provided in a comprehensible form and
should include modalities for withdrawal of consent. Consent may be
withdrawn by the person concerned at any time and for any reason
without any disadvantage or prejudice. Exceptions to this principle
should be made only in accordance with ethical and legal standards
adopted by States, consistent with the principles and provisions set out
in this Declaration, in particular in Article 27, and international human
rights law.
3. In appropriate cases of research carried out on a group of persons or a
community, additional agreement of the legal representatives of the
group or community concerned may be sought. In no case should a
collective community agreement or the consent of a community leader
or other authority substitute for an individual’s informed consent.
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Indicators:

Information:
• How does the company ensure that consent of human research
participants is informed?
• What is included in this information component?
• Are participants provided informed consent in a language and manner
that is appropriate?
Voluntariness:
• How does the company ensure that consent of human research
participants is voluntary and in no way coerced?
• How does the company provide measures against undue inducement?
Competence:
• How does the company ensure that the research participant is
competent to give consent?
Training of Researchers:
• How are researchers or investigators trained in the process of obtaining
informed consent, including providing information in an appropriate
manner that is understandable for the participant?
• When is it appropriate to consult family members and community
leaders in the consent process?
• Is the participant given the option of being informed about general
outcomes and results of the study?
• How is it ensured that emerging new information is promptly given to
trial participants in a long-term study that may affect their desire to stay
in the study?
• When is it appropriate to ask for re-consent during a trial?
Research Participants:
• How is the right to withdraw at any time ensured?
• Who determines if a person is competent to give consent and how is it
determined?
Compensation:
Who and how is it determined?
Human Biosamples:
• What is the company’s course of action in regards to biosamples used
in research that are collected by researchers after prior informed consent
for collection, storage and use/reuse? If consent of the participant is not
possible, has an ethics committee approved?

Consent is one of the ways in which human dignity and autonomy take on a tangible
form, and it is one of the most well known elements of modern-day bioethics. Though it is well
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known and generally accepted, there is oftentimes a lack of clarity when it comes to the question
of implementing the principle in various contexts.73 Valid informed consent is typically
understood to be comprised of at least four elements: 1) disclosure of information, 2)
understanding of information, 3) voluntariness of decision and competence, and 4) formal
consent.74
Problems with obtaining genuine informed consent linger. Ingrid Klingmann, chairman
of the European Forum for Good Clinical Practice, recently specified that the organization had
“clearly identified there is an urgent need to do informed consent better…The pressure is really
huge on all those involved to better enable patients to understand the implications of their study
participation, their benefits, risks and obligations.”75 It is simple for the process of informed
consent to merely become and exercise in box-ticking focused on offering legal protection to a
trial’s organizer rather than actually protecting participants. Indeed, there is data showing that the
median length of consent forms has tripled in the 15 year time frame between 1995 and 2009.76
In a study conducted on the understanding of informed consent on a small number of oncology
research participants in the US (n=207), 63% were unaware of the additional risk associated with
participating in the research study, and 70% did not realize that the treatments being offered were
unproven.77 While the study was small, which limits generalizability, it certainly raises questions
about the quality of informed consent on a larger scale.
Solutions to fix the perceived problems with the current informed consent process have
been proposed. One solution that has been proposed is to model informed consent forms on those
used in Norway, where a brief summary of the main aspects of a trial precedes more detailed
information. Yet, it is uncertain how much better the Norwegian forms are, if any, at increasing
understanding of a proposed study by participants. Further, others have offered that the greater
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use of graphics and charts might help patients better understand the proposed study.78
Nonetheless, ideas exist for improving the consent process, and some pharmaceutical and
biotechnology companies are, presumably, doing well at this. Hence, the global bioethics tool
and the dialogue it would create between companies would help to stimulate the sharing of best
practices so that a larger cohort of companies can implement these.
Application of consent may also be shaped by the cultural context in which it is applied.
This is especially important for pharmaceutical and biotechnology companies who regularly
conduct clinical trials in contexts that are foreign to them, oftentimes in LMICs. Further, as
clinical trials only continue to become more global, it is essential for study sponsors to
understand any cultural differences that may impact care and know how to appropriately address
them. While it is increasingly recognized that different strategies of application of informed
consent are needed in various cultural and social contexts, there is little agreement about what
processes and documentation are appropriate in these contexts. Once this is recognized, the true
challenge for pharmaceutical and biotechnology firms is to establish procedures and protocols
that are both ethically sound and culturally sensitive. It has been suggested that one manner of
resolving such situations is through careful and sustained community involvement in research,
which will be time, manpower, and resource consuming for firms, though it may be a necessary
step.79
Article 7 – Persons without the capacity to consent
UNESCO
UDBHR

In accordance with domestic law, special protection is to be given to
persons who do not have the capacity to consent:
(a) authorization for research and medical practice should be obtained in
accordance with the best interest of the person concerned and in
accordance with domestic law. However, the person concerned should
be involved to the greatest extent possible in the decision-making
process of consent, as well as that of withdrawing consent;
(b) research should only be carried out for his or her direct health
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Indicators:

benefit, subject to the authorization and the protective conditions
prescribed by law, and if there is no research alternative of comparable
effectiveness with research participants able to consent. Research which
does not have potential direct health benefit should only be undertaken
by way of exception, with the utmost restraint, exposing the person only
to a minimal risk and minimal burden and if the research is expected to
contribute to the health benefit of other persons in the same category,
subject to the conditions prescribed by law and compatible with the
protection of the individual’s human rights. Refusal of such persons to
take part in research should be respected.
General:
• Has authorization for research been obtained in accordance with the
best interest of the person concerned and in accordance with domestic
law?
• Has the research participant been involved to the greatest extent
possible in the decision-making process of consent, as well as that of
withdrawing consent?
• Do the results of the research have the potential to produce real and
direct benefit to the health of the incapable research participant?
• Can research of comparable effectiveness be carried out on individuals
capable of giving consent?
Training of Researchers:
• How are researchers/investigators trained in dealing with and
protecting persons with diminished capacity to consent?
Determination of Capacity:
• How it is determined who is not capable of providing consent?
• How is capacity determined in the protocol review process and by the
investigator(s) performing research?
• How do researchers obtain proxy or surrogate consent?
Exception:
If it is not possible to comply with the above, the UDBHR does
formulate as an exception for research that does not have the potential to
produce results of direct benefit to the health of the individual
concerned. The following conditions must be met to permit such
research:
• The research has the aim of contributing, through significant
improvement in the scientific understanding of the individual’s
condition, disease, or disorder, to the person concerned or to other
persons in the same category of disease or disorder.
• The research must only entail minimal risk and minimal burden for the
individual concerned.
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Article 7 addresses persons without the capacity to offer formal consent, such as the
demented, pediatric, or those in an unconscious state. Generally, capacity is assumed in adults
and incapacity has to be demonstrated.80 Conducting research activities on participants who do
not have the capacity to understand and consent to research activities is regarded as one of the
most complex and controversial areas of research ethics, especially when taking into account the
sordid history of research on vulnerable persons.81
Applying this principle within the pharmaceutical and biotechnology industry mainly
concerns clinical trials. For instance, it is plausible that a company would develop a new therapy
or drug for the treatment of Alzheimer’s and be ready for clinical trials in human participants.
However, the decision-making abilities of a person affected with Alzheimer’s, particularly
further along in the course of the disease, is seriously questionable. Hence, the goal of these
indicators for Article 7 is to provide some clarification on the ethical issues surrounding persons
who do not have the capacity to consent.
Part B of Article 7 provides guidance for how to implement this principle within the
medical research context. First, the research must have the real potential of producing direct
health benefit. Second, the research can only be conducted if no alternative research of
comparable effectiveness with research participants who are able to consent is possible. Third, if
research does not have the potential for direct health benefit, it should only be undertaken by
way of exception and not as a matter of principle. This should be undertaken with the utmost
restraint, with the aim of exposing the person only to a minimal risk and burden and if the
research is expected to contribute to the health benefit of other persons in the same category.
Fourth, if such persons, or their legally appointed guardian, do refuse to take part in research, this
should be respected. Having policies in place at the corporate level for such scenarios is a first,
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basic step for pharmaceutical and biotechnology companies. Additional steps, including how the
policies are actually implemented in the real world by researchers, need to be assessed.
Article 8 – Respect for human vulnerability and personal integrity
UNESCO
UDBHR
Indicators:

In applying and advancing scientific knowledge, medical practice and
associated technologies, human vulnerability should be taken into
account. Individuals and groups of special vulnerability should be
protected and the personal integrity of such individuals respected.
Vulnerability & Marginalization:
• How does the company define “vulnerable” persons and population?
• How does the company specify who needs specific consideration?
(UNGPBHR: Women, children, people with disabilities, indigenous
people, migrants, elders, prisoners, pregnant women, economically and
educationally disadvantaged are considered vulnerable)
• How are the vulnerable additionally safeguarded against undue
influence or coercion?
• Are the knowledge and products from the clinical trial made reasonably
available to benefit that group?
Identification:
• How does the company identify vulnerable individuals or groups?
Alternatives:
• Can the research be carried out in a non-vulnerable group? (Helsinki,
2013)
Protection:
• What guidelines has the company established to protect vulnerable
persons?
• Does the company comply with the laws concerning research with
vulnerable persons? If no such legislation exists in the context where the
research is being conducted (host community), what does the company
do?
Benefits:
• Does the vulnerable group stand to benefit from the knowledge,
practices or interventions that result from the research? (Helsinki, 2013)
• Is the medical research with a vulnerable group responsive to the health
needs or priorities of this group? (Helsinki, 2013)

Article 8, “Respect for human vulnerability and personal integrity,” connects seamlessly
to the previous Article due to the issue of vulnerability. The etymology of “vulnerability” is
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Latin, coming from the word vulnus, which means “wound”. Hence, “vulnerability” is defined as
the ability or susceptibility of being wounded.82 Everyone at one time or another is in a
vulnerable state, such as infants, and vulnerability is the general predicament of humans, while
autonomy is the exception.83 It could be argued that a chief aim of the Nuremberg Code was to
protect vulnerable persons from the harms of scientific research. One enduring quandary is how
to define a vulnerable person. The US Department of Health and Human Services provides extra
protections in its federal research guidelines for vulnerable persons, which it defines as children,
pregnant women, fetuses, and prisoners.84 However, is this encompassing enough? How the
company defines vulnerable persons, and the protections they have in place to ensure they are
safeguarded, is a necessary initial step to implement this principle.
The notion of personal integrity refers to the state of keeping one intact or not affecting a
person physically or psychologically. At the biomedical level it means that persons are entitled to
a negative right (a right of non-interference) that demands respect and reverence from others.85
Maria Patrão Neves has astutely recognized that,
The principle of vulnerability requires the recognition that the exercising of autonomy
and the giving of consent do not eliminate vulnerability which, subtly and surreptitiously,
is still susceptible to exploitation, for example through optimistic presentation of clinical
trials, for whom volunteers are needed, or the compensation offered to them, such as free
medical examinations and clinical assistance, or by the exaggeration of biomedical
successes in the media.86
Pharmaceutical and biotechnology companies must not only be aware of this, but must actively
work to combat such assaults on personal integrity and abuses of vulnerable persons. Therefore,
describing how the company seeks to define vulnerability and ensure that vulnerable persons are
protected and their personal integrity kept intact is vital for the indicators of this Article.
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Article 9 – Privacy and Confidentiality
UNESCO
UDBHR

Indicators:

The privacy of the persons concerned and the confidentiality of their
personal information should be respected. To the greatest extent possible,
such information should not be used or disclosed for purposes other than
those for which it was collected or consented to, consistent with
international law, in particular international human rights law.
Risk:
• What are the risks of the infringement of privacy?
• What is the risk of infringement of personal data?
Measures:
• What measures does the company take in order to maintain the right to
privacy of participants in human research?
• How is it ensured that information is only shared or disclosed as it has
been specified in the consent?

Article 9 states that the privacy and confidentiality of persons should be respected and
protected. Confidentiality in the realm of bioethics refers to the unique and oftentimes fiduciary
relationship between researcher/subject and doctor/patient, and specifies that the personal
information of the participant or patient shall remain undisclosed unless a strictly defined,
compelling interest justifies disclosure.87 Any aspect of the proposed research study that touches
on the privacy of the participant must be carefully explained, and any invasion of privacy must
be fully agreed upon by the participant and limited only to the needs of the study.88
Research into pharmacogenomics illustrates a current application of Article 9.
Pharmacogenomics is relatively novel field that investigates how genes affect a person’s
response to drugs.89 The goal of pharmacogenomics is to tailor treatments to the genetic makeup
of the individual, which allows for personalized care with maximized therapeutic drug response
and minimized adverse reactions. Pharmacogenomics aims to study the complete spectrum of
genes that are involved in determining a person’s response to a medication. Hence, studies into
pharmacogenomics require large databases of genomic profiles, which present new privacy
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challenges in the years ahead due to the scale of having comprehensive genetic makeups on
file.90 Companies will have to learn how best to navigate these challenges without compromising
the privacy of individuals. In dialogue with numerous companies, specific questions could be
crafted to more precisely aim at tackling these challenges.
Article 10 – Equality, justice and equity
UNESCO
UDBHR
Indicators:

The fundamental equality of all human beings in dignity and rights is to
be respected so that they are treated justly and equitably.
• How does the company manage scarce resources in order to guarantee
a just and equitable healthcare system?
• How does the company ensure certain groups are not under- or overrepresented in research?
• How does the company ensure that groups and communities are
invited to participate in a way that the burden and benefits are equitably
distributed?
• Will the participants, to the best of the company’s knowledge, be able
to afford the product when marketed without it being of significant
burden?
• How do the investigators ensure the research is fair to the subject?

One of the hallmarks of modern-day clinical trials is that they are often conducted in
LMICs. This brings to the forefront questions of equality, justice, and equity. These three terms
are often used interchangeably. Though they are closely related, they should not be confused and
simply amalgamated. Justice is a complex term that has been described in different ways. Justice
has received much attention in contemporary philosophical thought, due in no small part to the
work of John Rawls.91 Justice as fairness is the central motif of Rawls’ conception of justice,
which is a political conception and not intended as the application of a general moral conception
to the structure of society.92 Aristotle has at least two meanings for the word “just”. In its first
meaning, “just” is used to describe a conduct in agreement with the law. Hence, it is a conduct
that conforms to an established, authoritative rule of human conduct. In its second meaning,
“justice” signifies equality or a fair mean.93 Aristotle also espoused what has been known as a
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principle of formal justice (or formal equality): equals must be treated equally, and unequals
must be treated unequally.94 Hence, all persons must be treated in accordance with their merits,
which forms the idea of distributive justice. Gabriel d’Empaire notes that this concept of
distributive justice dominated until the modern era when it began to change. Today, distributive
justice, in pragmatic terms, is largely based on how a society ought to allocate its resources
among individuals who have competing needs but without taking into account their merits. It is
commonly accepted today that basic needs have to be awarded to everybody, not as a charity, but
as a right based on justice.95
In bioethics, and of importance for the pharmaceutical and biotechnology industry,
distributive justice becomes more significant under conditions of scarcity. In today’s world there
is rapid development of technology with the possibility for serious limitations on its fair use. As
d’Empaire recognizes, “This contrast becomes more evident when a serious intention of
achieving equality, equity, and justice is made in a time in which biotechnology should be taken
into account in a scenario of scarce resources.”96 Hence, distributive justice is a greatly important
concept in bioethics and for the pharmaceutical and biotechnology industry and should be
thoughtfully considered in dialogue with various stakeholders.
Aristotle generally equated justice to equity:
What is just, then, and what is equitable are generally the same, and both are good,
though what is equitable is better (Aristotle, 2004: 121).97
For Rawls, equity is a basic and necessary requirement in terms of justice. Equity is said to exist
when all participants freely define and accept the rules, benefits, and charges. Equality is a more
recent principle, though it has become fundamental in the context of human rights. No two
human beings are precisely physically, mentally, psychologically, or genetically equal. Nor is
humankind equal in terms of values or principles they hold. Nonetheless, it is generally accepted
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and desirable that all humanity, regardless of merit or opportunity, be considered equals in terms
of dignity, justice, and rights.98
New technologies, therapies, and drugs are constantly in various stages of development
by the pharmaceutical and biotechnology industry. This new reality needs a new way of
addressing the equality, justice, and equity issues that will naturally arise. This points to the
importance of both the indicators and the process of relevant stakeholders dialoguing on these
issues.
Article 11 – Non-discrimination and non-stigmatization
UNESCO
UDBHR
Indicators:

No individual or group should be discriminated against or stigmatized
on any grounds, in violation of human dignity, human rights and
fundamental freedoms.
• How does the company take care to avoid the systematic development
of medicines for one group within a population to the neglect of others?
• When conducting clinical trials, does the company discriminate or
stigmatize certain populations or genders so that they are underrepresented in research?
• Does the company have a grievance procedure for handling allegations
of discrimination and stigmatization?

Article 11 prohibits the discrimination and stigmatization of individuals and groups that
would violate human dignity, rights, and freedoms. Discrimination is a legal concept that has
longstanding tradition within human rights law, and stigmatization is a more recent construct in
the field of human rights law.99 Non-discrimination and non-stigmatization is also found in the
UNESCO International Declaration on Human Genetic Data (2003). Article 7 stipulates:
(a) Every effort should be made to ensure that human genetic data and human proteomic
data are not used for purposes that discriminate in a way that is intended to infringe, or
has the effect of infringing human rights, fundamental freedoms or human dignity of an
individual or for purposes that lead to the stigmatization of an individual, a family, a
group or communities.
(b) In this regard, appropriate attention should be paid to the findings of population-based
genetic studies and behavioural genetic studies and their interpretations.100
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Hence, this Article addresses discrimination and stigmatization resulting from developments in
behavioral genetic studies, which is certainly appropriate for the pharmaceutical and
biotechnology industry.
However, the UDBHR Article can also be applied more broadly. There is of course no
definitive, exhaustive list of discriminatory or stigmatizing practices that can be listed in order
for companies to avoid. Nonetheless, some particular practices stand out and should be
addressed. In the context of biomedical research, the selection of research subjects should not be
influenced by a belief that members of a given group are less deserving of protection from the
risks associated with research than others. Additionally, this Article is applicable to aspects of
gender bias or ethnic prejudice.101 In UNESCO’s Report of the IBC on the Principle of Nondiscrimination and Non-stigmatization, the IBC states that there are several persistent problem
areas for non-discrimination and non-stigmatization. These include neglected tropical diseases,
HIV/AIDS, and organ donation, transplantation, and trafficking. Further, emerging problems
include biobanks, nanotechnology, and developments in the field of neuroscience.102 This list is
not exhaustive, but it provides pharmaceutical and biotechnology companies with areas for
reflection. Finally, a system of due diligence for reporting and handling allegations of
discrimination and stigmatization should be present.
Article 12 – Respect for cultural diversity and pluralism
UNESCO
UDBHR

Indicators:

The importance of cultural diversity and pluralism should be given due
regard. However, such considerations are not to be invoked to infringe
upon human dignity, human rights and fundamental freedoms, nor upon
the principles set out in this Declaration, nor to limit their scope.
• In clinical trials with human research participants, how does the
company handle cultural differences regarding informed consent?
• When doing business in an unfamiliar cultural milieu, how does the
company approach these cultural differences?
• Does the company provide training for its employees on issues of
cultural diversity and pluralism?
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Article 12 of the UDBHR concerns the respect of cultural diversity and pluralism. In an
era where clinical trials have gone global, often sponsored by Western HICs and carried out on
populations in LMICs, this principle is of heightened importance. Reasons to conduct studies in
LMICs rather than in the sponsor’s home country include reduced expense, faster recruitment of
participants, less strict regulations, and simply because it has often been in LMICs that certain
disease outbreaks have occurred that as of yet have no treatment and companies want to test their
products.103 It is against this backdrop that pharmaceutical and biotechnology companies
regularly operate, and respect for cultural diversity and pluralism must be on their radar.
To instrumentalize this Article, indicators inquiring about what the company does in
regards to performing clinical trials in different cultures were created. Those who are involved in
the business aspects of the company in a different cultural context, including those tasked with
carrying out clinical trials (such as consenting people) should be trained on what is appropriate
for that setting, and some sort of education process should be ongoing, for cultures are not static.
There is no “one-size-fits-all” approach to this type of training, for each culture will differ and
have different nuances. Yet, a company should be striving to respect the culture in which they
work, and a first step of this is to understand that culture.
Article 13 – Solidarity and cooperation
UNESCO
UDBHR
Indicators:

Solidarity among human beings and international cooperation towards
that end are to be encouraged.
• How is the company working towards capacity-building in the area of
public and global health?
• How is the company contributing to the UN Sustainable Development
Goals?

This proposed global bioethics tool rests in part upon the premise that pharmaceutical and
biotechnology companies ought to work together, in solidarity and cooperation, on bioethics
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matters in order to have a greater impact. Solidarity and cooperation work on numerous levels.
There is the obvious level of work done between companies, as just mentioned, but there is also
partnership between a company and a particular geographical context or towards an area of
public concern. The work of capacity-building in public and global health is one area that is ripe
for the aid of the pharmaceutical industry. Further, the UN has 17 Sustainable Development
Goals that they want to see accomplished by the year 2030.104 Companies may consider how
they are contributing to these goals for the betterment of the entire world.
Solidarity can also be applied in the area of access to drugs. At the September 2010
Belgian EU presidency conference on “Innovation and Solidarity in Pharmaceuticals” held in
Brussels, the conference concluded with a call to make valuable innovative medicines accessible
in the EU, which also contained recommendations for coordinated action to stimulate, measure
and valorize pharmaceutical innovation.105 There are calls from the political sphere for greater
cooperation between states on achieving access to certain medicines.106 The pharmaceutical
industry would be prudent to take further steps on access to medicines and be seen as working
towards solidarity and cooperation, rather than have more regulations forced upon them
externally.
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Article 14 – Social responsibility and health
UNESCO
UDBHR

Indicators:

1. The promotion of health and social development for their people is a
central purpose of governments that all sectors of society share.
2. Taking into account that the enjoyment of the highest attainable
standard of health is one of the fundamental rights of every human
being without distinction of race, religion, political belief, economic or
social condition, progress in science and technology should advance:
(a) access to quality health care and essential medicines, especially for
the health of women and children, because health is essential to life
itself and must be considered to be a social and human good;
(b) access to adequate nutrition and water;
(c) improvement of living conditions and the environment;
(d) elimination of the marginalization and the exclusion of persons on
the basis of any grounds;
(e) reduction of poverty and illiteracy.
Promotion of Health and Social Development:
• How does the company aim to promote health and social
development?
• Article 14 states that “all sectors of society share” in the promotion of
social responsibility and health. How does the company seek to address:
1) access to quality health care and essential medicines, 2) access to
adequate nutrition and water, 3) the improvement of living conditions
and the environment, 4) the elimination of the marginalization and the
exclusion of persons on the basis of any grounds, and 5) the reduction of
poverty and illiteracy?
Relationship to Developing Countries:
• Does the company have differential pricing policies so that lower
income countries pay lower prices for essential medicines than higher
income countries?
• Does the company invest in research and development for diseases that
primarily affect lower income countries?
• Does the company have policies on access to treatment for developing
countries, including the five priorities of pricing, patent, joint public
private initiatives, R&D, and the appropriate use of drugs?

Social responsibility and the public perception of the pharmaceutical industry has already
been discussed at length earlier in this dissertation. Much has been written on incorporating
corporate social responsibility into pharmaceutical and biotechnology companies, and we must
bear in mind that these are primarily moral rather than legal obligations. One of the main
contexts for the concept of social responsibility to be applied is undoubtedly in the healthcare
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context, with the protection and promotion of human health.107 The IBC released a report on
Article 14 in 2010 detailing a number of ways in which the Article can be applied to the
pharmaceutical industry. Ways that the Article may apply to the industry, according to the IBC,
include in tackling global health crises, drug patents, and pricing.108
The indicators that have been developed for this Article aim at discerning how the
company is promoting health and social development, as well as the dealings of the company in
developing countries. Stefano Semplici has asserted that within Article 14 it is implicit that no
actual promotion of health for humankind is possible without also making development of the
whole society a pivotal issue.109 Hence, capacity building is an important feature of social
responsibility in this view, just as it was important in the preceding Article. This is an area that
will need increased attention, as capacity building is currently lacking. What is more, another
area that merits increased attention is that of research into diseases that are not likely to be highly
profitable for the pharmaceutical and biotechnology industry. Both the private and public sector
carry out research on diseases with the aim of curative therapies. The majority of scientific
development is driven by interest in potential financial reward rather than potential social
benefits or an inclination towards social responsibility.110 Yet, if the vision of social
responsibility in the UDBHR is to be instrumentalized, greater dialogue on research into less
profitable diseases, such as tropical diseases or so-called “orphan disases”, will need to be
carried out.
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Article 15 – Sharing of benefits
UNESCO
UDBHR

Indicators:

1. Benefits resulting from any scientific research and its applications
should be shared with society as a whole and within the international
community, in particular with developing countries. In giving effect to
this principle, benefits may take any of the following forms: (a) special
and sustainable assistance to, and acknowledgement of, the persons and
groups that have taken part in the research; (b) access to quality health
care; (c) provision of new diagnostic and therapeutic modalities or
products stemming from research; (d) support for health services; (e)
access to scientific and technological knowledge; (f) capacity-building
facilities for research purposes; (g) other forms of benefit consistent
with the principles set out in this Declaration.
2. Benefits should not constitute improper inducements to participate in
research.
Sharing of Benefits:
• How does the company ensure that the benefits resulting from its
scientific research are shared with society as a whole?
• When conducting clinical trials, does the company ensure that in
advance of the trial, provisions are made for post-trial access for all
participants who still need an intervention identified as beneficial in the
trial? (DoH, Article 34, 2013)
• If the company is involved in bioprospecting, how does it ensure that
indigenous knowledge and resources have been respected?
Undue Inducement:
• How does the company ensure against improper inducements to
participate in research?

Article 15 concerns the principle of sharing of benefits. Sharing of benefits, which has
alternatively been called benefit sharing, has been described in numerous manners and has
received greater attention in the past several years. The Convention on Biological Diversity,
adopted in 1992 at the UN Conference on Environment and Development, is a multilateral treaty
with three major aims: 1) the conservation of biodiversity, 2) the sustainable use of the
components of biodiversity; and 3) the fair and equitable sharing of benefits arising from genetic
resources. A supplementary agreement, the Nagoya Protocol, was adopted in 2010 and
specifically addressed genetic resources and the sharing of benefits arising from their
utilization.111 Since this time, much has been written on benefit sharing. A very simple definition
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of benefit sharing that has been proposed by Doris Schroeder states that, as a matter of justice,
those who contribute to scientific research ought to share in its benefits.112 This definition
slightly differs from Article 15, which indicates that scientific advances should not only benefit a
select group, but all humanity should benefit.
For this Article, indicators on benefit sharing and undue inducement were created that
tried to encapsulate both the UDBHR definition and more recent definitions, such as the one of
Schroeder. There are many applications of Article 15 to pharmaceutical and biotechnology
companies. Perhaps one of the most well known cases surrounding the type of benefit sharing
that Schroeder describes is that of the San people of Southern Africa and the traditional
knowledge they possessed about the Hoodia plant—a plant they had used for centuries to quench
thirst that also possibly had appetite suppression qualities. Hoodia and the plight of the San
peoples became a showcase of the challenges encountered by indigenous communities when
faced with bioprospecting of a major pharmaceutical company trying to bring Hoodia to
market.113 Hence, the indicators for Article 15 have been created with both the description of
sharing of benefits provided by the UDBHR and the usage that is more common today in mind.
Finally, benefit sharing is not often discussed without also discussing undue inducement,
which is also known as undue influence. The Belmont Report states,
Undue influence…occurs through an offer of an excessive, unwarranted, inappropriate or
improper reward or other overture in order to obtain compliance. Also, inducements that
would ordinarily be acceptable may become undue influences if the subject is especially
vulnerable.114
Undue influence could potentially arise in a clinical trial situation when a company offers
participants excessive rewards for their participation, or when persons view the company or its
representatives as persons in a position of authority or commanding influence over them. It is
important to note that not all incentives to participate in research are viewed as unethical.
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UNESCO’s International Bioethics Committee (IBC) in its Report on the Principle of Benefit
Sharing has suggested,
[W]hat characterizes inducement as improper is that the offer has the potential to
undermine a person’s ability to make a free choice and causes her or him to accept certain
risks imposed by participation against her or his better judgment. What is of relevance is
not the attractiveness of an offer but the potential of the offer to undermine the subjects’
ability to evaluate the situation as well as the risks that it could entail.”115
According to this understanding, three elements must then be taken into account when
determining whether an inducement is proper or improper. The first element is the nature and
seriousness of the risks that have the potential of impacting the participant. Physical or bodily
harms are only one aspect for consideration. Risks to privacy or moral integrity may be just as
important as physical harm, and therefore must also be considered. The second element to be
considered is the impact of an offer on the decision-making process of the research participant.
What may appear as an autonomous decision of the participant on the surface may in fact be
caused by the circumstances that they face, such as a need or desire for healthcare. The third
element of consideration, according the IBC, is veracity on the possible benefits of participating.
Inappropriate or misleading information provided to research participants on any possible
benefits can lead to improper inducement, for it may make the participant more willing to
consent. Hence, this is why the IBC states, “It is important to ensure that patients participating in
research are not victims of a therapeutic misconception or mis-estimation, where they overestimate the benefits they might gain from the research or under-estimate possible harms.”116
To conclude this Article, benefit sharing and the avoidance of undue inducement are ethical
obligations that may, to some, be difficult to align. Though this belief is held by some, other
commentators have concluded that the fear of undue inducement must not lead to neglecting
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benefit sharing.117 Hence, companies must look for ways to fulfill the moral obligation of benefit
sharing while also avoiding undue inducement.
Article 16 – Protecting future generations
UNESCO
UDBHR
Indicators:

The impact of life sciences on future generations, including on their
genetic constitution, should be given due regard.
• In bioethical decision-making, does the company take into account the
impact on the present generation and also try to evaluate the impacts on
future generations?
• If the company is involved in research on human genomic information,
how does the company ensure that such new technology will not result
in undesired outcomes for future generations?
• How does the company evaluate any possible influence a test
compound can have on genes or germ cells?

Article 16 is a very unique principle that the drafters of the UDBHR felt was imperative
to include.118 The Article broadly claims that due regard in the advancement of the life sciences
should be given to future generations, and specific regard is given to issues of genetics. Recently,
the content of this Article has come to the forefront with CRISPR-Cas9 technology. This
technology provides the potential for treating myriad diseases and also editing genes of human
embryos.119 Such edits would then be passed down to any progeny, having lasting effects, and
creating the potential for undesirable consequences. The bioethical decision-making process,
therefore, should not merely take into account the bearing on the present generation, but also try,
to the best of its abilities, to evaluate impacts on future generations. In the context of rapidly
developing medical technologies that have the potential to alter gene lines, scientists coming
from the healthcare milieu should not be the only ones involved in the decision-making process.
With the potential for mammoth implications on future generations, broad spectrums of
stakeholders should be involved in the process to contribute to the decisions, including social
scientists and even the general public. The necessity to examine thoughtfully the implications of
such monumental advances in biomedical technology should not be taken lightly.
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This concept is very similar to that of the “common heritage of mankind”—the juridical
notion that there are “common space areas” which no one can own though are hypothetically
managed by all.120 In the concept of common heritage, no single company or country owns the
rights to certain areas, but rather they are entrusted to the current age of humanity and to be
passed on to future generations, hopefully in an unaltered state. Hence, there is a forwardlooking aspect to common heritage, just as this Article is very much forward-looking. As
medical technology constantly advances, this Article may prove to be of immense importance in
guiding companies on their conduct and research in the decades to follow.

UNESCO
UDBHR

Article 17 – Protection of the environment, the biosphere and
biodiversity
Due regard is to be given to the interconnection between human beings
and other forms of life, to the importance of appropriate access and
utilization of biological and genetic resources, to respect for traditional
knowledge and to the role of human beings in the protection of the
environment, the biosphere and biodiversity.
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Indicators:

Impact on Environment:
• As it has been recognized that the company has a responsibility to
protect the environment, how does the company prevent advances in
molecular biology, recombinant technology, genetics, biotechnology,
and other advances from negatively impacting the environment?
• Does the company participate in the development of new technologies
that pose risk of irreversible damage to the environment?
• Does the company have in place emergency guidelines in the event of
an accident affecting the environment?
• Does the company minimize the use of chemicals and other dangerous
substances, as well as ensuring their safe handling and storage?
• If applicable to the business, does the company encourage the
development and use of environmentally friendly technologies?
Biosphere:
• How does the company seek the protection of experimental animals?
(cf Article 4)
• How does the company seek to eliminate the need for using animals in
research?
• How does the company seek to protect and promote the welfare on the
animals used in research?
Impact on Biodiversity:
• Does the company prevent, minimize and remedy impacts on
biodiversity?

Potter’s envision for global bioethics was of a discipline that married the biological
sciences with the rest of the created world. The inclusion of Article 17 on the protection of the
environment, biosphere, and diversity moves us closer to that vision. It is indisputable that there
are linkages between human activity and environmental issues. Global environmental concerns
require the cooperation of many actors and necessitate local action steps to be taken.121 For
example, the UN’s 2015 Paris Climate Change Conference brought together representatives from
195 countries to agree on steps to deal with greenhouse gas emissions.122 This large cohort of the
world’s countries has to take local action steps in order to see cumulative and lasting change.
Hence, having the pharmaceutical and biotechnology industry work in tandem to create lasting
change on areas where their business intersects with the environment seems advantageous.
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Prakash Tandon has asserted that it is essential that safeguarding the capacity of
ecosystems go hand in hand with the improvement of living standards and the promotion of
human flourishing and development, which includes the introduction of any advances of science
and technology for this purpose.123 The indicators that were created for this final principle
attempted to address the environment, biosphere, and biodiversity. As humanity learns more
about how we impact the world around us, these indicators will surely need to be revisited and
revised. Nonetheless, this principle showcases that when assessing the ethical implications of any
biological research or biotechnology, it is imperative to take into account not only its utility for
human welfare, but also its overall impact on the ecosystem.124
To conclude this chapter, it is worth recapping what chapter five has covered and
consider further the future direction of the global bioethics tool. Section 5.1 initially began by
looking at the history and development of the proposed global bioethics tool. This then moved
into a discussion of benchmarking. Prominent persons in the field of benchmarking, including
their theories, were presented and examined. A brief case study utilizing Camp’s model of
benchmarking and how this could be applied within the global bioethics tool was demonstrated.
It was established that Camp’s model of benchmarking is very instructive and could very well be
utilized to benchmark both companies and processes on their implementation of human rights
and bioethics. This is not to say that Camp’s model may not need tweaking, rather we should
view the model of Camp as an initial starting point from which the cohort of companies
comprising the global bioethics tool can then adjust as is best. The criticism of benchmarking
was also presented in 5.1, and rebuttals to the critiques were provided.
Finally, the Corporate Human Rights Benchmark (CHRB) was briefly discussed as a way
of demonstrating that it is possible to benchmark companies on their human rights approach. The
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CHRB is a very interesting endeavor that is just now getting off the ground and becoming
established. It will be curious in the years to come to see the results of this endeavor. As there are
many potential points of intersection between the CHRB and the global bioethics tool, it would
be worth exploring in the future areas of partnership and collaboration between the two
organizations.
Section 5.2 presented the global bioethics tool, including the indicators in the form of
questions that have been created for each of the fifteen principles (Articles 3-17) of the
UNESCO Universal Declaration on Bioethics and Human Rights. A section of commentary was
also provided for each of the Articles detailing how the indicators were created and why they are
important for the pharmaceutical and biotechnology industry. It is worth noting again that these
indicators will continue to be a work in progress. In the field of software development, a piece of
software is said to be in the “beta” phase when it has all of its primary features yet is likely to
contain a number of known and/or unknown flaws. The global bioethics tool is in such a stage of
its lifespan development. The indicators need to be tried and tested, deliberated on with
additional stakeholders, and further refined. Further, new indicators will surely need to be
created in the years to come. The future of medicine and technology is uncertain, as new
discoveries are constantly somewhere in the process of taking place. Bioethics must rise to meet
the new challenges presented by innovations in medicine and technology, and the global
bioethics tool must also arise to this challenge. In this way, the global bioethics tool is a living
tool; it is not static, but dynamic. Nonetheless, the indicators in their extant state present a
snapshot of how the UDBHR could be utilized to enhance the human rights and bioethics
interests of the pharmaceutical and biotechnology industry. In the following chapter we will
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apply these indicators to real-world companies to show the feasibility of the global bioethics
tool.
There are several steps that would have to be completed in order to see the proposed
global bioethics tool actually be put into practice for the pharmaceutical and biotechnology
industry. First, a smaller cohort of pharmaceutical and biotechnology companies would need to
partner together and resolve to further develop and implement the global bioethics tool.
UNESCO’s bioethics unit would also be involved if they would so choose to be. This smaller
cohort of companies would take the lead in initially overseeing the tool. Second, a pilot run of
the tool with this small cohort of companies would seem advisable. The cohort of companies
would need to each answer the indicators and then perform the benchmarking process on smaller
scale. Representative from each company would then all meet together in order to discuss the
outcomes of the pilot run. This pilot run would demonstrate to stakeholders the viability of the
tool and seek to remedy any apparent issues that may arise. Third, the cohort would then seek
expansion by inviting additional companies to join. All along this process then publicity around
the global bioethics tool would seek to be generated. This would involve giving interviews for
news outlets and publishing articles for academic journals and scholarly conferences on the
proposed tool.
These are merely preliminary steps that would need to take place in order to witness the
global bioethics tool be implemented in the pharmaceutical and biotechnology industry. These
steps may seem insurmountable, yet it would only take a handful of large companies in the
beginning to initiate this process and demonstrate to the rest of the industry the value of such a
tool.

244

Endnotes
1
Business for Social Responsibility, accessed November 1, 2016, available at: https://www.bsr.org/en/
2
IPIECA, accessed November 1, 2016, available at: http://www.ipieca.org
3
Jennifer E. Miller, “From Bad Pharma to Good Pharma: Aligning Market Forces with Good and Trustworthy
Practices through Accreditation, Certification, and Rating,” Journal of Law, Medicine & Ethics (Fall 2013): 601-10.
4
Miller, “From Bad Pharma to Good Pharma: Aligning Market Forces with Good and Trustworthy Practices
through Accreditation, Certification, and Rating,” 605.
5
Roy H. Perlis, Clifford S. Perlis, Yelena Wu, Cindy Hwang, Megan Joseph, and Andrew A. Nierenberg, “Industry
Sponsorship and Financial Conflict of Interest in the Reporting of Clinical Trials in Psychiatry,” American Journal
of Psychiatry 162, no. 10 (2005): 1957–60.
6
Ben Goldacre, Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients, (New York: Farrar,
Straus, and Giroux, 2013).
7
Miller, “From Bad Pharma to Good Pharma: Aligning Market Forces with Good and Trustworthy Practices
through Accreditation, Certification, and Rating,” 605.
8
Miller, “From Bad Pharma to Good Pharma: Aligning Market Forces with Good and Trustworthy Practices
through Accreditation, Certification, and Rating,” 605.
9
C. Lee Ventola, “Direct-to-Consumer Pharmaceutical Advertising,” Pharmacy & Therapeutics 36, no. 10 (2011):
669-74, 681-84.
10
American Medical Association, “AMA Calls for Ban on DTC Ads of Prescription Drugs and Medical Devices,”
November 17, 2015, accessed February 15, 2017, available at:
https://www.ama-assn.org/content/ama-calls-ban-direct-consumer-advertising-prescription-drugs-and-medicaldevices
11
Ashish Parekh, Roland Marcus, Melissa Roberts, and Dennis W. Raisch, “Risks and Benefits of Direct To
Consumer Advertising On Patient-Provider Relationships–Report of the ISPOR Direct to Consumer Advertisements
Working Group,” ISPOR Connections 18, no. 6 (2012), available at:
https://www.ispor.org/news/articles/june12/risks-and-benefits-of-direct-to-consumer.asp
12
Miller, “From Bad Pharma to Good Pharma: Aligning Market Forces with Good and Trustworthy Practices
through Accreditation, Certification, and Rating,” 605-6.
13
G. Anand and Rambabu Kodali, “Benchmarking the Benchmarking Models,” Benchmarking: An International
Journal 15, no. 3 (2008): 258.
14
Dean Elmuti and Yunus Kathawala, “An Overview of Benchmarking Process: A Tool for Continuous
Improvement and Competitive Advantage, Benchmarking for Quality Management & Technology 4, no. 4 (1997):
229.
15
N. Lema, and A. D. F. Price, “Benchmarking: Performance Improvement Toward Competitive Advantage,”
Journal of Management in Engineering 11, no. 1 (1995): 28-37.
16
Gregory H. Watson, Strategic Benchmarking Reloaded with Six Sigma: Improving Your Company’s Performance
Using Global Best Practice, (Hoboken: John Wiley & Sons, 2007), xxiv.
17
Clinical Improvement Action Guide, ed. Eugene C. Nelson, Paul B. Batalden, and Jeanne C. Ryer, (Oakbrook
Terrace, IL: Joint Commission on Accreditation of Healthcare Organizations, 1998), 77-79.
18
Graham Francis and Jacky Holloway, “What Have We Learned? Themes from the Literature on Best-Practice
Benchmarking,” International Journal of Management Reviews 9, no. 3 (2007): 172-73.
19
Corporate Human Rights Benchmark, “Pilot Methodology 2016,” accessed February 15, 2017, available at:
https://business-humanrights.org/sites/default/files/CHRB_report_06_singles.pdf
20
J. J. Graafland, S. C. W. Eijffinger, and H. Smid, “Benchmarking of corporate social responsibility:
Methodological problems and robustness,” MPRA, 5-7.
21
Elmuti and Kathawala, “An Overview of Benchmarking Process: A Tool for Continuous Improvement and
Competitive Advantage, 229.
22
Elmuti and Kathawala, “An Overview of Benchmarking Process: A Tool for Continuous Improvement and
Competitive Advantage, 229-43.
23
Robert C. Camp and Arthuer G. Tweet, “Benchmarking Applied to Health Care,” Journal on Quality
Improvement 20, no. 5 (1994): 229-38.
24
Robert C. Camp, Business Process Benchmarking: Finding and Implementing Best Practices, (Milwaukee: ASQC
Quality Press, 1995).
25
Camp, Business Process Benchmarking: Finding and Implementing Best Practices, 65-66.

245

26

Robert C. Camp, Benchmarking: The Search for Industry Best Practices that Lead to Superior Performance,
(Milwaukee: ASQC, 1989), 151.
27
Camp, Benchmarking: The Search for Industry Best Practices that Lead to Superior Performance, 175.
28
Camp, Benchmarking: The Search for Industry Best Practices that Lead to Superior Performance, 186.
29
Camp, Benchmarking: The Search for Industry Best Practices that Lead to Superior Performance, 205-6.
30
Camp, Benchmarking: The Search for Industry Best Practices that Lead to Superior Performance, 217.
31
Camp, Benchmarking: The Search for Industry Best Practices that Lead to Superior Performance, 227-32.
32
Camp, Benchmarking: The Search for Industry Best Practices that Lead to Superior Performance, 241.
33
Camp and Tweet, “Benchmarking Applied to Health Care,” 230-31.
34
Camp, Business Process Benchmarking: Finding and Implementing Best Practices, Press, 80-81.
35
Camp and Tweet, “Benchmarking Applied to Health Care,” 231.
36
Camp and Tweet, “Benchmarking Applied to Health Care,” 231.
37
Michael J. Spendolini, The Benchmarking Book, (New York: Amacom Books, 1992).
38
Gregory H. Watson, Strategic Benchmarking, (New York: John Wiley & Sons, 1993).
39
Mohamed Zairi, Benchmarking for Best Practice: Continuous Learning Through Sustainable Innovation,
(Oxford: Butterworth-Heinemann, 1998).
40
Dawn Iacobucci and Christie Nordhielm, “Creative Benchmarking,” Harvard Business Review, (NovemberDecember 2000).
41
Anand and Kodali, “Benchmarking the Benchmarking Models,” 269.
42
United States Patent and Trade Office, Benchmarking Workbook, September 2000, accessed February 15, 2017,
available at: https://www.uspto.gov/web/offices/com/oqm-old/benchmarking_workbook_9_00.pdf
43
Mohamed Zairi, “Benchmarking for Quality Management & Technology,” Benchmarking for Quality
Management & Technology 1, no. 1 (1994): 11-24.
44
Mohamed Zairi, Practical Benchmarking: The Complete Guide, (Dordrecht: Springer, 1996).
45
Iacobucci and Nordhielm, “Creative Benchmarking,” Harvard Business Review, (November-December 2000).
46
Andrew Campbell, “Tailored, not benchmarked: A fresh look at corporate planning,” Harvard Business Review,
77, no. 2 (1999): 41-50.
47
Metin Kozak and Kevin Nield, “An Overview of Benchmarking Literature: Its Strengths and
Weaknesses,” Journal of Quality Assurance in Hospitality & Tourism 2, no. 3/4 (2001): 7-32.
48
Watson, Strategic Benchmarking.
49
J. P. Moriarty, “A Theory of Benchmarking,” (doctoral dissertation, Lincoln University, 2008).
50
Robert Pederson, “The perils of TQM for the academy,” The Chronicle of Higher Education 39(S) (1992): B4.
51
Michael Hammer and James Champy, Reengineering the Corporation: A Manifesto for the Business Revolution,
(New York: Harper Collins, 1993).
52
Julie R. Wolfram Cox, Leon Mann, and Danny Samson, “Benchmarking as a mixed metaphor: Disentangling
Assumptions of Competition and Collaboration,” Journal of Management Studies, 34, no. 2 (1979): 285-314.
53
Karl W. Wöber, Benchmarking in Tourism and Hospitality Industries, (Wallingford, UK: CABI Publishing,
2002).
54
Corporate Human Rights Benchmark, accessed March 19, 2017, available at:
https://www.corporatebenchmark.org
55
S. Prakash Sethi, Emre A. Veral, H. Jack Shapiro, and Olga Emelianova, “Mattel, Inc., Global Manufacturing
(GMP): A Life-Cycle Analysis of a Company’s Voluntary Code of Conduct, in Globalization and Self-Regulation:
The Crucial Role that Corporate Codes of Conduct Play in Global Business, ed. S. Prakash Sethi, (New York:
Palgrave Macmillian, 2011) 17-18.
56
David Parmenter, Key Performance Indicators: Developing, Implementing, and Using Winning KPIs, 2nd ed,
(Hoboken: John Wiley & Sons, 2010), 4.
57
Carol T. Fitz-Gibbon, “Introduction and Overview,” in Performance Indicators, ed. Carol T. Fitz-Gibbon,
(Clevedon, Avon: Multilingual Matters Ltd., 1990), 1.
58
State of Victoria, Australia, Public Record Office, “Key Performance Indicators,” July 19, 2010, accessed October
9, 2016, available at: http://prov.vic.gov.au/wp-content/uploads/2011/05/1010g3.pdf
59
Henk ten Have and Michèle S. Jean, “Introduction,” in The UNESCO Universal Declaration on Bioethics and
Human Rights, ed. Henk ten Have and Michèle S. Jean, (Paris: UNESCO, 2009), 39.
60
UNESCO Universal Declaration on Bieothics and Human Rights, Article 15.
61
UNESCO, Second Session of the Intergovernmental Meeting of Experts Aimed at Finalizing a Draft Declaration
on Universal Norms on Bioethics, June 20-24, 2005, “Explanatory Memorandum on the Elaboration of the

246

Preliminary Draft Declaration on Universal Norms on Bioethics,” accessed February 28, 2017, available at:
http://portal.unesco.org/shs/en/files/8100/11175312051ExplanMemorandum_en.pdf/ExplanMemorandum_en.pdf
62
Roberto Andorno, “Human Dignity and Human Rights, in Handbook of Global Bioethics, ed. Henk ten Have and
Bert Gordijn, (Dordrecht: Springer, 2014), 49.
63
Roberto Andorno, “Human Dignity and Human Rights,” in The UNESCO Universal Declaration on Bioethics and
Human Rights, ed. Henk ten Have and Michèle S. Jean, (Paris: UNESCO, 2009), 95.
64
Immanuel Kant, Practical Philosophy, trans. Mary Gregor (Cambridge: Cambridge University Press, 1996), 429.
65
Edmund D. Pellegrino, “Benefit and Harm,” in The UNESCO Universal Declaration on Bioethics and Human
Rights, ed. Henk ten Have and Michèle S. Jean, (Paris: UNESCO, 2009), 103-4.
66
United States Food and Drug Administration, “Institutional Review Board Frequently Asked Questions—
Information Sheet,” accessed February 28, 2017, available at:
https://www.fda.gov/RegulatoryInformation/Guidances/ucm126420.htm
67
United States Department of Health and Human Services, Office of Research Integrity, “Conflicts of Interest,”
accessed February 28, 2017, available at:
https://ori.hhs.gov/education/products/columbia_wbt/rcr_conflicts/foundation/#1
68
Simon Festing and Robin Wilkinson, “The Ethics of Animal Research. Talking Point on the Use of Animals in
Scientific Research,” EMBO Reports 8, no. 6 (2007): 526–530.
69
PETA, “Animals Used for Experimentation,” accessed February 28, 2017, available at:
http://www.peta.org/issues/animals-used-for-experimentation/
70
Donald Evans, “Autonomy and Individual Responsibility,” in The UNESCO Universal Declaration on Bioethics
and Human Rights, ed. Henk ten Have and Michèle S. Jean, (Paris: UNESCO, 2009), 116-17.
71
O. Carter Snead and Kelli Mulder-Westrate, “Autonomy and Individual Responsibility,” in Handbook of Global
Bioethics, ed. Henk ten Have and Bert Gordijn, (Dordrecht: Springer, 2014), 79.
72
International Labour Organization, “Freedom of association and the effective recognition of the right to collective
bargaining,” accessed February 15, 2017, available at:
http://www.ilo.org/declaration/principles/freedomofassociation/lang--en/index.htm
73
Regine Kollek, “Consent,” in The UNESCO Universal Declaration on Bioethics and Human Rights, ed. Henk ten
Have and Michèle S. Jean, (Paris: UNESCO, 2009), 130-31.
74
Tom L. Beauchamp and James F. Childress, Principles of Biomedical Ethics, 7th ed. (Oxford: Oxford University
Press, 2013), 120-40.
75
Daniel Cressey, “Informed consent on trial,” Nature 482 (February 2, 2012): 16.
76
Cressey, “Informed consent on trial,” 16.
77
Steven Joffe, E. Francis Cook, Paul D. Cleary, Jeffrey W. Clark, and Jane C. Weeks, The Lancet 358, no. 9295
(2001): 1772–1777.
78
Cressey, “Informed consent on trial,” 16.
79
Kollek, “Consent,” in The UNESCO Universal Declaration on Bioethics and Human Rights, 134.
80
Jean F. Martin, “Persons without the Capacity to Consent,” in The UNESCO Universal Declaration on Bioethics
and Human Rights, ed. Henk ten Have and Michèle S. Jean, (Paris: UNESCO, 2009), 146.
81
Eugenijus Gefenas and E. Tuzaite, “Persons without the Capacity to Consent,” in Handbook of Global Bioethics,
ed. Henk ten Have and Bert Gordijn, (Dordrecht: Springer, 2014), 97-98.
82
Maria Patrão Neves, “Respect for Human Vulnerability and Personal Integrity,” in The UNESCO Universal
Declaration on Bioethics and Human Rights, ed. Henk ten Have and Michèle S. Jean, (Paris: UNESCO, 2009), 155.
83
Henk ten Have, Vulnerability: Challenging Bioethics, (Oxon: Routledge, 2016).
84
United States Department of Health and Human Services, “45 CFR 46,” accessed February 22, 2017, available at:
https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/index.html
85
Neves, “Respect for Human Vulnerability and Personal Integrity,” in The UNESCO Universal Declaration on
Bioethics and Human Rights, 159-60.
86
Neves, “Respect for Human Vulnerability and Personal Integrity,” in The UNESCO Universal Declaration on
Bioethics and Human Rights, 159-60.
87
UNESCO, Second Session of the Intergovernmental Meeting of Experts Aimed at Finalizing a Draft Declaration
on Universal Norms on Bioethics, June 20-24, 2005, “Explanatory Memorandum on the Elaboration of the
Preliminary Draft Declaration on Universal Norms on Bioethics.
88
Jean F. Martin, “Privacy and Confidentiality,” in Handbook of Global Bioethics, ed. Henk ten Have and Bert
Gordijn, (Dordrecht: Springer, 2014), 124.

247

89

National Institutes of Health, U.S. National Library of Medicine, “What is pharmacogenomics?” accessed
February 15, 2017, available at: https://ghr.nlm.nih.gov/primer/genomicresearch/pharmacogenomics
90
L. T. Vaszar, G. D. Rosen, and T. A. Raffin, “Pharmacogenomics and the challenge to privacy,” The
Pharmacogenomics Journal 2 (2002): 144-47.
91
John Rawls, A Theory of Justice, (Cambridge, MA: Belknap, 1971).
92
John Rawls, “Justice as Fairness: Political not Metaphysical,” Philosophy & Public Affairs 14, no. 3 (1985): 22351.
93
Anton-Hermann Chroust and David L. Osborn, “Aristotle’s Conception of Justice,” Notre Dame Law Review 17,
no. 2 (1942): 129-43.
94
Beauchamp and Childress, Principles of Biomedical Ethics, 250.
95
Gabriel d’Empaire, “Equality, Justice and Equity,” in The UNESCO Universal Declaration on Bioethics and
Human Rights, ed. Henk ten Have and Michèle S. Jean, (Paris: UNESCO, 2009), 173-74.
96
d’Empaire, “Equality, Justice and Equity,” in The UNESCO Universal Declaration on Bioethics and Human
Rights, 175.
97
d’Empaire, “Equality, Justice and Equity,” in The UNESCO Universal Declaration on Bioethics and Human
Rights, 175.
98
d’Empaire, “Equality, Justice and Equity,” in The UNESCO Universal Declaration on Bioethics and Human
Rights, 175.
99
Glenn Rivard, “Non-Discrimination and Non-Stigmatization,” in The UNESCO Universal Declaration on
Bioethics and Human Rights, ed. Henk ten Have and Michèle S. Jean, (Paris: UNESCO, 2009), 192-94.
100
UNESCO, “International Declaration on Human Genetic Data,” October 16, 2003, accessed February 15, 2017,
available at:
http://portal.unesco.org/en/ev.php-URL_ID=17720&URL_DO=DO_TOPIC&URL_SECTION=201.html
101
Rivard, “Non-Discrimination and Non-Stigmatization,” in The UNESCO Universal Declaration on Bioethics and
Human Rights, 196.
102
UNESCO, International Bioethics Committee, Report of the IBC on the Principle of Non-Discrimination and
Non-Stigmatization, (Paris: UNESCO, 2014).
103
Trudie Lang and Sisira Siribaddana, “Clinical Trials Have Gone Global: Is This a Good Thing?” PLoS:
Medicine, accessed February 15, 2017, available at:
http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001228
104
United Nations, “Sustainable Development Goals,” accessed March 1, 2017, available at:
http://www.un.org/sustainabledevelopment/sustainable-development-goals/
105
Council of the European Union, “Council Conclusions on Innovation and Solidarity in Pharmaceuticals, 3053rd
Employment, Social Policy Health and Consumer Affairs Council meeting Brussels,” 6 December 2010, accessed
February 15, 2017, available at:
https://www.consilium.europa.eu/uedocs/cms_data/docs/pressdata/en/lsa/118278.pdf
106
R. DeRidder, C. Adriaens, D. Kleinermans, M. Mortier, A. Quanten, and F. Arickx, “Mechanism of Coordinated
Access to Orphan Drugs,” Orphanet Journal of Rare Diseases 7, no. 2 (2012): A24, doi:10.1186/1750-1172-7-S2A24.
107
Stefano Semplici, “Social Responsibility and Health,” in Handbook of Global Bioethics, ed. Henk ten Have and
Bert Gordijn, (Dordrecht: Springer, 2014), 187-88.
108
UNESCO, Report of the International Bioethics Committee of UNESCO (IBC): On Social Responsibility and
Health, (Paris: UNESCO, 2010), 31-32.
109
Semplici, “Social Responsibility and Health,” in Handbook of Global Bioethics, 189.
110
Semplici, “Social Responsibility and Health,” in Handbook of Global Bioethics, 198.
111
Convention on Biological Diversity, “About the Nagoya Protocol,” accessed February 15, 2017, available at:
https://www.cbd.int/abs/about/
112
Gardar Arnason and Doris Schroeder, “Exploring Central Philosophical Concepts in Benefit Sharing:
Vulnerability, Exploitation and Undue Inducement,” in Benefit Sharing: From Biodiversity to Human Genetics, ed.
Doris Schroeder and Julie Cook Lucas (Dordrecht: Springer, 2013), 9.
113
Indigenous Peoples, Consent and Benefit Sharing: Lessons from the San-Hoodia Case, ed. Rachel Wynberg,
Doris Schroeder, and Roger Chennells, (Dordrecht: Springer, 2009).
114
U.S. Department of Health & Human Services, Office for Human Research Protections, “The Belmont Report,”
accessed October 21, 2016, available at: http://www.hhs.gov/ohrp/regulations-and-policy/belmont-report/

248

115

UNESCO, International Bioethics Committee, Report of the IBC on Principle of Benefit Sharing, (Paris:
UNESCO, 2015), 8.
116
UNESCO, International Bioethics Committee, Report of the IBC on Principle of Benefit Sharing, 8-9.
117
Roger Scarlin Chennells, Equitable Access to Human Biological Resources in Developing Countries: Benefit
Sharing Without Undue Inducement, (New York: Springer, 2016).
118
Takayuki Morisaki, “Protecting Future Generations,” in The UNESCO Universal Declaration on Bioethics and
Human Rights, ed. Henk ten Have and Michèle S. Jean, (Paris: UNESCO, 2009), 243.
119
Heidi Ledford, “CRISPR: gene editing is just the beginning,” Nature 531, no. 7593 (March 7, 2016), accessed
February 15, 2017, available at: http://www.nature.com/news/crispr-gene-editing-is-just-the-beginning-1.19510
120
Christopher C. Joyner, “Legal Implications of the Concept of the Common Heritage of Mankind,” The
International and Comparative Law Quarterly 35, no. 1 (1986): 190-99.
121
Prakash N. Tandon, “Protection of the Environment, the Biosphere and Biodiversity,” in The UNESCO Universal
Declaration on Bioethics and Human Rights, ed. Henk ten Have and Michèle S. Jean, (Paris: UNESCO, 2009), 252.
122
United Nations, “Sustainable Development Goals,” accessed February 15, 2017, available at:
http://www.un.org/sustainabledevelopment/
123
Tandon, “Protection of the Environment, the Biosphere and Biodiversity,” in The UNESCO Universal
Declaration on Bioethics and Human Rights, 253.
124
Tandon, “Protection of the Environment, the Biosphere and Biodiversity,” in The UNESCO Universal
Declaration on Bioethics and Human Rights, 253.

249

Chapter 6: Global Bioethics Tool: Application
Chapter six develops the reporting framework for the global bioethics tool and applies the
indicators that were presented in the previous chapter to two pharmaceutical and/or
biotechnology companies. As the implementation of human rights and bioethics principles is an
ongoing process, it is envisioned that the indicators discussed in the previous chapter will need
revising on a continuous basis in consultation with various stakeholders and as technology and
healthcare advances. Nonetheless, this first step of application is necessary in order to establish a
baseline of where certain companies are at in implementing the principles of the Universal
Declaration on Bioethics and Human Rights. In order to accomplish this, publicly accessible
information has been first utilized, specifically from the company’s website, past reports
submitted to the UN Global Compact, and corporate social responsibility documents put forth by
the company. Additionally, select persons from each company are to be contacted for further
information in gathering this information if needed.
Section 6.1 first examines a number of reporting frameworks that have been developed
over approximately the last decade to report on how companies are implementing the human
rights and corporate social responsibility principles from specific guidelines. Advantages and
disadvantages of each reporting framework will be studied. From this analysis a proposal will be
prepared for how to setup a reporting structure for the proposed global bioethics tool. Section 6.2
then applies the indicators that were developed in chapter five to specific companies and utilizes
the developed reporting framework from 6.1 to accomplish this task. GlaxoSmithKline, a very
large multinational pharmaceutical company based in London and Sun Pharmaceuticals,
headquartered in Mumbai, India, have been chosen as the two companies to examined in section
6.2.
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6.1) The Reporting Framework
Methods for the implementation of human rights principles are predominantly split into
reporting systems and petition systems, with the vast majority of human rights treaties relying on
some sort of reporting and/or monitoring system as the sole method of compelling compliance.
For UN treaties with this type of reporting mechanisms, a formal review by a neutral inspector,
termed a Special Rapporteur, might also occur. Increasingly, reporting is being combined with
some level of monitoring, making reporting more rigorous.1 Troubles with reporting in the
international human rights system are numerous, including bureaucratic redundancy and
overlapping jurisdiction. The UN has adopted nine core human rights treaties, and there is bound
to be redundancy in them, and yet, nonetheless, reporting for each has to be completed in order
to remain in good standing with the organization, which places a heavy administrative burden on
countries.2 This is a genuine concern for the proposed global bioethics tool and is an area in
which later revisions of this tool will need to take into account. While this tool is very unique in
its aim, there will certainly be some level of overlap with areas of human rights and corporate
social responsibility reporting.
A second manner of implementing human rights is a petition system. In a petition system
(also known as a complaints system), a state, organization, or individual makes a petition or
complaint against another state or organization to a central body. In the UN system, this can take
the form of states complaining about other states, individuals complaining about states, and
inquiries initiated by the treaty bodies in response to accusations of abuse.3 In reality, the petition
system has been underused by the UN system and often classified as ineffective. Historically, the
state-to-state complaints system has never been used in the UN. It has been utilized a few dozen
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times in Europe, and minimally in the Americas and Africa. Part of the ineffectiveness stems
from the hesitation of states to lodge complaints against fellow states.4
A third mode of implementation is a combination system that combines both selfreporting and petitions. For example, the Inter-American Convention on the Prevention,
Punishment and Eradication of Violence Against Women (1994) utilized reporting procedures,
advisory opinions (in which the States parties and the Inter-American Commission of Women
may request of the Inter-American Court of Human Rights advisory opinions on the
interpretation of the Convention), and petitions.5
However, implementing human rights and other principles, such as actions of corporate
social responsibility, may also take form through pressure from external bodies, which may
include social pressure. By joining an initiative such as the UN Global Compact or the UN
Guiding Principles Reporting Framework, companies assume certain responsibilities
(implementation of principles) and they also accept that they will report and be monitored for
their work and transparency by external bodies (such as the UNGC, Access to Medicine
Foundation, or similar NGO) and the general public. The below chart summarizes these
implementation mechanisms succinctly:
Implementation
Advantages
Mechanism
Self-Reporting
-Straightforward
(e.g. UN Global implementation
Compact)

Petition
(complaints)
System

Disadvantages

-Some type of petition or
complaints is advantageous so
that individuals or other
companies who learn about
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-Reporting can be laborious and
redundant
-No incentives for increased activities
as it is very difficult to get an overview,
to compare performance and identify
best practices.
- No clear advantage or gain by being a
good or the best performer
- This model is reactive and not
proactive, as misconduct has already
taken place.
-Many persons who might suffer abuse

abusive practices have a way to
voice their concerns.

Combination
System: Self
reporting and
petition

External Body

from a company may not have the
resources or knowledge to access the
complaints system (whether it be
because they do not have access to the
internet or simply because they are
unaware that such a system is in place)
and effectively file a complaint.
-Complaints can sit in backlog for
months, as persons must investigate
-Consequences for violation are
uncertain
-A model of implementation
-Combining the two systems do not
could include elements of both eliminate the weaknesses of any of the
self-reporting and petition
systems.
(such as a whistleblower).
-Such a system would still need to
Advantage of this would be it
account for the main disadvantage of a
still includes self-reporting and petition system, which is the backlog
also leaves possible a
that can be created by numerous
mechanism for persons or
complaints if sufficient resources are
companies to file complaints
not allocated to meet demand. Further,
against another company
the cost of such a system might be an
obstacle to implementation.
-An external body may help to -This model is selective and depends
hold companies accountable for on the focus of the external body.
various aspects of how they
Hence, one might not get a broad idea
conduct business.
about a company’s performance.
-External body may be useful
-Consequences for violations of a
for spurring social action and
requirement or high/low ranking on an
garnering attention of media
index are uncertain, aside from social
-The constitutions and
consequences, such as a the report of
operations of the external
the external body being publicized and
bodies might provide additional investors, media, public, etc. reacting in
trustworthiness to information, a manner that may be undesirable.
indexes and ranking.

For the global bioethics tool, a complaints or petition system is not the aim. The aim is
collaboration between companies. Yet, the advantages of the external body model, as described
in the chart, must not be overlooked. Hence, in regards to reporting, the global bioethics tool is
envisioned as a set of questions, with a self-reporting framework, and an overarching central
body that seeks to hold companies accountable for their reporting and their conduct. It is
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envisioned that this centralized body would be a non-profit that “houses” the tool is responsible
administratively for it.
One problem with reporting frameworks in general is that they can become overly
cumbersome and laborious, as briefly mentioned above. Every reporting framework that a
company joins will require a separate report, which could result in numerous reports being filed
annually with much manpower utilized.6 The overabundance of reporting in the human rights
realm by state actors has been shown to spread a government’s available resources thinly rather
than investing in high-quality reporting.7 Global Reporting Initiative, an international
independent standards organization that helps businesses and governments understand and
communicate their impacts on issues such as climate change, human rights, and corruption,
estimates that the cost for a company to report issues of sustainability can vary from as little as
€2,000 to over €100,000. The majority of this cost stems from the time it takes to prepare the
report, including time for senior management and other staff to discuss the report, time for
gathering and inputting data, time to implement new processes, including staff training, data
collection, time for checking information, and time for preparation of the report itself.8 Indeed,
such reporting may even require a full-time employee to complete these tasks, not to mention the
smaller portions of time committed from other persons. For small and medium-sized businesses,
such reporting may be especially onerous, as economies of scale understandably limit their
personnel and resources.9 Hence, in order for an implementation mechanism such as the global
bioethics tool to be maximally effective, and for companies not to view the global bioethics tool
in a negative light, a self-reporting framework that seeks to minimize the burden placed upon
companies seems advantageous.
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The reporting frameworks of several organizations in the industry will be examined in
this section for their strengths and weaknesses in order to make a recommendation for the
proposed global bioethics tool. The first reporting framework to be discussed here is the one used
by the UN Global Compact (UNGC), known as the “communication on progress” (COP). COPs
have three minimum requirements: 1) There must be a statement by the CEO expressing
continued support for the UN Global Compact and renewing the participant’s ongoing
commitment to the initiative, 2) a description of practical actions the organization has taken or
plans to take to implement the Ten Principles of the UNGC in each of the four areas (human
rights, labor, environment, anti-corruption), and 3) there must be a measurement of outcomes.
Signatories are required to submit this report annually.10 Aside from these basic requirements,
there is little in regards to style or format requirements of the COP provided, leaving every
company to create their own process.
Therefore, there is often great variance between COPs. After reading the most recent
COPs compiled by several top pharmaceutical companies the impression received was that most
were very lengthy and not user-friendly. Of the nine COPs examined, page length varied
significantly, as displayed in the chart below.
Company (Year of COP)

Page Length of COP

AstraZeneca (2015)

80

Eli Lilly (2015)

134

GlaxoSmithKline (2015)

58

Johnson & Johnson (2015)

122

Merck & Co. (2015/2016)

392

Novartis (2016)

98

Novo Nordisk (2015)

35

Pfizer (2016)

137

255

Sanofi (2015)

122

The majority of COPs seemed to be prepared as a general document put out by the company’s
Corporate Social Responsibility (CSR) department rather than as a streamlined document
specifically for the UNGC outlining how the company efforts to implement the ten principles of
the UNGC. Further, of all the reports examined, each utilizes different styles for their COP and
lacked any uniformity. This is disadvantageous, for there is no systematic reporting style, which
leads to confusion, much difficulty when trying to ascertain how one company may compare to
another, and a general lack of user-friendliness. Lastly, the overall specificity in what a company
is actually doing on the ground to implement the principles of UNGC is not clear enough from
the majority of COPs as to provide evidence on progress or to be helpful to stakeholders. Such
knowledge should not be considered confidential, as one company attested in their COP, as this
seems to go against the spirit of implementing corporate sustainability. This does not allow for a
learning process to take place in which companies who are doing well at implementing aspects
of human rights and sustainability can share their expertise with companies who are not yet as
advanced.
While there are weaknesses to the UNGC’s COP system, strengths are also present. One
of the most pronounced strengths is the transparency that the UNGC COP system prompts and
promotes from companies. While this transparency could certainly be strengthened by further
prompting companies to divulge more real-world evidences of what they are doing to implement
the principles, the COPs are, nonetheless, openly published online and available to anyone with
Internet access. This level of transparency is unrivaled in the area of corporate sustainability
initiatives, particularly with the volume of organizations who have become signatories. It is the
ambition of the global bioethics tool to also emulate the transparency of the UNGC, and to
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surpass it, so that various stakeholders can freely ascertain what specific companies are doing in
regards to bioethics and human rights. Additionally, the three minimum requirements that the
UNGC requires of all its submitted COPs are also strengths. However, they could be made
considerably stronger. The second requirement of the COP is that it must contain, “A description
of practical actions the company has taken or plans to take to implement the Ten Principles in
each of the four areas (human rights, labour, environment, anti-corruption).”11 By requiring more
examples of practical ways companies have implemented the UNGC principles, as has been
stated, would significantly strengthen the COP. Further the third requirement of the COP is that
it must contain, “A measurement of outcomes.” By requiring that the COPs be arranged in a
systematic, easy-to-follow manner, might have the effect of further increasing their visibility due
to more people using them. Finally, an interesting feature of UNGC that is developed directly
from the COPs is that UNGC provides a Global Opportunity Report to inform companies on
ideas for future action.12 This is yet another way of inspiring companies to take sustainable
action towards key goals. For the global bioethics tool, in the future it should be considered how
creating a similar report that could accompany an account on best practices would be beneficial
for companies.
The second reporting framework to be discussed is a collaboration between The Danish
Institute for Human Rights, the Confederation of Danish Industry, the Ministry of Economic and
Business Affairs, and the Danish Investment Fund for Developing Countries has created a Global
Compact Self Assessment Tool that is designed to help a company evaluate how they are doing
in integrating and implementing the UNGC in their company. The tool is aimed at both small
and large companies and touts itself as being able to identify specific needs of companies,
regardless of sector or their context. This tool was briefly discussed in an earlier chapter, but the
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reporting framework will be scrutinized more closely here. The Global Compact Self
Assessment Tool contains indicators that are set up in the form of questions so that companies
can see how well they are doing in implementing the ten principles of the UNGC.13 This is very
similar to the setup followed by the proposed global bioethics tool, presented in the preceding
chapter.
The Global Compact Self Assessment Tool can be downloaded directly from their
website as a Microsoft Excel spreadsheet. It is composed of 45 questions with indicators for each
question. The indicators are close-ended—i.e. they are meant to be answered either “yes” or
“no”. While this is streamlined and presumably reduces the time a company utilizes in
completing the assessment, it is also limiting. There is surely variability in the answers to
questions that a simple “yes” or “no” response does not capture. For example, the initial question
in the human rights section of the self-assessment asks, “Does the company ensure that its
workers are provided safe, suitable and sanitary work facilities?” There are then eight indicators
listed beneath that question that are to be answered either “yes” or “no” to gauge how well the
company is doing in ensuring the workers’ facilities. This is similar to the proposed global
bioethics tool, yet there are weaknesses to this system. For example, one of the indicators for this
question states, “The company routinely monitors its production processes, machinery and
equipment to ensure that they are safe and in good working order.” A simple “yes” or “no” is not
specific enough to answer this adequately. For example, the machinery in question could be
examined routinely on an annual basis, but it is supposed to be examined monthly. However, the
indicator is not specific enough with simply a “yes” or “no” to ascertain this depth of
information. Hence, this is one weakness of the Global Compact Self Assessment Tool that the
proposed global bioethics tool has sought to remedy through the use of qualitative, open-ended

258

responses. Nonetheless, much can still be emulated from the Global Compact Self Assessment
Tool regarding the user-friendly layout.
The third reporting framework to be examined has been developed by the Human Rights
Reporting and Assurance Frameworks Initiative (RAFI), which is funded by the governments of
Norway, Sweden, and the United Kingdom. RAFI is co-facilitated by Shift, a non-profit
organization founded directly after the endorsement of the UN Guiding Principle on Business
and Human Rights, and Mazars, an international organization specializing in audit, advisory,
accounting, and tax services. In 2015 they launched a UN Guiding Principles Reporting
Framework that seeks to help companies self-report on their activities implementing the UN
Guiding Principles on Business and Human Rights.14 The Reporting Framework takes the form
of a questionnaire (12 main questions and 23 supporting questions) for companies to answer as
they strive to meet their human rights responsibilities. This framework was developed over a
period of two years the RAFI team led an open, global, consultative process involving
individuals from over 200 companies, investor groups, civil society organizations, governments,
assurance providers and other expert organizations from all regions of the world.
The questions in the framework are open-ended—i.e. they are not meant to be answered
with a simple “yes” or “no”. The guidelines state that companies claiming to use the UN Guiding
Principles Reporting Framework should, at a minimum, provide substantive response to the main
questions, which they state is designed in such a manner so as to be attainable by a company that
actually does seek to address aspects of human rights within its business conduct. Over time,
reporting companies should work towards answering the supporting questions as well, and, in
addition, improving the quality of their responses to all questions over time. A reporting database
is also available. The database does not judge how well a company is implementing the UN
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Guiding Principles, nor does it rate or rank corporate performance or disclosure. Instead, the
database enables companies and their stakeholders to draw their own conclusions about how
meaningfully a company is reporting on its progress towards implementation of the UN Guiding
Principles. The database draws only from information companies publish in their own websites
and reports, in order to support integrated approaches to how companies think and talk about
human rights in their core business. The database’s catalogue of corporate disclosure can be used
widely to support analysis, ranking or benchmarking of corporate reporting on human rights by
other initiatives.15
With these three reporting frameworks in mind, recommendations can be made for how
to setup the reporting of the proposed global bioethics tool. Admirable qualities from the above
frameworks are to be included in the proposed framework. These include making it user friendly,
stressing the need for uniformity, and making the process as streamlined as possible. Because it
is the hope that companies will self-report this information rather than a team of independent
researchers having to search for the data, companies will need to devote significant time to
answering the questions. Hence, making it as streamlined as possible is advantageous, but this
will have to occur with latter revisions of the global bioethics tool once it is in further stages of
stakeholder dialogue.
Items to consider in future revisions of the global bioethics tool would be whether to
amend any of the questions to include a Likert scale. Likert scales are a type of rating system that
is widely used in research, specifically questionnaires. They are commonly used to quantify
attitudes and behaviors. These types of scales provide respondents with a list of statements and
requests that they select the response that best represent the rank or degree of their answer.16 A
sample of how this would be used for the global bioethics tool would be to ask a question such
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as, “How well is the Company doing in ensuring that persons in LMICs on whom research is
conducted have recourse to share in the benefits of the research?” In a Likert scale model,
answers could be:
a)
b)
c)
d)
e)

Excellent
Good
Average
Needs Improvement
Poor

The company would then pick one of the choices and perhaps provide some supporting data or
narrative to support their choice. There are advantages and disadvantages to using Likert scales.
Advantages include their ease to create and, generally, to answer. They are also very flexible and
versatile, having the ability to be tailored to specific questions. On the other hand, disadvantages
include uncertainty in answers, which can skew results. For instance, what does “average” in
regards to benefit sharing really look like? Additionally, Likert scales assume a normal
distribution, generally. For instance, there is not room to answer somewhere between “average”
and “good”. Hence, there are both advantages and disadvantages to using a Likert scale in the
reporting framework, and this will need to be discussed with more stakeholders.
6.2) Application to the Industry
This section will seek to apply the global bioethics tool, with the list of indicators
developed in section 5.2 and the reporting framework developed in section 6.1, to two
pharmaceutical companies—one of which is a major Western company and the second a midsized firm based in a LMIC. The purpose of choosing a company both from a HIC and a LMIC is
to demonstrate that the global bioethics tool is a useful instrument for any pharmaceutical or
biotechnology company that is involved in research and development, not only large Western
entities. In the exploratory phase of this study (July-December 2016), conducted in conjunction
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with Novo Nordisk, companies were initially screened for whether they were signatories to the
UN Global Compact, if they were included in the 2014 Access to Medicine Index, Dow Jones
Sustainability Indices, and whether they were a member of Business for Social Responsibility. If
a company was found in multiple of these then they were viewed as having interests in the area
of CSR. Hence, this formed the initial criterion for contacting companies to ascertain their
interest in a bioethics tool. At the time of this writing, the following companies have been
contacted to ascertain their interest in forming a collaborative partnership to develop the global
bioethics tool: Merck, Genentech (biotechnology subsidiary of Roche), Novartis, Pfizer, Johnson
& Johnson, Takeda, Bristol-Myers Squibb, GlaxoSmithKline, and Sanofi.
As of this writing, the funding for the global bioethics by the industry has not continued.
Hence, this section is largely hypothetical, though it does use real-world, publically accessible
data to apply the indicators to specific companies. Public information found on the company’s
websites, available in academic literature, and reported through alternative mechanisms such as
the UN Global Compact COP has been scoured. Additionally, representatives from each
company have been contacted for further information on an as needed basis. While this section is
largely hypothetical, as the global bioethics tool is still in a state of some flux, the purpose of
applying the tool in this section is to demonstrate its viability. Hence, the global bioethics tool is
not merely a curious academic exercise, but it is a practical way to more fully implement
bioethical principles into the business practices of the pharmaceutical and biotechnology
industry. Applying the tool to specific companies will also showcase areas where the tool is in
need of refinement. However, refinement will best come through engagement with multiple
stakeholders and having intimate knowledge of the workings and practices of specific
companies, which is difficult to accomplish by an outsider.
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If the funding of the global bioethics tool by industry were to begin in the future, the tool,
its development, and its refinement will primarily be driven by a cooperation of several
pharmaceutical and biotechnology companies. Hence, the engagement and commitment of others
in this industry is the first key step to seeing the global bioethics tool take on a meaningful role
for the industry. Nonetheless, seeing that the global bioethics tool has not continue to be funded
by industry, reasons for not implementing the tool will be studied in the concluding chapter.
Further options for seeing the tool adopted by the pharmaceutical and biotechnology industry,
such as alternate ways of promotion or seeking support from others in the industry, will be
assessed.
The companies that have been chosen to assess for this section include: 1)
GlaxoSmithKline and 2) Sun Pharmaceuticals. The reason GlaxoSmithKline (GSK) was selected
is multifaceted. First, GSK is a large multinational corporation that is based in a HIC, the UK.
Second, GSK has topped the Access to Medicine Index since the ranking was first published in
2008. For this reason, there is ample data available about what GSK is doing in regards to
corporate social responsibility. Because of the ample public data available, GSK serves as a good
indicator to see how much of the data requested by the global bioethics tool is publically
available. The second company, Sun Pharmaceuticals, was chosen for two reasons. First, the
global bioethics tool is envisioned as not only a tool for companies based in HICs, but also those
in LMICs. Sun is headquartered in Mumbai, India and is a sizable company with over 52,000
employees and $4 billion USD in revenue. Nonetheless, though Sun is a sizable company, it is
still much smaller than other major Western pharmaceutical companies, is not a signatory to
UNGC, and lags behind other companies in terms of what bioethics information is publically
available. Hence, this is a second reason Sun was chosen, in order to showcase that pulling
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publically available data is simply not enough to answer the indicators of the global bioethics
tool. For the vision of the global bioethics tool to be fully realized, and for stakeholders to gain
an honest and transparent look at what companies are doing to fulfill their responsibilities, an
insider perspective must be achieved.
In what follows, the global bioethics tool is first applied to GSK. Some concluding notes
on that application process directly follows. Then, the application will be mimicked for Sun
Pharmaceuticals, along with some concluding thoughts on that process and how it could
improve.

Global Bioethics Tool for Pharmaceutical and Biotechnology Companies
Instructions: Please answer the following questions about your company as truthfully and succinctly as possible.

Company Name: GlaxoSmithKline
1) Article 3: Human dignity and human rights
1.1: How does the company avoid infringing on the human rights of others? (cf UN Guiding
Principles on Business and Human Rights (UNGPBHR) Principle 11)
In 2012, GSK undertook an independent third-party assessment to help them understand
potential human rights impacts associated with their business practices. Seven priority areas were
identified from this: access to health care, air quality impact relating to propellants, clinical trial
standards, employment practices, patient safety, product counterfeiting and use of third-party
suppliers.17
GSK also has a human rights statement which states their commitment to the Universal
Declaration of Human Rights and the UN Guiding Principles on Business and Human Rights.
They state their commitment to providing fair wages and safe working conditions. GSK also
reserves the right to enter into their third party supplier’s premises to monitor compliance of their
human rights statement.18
1.2: How does the company ensure the welfare of its employees by providing safe and suitable
working conditions?
As stated in 1.1, the company has policies in place that state it does ensure employees have safe
and suitable working conditions. Further, GSK states that they focus on incident prevention and
risk assessment through trainings and communications on key risks.19
1.3: How does the company implement standards of working hours for its employees, such as
those put forth by the International Labour Organization?
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No information could be located.
1.4: How does the company ensure fair living wages in relation to the context of their employees
such as to meet the basic needs of employees and dependents?
GSK states that they are “committed to providing a fair salary and good conditions of
employment,” yet it is unclear how “fair salary” is determined.
1.5: How does the company ensure the elimination of all forms of forced or compulsory labor in
its employees and suppliers? (cf UN Global Compact (UNGC) Principle 4)
In its human rights statement, GSK states that their contracts with suppliers and business partners
contain a labor rights clause that requires the supplier to warrant, “It does not use forced labour
in any form (prison, indentured, bonded or otherwise) and its employees are not required to
lodge papers or deposits on starting work.”20 GSK reserves the right to monitor compliance with
this, though it is uncertain how, or if, this is done.
1.6: How does the company ensure the effective abolition of child labor of its employees and its
suppliers? (UNGC Principle 5)
In its human rights statement, GSK states it is, “opposed to all forms of slavery and exploitative
child labour and will work with appropriate partners to address this problem responsibly
wherever we encounter it.” Further, GSK requires their suppliers to assure, “It does not employ
engage or otherwise use any child labour in circumstances such that the tasks performed by any
such child labour could reasonably be foreseen to cause either physical or emotional impairment
to the development of such child.”21
The indicator, however, asks how the company “ensures” that child labor has effectively been
abolished in its company and suppliers rather than merely stating opposition to it. It is unclear
how this is guaranteed.
1.7: How does the company ensure that a system is in place so that employees may voice
concerns regarding aspects of human dignity and human rights? (UNGPBHR Principle 18)
GSK states that its suppliers shall “ensure that it has ethical and human rights policies and an
appropriate complaints procedure to deal with any breaches of such policies.”22 Further, GSK
has a system for expressing concerns regarding breaches of its code of conduct or other corporate
policies.23 The company states that concerns will be handled promptly, discreetly, and
professionally. Complaints may be lodged by speaking to local management, HR, or legal
services, via telephone, letter, or filling out an online report.
1.8: Does the company have in place a human rights due diligence process to identify, prevent,
mitigate and account for how they address their impacts on human rights? (UNGPBHR
Principle 15b)

265

GSK states that after a complaint about a possible breach of their code of conduct, company
policies, or procedures is lodged, the steps that happen afterward are:
• Your report will be forwarded to appropriate GSK management for follow-up
• Members of management will review and address your concern; they may include
representatives from the Global Ethics and Compliance function, Human Resources,
and/or Legal
• Your concern will be handled promptly, discreetly, and professionally. Discussions and
enquiries will be kept in confidence to the extent appropriate and permitted by law
• On request, you may obtain certain follow-up information about how your concern was
addressed.24
1.9: How does the company promote and safeguard the health, wellbeing, and rights of human
research participants?
In their policy statement entitled, “Clinical Trials in the Developing World,” GSK follows the
ICH-GCP guidelines and the Declaration of Helsinki (DoH), only performs clinical trials in
countries where the medicines are likely to be suitable for the wider community in the country,
and, when necessary, reaches agreement before the start of the trial, on issues such as
responsibilities for the standard of care and post-trial treatment (type of benefit sharing).25
1.10: Does the company place the goal of generating new knowledge in clinical trials above the
rights and interests of the individual research participant?
From the policy statement, “Clinical Trials in the Developing World,” it does not appear so.
1.11: How is the priority of patient safety respected during a trial, and after market marketing of
a new product?
Trials are conducted in accordance with ICH-GCP guidelines and the DoH. After a product
comes to market, monitoring is overseen by GSK’s Global Safety Board, which is chaired by the
chief medical officer. The board reviews safety reports of its products.26
1.12: How do investigators ensure the research is acceptable within the community it takes
place? How does a company ensure it complies with good scientific principles that would lead to
best science and greatest benefit?
GSK states, “GSK follows ICH methodologies as a minimum standard and works, where
appropriate, with community leaders, charities, religious figures and Health Authorities, in
compliance with local laws and practices, to ensure that the risks and benefits for trial
participants are effectively evaluated and appropriate measures put in place.”27
1.13: How is it ensured that participants during a trial obtain new information that might affect
their decision to continue in the trial?
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No information could be found publically available on this.

2) Article 4: Benefit and harm
2.1: How is any possible harm minimized?
GSK states that it follows ICH-GCP guidelines “to ensure that the risks and benefits for trial
participants are effectively evaluated and appropriate measures put in place.”28 Further, all
clinical trials are evaluated for harms and risks by an IRB, and they must demonstrate that the
anticipated benefits justify the risks.
2.2: How is direct and indirect benefit maximized?
As 2.1 states, clinical trials must be approved by an IRB and demonstrate that benefits justify any
risks. It is not clear from the published materials how direct and indirect benefit is maximized
specifically.
2.3: How does a company ensure that investigators and staff are trained and scientifically
qualified?
No information could be found publically available on this.
2.4: How is the continued evaluation of a marketed product through research of safety, efficacy,
accessibility and quality ensured?
After a product comes to market, monitoring is overseen by GSK’s Global Safety Board, which
is chaired by the chief medical officer. The board reviews safety reports of its products.29
2.5: If a clinical trial participant is harmed, how is harm assessed and who determines/assesses
if compensation is appropriate?
No information could be found publically available on this.
2.6: Are qualified research ethics committees (institutional review board/ethical review board)
present and reviewing research protocols to ensure benefit is maximized and harm minimized?
Yes. As GSK follows ICH-GCP guidelines, an IRB is in place to review research protocols.
2.7: Who and how is it decided if the non-clinical and clinical knowledge is adequate to support
a clinical trial?
The GSK public policy position on “Pharmacovigilance” states, “Before evaluation of a potential
new medicine in humans can begin, extensive preclinical (or laboratory research) must be
conducted. This research typically involves years of experiments including animals and human
cells. If this stage of testing is successful, these data are provided to regulatory authorities,
requesting approval to begin evaluating the potential new medicine in humans. This evaluation is
done through clinical trials and is usually conducted in three main phases. Each phase addresses
different questions that determine if the testing of the “Investigational Medicinal Product” (IMP)
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can proceed to the next phase.” Further, GSK states that the “benefit/risk profile of a GSK
medicine is assessed throughout its lifecycle using a benefit/risk framework and appropriate
analyses.”30 However, it is uncertain that exactly how this benefit/risk profile is assessed and
what are the steps of remediation if it is found that risks are too high.
2.8: How are conflicts of interest amongst research ethics committee members and affiliated
researchers stated and mitigated?
GSK, in a public policy statement, says that it “expects all staff to be free from actual or potential
conflicts of interest.”31 In its public policy position on performing clinical trials in the developing
world, GSK asserts: “GSK will always seek formal approval for trials from independent ethics
committees. In some developing countries independent ethics committees do not exist or their
membership is not in line with international regulatory requirements. If a local ethics committee
does not exist, GSK will not conduct the trial.” Hence, it appears that the company uses
independent ethics committees to approve its clinical trials, which would have their own sets of
rules for conflict mitigation. Additionally, within the company, GSK has stopped paying doctors
to promote its products and ended the practice of tying compensation of sales representatives to
the number of prescriptions doctors write.32
2.9: How is harm/benefit ratio determined by the company?
This is uncertain. From 2.7, GSK has a system to determine this, and notes that, “When
information is found that changes the benefit/risk balance in a negative direction, action is taken
to characterise, communicate and minimise the risk. Proposed actions are discussed with
regulatory authorities and can include modifying the prescribing information (which includes the
patient information leaflet), communications to physicians and other healthcare providers and
sometimes carrying out further clinical trials. In certain cases it may be appropriate to stop
clinical trials or to withdraw the medicine from the market.”33 However, it is still uncertain how
harm/benefit ratio is exactly determined.
2.10: What is the procedure for stopping a research study if the risks of proceeding are shown to
outweigh the potential benefits? (WMA Declaration of Helsinki Article 20, 2008)
This is not known. GSK does states that, in certain cases, it may appropriate to halt a trial due to
the risk/benefit ratio, though actual procedures do not appear to be public knowledge.
2.11: How does the company respond to a situation in which a research participant has an
apparent research-related harm occur?
No information could be found publically available on this.

3) Article 5: Autonomy and individual responsibility
3.1: How does the company ensure the autonomy (freedom, liberty, self-determination) of human
research participants?
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GSK states that they follow ICH-GCP guidelines, which has inclusion for the autonomy of
persons in clinical trials. No other information could be located on this.
3.2: How is the right to withdraw at any time without repercussions for the participant ensured?
GSK states that they follow ICH-GCP guidelines, which has inclusion for a participant’s right to
withdraw from clinical trials. No other information could be located on this.
3.3: How does the company uphold the freedom of association and the effective recognition of
the right to collective bargaining? (UNGC Principle 3)
In its Human Rights Statement, GSK states that they are, “respectful of the right of employees to
join an independent trade union, the right to collectively bargain, and of freedom of
association.”34

4) Article 6: Consent
Information
4.1: How does the company ensure that consent of human research participants is informed?
GSK follows ICH-GCP guidelines, which requires the voluntary and informed consent of
research participants. The company states, “In cultures other than those in Western society,
additional measures may often be needed to ensure the objectives of informed consent are met.
While still complying with ethical and legal requirements, additional steps are therefore taken to
match the objectives of informed consent to local culture. For example, local leaders and/or
family members may need to be involved. Where formal written informed consent from the
participant is not possible in a GSK sponsored trial (due, for example, to poor literacy)
investigators will work with independent witnesses to document a verbal consent process. They
will formally verify that the purpose of the trial has been explained to the participant and he/she
has understood what is proposed and involved.”35
4.2: What is included in this information component?
No information could be found publically available on this.
4.3: Are participants provided informed consent in a language and manner that is appropriate?
Yes, see 4.1. However, examples on how this has been accomplished successfully in the past
would be appropriate in this section.
Voluntariness
4.4: How does the company ensure that consent of human research participants is voluntary and
in no way coerced?
As GSK follows ICH-GCP guidelines, it does try to ensure that participation in human research
is completely voluntary. This is addressed by the company, in particular, in regards to payments
and other recompense to participants:
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“At the individual level, reimbursement for costs incurred by the participant is reasonable, and in
poorer societies it is particularly important that the individuals do not incur loss as a result of
involvement in a trial. Also, the reverse is a concern as in some societies it is important that
individuals do not benefit from study involvement to an extent that it sets them apart in that
society. In all circumstances, problems can be avoided by involving the local ethics committee
(disclosure of payment plans has been an obligatory part of the ethical review process since the
mid-1990s) and ensuring that any payments are appropriate to the local setting. The standard
continues to be that participation in clinical trials is voluntary. Care must therefore be taken to
avoid undue financial influence on participants’ decisions.”36
4.5: How does the company provide measures against undue inducement?
See 4.4. GSK seeks to make any recompense available to participants appropriate to the local
economy so as not to unduly influence persons.
Competence
4.6: How does the company ensure that the research participant is competent to give consent?
No information could be found publically available on this.
Training of Researchers
4.7: How are researchers or investigators trained in the process of obtaining informed consent,
including providing information in an appropriate manner that is understandable for the
participant?
No information could be found publically available on this.
4.8: When is it appropriate to consult family members and community leaders in the consent
process?
GSK states, “In cultures other than those in Western society, additional measures may often be
needed to ensure the objectives of informed consent are met. While still complying with ethical
and legal requirements, additional steps are therefore taken to match the objectives of informed
consent to local culture. For example, local leaders and/or family members may need to be
involved. 37
4.9: Is the participant given the option of being informed about general outcomes and results of
the study?
No information could be found publically available on this.
4.10: How is it ensured that emerging new information is promptly given to trial participants in
a long-term study that may affect their desire to stay in the study?
No information could be found publically available on this.
4.11: When is it appropriate to ask for re-consent during a trial?
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No information could be found publically available on this.
Research Participants
4.12: How is the right to withdraw at any time ensured?
No information could be found publically available on this.
4.13: Who determines if a person is competent to give consent and how is it determined?
No information could be found publically available on this.
Compensation
4.14: Who and how is it determined?
GSK attempts to make compensation appropriate to the local economy. Their proposal is then
submitted to an independent ethics committee for consideration. Since the mid-1990s, GSK has
made the disclosure of payment plans to the local ethics committee an obligatory part of its
ethics review process.38
Human Biosamples
4.15: What is the company’s course of action in regards to biosamples used in research that are
collected by researchers after prior informed consent for collection, storage and use/reuse? If
consent of the participant is not possible, has an ethics committee approved?
No information could be found publically available on this.

5) Article 7: Persons without the capacity to consent
General
5.1: Has authorization for research been obtained in accordance with the best interest of the
person concerned and in accordance with domestic law?
GSK follows ICH-GCP guidelines in its clinical trials. Each clinical trial must be approved by an
IRB and states that it works within local laws and practices.39
5.2: Has the research participant been involved to the greatest extent possible in the decisionmaking process of consent, as well as that of withdrawing consent?
As GSK states that they follow ICH-GCP, Guideline 4.3.4 of ICH-GCP states that a research
participant may withdraw from a study at any time for any reason. Specific details of how
potential participants are involved in the consent process and ensured that they are able to
withdraw at any time is uncertain.
5.3: Do the results of the research have the potential to produce real and direct benefit to the
health of the incapable research participant?
No information could be found publically available on this.
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5.4: Can research of comparable effectiveness be carried out on individuals capable of giving
consent?
No information could be found publically available on this.
Training of Researchers
5.5: How are researchers/investigators trained in dealing with and protecting persons with
diminished capacity to consent?
No information could be found publically available on this.
Determination of Capacity
5.6: How it is determined who is not capable of providing consent?
No information could be found publically available on this.
5.7: How is capacity determined in the protocol review process and by the investigator(s)
performing research?
No information could be found publically available on this.
5.8: How do researchers obtain proxy or surrogate consent?
No information could be found publically available on this.
Exception
If it is not possible to comply with the above, the UDBHR does formulate as an exception for
research that does not have the potential to produce results of direct benefit to the health of the
individual concerned. The following conditions must be met to permit such research:
1) The research has the aim of contributing, through significant improvement in the scientific
understanding of the individual’s condition, disease, or disorder, to the person concerned or to
other persons in the same category of disease or disorder.
2) The research must only entail minimal risk and minimal burden for the individual concerned.

6) Article 8: Respect for human vulnerability and personal integrity
Vulnerability & Marginalization
6.1) How does the company define “vulnerable” persons and population?
As GSK follows ICH-GCP, vulnerable persons are defined as ICH defines them. Guideline 1.61
of ICH-GCP defines vulnerable subjects in research.40 No information could be found publically
available on this.
6.2) How does the company specify who needs specific consideration? (UNGPBHR: Women,
children, people with disabilities, indigenous people, migrants, elders, prisoners, pregnant
women, economically and educationally disadvantaged are considered vulnerable)
See 6.1. No other publicly available information could be found on this.
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6.3) How are the vulnerable additionally safeguarded against undue influence or coercion?
In clinical trials in the developing world, which could be considered a vulnerable population,
local ethics committees are involved to ensure that any payments participants receive are
appropriate to the context.41 No additional information could be found publically available on
this.
6.4) Are the knowledge and products from the clinical trial made reasonably available to benefit
that group?
GSK has the following policy statement on the post-trial availability of medicines:
“GSK strongly supports the goal of improving access to medicines and we recognise our
responsibility for helping to improve access to our products worldwide. Where appropriate,
working with host country governments and researchers, GSK will endeavour to make
provisions for post-trial access to any interventions identified as beneficial in the trial, notifying
participants of any such provisions made through the informed consent process in advance of the
trial.”42
Identification
6.5) How does the company identify vulnerable individuals or groups?
No information could be found publically available on this.
Alternatives
6.6) Can the research be carried out in a non-vulnerable group? (Helsinki, 2013)
No information could be found publically available on this.
Protection
6.7) What guidelines has the company established to protect vulnerable persons?
GSK follows ICH-GCP guidelines and tries to seek input from local community members and
leaders prior to beginning a research trial in a developing country. No other information on
performing research on vulnerable persons could be located.
6.8) Does the company comply with the laws concerning research with vulnerable persons? If no
such legislation exists in the context where the research is being conducted (host community),
what does the company do?
No information could be found publically available on this.
Benefits
6.9) Does the vulnerable group stand to benefit from the knowledge, practices or interventions
that result from the research? (Helsinki, 2013)
GSK states, “GSK-sponsored clinical trials are only conducted in countries where the medicines
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are likely to be suitable for the country’s wider community. Furthermore, clinical trials of
investigational medicines are not conducted in countries when it is known at the outset that there
is no intent to pursue registration and make the medicine available for use in that country.”43
6.10) Is the medical research with a vulnerable group responsive to the health needs or priorities
of this group? (Helsinki, 2013)
GSK states, “GSK-sponsored clinical trials are only conducted in countries where the medicines
are likely to be suitable for the country’s wider community. Furthermore, clinical trials of
investigational medicines are not conducted in countries when it is known at the outset that there
is no intent to pursue registration and make the medicine available for use in that country.”44

7) Article 9: Privacy and confidentiality
Risk
7.1) What are the risks of the infringement of privacy?
The exact risks of the infringement of privacy are not known. However, “GSK is committed to
exercising high standards of integrity in dealing with personally identifiable information, and
takes several measures to protect the PII of employees, researchers and clinical trial
participants.”45
7.2) What is the risk of infringement of personal data?
The exact risks of infringement of personal data are not known. See 7.1.
Measures
7.3) What measures does the company take in order to maintain the right to privacy of
participants in human research?
GSK does take measures to protect the privacy of research participants. However, in their public
policy position paper, “Safeguarding Personally Identifiable Information A Summary of GSK’s
Binding Corporate Rules,” it is not quite clear exactly what methods they use to protect the
privacy of research participants and how/if this differs from protecting the personally identifiable
information of employees.46
7.4) How is it ensured that information is only shared or disclosed as it has been specified in the
consent?
No information could be found publically available on this.

8) Article 10: Equality, justice, and equity
8.1) How does the company manage scarce resources in order to guarantee a just and equitable
healthcare system?
GSK is a signatory of the United Nations CEO Water Mandate. The company has a policy
statement asserting how they steward water, which is a scarce resource.47 It is not certain how the
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company manages scarce healthcare resources, specifically scarce pharmaceuticals, in a just and
equitable manner.
8.2) How does the company ensure certain groups are not under- or over-represented in
research?
No information could be found publically available on this.
8.3) How does the company ensure that groups and communities are invited to participate in a
way that the burden and benefits are equitably distributed?
No information could be found publically available on this.
8.4) Will the participants, to the best of the company’s knowledge, be able to afford the product
when marketed without it being of significant burden?
In its policy position on clinical trials in the developing world, GSK states, “Where appropriate,
working with host country governments and researchers, GSK will endeavour to make
provisions for post-trial access to any interventions identified as beneficial in the trial, notifying
participants of any such provisions made through the informed consent process in advance of the
trial.” The company also states, “GSK is not, in general, responsible for the provision of
nationally licensed medicines after a trial. This responsibility lies with governments as part of
national healthcare programmes. For this reason, GSK-sponsored clinical trials in chronic
conditions will not be carried out unless we are assured at the outset by the investigator that
subjects will receive or be referred for any necessary continued healthcare and that the healthcare
system is able to provide for the continued care of study subjects.”48
8.5) How do the investigators ensure the research is fair to the subject?
Aside from following ICH-GCP guidelines and the Declaration of Helsinki, no other specific
information could be found.

9) Article 11: Non-discrimination and non-stigmatization
9.1) How does the company take care to avoid the systematic development of medicines for one
group within a population to the neglect of others?
In their policy statement on clinical trials in the developing world, GSK states:
“GSK has a long-standing commitment to research and development into diseases of the
developing world (DDW). Our R&D portfolio includes projects for a number of diseases of
particular relevance to developing countries including: bacterial meningitis, Chagas disease,
Chlamydia, dengue fever, HIV/AIDS, human African trypanosomiasis, leishmaniasis, malaria,
pandemic flu, pneumococcal disease and TB.
We are keen to do more but we recognise that the challenges are too complex to be addressed by
any one organisation alone. Partnership is essential and that is why we are pursuing an ‘open
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innovation’ approach to DDW research, working together with industry, academia, NGOs and
governments.
Open innovation at GSK includes:
– Sharing our expertise and resources with scientists from around the world through our Tres
Cantos Open Lab.
– Sharing our intellectual property and know-how through the Pool for Open Innovation against
Neglected Tropical Diseases.
– Being more open with our data and DDW research to help stimulate research outside GSK.”49
In particular, these are the areas GSK is currently working in to meet the needs of the developing
world:
“In 2016, we committed to working with governments, multinational organisations and NGOs to
enhance preparedness against potential future outbreaks of diseases such as Ebola and Zika. We
are supporting the Coalition for Epidemic Preparedness Innovation and are proposing to create a
permanent ‘biopreparedness organisation’ at our Rockville, Maryland Vaccines site.
In 2016, our gel to help prevent umbilical cord infections in newborns received a positive
scientific opinion from the European Medicines Agency (EMA). Three million babies die each
year from infection, often when the newly-cut umbilical cord attracts bacteria – a particular issue
in developing countries. If approved by local regulators, we will make the gel available at a notfor-pro t price and share manufacturing knowledge so it can be widely made.
Our Mosquirix vaccine targets a significant health threat – malaria. Phase III trials of the vaccine,
which received a positive opinion from the EMA in 2015, have shown the vaccine could have a
considerable public health impact when used in combination with malaria control measures.
In 2016, the World Health Organization confirmed that full funding has been committed to
enable the pilot implementation of Mosquirix in three settings in sub-Saharan Africa due to begin
in early 2018.”50
9.2) When conducting clinical trials, does the company discriminate or stigmatize certain
populations or genders so that they are under-represented in research?
No information could be found publically available on this.
9.3) Does the company have a grievance procedure for handling allegations of discrimination
and stigmatization?
GSK has a procedure for handling allegations of discrimination and stigmatization amongst its
employees,51 but it a policy on research participants could not be located.

10) Article 12: Respect for cultural diversity and pluralism
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10.1) In clinical trials with human research participants, how does the company handle cultural
differences regarding informed consent?
In their public policy statement, “Clinical Trials in the Developing World,” GSK states, “In
cultures other than those in Western society, additional measures may often be needed to ensure
the objectives of informed consent are met. While still complying with ethical and legal
requirements, additional steps are therefore taken to match the objectives of informed consent to
local culture. For example, local leaders and/or family members may need to be involved.
Where formal written informed consent from the participant is not possible in a GSK sponsored
trial (due, for example, to poor literacy) investigators will work with independent witnesses to
document a verbal consent process. They will formally verify that the purpose of the trial has
been explained to the participant and he/she has understood what is proposed and involved.”52
10.2) When doing business in an unfamiliar cultural milieu, how does the company approach
these cultural differences?
As stated in 10.1, GSK has “additional measures” in place for cultures that differ from Western
society. They state that involving cultural leaders and/or family members may be appropriate,
but no other measures are specified.
10.3) Does the company provide training for its employees on issues of cultural diversity and
pluralism?
No information could be found publically available on this.

11) Article 13: Solidarity and Cooperation
11.1) How is the company working towards capacity-building in the area of public and global
health?
In March 2014 GSK announced strategic investments in Africa to increase access to medicines,
build capacity, and deliver sustainable growth. They are working towards increasing selfsufficiency in Africa.53 This is only one example of the capacity-building GSK is involved
with.54
11.2) How is the company contributing to the UN Sustainable Development Goals?
GSK has a policy position statement on the UN Sustainable Development Goals stating that they
are fully committed to the SDGs.55 The position statement includes many ways GSK has tried to
implement the SDGs in their business conduct, including delivering over 690 million vaccine
doses, research into diseases of the developing world, setting environmental emission limits for
its manufacturing sites, support of the Paris Agreement on climate change, and working with the
organization Save the Children to widen immunization coverage, address nutritional needs of
children, and train researchers in the poorest communities.

12) Article 14: Social responsibility and health
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Promotion of Health and Social Development
12.1) How does the company aim to promote health and social development?
12.2) Article 14 states that “all sectors of society share” in the promotion of social responsibility
and health. How does the company seek to address: 1) access to quality health care and essential
medicines, 2) access to adequate nutrition and water, 3) the improvement of living conditions
and the environment, 4) the elimination of the marginalization and the exclusion of persons on
the basis of any grounds, and 5) the reduction of poverty and illiteracy?
Relationship to Developing Countries:
12.3) Does the company have differential pricing policies so that lower income countries pay
lower prices for essential medicines than higher income countries?
GSK leads the Access to Medicine Index in equitable pricing. “All of its products with equitable
pricing are priced with consideration for socio-economic factors in at least some countries in
scope; it uses equitable pricing for more products than any other company in scope; and has the
most marketed products with equitable pricing strategies that target countries with a particular
need for access to the products in question.”56
12.4) Does the company invest in research and development for diseases that primarily affect
lower income countries?
GSK does invest in such research and development. In early 2014 GSK announced that they
would “invest £25 million to create the world’s first R&D Open Lab for non-communicable
diseases (NCDs) in Africa.” The company also works on developing “new products designed to
meet the specific needs of Africa, for example through its ongoing work with partners to develop
the world’s first vaccine against malaria and to create new nutritional products fortified with
micro-nutrients to tackle childhood malnourishment.”57
12.5) Does the company have policies on access to treatment for developing countries, including
the five priorities of pricing, patent, joint public private initiatives, R&D, and the appropriate
use of drugs?
In the 2016 Access to Medicine Index (ATMI) report, ATMI reported that “GSK has more
products with equitable pricing strategies than in 2014, covering a broad range of diseases,
including HIV/AIDS, lower respiratory infections, asthma, pertussis and hypertensive heart
disease. Some (38%) of GSK’s products have equitable pricing strategies that target priority
countries (disease-specific sub-sets of countries with a particular need for access to the product
in question).” Further, has stated that GSK is a leader in intellectual property management and
consistently engages in voluntary licensing.58

13) Article 15: Sharing of benefits
Sharing of Benefits
13.1) How does the company ensure that the benefits resulting from its scientific research are
shared with society as a whole?
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In regards to post-trial provisions of drugs, GSK states: “Where appropriate, working with host
country governments and researchers, GSK will endeavour to make provisions for post-trial
access to any interventions identified as beneficial in the trial, notifying participants of any such
provisions made through the informed consent process in advance of the trial.”59
13.2) When conducting clinical trials, does the company ensure that in advance of the trial,
provisions are made for post-trial access for all participants who still need an intervention
identified as beneficial in the trial? (DoH, Article 34, 2013)
Yes. See 13.1.
13.3) If the company is involved in bioprospecting, how does it ensure that indigenous
knowledge and resources have been respected?
“GSK is not directly involved in any bioprospecting,” and they uphold the Nagoya Protocol.60
Undue Inducement
13.4) How does the company ensure against improper inducements to participate in research?
GSK states that they attempt to ensure that post-trial access to medicines and healthcare, as well
as capacity-building, does not constitute undue inducement. Specificity on how this is
accomplished is not stated.61

14) Article 16: Protecting future generations
14.1) In bioethical decision-making, does the company take into account the impact on the
present generation and also try to evaluate the impacts on future generations?
No information could be found publically available on this.
14.2) If the company is involved in research on human genomic information, how does the
company ensure that such new technology will not result in undesired outcomes for future
generations?
No information could be found publically available on this.
14.3) How does the company evaluate any possible influence a test compound can have on genes
or germ cells?
No information could be found publically available on this.

15) Article 17: Protection of the environment, the biosphere and biodiversity
Impact on Environment
15.1) As it has been recognized that the company has a responsibility to protect the environment,
how does the company prevent advances in molecular biology, recombinant technology,
genetics, biotechnology, and other advances from negatively impacting the environment?
No information could be found publically available on this.
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15.2) Does the company participate in the development of new technologies that pose risk of
irreversible damage to the environment?
It does not appear so. GSK has environmental policies and procedures in place to reduce carbon
emissions, waste, and water usage.62
15.3) Does the company have in place emergency guidelines in the event of an accident affecting
the environment?
No information could be found publically available on this.
15.4) Does the company minimize the use of chemicals and other dangerous substances, as well
as ensuring their safe handling and storage?
No information could be found publically available on this.
15.5) If applicable to the business, does the company encourage the development and use of
environmentally friendly technologies?
GSK has invested in sustainable buildings that use less energy, including the use of solar panels.
Their Philadelphia operations hub was awarded LEEDS Platinum certification.63 Hence, GSK
encourages the use of environmentally friendly technologies.
Biosphere
15.6) How does the company seek the protection of experimental animals? (cf Article 4)
GSK follows the three Rs of animal welfare: replace, reduce, refine.
• Replace animal research with other methods where/when possible
• Reduce the quantity of animals used in a study while still providing information of a given
amount and precision
• Refine techniques to minimize pain and distress and improve the welfare of animals
GSK scientists make attempts to design studies that do not require animals. All proposed animal
research is reviewed by an ethics panel, which is independent of the scientific group
commissioning the study.64
15.7) How does the company seek to eliminate the need for using animals in research?
GSK has made strides in their application of the 3Rs. GSK researchers have:
• replaced some research in animals with computer simulations and ‘in vitro’ techniques,
where tests are done on individual cells, cultures or tissues
• applied statistical methods to our work, so that we can be confident in results obtained
using many fewer animals
• introduced the use of imaging that can track physical and chemical changes caused by
treatment over time, removing the need to compare treated animals with non-treated
animals65
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15.8) How does the company seek to protect and promote the welfare on the animals used in
research?
In addition to the above, GSK shares their practices with other scientists and regulatory
authorities and publish the results of our research in scientific journals. They are also involved
with other organizations that aim to reduce the need for animal testing and promote animal
welfare including:
• UK National Centre for the 3Rs (NC3Rs)
• European Centre for the Validation of Alternative Methods (ECVAM)
• European Partnership for Alternative Approaches to Animal Testing (EPAA)
• Center on Alternatives for Animal Testing (CAAT)
• Scientist Center for Animal Welfare (SCAW)
• Institute for Laboratory Animal Research (ILAR)66
Impact on Biodiversity
15.9) Does the company prevent, minimize and remedy impacts on biodiversity?
GSK has sought to reduce its water and waste expenditures. They have cut operational carbon
emissions by 18% since 2010.67

As is evident from the above application of the global bioethics tool to GlaxoSmithKline,
there is a lack of knowledge, from a standpoint of what is publically available, in what the
company is substantively doing in regards to the indicators of the global bioethics tool. Some
specificity is present, though there is not enough to gain best practices and to be able to
benchmark companies well. This is one of the limitations with this hypothetical application in
which an external researcher (the author) attempts to respond to the indicators rather than have a
more knowledgeable person from inside the company complete the global bioethics tool
questionnaire.
In regards to human rights aspects, accountability is a central feature of human rights, for
absent of accountability, human rights can develop into little more than window-dressing.
Accountability is an essential, and achievable, goal of the global bioethics tool. Accountability
provides individuals and communities with an opportunity to understand how those with human
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rights responsibilities have discharged their duties. Equally, it provides those with human rights
responsibilities the opportunity to explain what they have done and why.68 GSK has a standalone human rights and has also been responsive to in-depth questions posed to them by the
Business & Human Rights Resource Centre, a London-based charity existing to advance human
rights in the business sector.69 Hence, it would be optimal if an insider from GSK would answer
the indicator questions of the global bioethics tool as well in order to gain insight into their
bioethics processes.
While much information could be located on GSK’s bioethics, human rights, and CSR
actions, some details are still lacking. The following inquiry was sent to GSK’s Senior Vice
President of Global Ethics and Compliance regarding several of the items that could not be
publically located:
Greetings,
I am a PhD student in bioethics in the United States at Duquesne University and am
writing my dissertation on bioethics, human rights, and corporate social responsibility as
it relates to the pharmaceutical industry. Particularly, my dissertation takes the 15
principles from the 2005 UNESCO Universal Declaration on Bioethics and Human
Rights and attempts to turn these principles into measurable indicators and benchmarks.
I have been scouring your website, reports from the UN Global Compact, and the Access
to Medicine Foundation for more information about GSK’s actions in regards to
bioethics, human rights and CSR.
In particular, it would be helpful to know how clinical researchers who are performing
research trials are trained by the company on informed consent, how capacity to
participate in a trial is determined, how researchers go about obtaining proxy or surrogate
consent, if/how GSK provides training for its employees on issues of cultural diversity
and pluralism, and if/how the company seeks to protect future generations which may be
effected by GSK’s work. Any information on the above would be greatly appreciated.
Thank you.
As of the time of this writing, GSK had not yet responded to the email.
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Global Bioethics Tool for Pharmaceutical and Biotechnology Companies
Instructions: Please answer the following questions about your company as truthfully and succinctly as possible.

Company Name: Sun Pharmaceutical Industries Limited
1) Article 3: Human dignity and human rights
1.1: How does the company avoid infringing on the human rights of others? (cf UN Guiding
Principles on Business and Human Rights (UNGPBHR) Principle 11)
Sun Pharmaceuticals states in its 2015-16 Business Responsibility Report that they have an “allencompassing Human Rights Policy covering various principles ranging from freedom of
association to freedom from harassment.”70 However, this policy could not be located publically.
1.2: How does the company ensure the welfare of its employees by providing safe and suitable
working conditions?
In regards to the health and safety of its employees, Sun states, “Wellness of the workforce is
given pivotal importance at Sun Pharma. Our robust Environment, Health and Safety (EHS)
policy and operating guidelines ensure a safe and healthy environment. Compliance to
ISO/OHSAS 18001 standards and to the laws of the land is non-negotiable…We encourage
reporting of accidents, injuries and near- misses, which enables us to be better prepared in the
future. Safe work practices are endorsed and the usage of unsafe equipment is disallowed.”71
However, the EHS policy referenced could not be located publically.
1.3: How does the company implement standards of working hours for its employees, such as
those put forth by the International Labour Organization?
No information could be found publically available on this.
1.4: How does the company ensure fair living wages in relation to the context of their employees
such as to meet the basic needs of employees and dependents?
No information could be found publically available on this.
1.5: How does the company ensure the elimination of all forms of forced or compulsory labor in
its employees and suppliers? (cf UN Global Compact (UNGC) Principle 4)
Sun states, “Our actions emanating from these policies [Human Rights policies] speak louder
than our intentions. Not only are we compliant with all the statutory laws and regulations, we
have grievance redressal mechanisms in place for violations, if any. In the reporting year, there
were no human rights violation complaints, relating either to child, forced and involuntary labour
or sexual harassment / discriminatory employment, against the Company.”72 However, no other
information could be found about the actions they speak of.
1.6: How does the company ensure the effective abolition of child labor of its employees and its
suppliers? (UNGC Principle 5)
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See 1.5. Sun merely states they are compliant with laws and does not make any mention of how
they ensure this.
1.7: How does the company ensure that a system is in place so that employees may voice
concerns regarding aspects of human dignity and human rights? (UNGPBHR Principle 18)
It is uncertain how or if Sun Pharmaceuticals ensures this.
1.8: Does the company have in place a human rights due diligence process to identify, prevent,
mitigate and account for how they address their impacts on human rights? (UNGPBHR
Principle 15b)
Sun Pharmaceuticals states, “we have grievance redressal mechanisms in place for violations” of
human rights.73 Yet, it is unclear what these mechanisms entail.
1.9: How does the company promote and safeguard the health, wellbeing, and rights of human
research participants?
No information could be found publically available on this.
1.10: Does the company place the goal of generating new knowledge in clinical trials above the
rights and interests of the individual research participant?
No information could be found publically available on this.
1.11: How is the priority of patient safety respected during a trial, and after market marketing of
a new product?
No information could be found publically available on this.
1.12: How do investigators ensure the research is acceptable within the community it takes
place? How does a company ensure it complies with good scientific principles that would lead to
best science and greatest benefit?
No information could be found publically available on this.
1.13: How is it ensured that participants during a trial obtain new information that might affect
their decision to continue in the trial?
No information could be found publically available on this.

2) Article 4: Benefit and harm
2.1: How is any possible harm minimized?
No information could be found publically available on this.
2.2: How is direct and indirect benefit maximized?
No information could be found publically available on this.
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2.3: How does a company ensure that investigators and staff are trained and scientifically
qualified?
No information could be found publically available on this.
2.4: How is the continued evaluation of a marketed product through research of safety, efficacy,
accessibility and quality ensured?
No information could be found publically available on this.
2.5: If a clinical trial participant is harmed, how is harm assessed and who determines/assesses
if compensation is appropriate?
No information could be found publically available on this.
2.6: Are qualified research ethics committees (institutional review board/ethical review board)
present and reviewing research protocols to ensure benefit is maximized and harm minimized?
No information could be found publically available on this.
2.7: Who and how is it decided if the non-clinical and clinical knowledge is adequate to support
a clinical trial?
No information could be found publically available on this.
2.8: How are conflicts of interest amongst research ethics committee members and affiliated
researchers stated and mitigated?
No information could be found publically available on this.
2.9: How is harm/benefit ratio determined by the company?
No information could be found publically available on this.
2.10: What is the procedure for stopping a research study if the risks of proceeding are shown to
outweigh the potential benefits? (WMA Declaration of Helsinki Article 20, 2008)
No information could be found publically available on this.
2.11: How does the company respond to a situation in which a research participant has an
apparent research-related harm occur?
No information could be found publically available on this.

3) Article 5: Autonomy and individual responsibility
3.1: How does the company ensure the autonomy (freedom, liberty, self-determination) of human
research participants?
No information could be found publically available on this.
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3.2: How is the right to withdraw at any time without repercussions for the participant ensured?
No information could be found publically available on this.
3.3: How does the company uphold the freedom of association and the effective recognition of
the right to collective bargaining? (UNGC Principle 3)
Sun states that their Human Rights Policy covers freedom of association, yet that policy could
not be found publically.74

4) Article 6: Consent
Information
4.1: How does the company ensure that consent of human research participants is informed?
No information could be found publically available on this.
4.2: What is included in this information component?
No information could be found publically available on this.
4.3: Are participants provided informed consent in a language and manner that is appropriate?
No information could be found publically available on this.
Voluntariness
4.4: How does the company ensure that consent of human research participants is voluntary and
in no way coerced?
No information could be found publically available on this.
4.5: How does the company provide measures against undue inducement?
No information could be found publically available on this.
Competence
4.6: How does the company ensure that the research participant is competent to give consent?
No information could be found publically available on this.
Training of Researchers
4.7: How are researchers or investigators trained in the process of obtaining informed consent,
including providing information in an appropriate manner that is understandable for the
participant?
No information could be found publically available on this.
4.8: When is it appropriate to consult family members and community leaders in the consent
process?
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No information could be found publically available on this.
4.9: Is the participant given the option of being informed about general outcomes and results of
the study?
No information could be found publically available on this.
4.10: How is it ensured that emerging new information is promptly given to trial participants in
a long-term study that may affect their desire to stay in the study?
No information could be found publically available on this.
4.11: When is it appropriate to ask for re-consent during a trial?
No information could be found publically available on this.
Research Participants
4.12: How is the right to withdraw at any time ensured?
No information could be found publically available on this.
4.13: Who determines if a person is competent to give consent and how is it determined?
No information could be found publically available on this.
Compensation
4.14: Who and how is it determined?
No information could be found publically available on this.
Human Biosamples
4.15: What is the company’s course of action in regards to biosamples used in research that are
collected by researchers after prior informed consent for collection, storage and use/reuse? If
consent of the participant is not possible, has an ethics committee approved?
No information could be found publically available on this.

5) Article 7: Persons without the capacity to consent
General
5.1: Has authorization for research been obtained in accordance with the best interest of the
person concerned and in accordance with domestic law?
No information could be found publically available on this.
5.2: Has the research participant been involved to the greatest extent possible in the decisionmaking process of consent, as well as that of withdrawing consent?
No information could be found publically available on this.
5.3: Do the results of the research have the potential to produce real and direct benefit to the
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health of the incapable research participant?
No information could be found publically available on this.
5.4: Can research of comparable effectiveness be carried out on individuals capable of giving
consent?
No information could be found publically available on this.
Training of Researchers
5.5: How are researchers/investigators trained in dealing with and protecting persons with
diminished capacity to consent?
No information could be found publically available on this.
Determination of Capacity
5.6: How it is determined who is not capable of providing consent?
No information could be found publically available on this.
5.7: How is capacity determined in the protocol review process and by the investigator(s)
performing research?
No information could be found publically available on this.
5.8: How do researchers obtain proxy or surrogate consent?
No information could be found publically available on this.
Exception
If it is not possible to comply with the above, the UDBHR does formulate as an exception for
research that does not have the potential to produce results of direct benefit to the health of the
individual concerned. The following conditions must be met to permit such research:
1) The research has the aim of contributing, through significant improvement in the scientific
understanding of the individual’s condition, disease, or disorder, to the person concerned or to
other persons in the same category of disease or disorder.
2) The research must only entail minimal risk and minimal burden for the individual concerned.

6) Article 8: Respect for human vulnerability and personal integrity
Vulnerability & Marginalization
6.1) How does the company define “vulnerable” persons and population?
No information could be found publically available on this.
6.2) How does the company specify who needs specific consideration? (UNGPBHR: Women,
children, people with disabilities, indigenous people, migrants, elders, prisoners, pregnant
women, economically and educationally disadvantaged are considered vulnerable)
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No information could be found publically available on this.
6.3) How are the vulnerable additionally safeguarded against undue influence or coercion?
No information could be found publically available on this.
6.4) Are the knowledge and products from the clinical trial made reasonably available to benefit
that group?
No information could be found publically available on this.
Identification
6.5) How does the company identify vulnerable individuals or groups?
No information could be found publically available on this.
Alternatives
6.6) Can the research be carried out in a non-vulnerable group? (Helsinki, 2013)
No information could be found publically available on this.
Protection
6.7) What guidelines has the company established to protect vulnerable persons?
No information could be found publically available on this.
6.8) Does the company comply with the laws concerning research with vulnerable persons? If no
such legislation exists in the context where the research is being conducted (host community),
what does the company do?
The guidelines that Sun Pharmaceuticals follows in regards to clinical trials is uncertain. Sun
states on their website under their “Research & Development section that, “Our 408-bed clinical
pharmacology unit with expert staff works on bioequivalence/bioavailability studies in
compliance with GCP. Facilities include a full-fledged site for Phase I clinical studies. Our CPU
has been audited by US FDA, ANVISA, MHRA, and DCGI among others.”75 However, this
statement is not entirely clear at all.
Benefits
6.9) Does the vulnerable group stand to benefit from the knowledge, practices or interventions
that result from the research? (Helsinki, 2013)
No information could be found publically available on this.
6.10) Is the medical research with a vulnerable group responsive to the health needs or priorities
of this group? (Helsinki, 2013)
No information could be found publically available on this.

7) Article 9: Privacy and confidentiality
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Risk
7.1) What are the risks of the infringement of privacy?
No information could be found publically available on this.
7.2) What is the risk of infringement of personal data?
No information could be found publically available on this.
Measures
7.3) What measures does the company take in order to maintain the right to privacy of
participants in human research?
No information could be found publically available on this.
7.4) How is it ensured that information is only shared or disclosed as it has been specified in the
consent?
No information could be found publically available on this.

8) Article 10: Equality, justice, and equity
8.1) How does the company manage scarce resources in order to guarantee a just and equitable
healthcare system?
No information could be found publically available on this.
8.2) How does the company ensure certain groups are not under- or over-represented in
research?
No information could be found publically available on this.
8.3) How does the company ensure that groups and communities are invited to participate in a
way that the burden and benefits are equitably distributed?
No information could be found publically available on this.
8.4) Will the participants, to the best of the company’s knowledge, be able to afford the product
when marketed without it being of significant burden?
No information could be found publically available on this.
8.5) How do the investigators ensure the research is fair to the subject?
No information could be found publically available on this.

9) Article 11: Non-discrimination and non-stigmatization
9.1) How does the company take care to avoid the systematic development of medicines for one
group within a population to the neglect of others?
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Sun states, in its Business Responsibility Report from 2015-16, the following:
“We leverage the intrinsic nature of our business to further the cause of healthcare and care for
patients across the economic strata. While making medicines which are more accessible and
affordable is our role, we also up the ante by offering certain medicines free of cost to the
socially challenged.”76 However, this does not specifically address the precise question of nondiscrimination and non-stigmatization. No other information could be found.
9.2) When conducting clinical trials, does the company discriminate or stigmatize certain
populations or genders so that they are under-represented in research?
No information could be found publically available on this.
9.3) Does the company have a grievance procedure for handling allegations of discrimination
and stigmatization?
In its Code of Conduct, Sun has a policy in place on non-discrimination and encourages
employees to report any violations. The Code of Conduct states that any concern will be handled
confidentially and without fear of retribution.77

10) Article 12: Respect for cultural diversity and pluralism
10.1) In clinical trials with human research participants, how does the company handle cultural
differences regarding informed consent?
No information could be found publically available on this.
10.2) When doing business in an unfamiliar cultural milieu, how does the company approach
these cultural differences?
No information could be found publically available on this.
10.3) Does the company provide training for its employees on issues of cultural diversity and
pluralism?
No information could be found publically available on this.

11) Article 13: Solidarity and Cooperation
11.1) How is the company working towards capacity-building in the area of public and global
health?
Sun Pharmaceuticals, in its 2015-16 Business Responsibility Report, stated a number of
capacity-building projects they have completed:
• The provision of drinking water supply to 4 hamlets of Malaipalayam village in
Madurantakam Taluka of Kanchipuram District was completed, providing 960
households with potable water.
• Education: Upgrading infrastructure of surrounding schools and enhancing the standard
of education, impacting 3,859 students.
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•

Organization of a festival to promote local art and culture, with a broader aim of
promoting tourism for the economic enhancement of the area surrounding the UNESCO
World Heritage Site of Champaner-Pavagadh at Halol Taluka – Panchmahal District.78

11.2) How is the company contributing to the UN Sustainable Development Goals?
No information could be found publically available on this.

12) Article 14: Social responsibility and health
Promotion of Health and Social Development
12.1) How does the company aim to promote health and social development?
Sun is involved in a number of projects aimed to promote health and social development. The
following are listed in their 2015-16 Business Responsibility Report:
• Distribution of medicines to monasteries
• Financial support of a 450-bed cancer hospital
• Providing access to potable water and sanitation
• Assisting in disaster relief
• Medical mobile units
• Upgrading infrastructure of primary schools79
12.2) Article 14 states that “all sectors of society share” in the promotion of social responsibility
and health. How does the company seek to address: 1) access to quality health care and
essential medicines, 2) access to adequate nutrition and water, 3) the improvement of living
conditions and the environment, 4) the elimination of the marginalization and the exclusion of
persons on the basis of any grounds, and 5) the reduction of poverty and illiteracy?
Sun has attempted to address several of these areas:
1) The company aids financially-challenged persons with free medicines. Sun also distributes
medicines to monasteries.
2) Sun has a large sanitation program in several villages, installing toilets and providing potable
water.
3) Sun has taken steps to be environmentally-friendly, which are detailed in section 15.
4) No information could be found publically available on this.
5) No information could be found publically available on this.
Relationship to Developing Countries:
12.3) Does the company have differential pricing policies so that lower income countries pay
lower prices for essential medicines than higher income countries?
This is not fully known. However, Sun states, “We directly support the socio-economically
challenged sections of the society by providing medicines at no or subsidised costs to the patients
in need.”80
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12.4) Does the company invest in research and development for diseases that primarily affect
lower income countries?
This is not altogether clear from Sun’s publically available information. The company itself is
headquartered in a LMIC (India) and does have a robust R&D department, yet the extent to
which it targets diseases that primarily affect lower income countries is not known.
12.5) Does the company have policies on access to treatment for developing countries, including
the five priorities of pricing, patent, joint public private initiatives, R&D, and the appropriate
use of drugs?
No information could be found publically available on this.

13) Article 15: Sharing of benefits
Sharing of Benefits
13.1) How does the company ensure that the benefits resulting from its scientific research are
shared with society as a whole?
In their 2015-16 annual report, Sun states, “We directly support the socio-economically
challenged sections of the society by providing medicines at no or subsidised costs to the patients
in need. Financially challenged patients continue to gain our assistance in the form of free-ofcost medicines. In the reporting period, we continued to dispense free Riluzole which is used in
the treatment of Amyotrophic Lateral Sclerosis (a life-threatening disease) to all patients.
We have also been regularly distributing medicines to monasteries in Sikkim.”81
13.2) When conducting clinical trials, does the company ensure that in advance of the trial,
provisions are made for post-trial access for all participants who still need an intervention
identified as beneficial in the trial? (DoH, Article 34, 2013)
No information could be found publically available on this.
13.3) If the company is involved in bioprospecting, how does it ensure that indigenous
knowledge and resources have been respected?
No information could be found publically available on this.
Undue Inducement
13.4) How does the company ensure against improper inducements to participate in research?
No information could be found publically available on this.

14) Article 16: Protecting future generations
14.1) In bioethical decision-making, does the company take into account the impact on the
present generation and also try to evaluate the impacts on future generations?
No information could be found publically available on this.
14.2) If the company is involved in research on human genomic information, how does the
company ensure that such new technology will not result in undesired outcomes for future
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generations?
No information could be found publically available on this.
14.3) How does the company evaluate any possible influence a test compound can have on genes
or germ cells?
No information could be found publically available on this.

15) Article 17: Protection of the environment, the biosphere and biodiversity
Impact on Environment
15.1) As it has been recognized that the company has a responsibility to protect the environment,
how does the company prevent advances in molecular biology, recombinant technology,
genetics, biotechnology, and other advances from negatively impacting the environment?
No information could be found publically available on this.
15.2) Does the company participate in the development of new technologies that pose risk of
irreversible damage to the environment?
Sun states on their website that they have had a policy on the environment, health & safety
(EHS), yet it could not be located. Nonetheless, the company does state that care for the
environment is a core value. They state, “Our EHS policy provides for the creation of a safe and
healthy workplace and a clean environment for employees and the community. It aims for the
highest international standards in plant design, equipment selection, maintenance and operations.
The policy is a commitment that we will manufacture products safely and in an environmentally
responsible manner.”82
15.3) Does the company have in place emergency guidelines in the event of an accident affecting
the environment?
No information could be found publically available on this.
15.4) Does the company minimize the use of chemicals and other dangerous substances, as well
as ensuring their safe handling and storage?
No information could be found publically available on this.
15.5) If applicable to the business, does the company encourage the development and use of
environmentally friendly technologies?
Sun states, “Investments have been made in process improvements as well as upgradation of
effluent treatment plants, using membrane based technologies, multi-effect thermal evaporators,
agitated thin film dryers and hazardous waste incinerators. These measures have helped to reduce
the environmental burden. With these equipment installed at all our major facilities for recycling
of the treated effluent, we have achieved the status of “zero liquid discharge”.83
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Further, Sun states specifically that, “We have invested significantly in green energy, principal
amongst which is our investment in wind energy. One of our facilities is dedicated towards
harnessing the power of wind to generate energy. In FY16, we generated around 1,145,560 kWh
of clean energy.”84
Biosphere
15.6) How does the company seek the protection of experimental animals? (cf Article 4)
No information could be found publically available on this.
15.7) How does the company seek to eliminate the need for using animals in research?
No information could be found publically available on this.
15.8) How does the company seek to protect and promote the welfare on the animals used in
research?
No information could be found publically available on this.
Impact on Biodiversity
15.9) Does the company prevent, minimize and remedy impacts on biodiversity?
Sun has put in place a number of projects to reduce their impact upon the environment and
biodiversity, including reducing the reduction of waster, recycling materials when able, and
reusing materials when possible. Further, Sun has six functional facilities equipped the biomassfuelled boilers.85
Very little information could be located publically regarding the bioethics, corporate
social responsibility, and human rights performance and activities of Sun Pharmaceuticals. The
company is not a member of the UN Global Compact and nearly the only information that could
be located publically about their activities in the areas of human rights and bioethics comes from
their website. The author contacted the research and development department of Sun
Pharmaceuticals through their website with the following message:
Greetings,
I am a PhD student in bioethics in the United States and am writing my dissertation on
bioethics, human rights, and corporate social responsibility as it relates to the
pharmaceutical industry. I have been scouring your website for more information about
what Sun does in regards to bioethics. In particular, it would be helpful to know which, if
any, international bioethics guidelines the company adheres to (such as Helsinki, ICH295

GCP) and where the company’s Human Rights Policy can be located. Additionally, any
information you could provide on clinical trials, how participants are chosen, and
information about how their protection is ensured would be greatly appreciated. Thank
you.
As of the time of this writing, Sun had yet to respond to this message.
From the above application, this is an example of how the global bioethics tool would
positively serve a pharmaceutical or biotechnology company, aiding the company in disclosing
publically what they are doing in areas of bioethics, human rights, and corporate social
responsibility. We should not get the picture that Sun Pharmaceuticals is simply not involved in
the indicators that could not be answered. Rather, it is assumed that they are simply not reported
via their public website. However, stakeholders, shareholders, and the general public want this
type of information to be accessible to them. Hence, a company such as Sun may greatly benefit
by utilizing the global bioethics tool.
As this final body chapter concludes, it is necessary to review the contents of this chapter.
The first section examined several reporting systems and recommended a reporting framework
for the global bioethics tool. Reporting and petition systems were first examined and the merits
and weaknesses of each were discussed. The reporting style of the UN Global Compact, known
as the Communication on Progress, was then analyzed in detail. There are many positive aspects
of the UNGC’s COP, such as the transparency it promotes. However, several limitations also
exist in order for the COP to be more functional as a way to compare companies in a manner that
is user-friendly.
As has been argued throughout this dissertation, the global bioethics tool aims to promote
the transparency of the pharmaceutical and biotechnology industry and to do so in a manner that
stakeholders can easily compare how Company X is doing in comparison to Company Y. This is
not currently easily accessible with the present COP system. Further, another principal goal of
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the global bioethics tool is to promote industry best practices in areas of bioethics, human rights,
and corporate social responsibility. Again, this is not presently a chief concern of the COP
system. Hence, these are major ways in which the reporting and management style of the global
bioethics tool would differ from the UNGC COP. To be certain, the reporting style is important,
but what is of equal importance is what an organization does with the information they collect.
The global bioethics tool would like to publically disseminate the reports on its website for free
of charge (similar to what the UNGC does) but would also like to organize either an annual or
biennial forum in which representatives from participant pharmaceutical and biotechnology
companies would gather together and be able to discuss best practices and how to move forward
in the area of bioethics. This would also be an opportunity for collaboration on how to improve
the global bioethics tool.
The second section then sought to apply the global bioethics tool to two pharmaceutical
companies: GlaxoSmithKline and Sun Pharmaceuticals. These two specific companies were
chosen for different reasons, as was detailed above. This lengthy application section was a
necessary component of this chapter in order to practically demonstrate that the global bioethics
tool is much more than merely a curious exercise. Rather, the global bioethics tool, as is
demonstrated by this application section, is a feasible mechanism to measure qualitatively how
well pharmaceutical and biotechnology companies are doing in disclosing these important
aspects of bioethics, human rights, and CSR.
As was seen in section 2, there is great contrast between GlaxoSmithKline and Sun
Pharmaceuticals. First, GSK is based in a high-income country (UK), while Sun is headquartered
in a developing country (India). Second, their philosophies in regards to what they publically
disseminate in regards to bioethics, human rights, and corporate social responsibility differs
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considerably. Showcasing this contrast is advantageous for the purposes of the global bioethics
tool because it highlights the benefit of the global bioethics tool for companies such as Sun that
have not seemingly previously placed considerable emphasis on publically broadcasting such
information. As was seen in section 2, there were numerous areas in Sun’s report in which
responses to the questions could not be located publically, and it was recorded as such. This
demonstrates that a company such as Sun would, assumedly, benefit greatly by utilizing such a
system as the global bioethics tool in order to make its bioethics activities more prominent as
well as public. What is more, by participating in the global bioethics tool, a company such as Sun
could learn from larger companies with more robust bioethics activities (such as GSK) on how
best to begin more work in that area.
The following, concluding chapter offers final thoughts on this dissertation. Included in
this will be ways to see the global bioethics tool achieve implementation within the
pharmaceutical and biotechnology industry. Limitations to this current study and manners of
overcoming them in the future if the global bioethics tool gains greater traction will also be
discussed. This concluding chapter will also offer a grand vision of what the author would like to
see done with the global bioethics tool in the future and reiterate both the usefulness and
necessity of such a system for the pharmaceutical and biotechnology industry to take its
bioethics, human rights, and corporate social responsibility obligations more sincerely and make
it an emphasis to stakeholders.
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Chapter 7: Conclusion
The purpose of this dissertation has been to highlight the need of creating and
implementing a global bioethics tool for the pharmaceutical and biotechnology industry. It is the
author’s desire to see the pharmaceutical and biotechnology industry firmly implant systems to
measure, report, and enhance issues of bioethics, human rights, and corporate social
responsibility. To this end, the global bioethics tool that has been presented and argued for would
be helpful in creating this culture of bioethical responsibility.
Chapter 2 examined the relationship between global bioethics and human rights. This
relationship is fundamental to this dissertation, and it was seen that a symbiotic relationship
exists. Global bioethics has grown out of the older, more traditional field of healthcare ethics or
bioethics. Van Rensselaer Potter was instrumental in the formation of bioethics as a separate
discipline with the aim of bridging science and values, nature and culture, and man and nature.
Almost two decades after coining the term “bioethics” he would also coin the phrase “global
bioethics,” which focused largely on environmental and conservational issues in the stream of
Aldo Leopold. Yet, Potter also envisioned this field as addressing the crucial questions of the
day, such as poverty, war, politics, and population growth—all of which were not being
addressed by the more mainstream version of bioethics coming out of academic centers such as
Georgetown University.
The symbiotic relationship between global bioethics and human rights was showcased in
this chapter in order to solidify further the foundational principles of this dissertation. Global
bioethics contributes to human rights, and human rights contribute to global bioethics. It was
described how global bioethics is able to reinforce the normative claims of international human
rights law, how it can broaden the advocacy framework of human rights, and how it can aid in
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the debate between individual human rights versus public health. Further, human rights
contribute to and advances global bioethics in at least six ways that were each described in this
chapter.
Chapter 3 examined the growing importance of corporate social responsibility within the
pharmaceutical and biotechnology industry. The initial section presented the topic of social
responsibility and its role in health. It was argued that social responsibility and health combines
two basic ideas: 1) several actors aside from states and governments are responsible for health,
and 2) global problems reflect common challenges and, therefore, should be addressed through
common action. Social responsibility as presented within the UNESCO Universal Declaration on
Bioethics and Human Rights was introduced, and it was seen that placing the principle of social
responsibility into a bioethics guideline reiterates the need for bioethics to be able to reflect on
meta-issues within science, including issues that touch the corporate, political, and social world.
The second section of this chapter applied corporate social responsibility to the
pharmaceutical and biotechnology industry. The central thesis in this section was that companies
that are integrally tied to human health and flourishing, such as the pharmaceutical industry, may
be especially addressed by calls for social responsibility in global health. The area of pricing has
been on center stage for the pharmaceutical industry and, because of the pressing nature of this
issue, was heavily utilized in this section. The chapter concluded by considering ways of further
infusing corporate social responsibility into the pharmaceutical industry. Social pressure and
some sort of mechanism to measure how well the industry is doing were seen as practical and
viable solutions.
The fourth chapter opened by analyzing the bioethics guidelines that have been produced
since the end of World War II. A number of documents were compared and it was seen how
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bioethics has evolved over the decades. The second section then concentrated on the UNESCO
Universal Declaration on Bioethics and Human Rights. UNESCO was well-situated for the task
of creating universal ethical norms due to its work in science and values, its unique position as an
intergovernmental agency, and the way it acts as a bridge between science and values.
Further, the uniqueness of the Universal Declaration on Bioethics and Human Rights and
its ability to be translated into a global bioethics tool for the pharmaceutical and biotechnology
industry was examined. Indeed, it was argued that the UDBHR is better positioned than any
other biomedical ethics framework, including the Declaration of Helsinki, to be the framework
upon which the global bioethics tool is built for the following reasons: 1) it is the first and only
bioethics declaration to gain the approval of international governments with the input of
bioethics experts, rather than solely a group of individuals with bioethics or scientific expertise,
2) it efforts to incorporate major principles in bioethics, such as those included in the Declaration
of Helsinki and ICH-GCP, 3) the Declaration reaches beyond individual orientations to bioethics
to a global perspective, focusing on issues such as the environment, respect for cultural diversity,
capacity building, and future generations, and 4) the Declaration is very useful for countries that
lack an infrastructure in bioethics. The need for worldwide standard-setting in bioethics has been
strongly expressed by LMICs who want to share the benefits of the developments of science and
technology and not only be the providers of data and resources for the world.
Chapter 5 presented the global bioethics tool. The first section offered greater detail on
the rationale, methodology, and benchmarking process that is envisioned for the tool.
Benchmarking was not completed within the space of this dissertation, but the process was
described, and it is hoped that in the future this will lead to the promotion of best practices. The
second section developed the indicators that comprise the global bioethics tool. Justification was
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provided for why the particular indicators were created. It is worth noting that these indicators
are not set in stone. While a type of peer-review process was undertaken with them, as experts in
global bioethics and CSR were consulted, more discussion and consultation needs to take place.
Chapter 6 first set up the reporting framework of the global bioethics tool. Several
reporting frameworks were discussed and analyzed for their effectiveness and usefulness for the
proposed global bioethics tool. In particular, the reporting framework of the UN Global
Compact, known as the Communication on Progress, was assessed. Strengths and weaknesses of
the Communication on Progress were evaluated, and suggestions for the global bioethics tool
reporting framework were presented. In the second section the indicators of the global bioethics
tool were applied to GlaxoSmithKline and Sun Pharmaceuticals.
In order to achieve implementation of the proposed global bioethics tool presented in this
dissertation within the pharmaceutical and biotechnology industry, several steps are necessary. It
is currently envisioned that the pharmaceutical and biotechnology industry would internally
create and support this initiative. This seems advantageous versus having regulators or an NGO
impose this on the industry externally. For this to happen, a company or coalition of companies
would need to adopt this tool and publicize it to other companies. This small cohort of
companies would showcase how the tool works and promote the reasons they feel it is needed.
This is going to take substantial effort as well as resources. However, one full-time employee
working on behalf of a small cohort of companies could be enough in the beginning phases of
this project in order to get the project running. Costs spread over a small cohort of companies
would be minimal.
If this vision of the pharmaceutical and biotechnology industry adopting the global
bioethics tool were to become a reality, embraced by a larger cohort of companies, then it would
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be advisable for a non-profit to be created that houses the tool and handles the administrative
duties. This would be supported financially by the industry. Realistically, this would be years
away. However, the issue of bioethics, human rights, and corporate social responsibility within
the pharmaceutical and biotechnology industry is pressing and ever-present; it is not going away.
Hence, one must have a long-term goal in view and not be shortsighted or discouraged by small
gains and advancements.
This study also has some limitations that must be considered. As has been previously
discussed, more input from various stakeholders should be accumulated. The input and data from
this will need to be used to re-assess the indicators that were created for the proposed global
bioethics tool. What is more, other stakeholders also need to be consulted in order to reach some
level of research saturation in order to ensure that adequate and quality data on the indicators
have been collected.
Nonetheless, while some limitations exist in this study due to the nature of its design as
primarily a hypothetical exercise, this does not negate the viability of the global bioethics tool
and its usefulness for the pharmaceutical and biotechnology. The global bioethics tool is a
practical way of holding the industry further accountable for certain actions within bioethics,
human rights, and corporate social responsibility. However, it also more than this. The global
bioethics tool is a very innovative tool for the pharmaceutical and biotechnology industry,
because at the heart of the tool is the idea of determining and sharing best practices. When the
author was seeking to gather support for the tool then many stakeholders expressed their
enthusiasm regarding it and saw the potential for its usefulness within the industry.
Representatives from the bioethics section at UNESCO were encouraging and offered their
assistance. A small number of pharmaceutical and biotechnology companies also expressed their
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interest in collaborating on the project, demonstrating that there is support for such a tool from
those within the industry.
To move forward with this project with the hopes of seeing the global bioethics tool
adopted by the pharmaceutical and biotechnology industry, the next phase would require
soliciting a greater level of industry support. Greater numbers of stakeholders and experts in
pharmaceutical, global, and research ethics would need to be consulted regarding the indicators.
Indeed, with the public’s general mistrust of specific pharmaceutical companies and the industry
in general, and with the excessive number of pricing scandals, charges of clinical trial data
manipulation, and other acts of misconduct that have rocked the industry, the moment is prime
for a tool such as this to impact the industry immensely. Undeniably this is an area that needs
focused attention by the pharmaceutical and biotechnology industry. This dissertation has made
the case for a global bioethics tool to act as one piece of the puzzle to aid the pharmaceutical and
biotechnology industry in its reputation and see their obligations towards bioethics, human
rights, and corporate social responsibility take center stage.
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